



Effective Health Care Program

Comparative Effectiveness Review
Number 31

Effectiveness of Early Diagnosis, Prevention, and Treatment of *Clostridium difficile* Infection



Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

Effectiveness of Early Diagnosis, Prevention, and Treatment of *Clostridium difficile* Infection

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. 290-02-0009 (EPC2)

Prepared by:

Minnesota Evidence-based Practice Center
Minneapolis, Minnesota

Investigators:

Mary Butler, Ph.D., M.B.A.
Donna Bliss, R.N., Ph.D.
Dimitri Drekonja, M.D.
Gregory Filice, M.D.
Thomas Rector, Pharm.D., Ph.D.
Roderick MacDonald, M.S.
Timothy Wilt, M.D., M.P.H.

This report is based on research conducted by the Minnesota Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0009—EPC2). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment.

This report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without the specific permission of copyright holders.

Persons using assistive technology may not be able to fully access information in this report. For assistance, contact EffectiveHealthCare@ahrq.hhs.gov.

No investigators have any affiliations or financial involvement (e.g., employment, consultancies, honoraria, stock options, expert testimony, grants or patents received or pending, or royalties) that conflict with material presented in this report.

Suggested Citation: Butler M, Bliss D, Drekonja D, Filice G, Rector T, MacDonald R, Wilt T. Effectiveness of Early Diagnosis, Prevention, and Treatment of Clostridium difficile Infection. Comparative Effectiveness Review No. 31 (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-02-0009.) AHRQ Publication No. 11(12)-EHC051-EF. Rockville, MD. Agency for Healthcare Research and Quality. December 2011.

Preface

The Agency for Healthcare Research and Quality (AHRQ) conducts the Effective Health Care Program as part of its mission to organize knowledge and make it available to inform decisions about health care. As part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Congress directed AHRQ to conduct and support research on the comparative outcomes, clinical effectiveness, and appropriateness of pharmaceuticals, devices, and health care services to meet the needs of Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

AHRQ has an established network of Evidence-based Practice Centers (EPCs) that produce Evidence Reports/Technology Assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care. The EPCs now lend their expertise to the Effective Health Care Program by conducting Comparative Effectiveness Reviews (CERs) of medications, devices, and other relevant interventions, including strategies for how these items and services can best be organized, managed, and delivered.

Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews are useful because they define the strengths and limits of the evidence, clarifying whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about systematic reviews, see <http://effectivehealthcare.ahrq.gov/reference/purpose.cfm>.

AHRQ expects that CERs will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. In addition, AHRQ is committed to presenting information in different formats so that consumers who make decisions about their own and their family's health can benefit from the evidence.

Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an e-mail list to learn about new program products and opportunities for input. Comparative Effectiveness Reviews will be updated regularly.

We welcome comments on this CER. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to epc@ahrq.hhs.gov.

Carolyn M. Clancy, M.D.
Director
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.
Director, Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.
Director, EPC Program
Agency for Healthcare Research and Quality

Shilpa Amin, M.D., MBsc, FAAFP
Task Order Officer
Agency for Healthcare Research and Quality

Robert Zuhlke
Contracting Officer
Agency for Healthcare Research and Quality

Acknowledgments

We sincerely thank all peer and public reviewers and David Samson for their comments and suggestions. The report is better because of their contributions.

We would like to thank Christa Prodzinski, Maureen Carlyle, and especially Marilyn Eells, for editing support. We would also like to thank Michelle Brasure, Jim Tacklind, and Indy Rutks, for their librarian expertise, database management, abstracting skills, and all-around general support.

Effectiveness of Early Diagnosis, Prevention, and Treatment of *Clostridium difficile* Infection

Structured Abstract

Objectives. To conduct a systematic review and synthesize evidence for differences in the accuracy of diagnostic tests, and the effects of interventions to prevent and treat *Clostridium difficile* infection (CDI) in adult patients.

Data Sources. Searching for relevant literature was conducted in MEDLINE, the Cochrane Library, and Allied and Complementary Medicine (AMED). ClinicalTrials.gov and expert consultants provided leads to additional studies. We also manually searched reference lists from relevant literature.

Review Methods. Standard Evidence-based Practice Center methods were employed. Screening of abstracts and full text articles to identify studies meeting inclusion/exclusion criteria was performed by two independent reviewers. High-quality direct comparison studies were used to examine differences in diagnostic tests. Randomized controlled trials (RCTs) were used to examine comparative effectiveness of antibiotic treatment for CDI. Quality of data extraction was checked by separate reviewers. Quality ratings and strength of evidence grading was performed on included studies. Evidence on diagnostic tests was quantitatively synthesized focusing on differences between test sensitivities and specificities. Evidence on antibiotic treatment was quantitatively examined using pooled analysis. Qualitative narrative analysis was used to synthesize evidence from all available study types for environmental prevention and nonstandard prevention and treatment, with the exception of probiotics as primary prevention, for which a forest plot is provided.

Results. Overall, literature was sparse and strength of evidence was generally low due to small sample sizes or lack of adequate controls. For diagnostic testing, direct comparisons of commercially available enzyme immunoassays for *C. difficile* toxins A and B did not find major differences in sensitivity or specificity. Limited evidence suggests that tests for genes related to the production of *C. difficile* toxins may be more sensitive than immunoassays for toxins A and B while the comparisons of these test specificities were inconsistent. Moderate evidence in favor of antibiotic restriction policies for prevention was found. Environmental preventive interventions such as glove use and disposable thermometers have limited evidence. However, this literature is largely based on controlling outbreaks. Use of multiple component interventions further limits the ability to synthesize evidence in a meaningful way. Numerous potential new forms of treatment are being examined in placebo controlled RCTs, case series, and case reports. For standard treatment, no antimicrobial is clearly superior for the initial cure of CDI. Recurrence is less frequent with fidaxomicin than with vancomycin. Monoclonal antibodies for prevention and fecal flora reconstitution for multiple recurrences appear promising.

Conclusions. Given the frequency and severity of CDI and the fact that future reimbursement policy may withhold payment for hospital-acquired infections, this is an under-researched topic. More precise estimates of the magnitude of differences in test sensitivities and specificities are needed. More importantly, studies have not established that any of the possible differences in test accuracy would lead to substantially different patient outcomes in clinical practice. More research on effective treatment and unintended consequences of treatment, such as resistance, is needed. Gut flora may be important, but improved understanding of healthy gut ecology and the complex interactions is necessary before continuing to pursue probiotics.

Contents

Executive Summary	ES-1
Introduction	1
Background	1
Diagnosis	2
Treatment	3
Prevention	3
Scope of the Review	4
Key Questions	4
Review Framework	5
Diagnostic Test Descriptions	9
Methods	11
Topic Refinement	11
Systematic Review	11
Search Strategy	11
Inclusion/Exclusion Criteria	11
Study Selection	15
Data Extraction	15
Quality Assessment	16
Rating the Body of Evidence	17
Applicability	17
Data Synthesis	18
Publication Bias	18
Results	20
Key Question 1. How do Different Methods for Detection of Toxigenic <i>C. difficile</i> Compare in Their Sensitivity and Specificity?	21
Search Results	21
Key Points	21
Quality of the Comparative Studies	21
Detailed Analysis	22
Key Question 2. What are Effective Prevention Strategies?	28
Search Results	28
Key Points	28
Quality of the Studies	29
Detailed Analysis	29
Key Question 3. What are the Comparative Effectiveness and Harms of Different Antibiotic Treatments?	45
Search Results	45
Key Points	45
Quality of the Studies	46
Detailed Analysis	46
Key Question 4. What are the Effectiveness and Harms of Nonstandard Adjunctive Interventions?	56
Search Results	56
Key Points	56

Quality of the Studies	56
Detailed Analysis	57
Summary and Discussion.	77
Diagnostic Testing (Key Question 1)	77
Prevention (Key Question 2)	78
Standard Treatment (Key Question 3).....	79
Nonstandard Interventions (Key Question 4)	80
Future Research	81
Diagnostic Tests	82
Prevention.....	82
Standard Treatment	83
Nonstandard Treatment	83
References and Included Studies	91
Abbreviations	102
Glossary of Terms	103

Tables

Table A. Summary of Evidence.....	ES-11
Table B. Future Research Recommendations.....	ES-13
Table 1. Summary of Diagnostic Comparisons in Included Studies	24
Table 2. Comparisons of Immunoassays for Toxins A and B	25
Table 3. Toxin Gene Tests Compared to Immunoassays	27
Table 4. Prevention Interventions	35
Table 5. (A) Studies of Multiple Interventions Used Together to Reduce CDI Incidence	40
Table 6. (B) Studies of Multiple Interventions Used Together to Reduce CDI Incidence.....	42
Table 7. Summary of Risk Factors for CDI.....	44
Table 8. Summary of Trial Comparators for 10 Trials of Antibiotic Treatment of CDI.....	45
Table 9. Initial Clinical Cure (# Subjects / # Randomized) for Vancomycin Versus Metronidazole	46
Table 10. Initial Clinical Cure (# Subjects / # Randomized) for all Other Standard Treatment Trials.....	47
Table 11. Clinical Recurrence: # Subjects / # Initially Cured (Percent) for Vancomycin Versus Metronidazole	47
Table 12. Clinical Recurrence: # Subjects / # Initially Cured (Percent) for all Other Standard Treatment Trials.....	48
Table 13. Mean Days to Resolution of Diarrhea/Clinical Improvement for Vancomycin Versus Metronidazole	49
Table 14. Mean Days to Resolution of Diarrhea/Clinical Improvement for all Other Standard Treatment Trials.....	49
Table 15. All Cause Mortality (# Subjects / # Randomized) for Vancomycin Versus Metronidazole	50
Table 16. All Cause Mortality (# Subjects / # Randomized) for all Other Standard Treatment Trials.....	50
Table 17. Other Outcomes (# Subjects / # Assessed) for Vancomycin Versus Metronidazole	50
Table 18. Outcomes for all Standard Treatment Trials.....	53

Table 19. Nonstandard Intervention for Treatment of Initial and Recurrent CDI.....	61
Table 20. Probiotic or Prebiotic Interventions for Prevention of Initial and Recurrent CDI.....	66
Table 21. Summary of Case Studies/Series and Potential Harms of Nonstandard Interventions for CDI.....	76
Table 22. Summary of Evidence.....	85
Table 23. Trials from ClinicalTrials.gov and Other Sources.....	87
Table 24. Future Research Recommendations.....	90

Figures

Figure 1. Pathogenesis of CDI.....	6
Figure 2 Analytic Framework for CDI Diagnostic Testing, Prevention, and Treatment	7
Figure 3. Supplemental Prevention Framework	8
Figure 4. Reference Flow Diagram.....	20
Figure 5. Overall Incidence of CDI From Probiotic Primary Prevention Trials	59

Appendixes

Appendix A. Technical Expert Panel
Appendix B. Search Strategies
Appendix C. Evidence Tables
Appendix D. Excluded Studies

Executive Summary

Introduction

Clostridium difficile infection (CDI) is a serious healthcare-associated infection and a growing health care problem. *C. difficile* is a Gram-positive, spore-forming, anaerobic bacterium that, when ingested, can cause CDI if it is a toxigenic strain. CDI symptoms include varying levels of diarrhea severity, as well as pseudomembranous colitis and toxic megacolon. CDI incidence is estimated at 6.5 cases per 10,000 patient days in hospital.¹ About 250,000 hospitalizations were associated with CDI in 2005.² Direct attributable mortality from CDI has been reported to be as high as 6.9 percent of cases.³ Elderly people in hospitals account for the vast majority of severe morbidity and mortality.⁴⁻⁶ Residents of long-term care facilities are also at higher risk.^{7,8} Incidence rates may increase by fourfold or fivefold during outbreaks.⁹ In addition to institutional care environments, *C. difficile* is also common in the community, being easily isolated from soil and water samples.¹⁰ Community-associated CDI rates are generally much lower, accounting for 27 percent of all CDI cases in a recent prevalence study,⁹ but are also on the rise.¹¹ However, the source of the *C. difficile* organisms responsible for cases of CDI in the community is not well understood.

In order for CDI to develop, a person must be infected with a strain of *C. difficile* capable of making toxin in the person's colon. Toxigenic strains are those that make toxin B (a cytotoxin), with or without toxin A (an enterotoxin). Approximately 1–2 percent of healthy individuals are colonized with *C. difficile*.¹² If these people have usual, healthy colonic flora, the risk of CDI is very low. There is a small risk of CDI if the colon flora becomes disturbed, commonly through antibiotic use, while the person is colonized with a toxigenic strain. Antibiotics that disturb colon flora enough to allow CDI to develop must get into the colon, and they are associated with alterations in relative amounts of colon bacterial constituents.^{13,14} The immune status of the patient also contributes to the risk of developing CDI and the experienced severity.¹⁵ Other risk factors include increasing age, female gender, comorbidities, gastrointestinal procedures, and use of gastric acid suppression medications.¹⁶⁻²⁵ Risk profiles for recurrent CDI are similar.²¹ One study, which statistically modeled CDI within the hospital setting, suggested that reducing patient susceptibility to infection is more effective in reducing CDI cases than lowering transmission rates.²⁶

New, more virulent strains have emerged since 2000. Characteristics associated with hypervirulent strains can include increased toxin production (due to a deletion in a toxin regulatory gene), an additional binary toxin, whose role in disease etiology is not well understood, hypersporulation, and high-level resistance to fluoroquinolone antibiotics.²⁷ These new strains affect a wider population, often people with a lack of established risk factors for CDI based on older strains, such as previous hospitalization or antibiotic use, and include children, pregnant women, and other healthy adults.²⁸ With hypervirulent strains, the time from symptom development to septic shock may be reduced, making quick diagnosis and proactive treatment regimens critical for positive outcomes.

The highly virulent strain associated with the epidemic of CDI described in the early 2000s may be decreasing in prevalence in limited locations.²⁹ Recent analysis of an archived collection of *C. difficile* isolates revealed that predominant strains shifted from year to year among a population served at a single institution,³⁰ suggesting that this strain shift may occur on a larger

scale. However, this phenomenon potentially cuts both ways as strains drift toward lesser or higher virulence, and the possible future risks and costs of CDI remain significant.

Scope and Key Questions

The purpose of this systematic review was to provide an overarching assessment of the evidence for comparing the accuracy of diagnostic tests and the effectiveness of prevention and treatment interventions on initial and recurrent CDI-related patient outcomes in adult patients. This purpose was developed during the project's topic refinement stage. There was consensus among key informants that this systematic review's single greatest contribution to the field could be to provide a comprehensive review by an independent organization that covered the major concerns of the field. CDI is an active topic in the literature as well as a vital clinical concern. The consensus opinion included the idea that clinicians and researchers both would be well served by a reaffirmation of what is and is not supported by evidence in the literature, and at what level of evidence, to balance against this activity level.

The major impetus of this review is the presence of clinical disease, not asymptomatic carriage of the *C. difficile* organism. While we were interested in how treatment of CDI varies by organism strain, molecular epidemiology studies whose main purpose was to identify the strains of *C. difficile* present in the population are also outside the scope of this review. The review focuses on adult patients because adults, and particularly elderly adults, carry the large majority of the morbidity and mortality burden.

The following Key Questions (KQs) form the basis for this review:

- **KQ 1.** How do different methods for detection of toxigenic *C. difficile* to assist with diagnosis of CDI compare in their sensitivity and specificity?
 - Do the differences in performance measures vary with sample characteristics?
- **KQ 2.** What are effective prevention strategies?
 - What is the effectiveness of current prevention strategies?
 - What are the harms associated with prevention strategies?
 - How sustainable are prevention practices in health care (outpatient, hospital inpatient, extended care) and community settings?
- **KQ 3.** What are the comparative effectiveness and harms of different antibiotic treatments?
 - Does effectiveness vary by disease severity or strain?
 - Does effectiveness vary by patient characteristics: age, gender, comorbidity, hospital- versus community-acquired setting?
 - How do prevention and treatment of CDI affect resistance of other pathogens?
- **KQ 4.** What are the effectiveness and harms of nonstandard adjunctive interventions?
 - In patients with relapse/recurrent CDI?

Methods

We used the key word “difficile” to identify all articles related to *C. difficile*. Articles were limited to English language and humans. No date limits were applied. We searched MEDLINE, AMED, the Cochrane Library, and ClinicalTrials.gov. For systematic reviews, we searched MEDLINE, the Cochrane Database of Systematic Reviews, and the Web sites of the National Institute for Clinical Excellence, Guidelines.gov, and the National Health Service Health

Technology Assessment Programme. We also manually searched reference lists of review articles and articles that were read for the review. Searches were conducted in February 2010 and updated in March and June 2010. An updated search was performed specifically for KQ 3 (standard treatment) in August 2011, because of a new study that led to FDA approval of fidaxomicin in May 2011.

For KQ 1, we included studies that used clinical stool specimens from patients suspected to have CDI. We included studies that concurrently compared at least two diagnostic tests in the same laboratory using the same stool samples and using the same reference standard to reduce heterogeneity in the estimates. Studies must have used toxigenic culture, cell cytotoxicity assay, or combinations of tests as the reference test for toxigenic CDI. Direct comparisons of diagnostic tests without a reference test were not included. We sought studies that included patient outcomes or outcomes related to changes in therapy. We present study results in positive terms, that is, true positives (sensitivity) and false positives (1 minus specificity).

For KQ 2, we included studies that examined the effects of prevention strategies aimed at breaking routes of transmission within institutional settings or reducing susceptibility to CDI through antibiotic prescribing practices. We included only studies with CDI incidence, or other measures of CDI, as an outcome. We excluded studies that used only intermediate outcomes, such as reduced spore count in environmental samples. Accepted study designs included randomized controlled trials (RCTs), prospective cohort, retrospective cohort, time series, and before/after trials. We also identified good quality studies that identified specific risk factors for development of CDI in general hospital inpatients to facilitate infectious disease control efforts to target likely effective preventive strategies.

For KQ 3, we included RCTs that compared two active antimicrobial treatments, including vancomycin, metronidazole, bacitracin, nitazoxanide, rifaximin, fidaxomicin, and rifampin, on adult patients. We also included placebo-controlled trials for vancomycin or metronidazole, the agents of most interest. We included initial cure, recurrence (variably defined by symptoms with or without a positive test for *C. difficile*), and mortality, which are outcomes of interest to clinicians and are reported in most studies. We also included time to resolution of diarrhea.

For KQ 4, we included all studies that examined any nonstandard intervention, such as toxin binding agents, probiotics, vaccinations, or other treatments aimed at enhancing a patient's resilience. Outcomes included resolution of symptoms and recurrence.

Diagnostics (KQ1) Results

We found 13 references that provided comparative data about diagnostic tests of interest.³¹⁻⁴³ The number and type of paired (within study) comparisons available for each diagnostic test varied considerably, and not all possible comparisons were available.

Sixteen paired comparisons of seven commonly used immunoassays for toxins A and B provided low-strength evidence that the test sensitivities do not differ. There was moderate-strength evidence for no differences in test specificities for two comparisons and for a difference of 2 percent in one comparison. Otherwise, there was only low-strength evidence for or against differences in test specificities. There was insufficient evidence of differences between all tests that were not directly compared.

Nine comparisons of two toxin gene detection tests that focus on toxin B to toxin immunoassays provided only low-strength evidence that the gene-based tests are substantially more sensitive. There was moderate evidence that the test specificities in one comparison did not differ. Otherwise, there was only low-strength evidence for differences in either direction

between test specificities. There was insufficient evidence of differences between all tests that were not directly compared.

There was no evidence to determine whether any differences in sensitivity or specificity between diagnostic tests depend on patient or specimen characteristics or the clinical scenarios that lead to testing for toxigenic CDI.

Prevention (KQ2) Results

We found 1 Cochrane review,⁴⁴ 4 studies on antibiotic prescribing restrictions,⁴⁵⁻⁴⁸ 11 on single preventive practices aimed at transmission interruption,⁴⁹⁻⁵⁸ and 10 studies that bundled multiple practices into a prevention strategy.⁵⁹⁻⁶⁸ We updated a previous systematic review and found 11 studies examining risk factors that met the inclusion criteria.²⁰

Overall, the evidence available to link prevention strategies to clinically important outcomes, such as CDI incidence, is of low quality and is not extensive.

Four observational studies⁴⁵⁻⁴⁸ and one Cochrane review⁴⁴ found that prescribing practice interventions decreasing the use of high-risk antimicrobials are associated with decreased CDI incidence. Prescribing practices were also used in multicomponent interventions credited with reducing CDI incidence; however, it is difficult to isolate the specific effects of the prescribing practices.

One controlled trial found glove use significantly reduced CDI incidence in the hospital setting.⁴⁹ Likewise, three observational studies, including two controlled, found that disposable thermometer use is likely to reduce CDI incidence.⁵⁰⁻⁵²

No study examined the effect of handwashing on CDI incidence. Four studies found use of alcohol gels as interventions for other infectious diseases, presumably in the presence of common protocols requiring handwashing in the presence of CDI or visible soiling, did not increase CDI incidence.^{53-55,69}

Four single-component intervention studies provide low evidence that disinfection with a chemical compound that kills *C. difficile* spores in the hospital environment prevents CDI, at least in epidemic or hyperendemic settings.^{56-58,70} Seven studies included disinfection in multicomponent interventions.^{60,62,63,66,71} Disinfection agents examined included hypochlorite solution, hydrogen peroxide, aldehydes, and detergent.

Ten time series/before–after studies have examined bundled multiple interventions using before–after study designs.^{59-68,71} All of the studies described the use of the measures to bring epidemic CDI, or endemic CDI which was felt to be excessive, under control. The number of interventions, and the specific nature of any particular intervention, varied widely. Studies employed between two and nine different types of interventions. Study design and intervention complexity, along with the fact that many outbreaks naturally diminish, made it difficult to conclude whether the reduced CDI prevalence was due to one or more intervention components, or entirely independent.

Risk factors for developing CDI include antibiotic use, substantial chronic illness, hospitalization in an ICU, acid suppression, and age.

No data on patient harms or harms to hospital staff due to preventive interventions were reported. Likewise, no studies assessed the sustainability of a prevention program beyond an intervention period.

Standard Treatment (KQ3) Results

Eleven randomized clinical trials were identified that evaluated different antimicrobials (or different doses of a single drug) available for treatment of CDI in the United States.⁷²⁻⁸² These 11 studies enrolled 1,463 patients and reported efficacy analysis on 1,239 patients.

Overall, study quality is low. Vancomycin and metronidazole, the most frequently clinically used antimicrobials, were also the most frequently compared antimicrobials. Three RCT comparisons of vancomycin to metronidazole, with a total of 335 pooled subjects, found no significant differences in any examined outcome.^{73,76,79} One RCT comparing vancomycin to metronidazole, using a prespecified subgroup analysis of 69 patients, found a small but significant increase in the proportion of subjects with severe CDI who achieved initial clinical cure with vancomycin, using a treatment-received analysis.⁷³ The significance of this difference did not persist when a strict intention-to-treat analysis was performed.

Moderate-strength evidence from one large, high-quality study demonstrated that vancomycin and fidaxomicin performed equally well for initial cure, but that recurrence was significantly decreased with fidaxomicin versus vancomycin.⁸² No other head-to-head trial demonstrated superiority of any single antimicrobial for initial clinical cure, clinical recurrence, or mean days to resolution of diarrhea. Combination therapy with rifampin and metronidazole resulted in significantly higher mortality when compared to treatment with metronidazole only.⁷⁴ Pooled data of 104 subjects comparing vancomycin to bacitracin showed significantly higher rates of organism or toxin clearance for vancomycin.^{77,80}

Harms were not reported with sufficient detail to compare the risks of any particular antimicrobial with another antimicrobial. When harms were reported, they were generally not serious (e.g. nausea, emesis) and transient.

A single study assessed initial cure and recurrence by strain, categorized as North American pulsed-field gel electrophoresis type 1 (NAP1) versus non-NAP1.⁸² Strain data was available for 324 of 629 (51.5%) participants. For initial cure, no significant difference was observed, regardless of strain. However, among patients with non-NAP1 strains, those treated with fidaxomicin recurred less frequently than those treated with vancomycin (10% vs. 28%; $P < 0.001$), whereas among patients with the NAP1 strain, recurrence was similarly frequent regardless of treatment.⁸²

Nonstandard Treatment (KQ4) Results

Five RCTs on nonstandard adjunctive treatments of CDI and 13 studies that addressed prevention of CDI formed the basis of this analysis. Four of the studies on treatment of CDI compared a nonstandard intervention with an active control, that is, a standard antibiotic treatment for CDI, oral vancomycin or metronidazole.⁸³⁻⁸⁶ One study compared a nonstandard intervention with placebo.⁸⁷ All of the 13 prevention studies compared the nonstandard intervention with placebo rather than with another intervention, reflecting the current state of the science in this area. Five of the 13 prevention studies analyzed antibiotic-acquired diarrhea as a primary outcome and CDI as a secondary outcome.⁸³⁻⁸⁶ Numerous published case reports, as well as nonexperimental studies, describe additional nonstandard approaches for treatment of CDI and their possible harms. As found with the other Key Questions, overall, study quality was low. Definitions of CDI with regard to diarrhea, that is, number and consistency of stools, were inconsistent across studies.

For treatment of CDI, *C. difficile* immune whey that binds *C. difficile* toxin A is similar to metronidazole in a small study of 38 patients with recurrent CDI.⁸⁵ Colestipol, an absorptive resin, is not more effective in treating CDI than placebo.⁸⁷ Probiotics administered as an adjunct to antibiotic treatment were not more effective than treatment with antibiotics alone.^{83,84,86}

There is low-strength limited evidence that the probiotic⁸⁸⁻⁹³ interventions in this review are not more effective than placebo for primary prevention of CDI. There is low-strength limited evidence from one subgroup analysis that a prebiotic may reduce diarrhea recurrence in patients treated for CDI more so than placebo with standard antibiotics.^{94,95} Fungemia is a serious potential harm associated with administration of probiotics for CDI in critically ill patients.^{96,97} In one review, 46 percent of 60 critically ill patients who developed fungemia had been administered a probiotic containing *Saccharomyces boulardii* and 5 more patients were in the vicinity of an administered probiotic. Seventeen patients subsequently died.⁹⁶

There is limited moderate-strength evidence from one study that monoclonal antibodies are effective in preventing recurrence of CDI.⁹⁸

There is limited low-strength evidence from two case series that fecal flora reconstitution is effective in treating recurrent CDI for up to 1 year.^{99,100}

Discussion

There is very limited high-strength evidence to support the diagnostic, preventive, and treatment practices for CDI carried out by providers in hospital, long-term care, and outpatient settings. Table A provides a summary of the evidence and results presented in this review. Inconsistency in definitions of diarrhea, severity, resolution of symptoms, recurrence, or cure contributes to the difficulty in drawing conclusions from the evidence.

In general, there is little evidence that the sensitivities of commonly used immunoassays for toxins A and B differ, and any differences in their percent of false positives (1 minus specificity) most likely are small (3 percent or less). However, the strength of the evidence is low due to the number of studies that have directly compared various immunoassays in the literature. Future research possibly could impact the findings. The available comparative data does not rule out the possibility of larger differences in test sensitivities between some of the immunoassays that have or have not been directly compared in adequate numbers. While the precision of the findings is such that we cannot rule out the possibility of differences in sensitivity on the order of 3 to 5 percent, it is unclear whether such differences would affect clinical decisionmaking.

Gene detection tests that focus on toxin B tended to have better sensitivity than immunoassays for toxins A and B. Results, however, should be viewed with caution, given rather imprecise confidence intervals on the estimated differences. Further study of the differences in false positives, if any, is needed, too. Few studies contributed to the findings, and many direct comparisons were not found. Furthermore, variation in the stability of the toxins in stool specimens as they were collected, stored, and processed may have contributed to the observed variation between studies in the estimates of the sensitivities of the immunoassays, whereas detection of amplified toxin gene fragments could be less susceptible to specimen degradation and more susceptible to contamination of specimens. Differences in the sensitivities of the reference tests could affect the estimated sensitivity for immunoassays to greater degrees than gene detection tests as well.

The immunoassays and gene detection tests require varying skills, equipment, and time to carry out, and heterogeneity is a significant factor in reviewing the literature. Previous reviews by Planche et al.¹⁰¹ and Crobach et al.¹⁰² encountered difficulty comparing the sensitivities and

specificities of immunoassays in large part because there was too much variation between studies in the estimates of the sensitivity and specificity of a particular test. We attempted to control for the heterogeneity between studies by examining the differences in sensitivity and specificity in stool samples tested within the same lab using the sample patient stool specimens and reference test, and we did not find strong evidence of differences between tests within several immunoassays for toxins type A and B. The extent of any publication bias for these comparisons is unknown.

A clinically important question is whether the potential differences in the accuracy of the diagnostic tests being employed in practice would translate into differences in clinical behaviors or patient outcomes. Indeed, how well clinicians actually know the sensitivity and specificity of the test(s) for toxigenic *C. difficile* employed by their laboratories and incorporate this information into their patient care decisions is not clear. If test results are combined with pretest probabilities that patients have toxigenic *C. difficile* using Bayes' formula, then the differences in post-test probabilities might not lead to different clinical decisions even if there are substantial differences in the sensitivities and specificities of tests for toxigenic *C. difficile*.

Very little evidence connects prevention strategies and techniques directly to patient-related outcomes, such as CDI incidence. Available evidence is generally from before–after study designs or limited time series. Hospital settings with outbreaks or hyperendemic episodes further limit applicability of the findings and leave open the question of the relative contribution of regression to the mean (i.e., that CDI rates returned to baseline rates even in the absence of effective interventions). The studies also varied in the degree to which they described CDI surveillance, diagnostic accuracy, or laboratory performance. In most, surveillance was passive and depended on a positive toxin test on a stool specimen sent by clinicians caring for a patient with diarrhea. Unknown numbers of cases might have been missed or misdiagnosed. Additionally, attention has not been given to describing a prevention strategy's potential harm (e.g., increase in other pathogens, reduction in direct patient care contact due to isolation or restrictive contact requirements, increased costs) or the long-term sustainability of a practice.

There is low-strength evidence that antibiotic prescribing practices appear to reduce CDI incidence, a finding consistent with the Cochrane review.⁴⁴ None of the studies explicitly addressed the potential harms of changes in antibiotic use policy, but there are several theoretical harms. They include the possibility that preferred drugs will be less effective than drugs that physicians are discouraged from using, or drugs that are made unavailable for treating infections other than CDI. Preferred antimicrobials might have greater costs or greater toxicities unrelated to CDI. *C. difficile* strains might evolve to develop resistance to the preferred antibiotics, which might increase the likelihood that the recommended antibiotics might induce CDI.

While several studies found increased risk with specific antibiotics or antibiotic classes, the antibiotics that confer greater risk for CDI have changed over time and vary by location because of differences in prevalent toxigenic strains and especially the susceptibility patterns of those strains.¹⁰³ Clindamycin resistance was identified soon after the role of *C. difficile* in pathogenesis was discovered.^{49,104,105} More recently, quinolones have assumed greater importance because strains have become more resistant over time.¹⁰⁶

Fewer studies are available to support prevention practices aimed at breaking transmission. There was limited low-strength evidence that gloves, disposable thermometers, handwashing, and intensive disinfection solutions help to reduce CDI incidence. In addition, the presence and use of alcohol gel to prevent other hospital-acquired infections, such as MRSA, did not increase the rate of CDI incidence as might be expected if alcohol gel use replaced handwashing.

Similar to the antibiotic prescribing practice research, none of the studies aimed at breaking transmission addressed potential harms for other prevention practices. Costs of disinfection, time to perform disinfection, and the possible harm to surfaces and equipment should be anticipated. Failures with vapor disinfection systems would be possible and might lead to toxic exposures of personnel or patients. Nor is there evidence to inform infection control professionals whether such practices are sustainable after an intervention period. That is, we cannot answer whether environmental cleaning staff will have developed professional habits that will continue when the intense monitoring related to an intervention period discontinues.

The potential for prevention research is often compromised by the swift uptake of newly described prevention strategies with the belief that these will improve institutional practices and health care quality and will reduce CDI morbidity and mortality. Current prevention strategies often rely on studies using intermediate outcomes such as process. Newly acquired strategies are then added to current practice, bundling them into multiple component interventions. When introduced in outbreak or hyperendemic situations, these “bundled” multipronged prevention efforts in natural settings have been associated with reduction in CDI incidence. The bundles appear to be beneficial, but from a research standpoint, it is challenging to design research that would tease out the relative contributions of single components to the overall bundle of prevention strategies to determine which ones are essential or what might be added.

The available evidence is insufficient to say whether any antimicrobial treatment is better than another, including the two most commonly used treatments, metronidazole and vancomycin. The total number of subjects from comparative studies on metronidazole and vancomycin is just 335 patients. This raises the possibility that, although a significant difference in effectiveness has not been detected, a true difference may exist. There is moderate strength of evidence that recurrence is less frequent with fidaxomicin than with vancomycin, and that these two agents are not significantly different from one another for initial cure. Otherwise, there is no evidence for a difference in effectiveness for other agents, but again the possibility remains that such a difference exists. However, at this time, any claims that one agent is superior to another for all cases of CDI are not supported by available evidence. The findings apply to general adult inpatients. Bias due to selectively reporting outcomes is possible if cut-points are changed for CDI definitions, for example, number or consistency of stools. The clinical differences of changes in cut-points are also unknown, however, so the clinical significance could remain.

We found insufficient evidence that vancomycin was superior to metronidazole for subjects classified as having severe disease. One subgroup analysis of a single trial used a prespecified analysis, and the severity classification appears to have been made before treatment allocation. However, the superiority of vancomycin over metronidazole does not persist when a strict intention-to-treat analysis is used.

We sought to document the range of treatments under investigation for treatment and prevention of CDI, particularly recurrent CDI. The evidence for effectiveness of nonstandard interventions for treating CDI shows that probiotics, prebiotics, *C. difficile* immune whey, and colestipol are not more effective in treating CDI than standard antibiotic treatment with oral vancomycin or metronidazole or compared with placebo. The evidence supporting this conclusion is limited and of low strength.

Prevention of CDI, both initial and recurrent cases, through interventions intended to improve gut flora and host immunity is also a very active topic in the literature. There is limited, low-strength evidence that the nonstandard prevention interventions are not more effective than placebo for primary prevention of CDI. There is limited evidence of low strength that

administering the prebiotic oligofructose or a monoclonal antibody to *C. difficile* toxins A and B along with standard antibiotics for CDI are better than placebo and active control in preventing recurrence of CDI in patients treated for CDI. Although the studies for both treatment and prevention of CDI using a nonstandard intervention included components of experimental designs, few had adequate rigor to yield high-quality findings or power to detect a significant difference between the interventions (or placebo) compared. In some studies, a low rate of CDI precluded statistical testing.

Caution is recommended regarding new, nonstandard treatments and not extrapolating study findings beyond the data. For example, one cannot assume that if a probiotic treatment is effective for antibiotic-associated diarrhea, it will be effective for CDI. Likewise, attention should be paid to which patients were included and excluded in probiotic treatment studies. Such studies generally exclude high-risk patients. Thus, there is no evidence for the use of probiotics in high-risk patients.

Future Research

A number of important questions need to be addressed regarding diagnostic testing, prevention, and treatment of CDI. Table B summarizes the research recommendations.

Diagnostic Tests

It is difficult to apply the available evidence from comparative studies to help select the best diagnostic test(s) for clinical applications. The reviewed comparative studies did not clearly define the testing scenario including the setting, disease prevalence, patient selection criteria, patient characteristics, or signs and symptoms of the suspected CDI, making it difficult to judge to whom the study results might apply. Ultimately, the clinical importance of estimated differences in sensitivity (true positives), false positives, specificity (true negatives), and false negatives depends on how these types of test results would affect clinical decisions, hence patient outcomes.

More research is needed to understand how test sensitivities and specificities are used to make decisions in clinical practice, and to define clinically meaningful differences based on their effects on clinical decisions and patient outcomes. Multicenter studies that (1) consistently use the most clinically relevant reference test, (2) use explicit clinical criteria to select patients and stool specimens to be tested, (3) randomly assign patients to different diagnostic tests, and (4) use key clinical outcomes as study endpoints are needed to fill this major gap in knowledge about diagnostic tests for toxigenic *C. difficile*.

Questions about whether the newer toxin gene amplification and detection tests are more consistent across laboratories, and more sensitive than the currently used toxin immunoassays for toxin without substantial loss of specificity, need further study. Most importantly, studies are needed to demonstrate that use of tests that detect genetic residue related to *C. difficile* toxin production rather than the toxins per se lead to better patient outcomes.

Prevention

A number of potential prevention strategies can and should be investigated as a single intervention in a controlled trial in order to understand its potential contribution to a prevention program. However, the main obstacle to research in this area is the contextual setting.

Prevention happens within an institutional environment, as a comprehensive approach for preventing multiple potential hospital-acquired infectious agents and attending to multiple potential vectors of transmission and host susceptibility. Researchers and decisionmakers may need to consider another approach to inform decisionmaking: a collaborative research process in which consensus agreements are reached for minimum datasets and followup periods, and definitions of interventions are agreed to in order to facilitate pooling data across organizations. For example, minimum datasets might be those that would yield statistically significant results in a controlled trial if the intervention arm could prevent 10 to 20 percent of CDI cases. Datasets of this nature could allow for employing more sophisticated epidemiological and decision analytic techniques to tease apart the relative contributions of different prevention strategies. The nature of the decisions faced by infection control professionals is qualitatively different from a physician's clinical decisions for an individual CDI patient. Decision analytic techniques may be particularly valuable in this venue.

Standard Treatment

The greatest needs for future studies for CDI treatment are consistent definitions and reporting of outcomes, a uniform and clinically relevant definition of disease severity, and trials with adequate power to detect clinically meaningful differences in outcomes. In particular, trials need to include adequate numbers of subjects to allow stratification by patient characteristics such as age, gender, and comorbid conditions in order to address questions regarding the most effective therapy for CDI. A well-validated and clinically meaningful severity score would also assist in treatment decisions. Although most agents for CDI appear to be well tolerated, explicit reporting of adverse events by treatment allocation is another area where future research can improve our understanding of optimal management of this disease.

Although identifying the strain of *C. difficile* is of great relevance to researchers and can offer useful information to hospital epidemiologists, at present, strain identification is rarely performed in clinical settings. Thus, few clinicians treating CDI are aware of which strain of *C. difficile* is causing an individual patient's disease and can, at most, make an assumption as to the strain type based on current epidemiology reported in the literature. This limitation makes any difference by strain in treatment efficacy of uncertain relevance.

Nonstandard Treatment

Additional research on nonstandard interventions as adjunctive or alternatives to standard antibiotics for preventing and treating CDI is needed and encouraged. Studies to prevent recurrence of *C. difficile* are a priority of prevention. As no single approach has been shown to be superior, promoting studies of different types of interventions is reasonable at this time.

Fecal flora reconstitution is one novel therapy for which continued research is supported. Of all the nonstandard interventions, probiotics have been investigated in the most studies, and the results are not encouraging. Unlike fecal flora reconstitution, probiotics provide only a single strain or a few strains of bacteria, and thus may be insufficient to correct alterations in the complex and extensive microbiome to the extent needed to be therapeutic. The genomic mapping of indigenous microflora may offer new information to guide future formulation of a probiotic that can effectively target alterations in the microbiome in CDI and other diseases of the colon. A third strategy related to modifying microbial ecology in CDI for which additional research is supported is administration of a nontoxigenic strain of *C. difficile*.

Developing agents to treat severe cases of refractory CDI is another area in need of research. Identifying new antibiotics may be one approach. Two of the larger case series of immunoglobulin use are in severely ill patients, and results are inconsistent.^{107,108} Whether immunoglobulin might confer greater benefit if initiated earlier in the course of CDI prior to extensive systemic involvement is an area for further study.

Studies are needed to determine whether some patients might be more likely to respond to nonstandard interventions. Sampling in current studies of nonstandard interventions varies considerably, ranging from individuals who are just starting antibiotics for infections other than *C. difficile*, to those who have had multiple failures of antibiotic treatment for CDI itself, to those who have had *C. difficile* in the past. Whether any one type of nonstandard intervention is effective in all of these types of cases is a question. More information is needed about patients who are at high risk for recurrence of CDI.

The effect of sequencing therapies (antibiotic as well as nonstandard) on the resolution of CDI merits further research. Studies show a variety of procedures for administering probiotics to prevent CDI, for example, such as during standard antibiotic therapy or for a period after standard treatment is completed. Determining the optimal timing to introduce nonstandard interventions to possibly maximize their effect is recommended.

Methodological Improvements

It is essential that future studies of a nonstandard intervention for treatment or prevention of CDI be supported by a power analysis, adequate sample size, and an intent-to-treat analysis, in addition to other standard quality components of experimental design. Study designs must separate interventions for prevention versus treatment of recurrent CDI if this approach is desired. Multicenter studies may be necessary to achieve adequate sample sizes. Laboratory confirmation of a pathogenic *C. difficile* organism (e.g., by toxin testing) and clinical symptoms of disease (e.g., diarrhea) are essential not only for study eligibility but for determination of recurrence in long-term followup. Adoption of a standard definition of diarrhea as part of the definition of CDI is strongly recommended. Similarly, a standard definition of CDI resolution should be adopted. RCTs that compare more than one type of nonstandard intervention are suggested for efficiency.

Table A. Summary of evidence

Key Questions	Level of Evidence	Summary/Conclusion/Comments
Key Question 1 - Diagnostics		
Immunoassays for toxins A and B	Low to moderate	Ten studies directly compared at least 2 immunoassays for toxins A and B, providing 16 pairwise comparisons of 7 different immunoassays. Comparative data were not found for many currently used tests. There were no statistical differences between the sensitivities of immunoassays that were compared; however, the estimates of the differences in sensitivity were not very precise and could not rule out substantial differences. Substantial differences in false positives, that is, specificity, were not found among the tests that were compared.
Gene detection tests versus immunoassays for toxins A and B	Low to moderate	Four studies compared at least one toxin gene detection test to at least one immunoassay for toxins A and B, providing a total of nine direct comparisons. Comparative data were not always available for the three currently available gene detection tests. The gene detection tests could be substantially more sensitive than many immunoassays for toxins A and B, with no or relatively modest loss of specificity.

Table A. Summary of evidence (continued)

Key Questions	Level of Evidence	Summary/Conclusion/Comments
Patient characteristics	Insufficient	Insufficient patient information was provided in reports of comparative data.
Key Question 2 - Prevention		
Antibiotic use	Low	Sixteen studies, including six bundled prevention practice studies, found appropriate prescribing practices are associated with decreased CDI incidence. Harms were not reported.
Gloves	Low	One controlled trial found use of gloves in hospital settings reduced CDI incidence.
Disposable thermometer	Low	Three time series/before–after studies, two with controls, found use of disposable thermometers in hospital settings reduced CDI incidence.
Handwashing/ alcohol gel	Low	No study examined whether handwashing reduced CDI incidence. Two studies, one controlled trial and one before–after study, of use of alcohol gel to reduce MRSA transmission did not find significant differences in CDI incidence.
Disinfection	Low	Thirteen before–after studies of outbreaks or endemic hospital settings found intensive disinfection with a chemical compound that kills <i>C. difficile</i> spores reduced CDI incidence.
Sustainability	Insufficient	No evidence was available.
Risk factors	Low	Ten observational studies found evidence that antibiotic use, whether specific or general, increased risk of CDI. Severe underlying disease, acid suppression, and age are indicated as risk factors. A number of other potential factors may be indicated in single studies.
Multiple component strategies	Insufficient	Eleven time series/before–after studies examined bundles of prevention components in a single intervention. Data are insufficient to draw conclusions. Harms were not reported.
Key Question 3 - Antibiotic Treatment		
Vancomycin versus metronidazole	Moderate for clinical cure, low for all other outcomes	There were 3 head-to-head trials with a total of 335 subjects. Trials used various definitions of CDI patient and cure, especially with regard to stool count and consistency. No significant differences in outcomes, including initial cure, clinical recurrence, and mean days to resolved diarrhea, were found. Our results build upon, and are consistent with, the Cochrane Reviews search completed by Bricker et al. ¹⁰⁹
Severe disease, vancomycin versus metronidazole	Insufficient	One RCT examined a prespecified subgroup of 69 subjects with severe CDI; improved clinical cure was based on per-protocol analysis, but not with strict intention-to-treat analysis
Fidaxomicin versus vancomycin	Moderate	One large, high-quality RCT demonstrated decreased recurrence among those receiving fidaxomicin.
All other comparisons of standard treatments	Moderate for vancomycin versus fidaxomicin, low for all other comparisons	There were eight trials examining: vancomycin versus bacitracin (two trials), vancomycin versus fidaxomicin, vancomycin versus nitazoxanide, vancomycin high versus low dose, vancomycin versus placebo, metronidazole versus nitazoxanide, and metronidazole versus metronidazole plus rifampin (one each). No differences.
Strain of organism	Low	One RCT (fidaxomicin vs. vancomycin) demonstrated decreased recurrence among those receiving fidaxomicin when the infecting organism was a non-NAP1 strain.
Patient characteristics	Insufficient	No comparative data were available.
Resistance of other pathogens	Insufficient	No data were available.

Table A. Summary of evidence (continued)

Key Questions	Level of Evidence	Summary/Conclusion/Comments
Key Question 4 - Nonstandard Treatment		
Treating CDI, active control	Low	Probiotics, prebiotics, <i>C. difficile</i> immune whey, and colestipol are not more effective in treating CDI than standard antibiotic treatment with oral vancomycin or metronidazole or placebo.
Treating CDI, placebo	Low	Administration of a probiotic with live bacteria to treat CDI in critically ill patients increases risk for greater morbidity and mortality from fungemia without any known benefit.
Treating recurrent CDI	Low	There is limited evidence from two case series that fecal flora reconstitution is effective in treating recurrent CDI for up to 1 year.
Preventing CDI	Low	There is limited evidence that the nonstandard interventions in this review are not more effective than placebo for primary prevention of CDI.
Preventing recurrent CDI	Low to moderate	There is limited evidence from one subgroup analysis that a prebiotic may reduce diarrhea recurrence in patients treated for CDI more so than placebo with standard antibiotics. There is limited moderate-strength evidence from one study that monoclonal antibodies are effective in preventing recurrence of CDI.

CDI = *Clostridium difficile* infection; RCT = randomized controlled trial

Table B. Future research recommendations

Key Questions	Research Gaps	Types of Studies Needed to Answer Questions	Future Research Recommendations
Key Question 1. How do different methods for detection of toxigenic <i>C. difficile</i> compare in their sensitivity, specificity, and predictive values?	Few comparisons are available Heterogeneity is an obstacle Unknown what differences in sensitivity and specificity would alter clinician decisionmaking Unknown influence of patient and stool characteristics on test sensitivity and specificity	Comparison of diagnostic tests using same samples, same labs Multicenter studies with well-documented patient samples	Document stool sample characteristics, patient selection criteria, patient characteristics, and signs and symptoms of suspected CDI
Key Question 2. What are effective prevention strategies?	Little evidence available with clinically important outcomes	High-quality comparative studies evaluating effectiveness and harms of single and/or multicomponent prevention strategies, including cleaning, isolation, antibiotic restriction Discrete simulation models	Pool data from multiple participating hospital sites Establish minimum datasets for observational data points that can inform models
Key Question 3. What are the comparative effectiveness and harms of different antibiotic treatments?	Limited evidence available on whether vancomycin is more effective for severe CDI.	High-quality comparative studies with adequate power to detect significance in a priori subgroups	A uniform and clinically relevant definition of severity Subgroup analysis may include age, gender, comorbid conditions Explicit reporting of adverse events

Table B. Future research recommendations (continued)

Key Question	Research Gaps	Types of Studies Needed to Answer Questions	Future Research Recommendation
Key Question 4. What are the effectiveness and harms of nonstandard adjunctive interventions?	Probiotics as a treatment adjuvant is not supported. Potential harms to seriously ill patients may outweigh potential benefits for further prevention research Probiotics as prevention warrants further study Further research of monoclonal antibodies for prevention is warranted Further research of fecal transplant is warranted	High-quality comparative studies with adequate power	Placebo comparators would contribute indirect evidence to help guide potential combination therapies Quality research includes power analysis, intention to treat Multicenter trials are likely needed to achieve adequate samples Probiotics trials for prevention are well represented in ongoing studies Patient characteristics for subgroup analysis
Umbrella issues			Adoption of standard definitions for diarrhea, CDI resolution

CDI = *Clostridium difficile* infection

References

1. Gravel D, Miller M, Simor A, et al. Health care-associated *Clostridium difficile* infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. *Clinical Infect Dis* 2009 Mar 1; 48(5):568–76.
2. McDonald LC. Confronting *Clostridium difficile* in inpatient health care facilities. *Clin Infect Dis* 2007 Nov 15; 45(10):1274–6.
3. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *N Engl J Med* 2005 Dec 8; 353(23):2442–9.
4. Brandt LJ, Kosche KA, Greenwald DA, et al. *Clostridium difficile*-associated diarrhea in the elderly. *Am J Gastroenterol* 1999 Nov; 94(11):3263–6.
5. Hebuterne X. Gut changes attributed to ageing: effects on intestinal microflora. *Curr Opin Clin Nutr Metab Care* 2003 Jan; 6(1):49–54.
6. Kim J, Smathers SA, Prasad P, et al. Epidemiological features of *Clostridium difficile*-associated disease among inpatients at children's hospitals in the United States, 2001-2006. *Pediatrics* 2008 Dec; 122(6):1266–70.
7. Simor AE, Bradley SF, Strausbaugh LJ, et al. *Clostridium difficile* in long-term-care facilities for the elderly. *Infect Control Hosp Epidemiol* 2002 Nov; 23(11):696–703.
8. Laffan AM, Bellantoni MF, Greenough WB, 3rd, et al. Burden of *Clostridium difficile*-associated diarrhea in a long-term care facility. *J Am Geriatr Soc* 2006 Jul; 54(7):1068–73.
9. Jarvis WR, Schlosser J, Jarvis AA, et al. National point prevalence of *Clostridium difficile* in US health care facility inpatients, 2008. *Am J Infect Control* 2009 May; 37(4):263–70.
10. Kim KH. Isolation of *Clostridium difficile* from the environment and contacts of patients with antibiotic-associated colitis. *J Infect Dis* 1981 Jan; 143(1):42–50.
11. McFarland LV. Renewed interest in a difficult disease: *Clostridium difficile* infections--epidemiology and current treatment strategies. *Curr Opin Gastroenterol* 2009 Jan; 25(1):24–35.
12. Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of *Clostridium difficile* isolates from various patient populations. *Gastroenterol* 1981 Jul; 81(1):5–9.
13. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent *Clostridium difficile*-associated diarrhea. *J Infect Dis* 2008 Feb 1; 197(3):435–8.
14. Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. *J Clin Microbiol* 2004 Mar; 42(3):1203–6.
15. Aslam S, Musher DM. An update on diagnosis, treatment, and prevention of *Clostridium difficile*-associated disease. *Gastroenterol Clin North Am* 2006 Jun; 35(2):315–35.
16. Dial S, Alrasadi K, Manoukian C, et al. Risk of *Clostridium difficile* diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. *CMAJ* 2004 Jul 6; 171(1):33–8.
17. Dial S, Delaney JAC, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired *Clostridium difficile*-associated disease. *JAMA* 2005 Dec 21; 294(23):2989–95.
18. Aseeri M, Schroeder T, Kramer J, et al. Gastric acid suppression by proton pump inhibitors as a risk factor for *Clostridium difficile*-associated diarrhea in hospitalized patients. *Am J Gastroenterol* 2008 Sep; 103(9):2308–13.
19. Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent *Clostridium difficile* infection. *Arch Intern Med* 2010 May 10; 170(9):772–8.
20. Bignardi GE. Risk factors for *Clostridium difficile* infection. *J Hosp Infect* 1998 Sep; 40(1):1–15.

21. Garey KW, Sethi S, Yadav Y, et al. Meta-analysis to assess risk factors for recurrent *Clostridium difficile* infection. *J Hosp Infect* 2008 Dec; 70(4):298–304.
22. Cunningham R, Dial S. Is over-use of proton pump inhibitors fuelling the current epidemic of *Clostridium difficile*-associated diarrhoea? *J Hosp Infect* 2008 Sep; 70(1):1–6.
23. Thibault A, Miller MA, Gaese C. Risk factors for the development of *Clostridium difficile*-associated diarrhea during a hospital outbreak. *Infect Control Hosp Epidemiol* 1991 Jun; 12(6):345–8.
24. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. *Am J Gastroenterol* 2007 Sep; 102(9):2047–56; quiz 57.
25. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial *Clostridium difficile* infection. *Arch Intern Med* 2010 May 10; 170(9):784–90.
26. Starr JM, Campbell A, Renshaw E, et al. Spatio-temporal stochastic modelling of *Clostridium difficile*. *J Hosp Infect* 2009 Jan; 71(1):49–56.
27. Gerding DN, Muto CA, Owens RC, Jr. Measures to control and prevent *Clostridium difficile* infection. *Clin Infect Dis* 2008 Jan 15; 46 Suppl 1:S43–9.
28. Centers for Disease Control and Prevention. Severe *Clostridium difficile*-associated disease in populations previously at low risk: four states, 2005. *MMWR Morb Mortal Wkly Rep* 2005 Dec 2; 54(47):1201–5.
29. Hensgens MP, Goorhuis A, Notermans DW, et al. Decrease of hypervirulent *Clostridium difficile* PCR ribotype 027 in the Netherlands. *Euro Surveill* 2009; 14(45).
30. Belmares J, Johnson S, Parada JP, et al. Molecular epidemiology of *Clostridium difficile* over the course of 10 years in a tertiary care hospital. *Clin Infect Dis* 2009 Oct 15; 49(8):1141–7.
31. Alcalá L, Sánchez-Cambronero L, Catalan MP, et al. Comparison of three commercial methods for rapid detection of *Clostridium difficile* toxins A and B from fecal specimens. *J Clin Microbiol* 2008 Nov; 46(11):3833–5.
32. Eastwood K, Else P, Charlett A, et al. Comparison of nine commercially available *Clostridium difficile* toxin detection assays, a real-time PCR assay for *C. difficile* tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. *J Clin Microbiol* 2009 Oct; 47(10):3211–7.
33. Musher DM, Manhas A, Jain P, et al. Detection of *Clostridium difficile* toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay. *J Clin Microbiol* 2007 Aug; 45(8):2737–9.
34. Samra Z, Luzon A, Bishara J. Evaluation of two rapid immunochromatography tests for the detection of *Clostridium difficile* toxins. *Dig Dis Sci* 2008 Jul; 53(7):1876–9.
35. Sloan LM, Duresko BJ, Gustafson DR, et al. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of *Clostridium difficile* infection. *J Clin Microbiol* 2008 Jun; 46(6):1996–2001.
36. O'Connor D, Hynes P, Cormican M, et al. Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of *Clostridium difficile*-associated diarrhea. *J Clin Microbiol* 2001 Aug; 39(8):2846–9.
37. Kvach EJ, Ferguson D, Riska PF, et al. Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic *Clostridium difficile* infection. *J Clin Microbiol* 2010 Jan; 48(1):109–14.
38. Turgeon DK, Novicki TJ, Quick J, et al. Six rapid tests for direct detection of *Clostridium difficile* and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. *J Clin Microbiol* 2003 Feb; 41(2):667–70.

39. Miendje Deyi VY, Vandenberg O, Mascart G, et al. Diagnostic value of five commercial tests for the rapid diagnosis of *Clostridium difficile*-associated disease. *Clin Lab* 2008; 54(1–2):9–13.
40. Novak-Weekley SM, Marlowe EM, Miller JM, et al. *Clostridium difficile* testing in the clinical laboratory by use of multiple testing algorithms. *J Clin Microbiol* 2010 Mar; 48(3):889–93.
41. van den Berg RJ, Vaessen N, Endtz HP, et al. Evaluation of real-time PCR and conventional diagnostic methods for the detection of *Clostridium difficile*-associated diarrhoea in a prospective multicentre study. *J Med Microbiol* 2007 Jan;56(Pt 1):36–42.
42. Alcalá L, Marin M, Madrid M, et al. Comparison of ImmunoCard Toxins A&B and the new semiautomated Vidas *Clostridium difficile* Toxin A&B tests for diagnosis of *C. difficile* infection. *J Clin Microbiol* 2010 Mar;48(3):1014–5.
43. Swindells J, Brenwald N, Reading N, et al. Evaluation of diagnostic tests for *Clostridium difficile* infection. *J Clin Microbiol* 2010 Feb;48(2):606–8.
44. Davey P, Brown E, Fenelon L, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev* 2005;(4):CD003543.
45. Fowler S, Webber A, Cooper BS, et al. Successful use of feedback to improve antibiotic prescribing and reduce *Clostridium difficile* infection: a controlled interrupted time series. *J Antimicrob Chemother* 2007 May; 59(5):990–5.
46. Wilcox MH, Freeman J, Fawley W, et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of *Clostridium difficile* diarrhoea. *J Antimicrob Chemother* 2004 Jul; 54(1):168–72.
47. O'Connor KA, Kingston M, O'Donovan M, et al. Antibiotic prescribing policy and *Clostridium difficile* diarrhoea. *QJM* 2004 Jul; 97(7):423–9.
48. Ludlam H, Brown N, Sule O, et al. An antibiotic policy associated with reduced risk of *Clostridium difficile*-associated diarrhoea. *Age Ageing* 1999 Oct; 28(6):578–80.
49. Johnson S, Gerding DN, Olson MM, et al. Prospective, controlled study of vinyl glove use to interrupt *Clostridium difficile* nosocomial transmission. *Am J Med* 1990 Feb; 88(2):137–40.
50. Brooks SE, Veal RO, Kramer M, et al. Reduction in the incidence of *Clostridium difficile*-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. *Infect Control Hosp Epidemiol* 1992 Feb; 13(2):98–103.
51. Brooks S, Khan A, Stoica D, et al. Reduction in vancomycin-resistant *Enterococcus* and *Clostridium difficile* infections following change to tympanic thermometers. *Infect Control Hosp Epidemiol* 1998 May; 19(5):333–6.
52. Jernigan JA. A randomized crossover study of disposable thermometers for prevention of *Clostridium difficile* and other nosocomial infections. *Infect Control Hosp Epidemiol* 1998; 19(7):494–9.
53. Rupp ME, Fitzgerald T, Puumala S, et al. Prospective, controlled, cross-over trial of alcohol-based hand gel in critical care units. *Infect Control Hosp Epidemiol* 2008 Jan; 29(1):8–15.
54. Gordin FM, Schultz ME, Huber RA, et al. Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub. *Infect Control Hosp Epidemiol* 2005 Jul; 26(7):650–3.
55. Kaier K. Two time-series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant *Staphylococcus aureus* infection and *Clostridium difficile* infection. *Infect Control Hosp Epidemiol* 2009; 30(4):346–53.
56. Mayfield JL, Leet T, Miller J, et al. Environmental control to reduce transmission of *Clostridium difficile*. *Clin Infect Dis* 2000 Oct; 31(4):995–1000.

57. Kaatz GW, Gitlin SD, Schaberg DR, et al. Acquisition of *Clostridium difficile* from the hospital environment. *Am J Epidemiol* 1988 Jun; 127(6):1289–94.
58. Struelens MJ, Maas A, Nonhoff C, et al. Control of nosocomial transmission of *Clostridium difficile* based on sporadic case surveillance. *Am J Med* 1991 Sep 16; 91(3B):138S–44S.
59. Abbett SK, Yokoe DS, Lipsitz SR, et al. Proposed checklist of hospital interventions to decrease the incidence of healthcare-associated *Clostridium difficile* infection. *Infect Control Hosp Epidemiol* 2009 Nov; 30(11):1062–9.
60. Boyce JM, Havill NL, Otter JA, et al. Impact of hydrogen peroxide vapor room decontamination on *Clostridium difficile* environmental contamination and transmission in a healthcare setting. *Infect Control Hosp Epidemiol* 2008 Aug; 29(8):723–9.
61. Brown E, Talbot GH, Axelrod P, et al. Risk factors for *Clostridium difficile* toxin-associated diarrhea. *Infect Control Hosp Epidemiol* 1990 Jun; 11(6):283–90.
62. Cartmill TD, Panigrahi H, Worsley MA, et al. Management and control of a large outbreak of diarrhoea due to *Clostridium difficile*. *J Hosp Infect* 1994 May; 27(1):1–15.
63. Drudy D, Harnedy N, Fanning S, et al. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive *Clostridium difficile*. *Infect Control Hosp Epidemiol* 2007 Aug; 28(8):932–40.
64. McNulty C, Logan M, Donald IP, et al. Successful control of *Clostridium difficile* infection in an elderly care unit through use of a restrictive antibiotic policy. *J Antimicrob Chemother* 1997 Nov; 40(5):707–11.
65. Pear SM, Williamson TH, Bettin KM, et al. Decrease in nosocomial *Clostridium difficile*-associated diarrhea by restricting clindamycin use. *Ann Intern Med* 1994 Feb 15; 120(4):272–7.
66. Valiquette L, Cossette B, Garant MP, et al. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of *Clostridium difficile*-associated disease caused by the hypervirulent NAP1/027 strain. *Clin Infect Dis* 2007 Sep 1; 45 Suppl 2:S112–21.
67. Zafar AB, Gaydos LA, Furlong WB, et al. Effectiveness of infection control program in controlling nosocomial *Clostridium difficile*. *Am J Infect Control* 1998 Dec; 26(6):588–93.
68. Whitaker J, Brown BS, Vidal S, et al. Designing a protocol that eliminates *Clostridium difficile*: a collaborative venture. *Am J Infect Control* 2007 Jun; 35(5):310–4.
69. Vernaz N, Sax H, Pittet D, et al. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and *Clostridium difficile*. *J Antimicrob Chemother* 2008 Sep; 62(3):601–7.
70. Hacek DM, Ogle AM, Fisher A, et al. Significant impact of terminal room cleaning with bleach on reducing nosocomial *Clostridium difficile*. *Am J Infect Control* 2010 Jun; 38(5):350–3.
71. McMullen KM, Zack J, Coopersmith CM, et al. Use of hypochlorite solution to decrease rates of *Clostridium difficile*-associated diarrhea. *Infect Control Hosp Epidemiol* 2007 Feb; 28(2):205–7.
72. Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in *Clostridium difficile* infection: a randomized, double-blind study. *Clin Infect Dis* 2009 Feb 15; 48(4):e41–6.
73. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clin Infect Dis* 2007 Aug 1; 45(3):302–7.
74. Lagrotteria D, Holmes S, Smieja M, et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of *Clostridium difficile*-associated diarrhea. *Clin Infect Dis* 2006 Sep 1; 43(5):547–52.

75. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of *Clostridium difficile* colitis. *Clin Infect Dis* 2006 Aug 15; 43(4):421-7.
76. Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of *Clostridium difficile*-associated diarrhea. *Clin Infect Dis* 1996 May; 22(5):813-8.
77. Dudley MN, McLaughlin JC, Carrington G, et al. Oral bacitracin vs vancomycin therapy for *Clostridium difficile*-induced diarrhea. A randomized double-blind trial. *Arch Intern Med* 1986 Jun; 146(6):1101-4.
78. Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic-associated *Clostridium difficile* colitis with oral vancomycin: comparison of two dosage regimens. *Am J Med* 1989 Jan; 86(1):15-9.
79. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for *Clostridium-difficile*-associated diarrhoea and colitis. *Lancet* 1983 Nov 5; 2(8358):1043-6.
80. Young GP, Ward PB, Bayley N, et al. Antibiotic-associated colitis due to *Clostridium difficile*: double-blind comparison of vancomycin with bacitracin. *Gastroenterol* 1985 Nov; 89(5):1038-45.
81. Keighley MR, Burdon DW, Arabi Y, et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. *BMJ* 1978 Dec 16; 2(6153):1667-9.
82. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for *Clostridium difficile* infection. *N Engl J Med* 2011 Feb 3; 364(5):422-31
83. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent *Clostridium difficile* disease: use of high-dose vancomycin combined with *Saccharomyces boulardii*. *Clin Infect Dis* 2000 Oct; 31(4):1012-7.
84. Wullt M, Hagslatt ML, Odenholt I. *Lactobacillus plantarum* 299v for the treatment of recurrent *Clostridium difficile*-associated diarrhoea: a double-blind, placebo-controlled trial. *Scand J Infect Dis* 2003; 35(6-7):365-7.
85. Mattila E, Anttila VJ, Broas M, et al. A randomized, double-blind study comparing *Clostridium difficile* immune whey and metronidazole for recurrent *Clostridium difficile*-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. *Scand J Infect Dis* 2008; 40(9):702-8.
86. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of *Saccharomyces boulardii* in combination with standard antibiotics for *Clostridium difficile* disease. *JAMA* 1994 Jun 22-29; 271(24):1913-8.
87. Mogg GA, George RH, Youngs D, et al. Randomized controlled trial of colestipol in antibiotic-associated colitis. *Br J Surg* 1982 Mar; 69(3):137-9.
88. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by *Saccharomyces boulardii*: a prospective study. *Gastroenterol* 1989 Apr; 96(4):981-8.
89. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of *Saccharomyces boulardii* in the prevention of antibiotic-related diarrhoea in elderly patients. *J Infect* 1998 Mar; 36(2):171-4.
90. Thomas MR, Litin SC, Osmon DR, et al. Lack of effect of *Lactobacillus GG* on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. *Mayo Clin Proc* 2001 Sep; 76(9):883-9.
91. Plummer S, Weaver MA, Harris JC, et al. *Clostridium difficile* pilot study: effects of probiotic supplementation on the incidence of *C. difficile* diarrhoea. *Int Microbiol* 2004 Mar; 7(1):59-62.
92. Can M, Besirbellioglu BA, Avci IY, et al. Prophylactic *Saccharomyces boulardii* in the prevention of antibiotic-associated diarrhea: a prospective study. *Med Sci Monit* 2006 Apr; 12(4):P19-22.

93. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic *Lactobacillus* preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. *BMJ* 2007 Jul 14; 335(7610):80.
94. Lewis S, Burmeister S, Cohen S, et al. Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea. *Aliment Pharmacol Ther* 2005 Feb 15; 21(4):469–77.
95. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of *Clostridium difficile*-associated diarrhea: a randomized, controlled study. *Clin Gastroenterol Hepatol* 2005 May; 3(5):442–8.
96. Munoz P, Bouza E, Cuenca-Estrella M, et al. *Saccharomyces cerevisiae* fungemia: an emerging infectious disease.[see comment]. *Clin Infect Dis* 2005 Jun 1; 40(11):1625–34.
97. Eriksson S, Aronsson B. Medical implications of nosocomial infection with *Clostridium difficile*. *Scand J Infect Dis* 1989; 21(6):733–4.
98. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against *Clostridium difficile* toxins. *N Engl J Med* 2010 Jan 21; 362(3):197–205.
99. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing *Clostridium difficile* diarrhoea in six patients. *Lancet* 1989 May 27; 1(8648):1156–60.
100. Persky SE, Brandt LJ. Treatment of recurrent *Clostridium difficile*-associated diarrhea by administration of donated stool directly through a colonoscope. *Am J Gastroenterol* 2000 Nov; 95(11):3283–5.
101. Planche T, Aghaizu A, Holliman R, et al. Diagnosis of *Clostridium difficile* infection by toxin detection kits: a systematic review. *Lancet Infect Dis* 2008 Dec; 8(12):777–84.
102. Crobach MJ, Dekkers OM, Wilcox MH, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing *Clostridium difficile*-infection (CDI). *Clin Microbiol Infect* 2009 Dec; 15(12):1053–66.
103. Samore MH, DeGirolami PC, Tlucko A, et al. *Clostridium difficile* colonization and diarrhea at a tertiary care hospital. *Clin Infect Dis* 1994 Feb; 18(2):181–7.
104. Samore MH, Venkataraman L, DeGirolami PC, et al. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial *Clostridium difficile* diarrhea. *Am J Med* 1996 Jan; 100(1):32–40.
105. Shim JK, Johnson S, Samore MH, et al. Primary symptomless colonisation by *Clostridium difficile* and decreased risk of subsequent diarrhoea. *Lancet* 1998 Feb 28; 351(9103):633–6.
106. McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of *Clostridium difficile* infection. *N Engl J Med* 1989 Jan 26; 320(4):204–10.
107. Gerding DN, Johnson S, Peterson LR, et al. *Clostridium difficile*-associated diarrhea and colitis. *Infect Control Hosp Epidemiol* 1995 Aug; 16(8):459–77.
108. Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe *clostridium difficile*-associated diarrhea. *Am J Infect Control* 2007 Mar; 35(2):131–7.
109. Abougergi MS, Broor A, Cui W, et al. Intravenous immunoglobulin for the treatment of severe *Clostridium difficile* colitis: an observational study and review of the literature. *J Hosp Med* 2010 Jan; 5(1):E1–9.
110. Bricker E, Garg R, Nelson R, et al. Antibiotic treatment for *Clostridium difficile*-associated diarrhea in adults.[update in *Cochrane Database Syst Rev*. 2007;(3):CD004610; PMID: 17636768]. *Cochrane Database Syst Rev* 2005; (1):004610.

Introduction

Background

Clostridium difficile infection (CDI) is a serious healthcare-associated infection and a growing health care problem. *C. difficile* is a Gram-positive, spore-forming, anaerobic bacterium that, when ingested, can cause CDI if it is a toxigenic strain. CDI symptoms include varying levels of diarrhea severity, as well as pseudomembranous colitis and toxic megacolon. CDI incidence is estimated at 6.5 cases per 10,000 patient days in hospital.¹ About 250,000 hospitalizations were associated with CDI in 2005.² Direct attributable mortality from CDI has been reported to be as high as 6.9 percent of cases.³ Elderly people in hospitals account for the vast majority of severe morbidity and mortality.⁴⁻⁶ Residents of long-term care facilities are also at higher risk.^{7,8} Incidence rates may increase by fourfold or fivefold during outbreaks.⁹ In addition to institutional care environments, *C. difficile* is also common in the community, being easily isolated from soil and water samples.¹⁰ Community-associated CDI rates are generally much lower, accounting for 27 percent of all CDI cases in a recent prevalence study,⁹ but are also on the rise.¹¹ However, the source of the *C. difficile* organisms responsible for cases of CDI in the community is not well understood.

In order for CDI to develop, a person must be infected with a strain of *C. difficile* capable of making toxin in the person's colon (Figure 1). Toxigenic strains include those that make toxin B (cytotoxin), with or without toxin A (enterotoxin). Approximately 1 to 2 percent of healthy individuals are colonized with *C. difficile*.¹² If these people have usual, healthy colonic flora, the risk of CDI is very low. There is a small risk of CDI if the colon flora becomes disturbed, commonly through antibiotic use, while the person is colonized with a toxigenic strain. Antibiotics that disturb colon flora enough to allow CDI to develop must get into the colon, and they are associated with alterations in relative amounts of colon bacterial constituents.^{13,14} The immune status of the patient also contributes to the risk of developing CDI and the experienced severity.¹⁵ Other risk factors include increasing age, female gender, comorbidities, gastrointestinal procedures, and use of gastric acid suppression medications.¹⁶⁻²⁵ Risk profiles for recurrent CDI are similar.²¹ One study, which statistically modeled CDI within the hospital setting, suggested that reducing patient susceptibility to infection is more effective in reducing CDI cases than lowering transmission rates.²⁶

New, more virulent strains have emerged since 2000. Characteristics associated with hypervirulent strains can include increased toxin production (due to a deletion in a toxin regulatory gene), an additional binary toxin, whose role in disease etiology is not well understood, hypersporulation, and high-level resistance to fluoroquinolone antibiotics.²⁷ These new strains affect a wider population, often people with a lack of established risk factors for CDI based on older strains, such as previous hospitalization or antibiotic use, and include children, pregnant women, and other healthy adults.²⁸ With hypervirulent strains, the time from symptom development to septic shock may be reduced, making quick diagnosis and proactive treatment regimens critical for positive outcomes.

The highly virulent strain associated with the epidemic of CDI described in the early 2000s may be decreasing in prevalence in limited locations.²⁹ Recent analysis of an archived collection of *C. difficile* isolates revealed that predominant strains shifted from year to year among a population served at a single institution,³⁰ suggesting that this strain shift may occur on a larger

scale. However, this phenomenon potentially cuts both ways as strains drift toward lesser or higher virulence, and the possible future risks and costs of CDI remain significant.

Diagnosis

Effective prevention of transmission and treatment of CDI depends on swift and accurate diagnosis. None of the risk factors or clinical signs and symptoms alone or in combination, except possibly a documented presence of pseudo membranous colitis, is sufficient to surmise with a high degree of clinical certainty that a patient does or does not have CDI. Culturing *C. difficile* organisms in stool specimens followed by testing grown colonies for toxins (toxigenic culture) and cultured cell cytotoxicity assay of the stool specimens are historically held as the standard reference tests; however, results can take up to 48 hours, and these diagnostic methods require a level of expertise and equipment that are not widely available. A number of faster, less demanding diagnostic tests have been developed to detect the presence of toxins produced by most disease-causing *C. difficile* organisms, toxins A and/or B, or the genes involved in the production or regulation of toxins A and/or B. These tests have a variety of sensitivities, specificities, biotechnologies, costs, and time-to-results. The sensitivities and specificities of the newer tests have been studied mostly using toxigenic culture or a cultured cell cytotoxicity assay as the reference test, but the estimates vary substantially, making it difficult to determine whether there are clinically significant differences between tests.^{98,99} Some of the variation is due to differences in the accuracy of the reference tests that are not 100 percent sensitive or specific. Toxigenic culture can be more sensitive than cytotoxicity assays that can be more specific. When a new test is evaluated using a more sensitive reference test, the estimate of its sensitivity may be lower. Greater than 90 percent of labs in the United States use one of the commercially available immunoassays to detect toxins in stool samples or because they are fast, inexpensive, and technically easier to perform.¹⁰⁸ However, the use of toxin gene detection tests has increased in recent years. A more detailed discussion of types of diagnostic tests for *C. difficile* is provided in a supplemental section at the end of this chapter.

When evaluating laboratory tests for the presence of toxigenic *C. difficile* in patients, it is important to consider how patients were selected and the consistency of the stool specimens being tested. Testing for *C. difficile* infection is recommended for a person with diarrhea (generally three or more loose or unformed stools for 1 to 2 days) and one or more risk factors for CDI.^{109,110} However, these recommendations may not always be followed in practice. Several multivariable prediction models built on established risk factors have been published in an effort to optimize diagnostic testing for *C. difficile* infection.¹¹¹⁻¹¹³ The extent of their use in clinical practice is not known.

Identifying the most accurate diagnostics tests in clinical practice could be very important. Diagnostic tests with greater sensitivity (fewer false negatives) would reduce the number of patients who do not receive appropriate treatment and isolation. Tests with higher specificity (fewer false positives) could reduce the number of unnecessary and potentially detrimental interventions, such as withholding antibiotics for other medical conditions, or initiating treatment for CDI. Swift diagnosis leading to infection prevention precautions, faster treatment, and quicker resolution of diarrhea may reduce the amount of organisms or spores in the environment that can infect other patients.

Treatment

There are a number of algorithms available to guide treatment of CDI.^{11,114-116} The only antimicrobial currently approved for the treatment of CDI by the U.S. Food and Drug Administration is oral vancomycin, and consensus appears to exist for treatment of severe initial incident CDI with vancomycin. However, there also appears to be clinical consensus to treat mild to moderate CDI with metronidazole, in part because of the concern that overuse of vancomycin may contribute to increasing pathogen resistance¹¹⁷ and cost considerations. Pepin¹¹⁶ suggests that both vancomycin and metronidazole are implicated in increased frequency of vancomycin-resistant enterococci (VRE). Enterococci are part of the normal gastrointestinal (GI) flora, and VRE are a major problem. Whether the increased use of vancomycin for CDI will affect the rates of VRE is unclear, especially as increased density of VRE in stool has been demonstrated in subjects receiving antimicrobials active against anaerobes (the main colonic flora), including both oral vancomycin and metronidazole.¹¹⁸ Surgical treatment with colectomy can be life saving in patients with fulminant, or acute severe, colitis.¹¹⁹

Nonstandard interventions for the treatment and prevention of CDI have been sought for several reasons. Treatment with standard antibiotics, such as vancomycin and metronidazole, is ineffective in 8 to 36 percent of patients with CDI,^{72,73} no antibiotic kills *C. difficile* spores, and rates of infection are increasing. Treatment for relapsed or recurrent CDI is much more problematic. CDI recurs in about 20 percent of patients;¹¹⁴ a subset of recurrent patients spiral into several subsequent recurrences.¹²⁰ Clinicians have chosen from a number of antibiotics and dosing protocols and adjunctive treatments, such as the use of antimicrobials, probiotics, fecal transplant, toxin-binding agents, and immune system-enhancing agents.¹²¹⁻¹²³

Probiotics are a very active area of discussion for CDI.¹²⁴ Probiotics are live microorganisms, including bacteria or yeast, which, when administered in adequate amounts, confer a health benefit on the host.¹²⁵ Probiotics are believed to replenish nonpathogenic microorganisms to GI flora that has become altered by antibiotic therapy. It is important that the effectiveness of probiotics and related substances are evaluated specifically for their effect on CDI and not rely on the more broadly defined antibiotic-associated disease, which includes a much broader set of potential disease etiology. Fecal flora reconstitution is another intervention currently under investigation. This approach instills donor feces into the patient with CDI to normalize the intestinal flora. The procedure has been variously termed in the literature, including fecal bacteriotherapy,^{96,124,126,127} fecal transplantation,¹²⁷⁻¹²⁹ and donated stool.^{97,130}

Prevention

Prevention of CDI takes two general forms, breaking routes of transmission and improving a patient's resistance to disease should colonization occur. Preventing the spread of *C. difficile* by breaking routes of transmission within institutional settings depends on staff compliance with national guidelines and standards¹³¹ and locally determined hygiene protocols. *C. difficile* is common in the environment of people with CDI,¹⁰¹ most of whom have diarrhea, and many of whom have incontinence and often other medical problems that tend to diminish personal hygiene. *C. difficile* is found on the hands of hospital workers^{46,101} and is more likely to be found on hands of people who have been working in a heavily contaminated room.¹⁰¹ Thus, *C. difficile* acquired in hospital settings may be spread directly or indirectly from patient to patient.¹⁰³

Complicated recommendations are difficult to remember and implement, and protocols for different targeted hospital acquired infections are not always congruent. For example, the

availability of alcohol hand rubs improved physician compliance and reduced methicillin-resistant *Staphylococcus aureus* (MRSA) infections,⁵¹ yet *C. difficile* produces spores that can withstand hostile environments and are resistant to alcohol hand rubs and other routine antiseptics.¹³² One concern has been that health care workers will use alcohol-based rubs or gels in circumstances where handwashing is preferred. Other institutional prevention strategies may be required as *C. difficile* transmission knowledge develops. For example, a recent study isolated *C. difficile* spores from air samples in a hospital in the United Kingdom 4 to 7 weeks after the last confirmed CDI case in the ward, and successfully cultured bacterium from the spores.¹³³

Interventions to improve a patient's resistance to CDI or CDI recurrence include probiotics, a nonpathogenic strain of *C. difficile*, prebiotics, immune whey, *C. difficile* vaccine, and intravenous immunoglobulin. Probiotics, a nonpathogenic strain of *C. difficile*, and prebiotics aim to modify the patient's intestinal microbiocology to better resist CDI. Probiotics and a nonpathogenic strain of *C. difficile* deliver nonpathogenic microorganisms thought to compete with or inhibit *C. difficile*, while prebiotics aim to promote the growth of beneficial organisms. Immune whey, a *C. difficile* vaccine, and intravenous immunoglobulin confer passive immunity against *C. difficile* or its toxin.

Scope of the Review

The purpose of this systematic review was to provide an overarching assessment of the evidence for comparing the accuracy of diagnostic tests and the effectiveness of prevention and treatment interventions on initial and recurrent CDI related patient outcomes in adult patients. This purpose was developed during the project's topic refinement stage. There was consensus among key informants that this systematic review's single greatest contribution to the field could be to provide a comprehensive review by an independent organization that covered the major concerns of the field. CDI is an active topic in the literature as well as a vital clinical concern. The consensus opinion included the idea that clinicians and researchers both would be well served by a reaffirmation of what is and is not supported by evidence in the literature and at what level of evidence, to balance against this activity level.

The major impetus of this review is the presence of clinical disease, not asymptomatic carriage of the *C. difficile* organism. While we were interested in how treatment of CDI varies by organism strain, molecular epidemiology studies whose main purpose was to identify the strains of *C. difficile* present in the population are also outside the scope of this review. The review focuses on adult patients because adults, and particularly elderly adults, carry the large majority of the morbidity and mortality burden.

Key Questions

The following key questions form the basis for this review:

- Key Question 1. How do different methods for detection of toxigenic *C. difficile* to assist with diagnosis of CDI compare in their sensitivity and specificity?
 - Do the differences in performance measures vary with sample characteristics?
- Key Question 2. What are effective prevention strategies?
 - What is the effectiveness of current prevention strategies?
 - What are the harms associated with prevention strategies?
 - How sustainable are prevention practices in health care (outpatient, hospital inpatient, extended care) and community settings?


- Key Question 3. What are the comparative effectiveness and harms of different antibiotic treatments?
 - Does effectiveness vary by disease severity or strain?
 - Does effectiveness vary by patient characteristics: age, gender, comorbidity, hospital versus community-acquired setting?
 - How do prevention and treatment of CDI affect resistance of other pathogens?
- Key Question 4. What are the effectiveness and harms of nonstandard adjunctive interventions?
 - In patients with relapse/recurrent CDI?

Review Framework

The conceptual framework that guided this review is provided in Figure 2. The figure lays out the clinical path for patients with the potential to develop CDI, from diagnostic laboratory tests, through their impact on treatment decisions, to finally implications for prevention strategies, and locates the key questions of this review within the context of the framework. Diagnostic testing has two parts, the technical efficiency of the tests and diagnostic accuracy. Technical efficiency is outside the scope of this review; rather, for Key Question 1 we focus on the comparative diagnostic accuracy of commonly used rapid tests, such as immunoassays for *C. difficile* toxin and toxin gene detection tests, which may reduce the time lapse between the onset of symptoms and laboratory confirmation of CDI and treatment decisions. Repeat testing of selected specimens does not provide good comparative information about test accuracy and therefore is not covered in the focused review of diagnostic test accuracy. When a patient is treated for CDI, whether for an initial case, a relapse, or recurrence, the clinical outcomes of interest establish the patient treatment efficacy. Of particular interest, Key Question 3 will compare effectiveness of established treatments used for CDI, particularly vancomycin and metronidazole. For Key Question 4, the clinical question of interest is what nonstandard treatments are being utilized, and their efficacy, particularly for recurrent CDI. After diagnostic accuracy, treatment, and patient outcome efficacy concerns, prevention is a societal-level efficacy measure, as the benefits of prevention of infectious disease can extend beyond the individual patient. This is the area of focus for Key Question 2. Key Question 4 also contributes to this area to the extent that nonstandard treatments assist a patient in fending off an infection.


Figure 3 expands the framework for the key question related to prevention. The illustration lays the pathway of preventive strategies and practices from the target patient population of patients at risk for CDI due to potential for exposure, through intermediate outcomes and on to health outcomes. This framework was included to highlight both the linkage and the conceptual difference between the intermediate outcomes of prevention and health outcomes of clinical significance important to the patient. Intermediate outcomes are often process measures of the uptake of a prevention strategy, or counts of vegetative *C. difficile* or spores remaining in the environment. Key Question 2 is mainly concerned with evidence for the direct effect of prevention on health outcomes.

Figure 1. Pathogenesis of CDI




CDI = *Clostridium difficile* infection

Figure 2. Analytic framework for CDI diagnostic testing, prevention, and treatment



CDI = *Clostridium difficile* infection; KQ = Key Question

Figure 3. Supplemental prevention framework



CDI = *Clostridium difficile* infection; KQ = Key Question

Diagnostic Test Descriptions

Cytotoxicity Assay

The cultured cell cytotoxicity assay often has been used as a reference test for evaluating new diagnostic tests for toxigenic *C. difficile*. Briefly, a diluted and filtered aliquot of a stool sample is mixed with cultured test cells. The test cells are examined for toxin effects (cell rounding) that are not seen in comparator test cells where an excess amount of antitoxin is present.¹³⁴ The diagnostic rounding of cultured test cells and the clinical signs and symptoms of CDI can be caused by cellular interactions with both *C. difficile* toxins, although toxin B is much more cytotoxic and the cytotoxicity assay is often considered to be a test for toxin B.^{135,136} A cytotoxicity assay requires up to 48 hours for the toxin effects to appear, especially when toxin level in the test material is low. Cytotoxicity testing is not a perfectly accurate gold standard.¹³⁷ Methodological differences in the time to process and dilution of stool samples, the age and type of cultured test cells being used for the test, the antitoxins, and the interpretation of results all can cause cytotoxicity assay results to vary.¹³⁸ Toxins can degrade or be inactivated depending on how long stool specimens are stored before being tested and the storage temperature. Nevertheless, the imperfect cytotoxicity assay is often used as the reference test in the evaluation of other diagnostic tests for *C. difficile*.

Detection of *C. difficile* Organisms

Culturing *C. difficile* by anaerobic incubation of fecal aliquots on selective cycloserine-cefoxitin, fructose agar or other media can be more sensitive than the cytotoxicity assay for detecting the presence of *C. difficile* organisms.^{138,139} However, *C. difficile* culture techniques also are not standardized, are susceptible to methodological variation, and require expertise, equipment, and several days to complete. Furthermore, cultured *C. difficile* organisms need to be tested to determine whether they can produce disease-causing toxins because many individuals may be carriers of *C. difficile* organisms that do not produce toxins or clinically significant CDI. Nevertheless, expert culture of *C. difficile* from stool samples followed by a cytotoxicity assay or another method of detecting toxins is considered the most sensitive method for detection of toxigenic *C. difficile*, albeit not very practical.^{110,140} However, the concentration of toxins produced in culture might not be the same as that present in patients.

Assays for glutamate dehydrogenase enzyme constitutively produced by *C. difficile* have been used as a faster and less demanding alternative to culturing *C. difficile* organisms. These tests are not entirely specific because other organisms can produce glutamate dehydrogenase or interfering substances.^{104,138} Like stool cultures, a positive glutamate dehydrogenase test requires a second test to detect *C. difficile* toxins. Because stool cultures and the cytotoxicity assay are demanding, costly, and time consuming, and most stool samples sent to clinical laboratories turn out to be negative for toxigenic *C. difficile*, some laboratories have proposed using a test for glutamate dehydrogenase first, and then testing only the positive specimens for toxins.¹⁴¹⁻¹⁴³ In this two-stage approach, a negative test for glutamate dehydrogenase would preclude the need for a toxin test. However, the sensitivities of glutamate dehydrogenase assays need to be high enough to have an acceptably low number of false negatives.¹⁰⁹ Furthermore, the performance of a two-stage test also will depend on the sensitivity and specificity of the second test used to detect toxins.

Immunoassays for Toxins

A variety of faster (within a few hours), less costly commercial immunoassays for *C. difficile* toxins have been developed and have been commercially available since the late 1980s. Initially, most immunoassays detected only toxin A. More recently it was discovered that a small but increasing number of clinically significant *C. difficile* strains produced only toxin B.¹⁴⁴⁻¹⁴⁷ The incidence of clinically significant toxin A-negative, B-positive organisms in the United States is not known and could vary by site and time.¹⁴⁸ When the performance of a diagnostic test depends on the level of toxins in test specimens and most organisms produce both toxins A and B, immunoassays that detect both toxins might be more sensitive if other critical factors such as dilution of the specimens are equal.¹⁴⁹ Therefore, experts have recommended using immunoassays that can detect both toxins A and B.^{109,110,137,148} A highly sensitive and specific immunoassay for these toxins may be used as a second test after either stool culture or the glutamate dehydrogenase assay.

Data from the College of American Pathology proficiency testing program for *C. difficile* toxin detection indicated that 90 percent of labs used an immunoassay for toxins A and B in June 2009. The most commonly used tests were the Immunocard and Premier A & B test kits manufactured by Meridian, the TechLab Tox AB II and Toxin A/B QUIK CHEK kits, and the Remel ProSpecT and Xpect Toxin A/B tests. These data are consistent with an online survey of members of the Association for Professionals in Infection Control and Epidemiology, Inc. in 2008 that indicated that an immunoassay was used in 95 percent of patients who were diagnosed with CDI in 648 responding American laboratories, and 60 percent were diagnosed using an immunoassay for toxins A and B, while only 3 percent used an immunoassay for only toxin A.⁹

Toxin Gene Detection Tests

Three tests of stool specimens for the presence of genes involved in the production of *C. difficile* toxins have recently become commercially available. These tests use the polymerase chain reaction to amplify (replicate) targeted gene fragments to detect the presence of a gene or genes involved in the production of toxins, not the actual toxins. The target of the assays can be the genes that produce toxin B and a gene C that negatively regulates the production of toxins A and B. A mutation in gene C has been detected in an increasingly common hypervirulent strain of *C. difficile* that produces large amounts of toxins A and B.¹⁴⁸ One concern about using the tests based on amplification of toxin gene fragments is that very small, clinically unimportant genetic residue or specimen contamination may be detected. Clinically speaking, these would be false positives that would reduce test specificity. Therefore, some experts have recommended using this type of test only when a patient has clinical signs and symptoms suggestive of CDI.^{109,138}

Methods

Topic Refinement

The topic for this report was nominated in a public process through the Agency for Healthcare Research Quality's nomination Web site. We drafted the initial key questions with input from a key informant panel composed of researchers; clinicians; professional organizations representing hospitals, infectious diseases, and clinicians; federal and state agencies; patient-safety advocates; and consumers. After approval from AHRQ, the key questions were posted to a public Web site. The public was invited to comment on these questions. After reviewing the public commentary and conferencing with the Technical Expert Panel (Appendix A), we drafted final key questions and submitted them to AHRQ for approval.

Systematic Review

Search Strategy

Our search strategy used the key word “*difficile*” to identify all articles related to *C. difficile* because we found the keyword to be a more sensitive term than the National Library of Medicine's Medical Subject Headings (MeSH) keyword nomenclature. Articles were limited to English language, humans, and MeSH filters for adult populations. We searched MEDLINE, AMED, the Cochrane Library, and ClinicalTrials.gov. Details of the major search strategies are provided in Appendix B.

To identify systematic reviews, we searched MEDLINE, the Cochrane Database of Systematic Reviews, and the Web sites of the National Institute for Clinical Excellence, Guidelines.gov, and the NHA Health Technology Assessment Programme. We used results from previously conducted meta-analyses and systematic reviews when appropriate. We also manually searched reference lists of review articles and articles that were read for the review. All citations were imported into Refworks for initial screening, and then EndNote X for database management.

During the manual search of included articles' reference lists, we found a number of studies not identified in our original search. We performed a forensic examination of those missed articles and determined that diagnostic test and prevention articles in particular were often not indexed by patient ages. We therefore performed a second search without the age filters. These search strategies are also included in Appendix B.

We conducted the initial searches in October 2009. The no-age filtered searches were conducted in February 2010 and updated in March and June 2010. An updated search was performed specifically for Key Question 3 (standard treatment) in August 2011, because of a significant new study that led to FDA approval of fidaxomicin in May 2011.

Inclusion/Exclusion Criteria

In brief, we developed criteria for inclusion and exclusion of studies based on the patient populations, interventions, outcome measures, and types of evidence specified in the key questions. We retrieved full-text articles of potentially relevant abstracts and conducted a second review for inclusion by reapplying the inclusion criteria. Results published only in abstract form

are generally not included in our reviews unless adequate information was available to assess the validity of the data. Full details by key question are provided below.

Key Question 1

Patients

We restricted the review to studies that used clinical stool specimens from patients suspected to have *Clostridium difficile*-associated infection (CDI). Information that described patient characteristics that could be related to CDI, hence test performance, was of particular interest.

Study Selection

We sought studies that concurrently compared at least two diagnostic tests in the same laboratory using the same stool samples and the same reference standard. This was done in order to reduce the heterogeneity in the estimates of differences in sensitivity and specificity, given the inter- and intralaboratory variation in the application of diagnostic tests for toxigenic *C. difficile*, the varying accuracy of the reference standards, and differences in patient and stool specimen characteristics. Diagnostic tests of interest were the immunoassays commonly used in the United States to test for the presence of both toxins A and B, and newer tests to detect the presence of *C. difficile* gene fragments involved in the production of toxin. We did not include articles that only compared tests that are not currently commercially available in the United States. We focused on tests for toxigenic *C. difficile* because the presence of toxins is a requisite for diagnosing clinical disease or CDI. We sought diagnostic studies that included patient outcomes or outcomes related to changes in therapy.

Measures of Diagnostic Accuracy

We sought to compare diagnostic tests in terms of differences in their sensitivity (true positives for toxigenic *C. difficile*) and specificity (true negatives for toxigenic *C. difficile*). These statistics are believed to be most relevant to clinical decisionmakers. To be consistent with other common statistical analyses, such as receiver operator characteristic curves and likelihood ratios, we present and discuss study results in positive terms, that is, true positives (sensitivity) and false positives (1 minus specificity). The review was restricted to studies that used toxigenic culture, cell cytotoxicity assay, or combinations of tests as the reference test for the presence or absence of toxigenic *C. difficile*. To be able to compare estimates of sensitivity and specificity, the report had to provide the counts of test results for those that were positive or negative according to the reference test. Direct comparisons of diagnostic tests without a reference test were not included.

Key Question 2

Patients

We included studies targeting adult patients at risk for exposure to *C. difficile* in hospital and long-term care facilities.

Interventions

We included studies that examined the effects of prevention strategies aimed at (1) breaking routes of transmission within institutional settings, the major focus of institutional infectious

disease programs, and (2) reducing susceptibility to CDI through antibiotic prescribing practices. Reducing susceptibility to CDI through other agents is covered in Key Question 4.

Comparators

No restrictions were placed on the comparators, although we anticipated that most studies would use some form of usual processes of care.

Outcomes

We included only studies with CDI incidence, or other measures of CDI as an outcome. We excluded studies that used only process measures, or intermediate outcomes, such as reduced spore count in environmental samples, and did not tie these measures to CDI incidence. We looked for harms including difficulties experienced by employees responsible for environmental cleaning, or overtreatment harms, such as increased exposure risk to CDI if a patient without CDI is located in an isolation ward. We also sought evidence for how well prevention strategies and practices can be sustained past a study period or a period of intensive effort and monitoring.

Study Designs

Accepted study designs included randomized controlled trials (RCTs), prospective cohort, retrospective cohort, time series, and before/after trials.

In addition to studies examining prevention practices, we also identified good quality studies that identified specific risk factors for development of CDI to facilitate infectious disease control efforts to target likely effective preventive strategies. Inclusion criteria were: (1) prospective study design; (2) the methods for the risk factor analysis were specified; (3) the study included a clearly defined control group; (4) the study was of risk for CDI, not *C. difficile* colonization; (5) the CDI definition included diarrhea and a positive test for *C. difficile* toxin, and (6) the population was general hospital inpatients, not specialized patients. We included studies in which the influence of confounding variables was minimized in one of three ways: (1) randomization; (2) possible confounding variables were controlled in case and control selection process; or (3) multivariable analysis was done to determine the relative contribution of each potential risk factor included in the study.

Key Question 3

Patients

We included target populations of adult patients with clinical signs consistent with CDI in hospital, outpatient, or long-term care settings. We also looked for studies assessing efficacy when stratified by disease severity or strain, or by patient characteristics such as age, gender, comorbidity, and location of disease acquisition.

We sought studies that examined differences in treatment effect by disease severity. We did not exclude any studies based on the definitions they used for disease severity. In mild disease, discontinuation of the inciting antibiotic may be sufficient to resolve the symptoms of CDI,^{115,150} making it difficult to detect any difference in the efficacy of antimicrobial therapy. In severe disease, differences in treatment efficacy are easier to detect and are of more importance because of the high morbidity and mortality associated with severe CDI.¹⁵¹ However, a major difficulty with stratifying therapy by disease severity is the lack of a standardized, reproducible, and validated tool for measuring severity.^{110,152} Elements that have been incorporated into various

severity definitions include, but are not limited to, age, degree of leukocytosis, fever, ileus, endoscopic findings, presence of fecal leukocytes, and need for intensive care unit treatment or colectomy.⁷⁰

We sought studies that examined the comparative effectiveness of the antimicrobial treatments by organism strain. We also sought evidence of the potential impact of CDI treatment on developing antibiotic resistance in other infectious pathogens. There has historically been reluctance to use vancomycin as a first-line drug for CDI because of the drug's important role in treating serious bacterial infections, especially drug-resistant Gram-positive organisms such as methicillin-resistant *Staphylococcus aureus* and penicillin-resistant *Streptococcus pneumoniae*. However, with the increase in CDI incidence and severity,^{3,153} and a randomized trial reporting superiority to metronidazole in treating severe CDI,⁷⁰ this reluctance has been largely overcome. This may also be due to the high levels of vancomycin, which would likely inhibit even strains with reduced susceptibilities to vancomycin, and the emerging recognition that vancomycin resistance is complex (versus a single mutation).¹⁵⁴

Interventions

We sought studies that tested vancomycin, metronidazole, bacitracin, nitazoxanide, rifaximin, fidaxomicin, and rifampin, which have only been studied as an adjunct to other active drugs. As fusidic acid and teicoplanin are not currently approved for use in the United States, these treatments were excluded. Fidaxomicin was added as an intervention because FDA approval was granted in May 2011.

Comparators

We sought studies that compared two active antimicrobial treatments, although we accepted studies that included placebo as the comparator for the two antimicrobials of interest, vancomycin and metronidazole.

Outcomes

We included initial cure, recurrence (variably defined by symptoms with or without a positive test for *C. difficile*), and mortality, which are outcomes of interest to clinicians and are reported in most studies. We also included time to resolution of diarrhea, which may be important because of effects on patient comfort, duration of hospitalization, and for infection control purposes. While we included clearance of the organism or toxin where reported, it is an outcome of uncertain significance if it is used without taking into account the patient's clinical status. We included any reported harms to patients using any of the standard antimicrobial treatments.

Study Designs

We also included RCTs, prospective cohort or case control studies, retrospective cohort studies, and case control study designs.

Key Question 4

Patients

We included target populations of adult patients with clinical signs consistent with CDI in hospital, outpatient, or long-term care settings. Patients with relapsing or recurrent CDI are of

special concern due to the demonstrated difficulty with permanent cure of the infectious organism, and are often the stated targeted patient population for nonstandard treatments. Likewise, preventing recurrence is an important clinical goal. We sought studies that examined either preventing or treating relapsing or recurrent CDI, as the target population or a specified subgroup. When more than one nonstandard intervention was administered concurrently during the treatment of CDI before resolution of CDI was documented, both interventions were classified as treatment. We accepted both a priori and post hoc subgroup analysis.

Interventions

We included all studies that examined any nonstandard interventions. Nonstandard interventions include a broad range of treatments, such as antimicrobial agents, agents that bind the toxins produced by *C. difficile*, or treatments that reduce a patient's susceptibility, from prebiotics or probiotics that support the gut flora to vaccinations or antibodies to enhance immune functions. We did not limit studies to a particular set of nonstandard interventions but instead sought to catalogue the range of interventions. However, we did not include the toxin binding agent tolevamer as an intervention, as it is no longer under development in the United States.

Comparators

We included studies that used either another active treatment, such as metronidazole, or placebo.

Outcome

We examined patient outcomes, such as resolution of symptoms for treatment studies, and CDI incidence and presence of toxins for prevention studies. We sought evidence for harms associated with nonstandard interventions, whether for treatment or prevention, such as side effects or secondary infections.

Study Designs

We anticipated few controlled trials for newer interventions and so included all study designs. We did not limit comparators for nonstandard interventions; however, we did exclude studies on nonhuman, in vivo, and healthy volunteers.

Study Selection

Results of the literature search were imported to a bibliographic database for screening. At least two independent reviewers examined all titles and abstracts for eligibility based on the inclusion/exclusion criteria. Titles and abstracts with insufficient information to determine eligibility were pulled for full article text review. Disagreements between reviewers were resolved through consensus. Final results of the screening process were then imported to an EndNote file for database management.

Data Extraction

We extracted the following data from included trials directly into study tables: study design; setting; population characteristics (including sex, age, ethnicity, diagnosis); eligibility and exclusion criteria; characteristics of the interventions; numbers screened, eligible, enrolled, and

lost to followup according to the research design; method of outcome ascertainment; study quality items; and results for each outcome. All tables were subject to a quality check of all data items by independent reviewers.

Quality Assessment

Key Question 1

To assess the quality of reports for diagnostic studies, we used the criteria developed for the Quality Assessment of Diagnostic Accuracy Studies.^{155,156} These criteria include: (1) tested specimens (patients, stool) and their selection were clearly described and representative of those that are tested in clinical practice; (2) the time period and handling of specimens between tests most likely did not change what is being measured; (3) all test procedures were adequately described and replicable; (4) the same credible reference test was used for all specimens, performed regardless of other test results; (5) the reference and diagnostic tests being evaluated were conducted and interpreted independently of each other, that is, blinded; (6) any clinical information that was used in the interpretation of test results was reported; (7) indeterminate results were reported and analyzed in a reasonable manner; and (8) excluded test results, specimens, or patients were reported and explained. This quality assessment does not have a method for scoring the criteria or reliably categorizing the studies. Some studies that did not meet a key criterion for inclusion in the review were excluded without further assessment of their quality.

Studies that are summarized in this review were rated as having “good” internal validity. Comparisons were made in the same laboratory using the same specimens and a credible reference standard. There were no major differences in the processing and storing of the specimens between tests that were independently conducted. Indeterminate results were discussed and handled in a reasonable manner.

Key Question 2

Quality assessment for nonrandomized studies used primarily in assessing prevention strategies was based on study design (case control versus case series), the selection of cases or cohorts and controls (how well matched), and adjustment for confounders. Studies were rated as higher quality if they met the following a priori defined criteria: (1) prospective, (2) had explicitly detailed the methods of their study, (3) patients were representative of typical CDI patients, and (4) used multivariate analysis to isolate the effect of the variable in question.

Key Questions 3 and 4

We rated the study quality of individual randomized controlled or clinically controlled trials using criteria based on Cochrane Collaboration recommended domains.¹⁵⁷ These domains assess the risk of bias of studies included in a systematic review. The first domain is adequate allocation concealment, based on the approach by Schulz and Grimes.¹⁵⁸ The second domain regards blinding methods, such as participant, investigator, or outcome assessor. The third domain regards how incomplete data are addressed: did the study analyze the data based on the intention-to-treat principle (i.e., were all subjects who were randomized included in the outcomes analyses), and were reasons for dropouts/attrition reported?

Studies were rated to be of good, fair, or poor quality. A rating of good generally indicates that the trial reported adequate allocation concealment, blinding, analysis by intent to treat, and

reasons for dropouts or attrition. Studies were generally rated poor if the method of allocation concealment was inadequate or not defined, blinding was not defined, analysis by intent to treat was not utilized, and reasons for dropouts or attrition were not reported and/or there was a high rate of attrition.

Rating the Body of Evidence

For randomized trials, the overall strength of evidence was evaluated using methods developed by AHRQ and the Effective Health Care Program.¹⁵⁹ The strength of the evidence was evaluated based on four required domains: (1) risk of bias (do the studies for a given outcome or comparison have good internal validity); (2) consistency (the degree of similarity in the effect sizes [i.e., same direction of effect] of the included studies); (3) directness (reflecting a single, direct link between the intervention of interest and the outcome); and (4) precision (degree of certainty surrounding an effect estimate of a given outcome). The risk of bias, based on study design and conduct, is rated low, medium, or high. Consistency is rated consistent, inconsistent, or unknown/not applicable (e.g., a single study was evaluated). Directness can either be direct or indirect, and precision is either precise or imprecise. A precise estimate is one that would yield a clinically meaningful conclusion.

The evidence is rated using high, moderate, low, and insufficient for grades. A high grade indicates that further research is very unlikely to change the confidence in the estimate of effect, meaning that the evidence is believed to reflect the true effect. A moderate grade denotes further research may change our confidence in the estimate of effect and may, in fact, change the estimate. A low grade indicates that further research is very likely to have an important impact on the confidence in the estimate of effect and is likely to change the estimate. Thus, there is low confidence that the evidence reflects the true effect. An insufficient grade indicates that the evidence is unavailable or does not permit a conclusion. An overall rating of high strength of evidence would imply that the included studies were RCTs with a low risk of bias and consistent, direct, and precise domains.

We modified this approach for diagnostic tests in the following manner. As previously stated, all of the studies that provided comparative evidence for differences between diagnostic tests were selected based on having 'good' protection against bias (internal validity). Furthermore, all of the comparative studies were rated as providing only indirect evidence because none presented evidence that the differences in sensitivity and/or specificity of the diagnostic tests would lead to any differences in patient outcomes. Indeed, studies that provide evidence that the observed differences would or would not be clinically meaningful were not found, nor were estimates of how much of a difference would be required to make a different clinical decision about the diagnosis. Thus, any differences in the overall grades of the strength of evidence for comparisons of the diagnostic tests are based on the consistency (direction and size) of the estimated differences in sensitivity and specificity and the precision (width of the estimated confidence intervals).

Applicability

Applicability of the treatment results, both standard and nonstandard adjuvant treatment, of this review are affected by the representativeness of the patient samples in the included studies, which are general adult inpatient populations. Applicability of diagnostic test results is limited by the samples used in the analyses; to the extent that they were typical clinical samples derived from patients with suspected CDI, they represent the typical patient population that was tested.

However, the ability to explicitly state the applicability of such samples is dependent on the completeness of the study reporting on the characteristics of the patients/specimens that were selected for the study. Furthermore, the substantial heterogeneity between studies in estimates of sensitivity and specificity of many of the diagnostic tests being reviewed, and perhaps their differences, raises concerns about generalization of the results. The evidence tables in Appendix C identify reported details on the patient inclusion and exclusion criteria.

Data Synthesis

For key questions with trial data, we applied quantitative techniques to estimate a summary effect size for reported outcomes for which heterogeneity of interventions and outcomes measures was minimal. Qualitative narratives were provided for key questions for which heterogeneity of interventions or measured patient outcomes was too great, or for which available studies were observational. Results of the quantitative and qualitative analyses are compared to relevant published systematic reviews for consistency of findings. (See Appendix C tables for details of systematic reviews.)

Data were analyzed in Review Manager 5.2.¹⁶⁰ Random effects models were used to generate pooled estimates of relative risks and weighted mean differences with 95 percent confidence intervals. Statistical heterogeneity was summarized using the I^2 statistic (50 percent indicates moderate heterogeneity and 75 percent or greater indicates high heterogeneity).¹⁶¹

Key Question 1

We focused on the differences between test sensitivities and specificities rather than on the specific test sensitivities and specificities themselves. Thus, methods of meta-analysis typically used for clinical trials with binary endpoints were employed rather than methods typically used for sensitivities and specificities, such as diagnostic odds ratios. To be able to estimate the correlation between two tests that were applied to the same patients/stool specimens, hence calculate proper confidence intervals on the differences of the sensitivities and specificities of two tests, the results of each test for each individual are needed.¹⁶² Many reports did not provide this information. Therefore, the estimated confidence intervals on the differences in sensitivities and specificities ignored the unknown correlation between test results. Ignoring the correlation most likely increased the estimated variances of the differences and the width of the confidence intervals depending on the direction and magnitude of the correlation between the estimates for the two tests.

Each study had two primary endpoints, difference in sensitivities and difference in specificities. Furthermore, some studies made multiple comparisons. Some adjustment for multiple endpoints and comparisons was made by calculating 99 percent confidence intervals on the differences.

Publication Bias


Grey literature was searched for relevant trials and other material to inform the likelihood of publication bias. Regulatory sources included Federal Drug Administration, Health Canada, and Authorized Medicines for the European Union. Clinical trial registries accessed were ClinicalTrials.gov, Current Controlled Trials, Clinical Study Results, and World Health Organization's Clinical Trials. Grants and federally funded research sources included NIH RePORTER, a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other research institutions, and HSRProj, a database providing access

to ongoing grants and contracts in health services research. Other sources searched were Hayes, Inc. Health Technology Assessment, New York Academy of Medicine's Grey Literature Index, Conference Papers Index, and Scopus.

Results

The general search identified 1,078 citations from MEDLINE. Of these, 356 studies were pulled for full text screening. Of these 356 references, we included 69 randomized controlled trials (RCTs), systematic reviews, observational studies, and an additional 22 articles obtained from hand searching and review article bibliographies. We excluded 998 articles. A supplemental search for diagnostics identified 519 citations from MEDLINE, of which 516 references were excluded. Figure 4 provides a literature flow diagram. A bibliography of the excluded articles, and their reasons for exclusion, is provided in Appendix D.

Figure 4. Reference flow diagram



KQ = Key Question

Key Question 1. How do Different Methods for Detection of Toxigenic *C. difficile* Compare in Their Sensitivity and Specificity?

Search Results

We included 13 references that provided comparative data about diagnostic tests of interest. The studies were published from 2001 to 2010. Five studies were from the United States, two were from the United Kingdom and Spain, and one each were from Belgium, Ireland, Israel, and the Netherlands. Table 1 provides a summary of the available comparisons. Overall, these reports included data on seven named immunoassays for toxins A and B, one two-stage method where an immunoassay for glutamate dehydrogenase was combined with an immunoassay for toxins A and B, and two tests to detect gene fragments involved in the production of toxin B. Only three comparative studies included one of the recently FDA-approved toxin gene detection tests. Thus, the number and type of paired (within study) comparisons available for each diagnostic test varied considerably, and not all possible comparisons were available. Evidence summary tables, including study quality items, are available in Appendix C of this report (see Appendix Table C1).

Key Points

- Sixteen paired comparisons of seven immunoassays for toxins A and B provided low-grade evidence that the test sensitivities do not differ. There was moderate-grade evidence for no differences in test specificities for three comparisons and for a difference of 2 percent in one comparison. Otherwise, there was only low-grade evidence for or against differences in test specificities. There was insufficient evidence of differences between all tests that were not directly compared.
- Nine comparisons of two different gene detection tests to toxin immunoassays provided only low-grade evidence to support the notion that the gene-based tests are substantially more sensitive than immunoassays. There was moderate evidence that the test specificities in one comparison did not differ. Otherwise, there was only low-grade evidence for differences in either direction between test specificities. There was insufficient evidence of differences between all tests that were not directly compared.
- There was insufficient evidence to determine whether any differences in sensitivity or specificity between diagnostic tests depend on patient or specimen characteristics or the strain of toxigenic *Clostridium difficile*.

Quality of the Comparative Studies

All studies used stool specimens from mostly inpatients that were submitted by clinicians to test for *Clostridium difficile* infection (CDI). However, the clinical scenarios that prompted the clinicians to test for CDI, such as the nature of the patient's diarrhea, or exposure to antibiotics, were not described in many reports. Seven of the 13 studies that provided data mentioned that the stool samples were liquid, unformed, or diarrhea, whereas the other reports did not clearly describe the consistency of the stool specimens. Six of the studies included more than one specimen from some patients, and three studies only reported the total number of stool specimens and not the number of patients. Two studies selected stool samples based on previous diagnostic test results to enhance the percentage of positive tests in their sample, and two included a facility with a recent outbreak of CDI or high prevalence. Thus, the reviewed reports

were somewhat deficient in reporting pertinent information about patient selection criteria and the spectrum of patients/specimens included the comparisons (Appendix Table C2).

Differences within studies in the timing and handling of specimens for the different tests being compared were not a major issue in the reviewed studies. Verification using the reference standard was applied consistently to all stool specimens. However, the same reference standard was not used in all studies. Five of the 13 studies used a cell cytotoxicity test as the reference, five used a cell cytotoxicity test in conjunction with toxigenic culture, one used a toxin immunoassay in conjunction with toxigenic culture, one used multiple immunoassays for toxins A and B in conjunction with toxigenic culture, and one used an in-house gene detection test. None of the reference methods that were used are a true gold standard in that they are not 100 percent sensitive or specific for toxigenic *C. difficile* and their accuracies are not all the same. Within each study, the diagnostic tests were carried out independently of each other although the reports usually did not state that each test was interpreted without knowledge of other results. Only two reports explicitly stated that all diagnostic tests being compared, including the reference test, were conducted in a blinded manner. Sometimes the independence of the tests could be inferred from their sequence and the time needed to get results.

The handling of indeterminate test results presents problems when comparing the sensitivity and specificity of diagnostic tests. Some investigators repeated indeterminate tests and used the result of the second test as recommended, although some repeated tests were also indeterminate. Some assumed indeterminate results were negative and thereby could have inflated the number of false negatives. Some comparisons excluded indeterminate results; thus, the varying number of indeterminate tests did not count for or against a test. However, differences in the number of indeterminate results produced by different tests resulted in some differences in the stool specimens being used to compare the tests. Other types of subject or specimen withdrawal were not an issue in the studies that were reviewed.

Detailed Analysis

Comparisons of Immunoassays for Toxins A and B

As summarized in Table 2, none of the seven immunoassays for toxins A and B was compared to all others. When more than one study compared the same two immunoassays, the heterogeneity in the differences in sensitivity was significant in only one out of nine cases. None of the nine pooled comparisons based on two to four studies indicated that any of the immunoassays were more sensitive than another. The pooled estimates of the differences (99 percent confidence interval [CI]) in test sensitivities were 0 ± 6 percent, 1 ± 7 percent, 3 ± 6 percent, 3 ± 7 percent, -1 ± 10 percent, 3 ± 8 percent, 6 ± 12 percent, 1 ± 9 percent, and 3 ± 24 percent. The confidence intervals for single-study estimates of differences in sensitivity were wide. Thus, the available data often could not rule out substantial differences in sensitivities.

There was some significant heterogeneity in the corresponding estimates of differences in false positives (1 minus specificity) for two of the nine multiple study comparisons of immunoassays for toxins A and B. Ignoring the heterogeneity, the differences (99 percent CI) in false positives were 0 ± 2 percent, 0 ± 1 percent, 2 ± 1 percent, 0 ± 1 percent, -3 ± 3 percent, -1 ± 10 percent, -6 ± 14 percent, 3 ± 2 percent, and 2 ± 2 percent. Thus, the available data often ruled out differences in false positives of only a few percent. One study that compared several immunoassays found some differences in the false positives of approximately 6 percent.

Gene Detection Tests Versus Immunoassays for Toxins A and B

As summarized in Table 3, two studies compared the same tests to detect genes related to toxin B production to the same immunoassay for toxins A and B.^{32,37} There was significant heterogeneity between the estimated differences in sensitivities for both comparisons; however, in each case both studies suggested the gene-based test was more sensitive than the immunoassay. The pooled estimate of the difference in sensitivities was 17 percent in favor of the gene based test with a 99 percent confidence interval of from 3 to 37 percent in one comparison, and 25 with a 99 percent confidence interval of from -36 to 86 percent in the other comparison. There was no heterogeneity in the corresponding estimated differences in false positive percentages of these tests. The pooled estimate of the differences in the false positives were 0 percent with a 99 percent confidence interval of from 1 percent to 1 percent for one comparison, and 2 with a 99 percent confidence interval of from -1 percent to 5 percent for the other comparison. The percentage of false positives tended to be greater with the gene detection test in the later comparison.

Three studies provided one pairwise comparisons of a gene detection test to an immunoassay for toxins A and B.³² The sensitivity of the gene detection test was consistently better, although the point difference ranged widely from 3 percent to 56 percent, and the confidence intervals didn't always exclude a difference of zero. The false positives for the gene-based test were approximately 3 percent greater compared to one of the immunoassays for toxins A and B.

The sensitivities of the two gene detection tests in the three studies ranged from 89 percent to 100 percent. In contrast, the sensitivities of the immunoassays for toxins A and B were much more variable, ranging from 44 percent to 86 percent. The methodological differences between studies, including use of different reference tests, might have affected the toxin immunoassays more than the gene detection tests. The estimated sensitivities of the immunoassays were remarkably low (only 44 or 58 percent) in two studies that used the generally most sensitive reference test (toxigenic culture).

Table 1. Summary of diagnostic comparisons in included studies

Diagnostic Test	Premier Toxin A&B, Meridian	Tox A/B II, TechLab	Tox A/B QUIK CHEK, TechLab	ImmunoCard A&B, Meridian	Xpect Toxin A/B, Remel	ProSpecT Toxin A/B, Remel	<i>C. diff</i> Tox A/B, VIDAS
<i>A and B Toxin Immunoassays</i>							
Premier Toxin A&B, Meridian	n/a	4 studies	1 study	3 studies	2 studies	2 studies	2 studies
Tox A/B II, TechLab	none	n/a	2 studies	2 studies	none	none	none
Tox A/B QUIK CHEK, TechLab	none	none	n/a	4 studies	3 studies	1 study	1 study
ImmunoCard A&B, Meridian	none	none	none	n/a	none		1 study
Xpect Toxin A/B, Remel	none	none	none	none	n/a	1 study	1 study
ProSpecT Toxin A/B, Remel	none	none	none	none	none	n/a	1 study
<i>C. diff</i> Tox A/B, VIDAS	none	none	none	none	none	none	n/a
<i>Gene Detection Tests</i>							
GeneOhm, Becton Dickinson	1 study	2 studies	1 study	1 study	1 study	1 study	2 studies
GeneXpert, Cepheid	1 study	none	none	none	none	none	1 study

Table 2. Comparisons of immunoassays for toxins A and B

Study	Sensitivity (% True Positive)			% False Positives (1 Minus Specificity)		
	Toxin Immunoassay X	Toxin Immunoassay Y	% Difference	Toxin Immunoassay X	Toxin Immunoassay Y	% Difference
Eastwood, 2009 ³² Musher, 2007 ³³ Turgeon, 2003 ³⁸ O'Connor, 2001 ³⁶ Pooled Estimate heterogeneity†	<u>Premier Toxin A&B, Meridian</u> 101/125 (80.8%) 52/54 (96.3%) 74/101 (73.3%) 50/61 (82.0%)	<u>Tox A/B II, TechLab</u> 100/125 (80.0%) 52/54 (96.3%) 78/101 (77.2%) 49/61 (80.3%)	1 (-12 to 14)* 0 (-9 to 9) -4 (-20 to 12) 2 (-17 to 20) 0 (-7 to 6) p=0.92;I ² =0%	<u>Premier Toxin A&B, Meridian</u> 12/475 (2.5%) 5/77 (6.5%) 8/898 (0.9%) 1/139 (0.7%)	<u>Tox A/B II, TechLab</u> 19/475 (4.0%) 10/77 (13.0%) 5/902 (0.6%) 1/139 (0.7%)	-1 (-4 to 1) -6 (-19 to 6) 0 (-1 to 1) 0 (-3 to 3) 0 (-3 to 2) p=0.06;I ² =60%
Eastwood, 2009 ³² Alcala, 2008 ³¹ Miendje Deyi, 2008 ³⁹ Samra, 2008 ³⁴ Pooled Estimate heterogeneity	<u>Tox A/B QUIK CHEK, TechLab</u> 93/125 (74.4%) 56/102 (54.9%) 22/23 (95.7%) 89/94 (94.7%)	<u>ImmunoCard A&B, Meridian</u> 86/115 (74.8%) 68/102 (66.7%) 21/23 (91.3%) 89/94 (94.7%)	0 (-15 to 14) -12 (-29 to 6) 4 (-14 to 23) 0 (-8 to 8) -1 (-9 to 6) p=0.26;I ² =25%	<u>Tox A/B QUIK CHEK, TechLab</u> 3/473 (0.6%) 12/265 (4.5%) 0/77 (0%) 3/106 (2.8%)	<u>ImmunoCard A&B, Meridian</u> 2/444 (0.4%) 13/265 (4.9%) 0/77 (0%) 3/106 (2.8%)	0 (-1 to 1) 0 (-5 to 4) 0 (-3 to 3) 0 (-6 to 6) 0 (-1 to 1) p=0.98;I ² =0%
Eastwood, 2009 ³² Sloan, 2008 ³⁵ Musher, 2007 ³³ Pooled Estimate heterogeneity	<u>Premier Toxin A&B, Meridian</u> 101/125 (80.8%) 21/44 (47.7%) 75/76 (98.7%)	<u>ImmunoCard A&B, Meridian</u> 86/115 (74.8%) 21/44 (47.7%) 73/76 (96.1%)	6 (-8 to 20) 0 (-27 to 27) 3 (-4 to 9) 3 (-3 to 9) p=0.77;I ² =0%	<u>Premier Toxin A&B, Meridian</u> 12/475 (2.5%) 3/156 (1.9%) 10/370 (2.7%)	<u>ImmunoCard A&B, Meridian</u> 2/444 (0.4%) 2/156 (1.3%) 4/370 (1.1%)	2 (0 to 4) 1 (-3 to 4) 2 (-1 to 4) 2 (0 to 3) p=0.67;I ² =0%
Eastwood, 2009 ³² Alcala, 2008 ³¹ Miendje Deyi, 2008 ³⁹ Pooled Estimate heterogeneity	<u>Tox A/B QUIK CHEK, TechLab</u> 93/125 (74.4%) 56/102 (54.9%) 22/23 (95.7%)	<u>Xpect Toxin A/B, Remel</u> 86/117 (73.5%) 50/102 (49.0%) 21/23 (91.3%)	1 (-14 to 15) 6 (-12 to 24) 4 (-14 to 23) 3 (-6 to 13) p=0.84;I ² =0%	<u>Tox A/B QUIK CHEK, TechLab</u> 3/473 (0.6%) 12/265 (4.5%) 0/77 (0%)	<u>Xpect Toxin A/B, Remel</u> 3/475 (0.6%) 11/265 (4.2%) 0/77 (0%)	0 (-1 to 1) 0 (-4 to 5) 0 (-3 to 3) 0 (-1 to 1) p=0.96;I ² =0%
Eastwood, 2009 ³² Samra, 2008 ³⁴ Pooled Estimate heterogeneity	<u>Tox A/B QUIK CHEK, TechLab</u> 93/125 (74.4%) 89/94 (94.7%)	<u>Tox A/B II, TechLab</u> 100/125 (80.0%) 88/94 (93.6%)	-6 (-19 to 8) 1 (-8 to 10) -1 (-11 to 8) p=0.22;I ² =35%	<u>Tox A/B QUIK CHEK, TechLab</u> 3/473 (0.6%) 3/106 (2.8%)	<u>Tox A/B II, TechLab</u> 19/475 (4.0%) 6/106 (5.7%)	-3 (-6 to -1) -3 (-10 to 4) -3 (-6 to -1) p=0.85;I ² =0%
Eastwood, 2009 ³² Musher, 2007 ³³ Pooled Estimate heterogeneity	<u>Premier Toxin A&B, Meridian</u> 101/125 (80.8%) 52/54 (96.3%)	<u>ProSpecT Toxin A/B, Remel</u> 102/125 (81.6%) 49/54 (90.7%)	-1 (-14 to 12) 6 (-7 to 8) 3 (-6 to 11) p=0.31;I ² =4%	<u>Premier Toxin A&B, Meridian</u> 12/475 (2.5%) 5/77 (6.5%)	<u>ProSpecT Toxin A/B, Remel</u> 32/475 (6.7%) 2/77 (2.6%)	-4 (-8 to -1) 4 (-5 to 13) -1 (-11 to 10) p=0.02;I ² =80%
Eastwood, 2009 ³² Sloan, 2008 ³⁵ Pooled Estimate heterogeneity	<u>Premier Toxin A&B, Meridian</u> 101/125 (80.8%) 21/44 (47.7%)	<u>Xpect Toxin A/B, Remel</u> 86/117 (73.5%) 21/44 (47.7%)	7 (-7 to 21) 0 (-27 to 27) 6 (-7 to 18) p=0.54;I ² =0%	<u>Premier Toxin A&B, Meridian</u> 12/475 (2.5%) 3/156 (1.9%)	<u>Xpect Toxin A/B, Remel</u> 3/475 (0.6%) 25/156 (16.0%)	2 (0 to 4) -14 (-22 to -6) -6 (-32 to 20) p=0.0001;I ² =97%

Table 2. Comparisons of immunoassays for toxins A and B (continued)

Study	Sensitivity (% True Positive)			% False Positives (1 Minus Specificity)		
	Toxin Immunoassay X	Toxin Immunoassay Y	% Difference	Toxin Immunoassay X	Toxin Immunoassay Y	% Difference
Eastwood, 2009 ³² Samra, 2008 ³⁴ Pooled Estimate heterogeneity	<u>Tox A/B II, TechLab</u> 100/125 (80.0%) 88/94 (93.6%)	<u>ImmunoCard A&B, Meridian</u> 86/115 (74.8%) 89/94 (94.7%)	5 (-9 to 19) -1 (-10 to 8) 1 (-8 to 10) p=0.25;I ² =24%	<u>Tox A/B II, TechLab</u> 19/475 (4.0%) 6/106 (5.7%)	<u>ImmunoCard A&B, Meridian</u> 2/444 (0.4%) 3/106 (2.8%)	4 (1 to 6) 3 (-4 to 10) 3 (1 to 6) p=0.80;I ² =0%
Eastwood, 2009 ³² van den Berg, 2007 ¹⁶² Pooled Estimate heterogeneity	<u>Premier Toxin A&B, Meridian</u> 101/125 (80.8%) 30/31 (96.8%)	<u>VIDAS C. diff Tox A/B, bioMerieux</u> 100/116 (86.2%) 26/31 (83.8%)	-5 (-18 to 7) 13 (-6 to 32) 3 (-21 to 27) p=0.03;I ² =78%	<u>Premier Toxin A&B, Meridian</u> 12/475 (2.5%) 29/509 (5.7%)	<u>VIDAS C. diff Tox A/B, bioMerieux</u> 2/464 (0.4%) 15/509 (2.9%)	2 (0 to 4) 3(-1 to 6) 2 (1 to 4) p=0.62;I ² =0%
Eastwood, 2009 ³²	<u>Premier Toxin A&B, Meridian</u> 101/125 (80.8%)	<u>Tox A/B QUIK CHEK, TechLab</u> 93/125 (74.4%)	6 (-7 to 20)	<u>Premier Toxin A&B, Meridian</u> 12/475 (2.5%)	<u>Tox A/B QUIK CHEK, TechLab</u> 3/473 (0.6%)	2 (0 to 4)
Eastwood, 2009 ³²	<u>Tox A/B QUIK CHEK, TechLab</u> 93/125 (74.4%)	<u>ProSpecT Toxin A/B, Remel</u> 102/125 (81.6%)	-7 (-21 to 6)	<u>Tox A/B QUIK CHEK, TechLab</u> 3/473 (0.6%)	<u>ProSpecT Toxin A/B, Remel</u> 32/475 (6.7%)	-6 (-9 to -3)
Eastwood, 2009 ³²	<u>Tox A/B QUIK CHEK, TechLab</u> 93/125 (74.4%)	<u>VIDAS C. diff Tox A/B, bioMerieux</u> 100/116 (86.2%)	-12 (-25 to 1)	<u>Tox A/B QUIK CHEK, TechLab</u> 3/473 (0.6%)	<u>VIDAS C. diff Tox A/B, bioMerieux</u> 2/464 (0.4%)	0 (-1 to 1)
Eastwood, 2009 ³²	<u>Xpect Toxin A/B, Remel</u> 86/117 (73.5%)	<u>ProSpecT Toxin A/B, Remel</u> 102/125 (81.6%)	-8 (-22 to 6)	<u>Xpect Toxin A/B, Remel</u> 3/475 (0.6%)	<u>ProSpecT Toxin A/B, Remel</u> 32/475 (6.7%)	-6 (-9 to -3)
Eastwood, 2009 ³²	<u>Xpect Toxin A/B, Remel</u> 86/117 (73.5%)	<u>VIDAS C. diff Tox A/B, bioMerieux</u> 100/116 (86.2%)	-13 (-26 to 1)	<u>Xpect Toxin A/B, Remel</u> 3/475 (0.6%)	<u>VIDAS C. diff Tox A/B, bioMerieux</u> 2/464 (0.4%)	0 (-1 to 1)
Eastwood, 2009 ³²	<u>ProSpecT Toxin A/B, Remel</u> 102/125 (81.6%)	<u>VIDAS C. diff Tox A/B, bioMerieux</u> 100/116 (86.2%)	-5 (-17 to 8)	<u>ProSpecT Toxin A/B, Remel</u> 32/475 (6.7%)	<u>VIDAS C. diff Tox A/B, bioMerieux</u> 2/464 (0.4%)	6 (3 to 9)
Alcala, 2010 ¹⁶⁴	<u>ImmunoCard A&B, Meridian</u> 42/62 (67.7%)	<u>VIDAS C. diff Tox A/B, bioMerieux</u> 43/62 (69.4%)	-2 (-23 to 20)	<u>ImmunoCard A&B, Meridian</u> 21/425 (4.9%)	<u>VIDAS C. diff Tox A/B, bioMerieux</u> 8/425 (1.9%)	3 (0 to 6)

* Values in parentheses are 99% confidence intervals for the difference between tests conservatively assuming statistical independence between the paired tests.

† The p-value is a chi-square test for nonrandom variation in the differences between studies, and I² is the proportion of the total variance in the estimated differences that reflects true variation (i.e. heterogeneity between studies).

Table 3. Toxin gene detection tests compared to immunoassays

Study	Sensitivity (% True Positives)			% False Positives (1 Minus Specificity)		
	Toxin Gene Test	Toxin Immunoassay	% Difference	Toxin Gene Test	Toxin Immunoassay	% Difference
Kvach, 2010 ³⁷ Eastwood, 2009 ³² Pooled Estimate heterogeneity†	<u>GeneOhm.</u> <u>Becton Dickinson</u> 96/105 (91%) 92/103 (89%)	<u>Tox A/B II.</u> <u>TechLab</u> 70/105 (67%) 100/125 (80%)	25 (11 to 39)* 9 (-3 to 21) 17 (-3 to 37) p=0.03; I ² =79%	<u>GeneOhm.</u> <u>Becton Dickinson</u> 0/295 (0%) 16/449 (3.6%)	<u>Tox A/B II.</u> <u>TechLab</u> 1/295 (0.3%) 19/475 (4.0%)	0 (-4 to 3) 0 (-2 to 1) 0 (-1 to 1) p=0.90; I ² =0%
Swindells, 2010 ¹⁶⁵ Eastwood, 2009 ³² Pooled Estimate heterogeneity†	<u>GeneOhm.</u> <u>Becton Dickinson</u> 17/18 (94.4%) 92/103 (89%)	<u>VIDAS Clostridium</u> <u>difficile A and B.</u> <u>bioMerieux</u> 8/18 (44.4%) 100/116 (86%)	50 (17 to 83) 3 (-8 to 14) 25 (-36 to 86) p<0.001; I ² =92%	<u>GeneOhm.</u> <u>Becton Dickinson</u> 1/132 (0.8%) 16/449 (3.6%)	<u>VIDAS Clostridium</u> <u>difficile A and B.</u> <u>bioMerieux</u> 0/132 (0%) 2/464 (0.4%)	1 (-2 to 3) 3 (1 to 6) 2 (-1 to 5) p=0.07; I ² =70%
Eastwood, 2009 ³²	<u>GeneOhm.</u> <u>Becton Dickinson</u> 92/103 (89%)	<u>Premier Toxin A&B.</u> <u>Meridian</u> 101/125 (81%)	9 (-3 to 21)	<u>GeneOhm.</u> <u>Becton Dickinson</u> 16/449 (3.6%)	<u>Premier Toxin A&B.</u> <u>Meridian</u> 12/475 (2.5%)	1 (-2 to 4)
Eastwood, 2009 ³²	<u>GeneOhm.</u> <u>Becton Dickinson</u> 92/103 (89%)	<u>ImmunoCard A&B.</u> <u>Meridian</u> 86/115 (75%)	15 (1 to 28)	<u>GeneOhm.</u> <u>Becton Dickinson</u> 16/449 (3.6%)	<u>ImmunoCard Toxin</u> <u>A&B, Meridian</u> 2/444 (0.4%)	3 (1 to 6)
Eastwood, 2009 ³²	<u>GeneOhm.</u> <u>Becton Dickinson</u> 92/103 (89%)	<u>Tox A/B QUIK</u> <u>CHEK, TechLab</u> 93/125 (74%)	15 (2 to 28)	<u>GeneOhm.</u> <u>Becton Dickinson</u> 16/449 (3.6%)	<u>Tox A/B QUIK</u> <u>CHEK, TechLab</u> 3/473 (0.6%)	3 (0 to 5)
Eastwood, 2009 ³²	<u>GeneOhm.</u> <u>Becton Dickinson</u> 92/103 (89%)	<u>ProSpecT Toxin</u> <u>A/B, Remel</u> 102/125 (82%)	8 (-4 to 20)	<u>GeneOhm.</u> <u>Becton Dickinson</u> 16/449 (3.6%)	<u>ProSpecT Toxin</u> <u>A/B, Remel</u> 32/475 (6.7%)	-3 (-7 to 1)
Eastwood, 2009 ³²	<u>GeneOhm.</u> <u>Becton Dickinson</u> 92/103 (89%)	<u>Xpect Toxin A/B.</u> <u>Remel</u> 86/117 (74%)	16 (3 to 29)	<u>GeneOhm.</u> <u>Becton Dickinson</u> 16/449 (3.6%)	<u>Xpect Toxin A/B.</u> <u>Remel</u> 3/475 (0.6%)	3 (0 to 5)
Swindells 2010 ¹⁶⁵	<u>GeneXpert, Cepheid</u> 18/18 (100%)	<u>VIDAS Clostridium</u> <u>difficile A and B.</u> <u>bioMerieux</u> 8/18 (44.4%)	56 (25 to 86)	<u>GeneXpert, Cepheid</u> 1/132 (0.8%)	<u>VIDAS Clostridium</u> <u>difficile A and B.</u> <u>bioMerieux</u> 0/132 (0%)	1 (-1 to 3)
Novak-Weekly, 2010 ⁴⁰	<u>GeneXpert, Cepheid</u> 68/72 (94%)	<u>Premier Toxin A&B.</u> <u>Meridian</u> 42/72 (58%)	36 (20 to 53)	<u>GeneXpert, Cepheid</u> 13/356 (3.7%)	<u>Premier Toxin A&B.</u> <u>Meridian</u> 19/360 (5.3%)	-2 (-6 to 2)

* Values in parentheses are 99% confidence intervals for the difference between tests conservatively assuming statistical independence between the paired tests.

† The p-value is a chi-square test for nonrandom variation in the differences between studies, and I² is the proportion of the total variance in the estimated differences that reflects true variation (i.e. heterogeneity between studies).

Key Question 2. What are Effective Prevention Strategies?

Search Results

We found 1 Cochrane review,⁴¹ 4 studies on antibiotic prescribing restrictions,⁴²⁻⁴⁵ 12 on single preventive practices aimed at transmission interruption,^{46-55,67} and 10 that bundled multiple practices into a prevention strategy.⁵⁶⁻⁶⁵ Only two trials were controlled trials;^{46,49} one was an interrupted time series study,^{42,66} and the remaining studies were before/after designs.^{43-45,47,48,50-55,66,67} The included studies are provided in Table 4.

Eight studies examining risk factors met the inclusion criteria and updated the period following a systematic review²⁰ (Appendix Table C3). Five studies were conducted in the United States,^{111,166-169} two in Israel,^{112,170} and one in the United Kingdom.¹⁷¹ The average CDI patient sample was 86 patients, with a range of 28 to 154. Studies varied in the degree to which the investigators verified that positive tests reflected disease.

Key Points

- Overall, the evidence available to link prevention strategies to clinically important outcomes, such as CDI incidence, is of low strength and is not extensive.
- Four observational studies and one Cochrane review found prescribing practice interventions decreasing the use of high-risk antimicrobials are associated with decreased CDI incidence. Prescribing practices were also used in multicomponent interventions credited with reducing CDI incidence; however, it is difficult to isolate the specific effects of the prescribing practices.
- One controlled trial found glove use significantly reduced CDI incidence.
- Three observational studies, including two controlled, found disposable thermometer use is likely to reduce CDI incidence.
- No study examined the effect of handwashing, rather than alcohol gels, on CDI incidence. Four observational studies found use of alcohol gels as interventions for other infectious diseases, presumably in the presence of protocols requiring handwashing in the presence of CDI or visible soiling, did not increase CDI incidence.
- Three studies provide low evidence that disinfection with a chemical compound that kills *C. difficile* spores in the hospital environment prevents CDI, at least in epidemic or hyperendemic settings. Seven studies included disinfection in multicomponent interventions. Disinfection agents examined included hypochlorite solution, hydrogen peroxide, aldehydes, and detergent.
- Ten time series/before-after studies have examined bundled multiple interventions using before/after study designs. Data are insufficient to draw conclusions.
- Risk factors for developing CDI include antibiotic use, substantial chronic illness, hospitalization in an ICU, age, and acid suppression therapy.
- No data on patient harms or harms to hospital staff due to preventive interventions were reported.
- No studies assessed the sustainability of a prevention program beyond an intervention period.

Quality of the Studies

Overall, the quality of the evaluated studies was considered low (Table 4). In the Cochrane review⁴¹ focusing on improving antibiotic prescribing practices, the evidence from one article¹⁷² was judged to be of “good” quality, and evidence from the others was considered “weak.” The evidence for the 10 single preventive practices aimed at transmission interruption was low because they predominately used before/after design and were done in response to epidemic or hyperendemic conditions. In particular, there is insufficient evidence that handwashing is associated with reduced CDI incidence, as no study assessed this intervention. Of the four studies assessing alcohol based rubs or gels, only one had concurrent controls. Thirteen studies examining environmental disinfections were all before/after studies, generally done in response to epidemics.

For the 10 articles that described multiple component preventive interventions, none had concurrent controls or was blinded, and there was considerable variability in the types of interventions, so pooling could not be done. In addition, it was indeterminable to attribute decreases in CDI incidence to any single intervention in all of these studies.

Detailed Analysis

Due to the low-quality studies, we provide a qualitative narrative of the evidence for prevention practice interventions.

Antibiotic Use

The five studies summarized in the Cochrane review,⁴¹ and the additional four individual studies here,⁴²⁻⁴⁵ found that changes in antimicrobial education, policies, or formularies, which result in decreasing use of high-risk antimicrobials, are associated with decreased CDI incidence. It was not possible to clearly isolate the impact of the antibiotic-related interventions in the studies examining multiple interventions.^{58-60,62,63} In the individual studies, which were usually done in response to outbreaks, interventions in addition to those aimed at antibiotic use may have been done but not reported. The interventions and antibiotics targeted for reduction differed among the various studies.

The Cochrane review⁴¹ determined the impact of interventions to improve antibiotic prescribing practices for hospital inpatients on CDI incidence. The authors found that four interventions were associated with significant reductions in CDI incidence^{62,172-174} and that one was associated with a nonsignificant trend toward a reduction.⁶¹

A prospective controlled interrupted time series⁴² of an antibiotic improvement intervention on three acute medical wards for elderly people with 21-month predefined pre- and postintervention periods, evaluated a “narrow-spectrum” antibiotic policy (reinforced by an established program of audit and feedback of antibiotic usage and CDI rates). The program targeted broad-spectrum antibiotics (cephalosporins and amoxicillin/clavulanate) for reduction and narrow-spectrum antibiotics (benzyl penicillin, amoxicillin, and trimethoprim) for increase. CDI rates decreased significantly with incidence rate ratios of 0.35 (95 percent CI 0.17 – 0.73). Incidence of Methicillin-resistant *Staphylococcus aureus* (MRSA), the control, did not change significantly.

The effect of a new antibiotic policy favoring piperacillin-tazobactam over cefotaxime on the long-term incidence of CDI and antibiotic utilization in a large elderly medicine unit was studied in a before/after observational study.⁴³ Restrictions were associated with reduced cefotaxime use

and reduced CDI incidence. Subsequently, the piperacillin-tazobactam became unavailable at the end of 2001. Cefotaxime use and CDI incidence rates increased during 2002.

In a geriatrics department of a university hospital, antimicrobial recommendations for treatment of several common infectious diseases were changed from broad-spectrum cephalosporins to other drugs thought to be less likely to induce CDI.⁴⁴ Investigators changed department policy to reflect these recommendations, educated providers, monitored antibiotic use, and gave periodic feedback to providers. Cephalosporin use dropped, and the relative risk of CDI decreased to 0.31 (95 percent CI 0.93 to 0.10) compared with usage before the policy change.

In a geriatrics department of another university hospital, broad-spectrum cephalosporin use was restricted due to an increase in CDI incidence.⁴⁵ In the following year, cephalosporin use decreased 92 percent, and CDI incidence decreased 50 percent from the previous year incidence. CDI incidence did not change in other hospital departments.

Measures to Reduce Transmission

Gloves

One controlled trial examined the use of gloves to prevent *C. difficile* transmission, with CDI incidence monitored by active surveillance.⁴⁶ An intensive education campaign on two wards urged personnel to use gloves when handling body substances, and gloves were made easily available to personnel working with patients. Two other wards with no education campaign served as control wards, and gloves on these wards were stocked in supply rooms. Incidence of CDI decreased significantly from 7.7 cases/1,000 patient discharges during the 6 months before intervention to 1.5/1,000 during the six months of intervention on the intervention wards. No significant change in CDI incidence was observed on the control wards. Asymptomatic *C. difficile* carriage also decreased significantly on the intervention wards but not on the control wards. The cost of 61,500 gloves (4,505 gloves/100 patients) used was \$2,768 for the glove-using wards, compared with \$1,895 (42,100 gloves; 3,532 gloves/100 patients) on the control wards.

Disposable Thermometers

Three studies, one randomized crossover design,⁴⁹ and two before/after studies without concurrent controls^{47,48} have shown that use of disposable thermometers prevent CDI. In one hospital with an increased CDI incidence, 21 percent of electronic rectal thermometer handles were contaminated with *C. difficile*.⁴⁷ Efforts to reinforce infection control practices were already in place, but CDI incidence remained elevated. A before/after trial was conducted in that hospital and a chronic care facility to determine if use of disposable thermometers instead of multiple-use electronic rectal thermometers would reduce the CDI incidence. Surveillance for CDI was active, but toxin was detected with a latex agglutination test. During the 6-month postintervention period, the CDI incidence decreased from 2.71/1,000 patient days to 1.76/1,000 patient days in the acute hospital and from 0.41/1,000 patient days to 0.11/1,000 patient days in the skilled nursing facility. The harms associated with use of disposable thermometers were costs for purchase of disposable thermometers and the need to dispose of these thermometers. In these institutions, annual outlays increased from \$7,731 to \$14,055. These costs were offset by the need to purchase fewer electronic thermometers and to sterilize them periodically and by decreased costs of treating CDI cases.

In a later report, the same group reported that the rate of *C. difficile* infections increased from 1991 to 1993, although it was unclear how many patients had symptoms of disease with *C. difficile*.⁴⁸ One ward used disposable tympanic membrane thermometers instead of disposal oral or rectal thermometers. Different interventions were implemented in two other wards. Regression analysis determined that the *C. difficile* infection rate decreased 40 percent (relative risk [RR], 0.59, 95 percent CI, 0.47-0.67).

A randomized, controlled crossover study compared the use of disposable thermometers with electronic thermometers to prevent nosocomial CDI.⁴⁹ Twenty hospital wards were randomly assigned to disposable thermometers or electronic thermometers for 6 months, and then the assignments were reversed for 5 months. CDI rates were reduced 44 percent (P=0.026, 95 percent CI, 0.21 to 0.93) with disposable thermometers compared to electronic thermometers. Rates of nosocomial diarrhea or nosocomial infections did not differ significantly between the two groups. A cost analysis estimated that the hospital using disposable thermometers would need to spend an additional \$5,926 to prevent a single CDI case. It was estimated that a CDI case resulted in \$2,000 to \$6,000 in excess costs.

Handwashing

No study addressed whether handwashing was associated with reduced CDI incidence. Many institutions encourage the use of alcohol-based rubs or gels for hand hygiene unless hands are grossly soiled or unless a health care worker has had potential contact with *C. difficile* either from patient contact or environmental contamination. Neither alcohol nor soap will kill *C. difficile* spores, but when health care workers wash hands properly with soap, most spores are removed because of friction and the detergent action of soap. Complicated recommendations are difficult to remember and implement, and one concern has been that health care workers will use alcohol-based rubs or gels in circumstances where handwashing is preferred.

Four studies have addressed this concern. One 2-year, prospective, controlled, crossover trial compared alcohol-based hand gel provided in addition to hand soap containing the antimicrobial 0.3 percent chloroxylenol with antimicrobial soap alone in two intensive care units.⁵⁰ In units using adjuvant alcohol-based gel, there was a significant, sustained improvement in the rate of hand hygiene adherence but no detectable change in the incidence of healthcare-associated CDI (diagnosis determined by clinicians).⁵⁰ Employees still had access to soap and water when their hands were soiled or when they were caring for a patient with *C. difficile*, and if workers used soap and water in these circumstances, it would have decreased the likelihood that differences in CDI rates would be detected.

The second study used a before/after design.⁵¹ Hospital employees were encouraged to wash hands with the antimicrobial 0.3 percent triclosan in the first 3-year period, and an alcohol-based hand rub with 62.5 percent ethyl was placed in dispensers in inpatient and outpatient clinic rooms in the next 3 years. There was a 21 percent decrease in new, nosocomially acquired MRSA isolates and a 41 percent decrease in vancomycin-resistant enterococci (VRE) isolates, but the incidence of new CDI cases remained similar (diagnosis determined by clinicians/toxin A assay).⁵¹

A retrospective time-series analysis, the secondary objective, was done to determine the relationship between use of alcohol-based hand rub and antibiotic consumption on the incidence of CDI.⁵² CDI incidence was determined retrospectively from records of patients put in isolation for CDI. Multivariable time series analyses showed no association between alcohol-based hand

rub and CDI incidence. Macrolide and third-generation cephalosporin use was associated with increased CDI incidence after lag times of 1 to 3 months.

A retrospective, interventional time-series analysis was used to determine the effects of two interventions on CDI incidence.⁶⁶ The interventions were promotional campaigns to encourage use of alcohol-based hand rub for hand hygiene. Time series analysis was done with autoregressive integrated moving average models. There was no association between alcohol-based hand rub and CDI incidence.

Disinfection

Four studies examined if disinfection reduces the incidence of CDI as a single component intervention,^{53-55,67} and seven studies included disinfection in multicomponent interventions.^{56,57,59,60,63,65,68} Disinfection agents examined included hypochlorite solution, hydrogen peroxide, aldehydes, and detergent.

Three studies examined **hypochlorite solution** as a single intervention. One before/after intervention investigated whether cleaning patient rooms that tested positive for *C. difficile* toxin with unbuffered with 1:10 hypochlorite solution reduced the incidence of CDI in three patients' units.⁵³ Before the intervention, patient rooms were cleaned with quaternary ammonium. In one housing bone marrow transplant patients and having the greatest rate before the intervention, the CDI incidence rate decreased significantly, from 8.6 to 3.3 cases per 1,000 patient-days (hazard ratio 0.37, 95 percent CI, 0.19 to 0.74) after hypochlorite was used to clean rooms. In the other two with lesser rates before the intervention, there was no significant change. In response to a subsequent outbreak of VRE infections, the hospital used quaternary ammonium solution for all patient room disinfection. The incidence of VRE infection decreased, but the CDI incidence rate increased. Hypochlorite disinfection was reinstated and the CDI incidence rate subsequently decreased. A followup report documented subsequent increases in incidence and further interventions to control CDI.

An epidemiological investigation of an outbreak of CDI occurring in a single ward of a Michigan hospital documented nosocomial acquisition from the environment.⁵⁴ After use of unbuffered hypochlorite to disinfect wards, contamination decreased and the outbreak ended. Subsequently, it was shown that phosphate-buffered hypochlorite was even more effective for disinfection.

Hypochlorite was used in various ways in conjunction with other interventions to prevent CDI in seven studies (multiple intervention table part B).^{56,57,59,60,63,65,68} The effect of the hypochlorite disinfection cannot be isolated from the other intervention components.

A high rate of CDI was noted in three hospitals joined in a single health care system. Hospitals changed the disinfectant used for the discharge cleaning of rooms of patients with CDI from a quaternary ammonium compound to dilute bleach.⁶⁷ There was a 48 percent reduction in the prevalence of *C. difficile* after the bleaching intervention (P=0.0001, 95 percent CI, 36 to 58).

Two before/after studies were conducted to evaluate whether disinfection with **hydrogen peroxide** as part of multiple component interventions reduces CDI incidence.^{57,63} In the first study, an abrupt increase in nosocomial CDI (defined as diarrhea with a positive toxin test) incidence led to multiple interventions in attempts to control the outbreak. Surveillance was based on laboratory and patient medical records.⁵⁷ A liquid vapor hydrogen peroxide decontamination system was used to decontaminate five high incidence wards of *C. difficile* organisms.⁵⁷ There followed a slight decrease in nosocomial CDI incidence. Liquid vapor hydrogen peroxide was then used to decontaminate patient rooms vacated by patients with CDI

throughout the hospital on an ongoing basis. Nosocomial CDI incidence continued to decrease and remained at levels roughly equivalent to rates prior to the outbreak. Quality of the diagnosis and surveillance system was good. No harms to hospital personnel, patients, or equipment were observed. The authors noted that the area to be decontaminated must be appropriately sealed, hydrogen peroxide levels outside the area being decontaminated must be closely monitored, and hydrogen peroxide concentrations within the decontaminated area must be reduced to less than 1 part per million before allowing patients or health care workers to re-enter. A subsequent study by the same investigators reported that hydrogen peroxide vapor disinfection was feasible in their hospital.¹⁷⁵ The peroxide vapor disinfection took 2 hours and 20 minutes to complete compared with 32 minutes for routine cleaning. The median cumulative times for all phases of cleaning and disinfection were 234 minutes (range 174–838) for peroxide vapor compared with 55 minutes (range 28–256) for conventional hypochlorite.

In the second study, 7 percent accelerated hydrogen peroxide was used for terminal disinfection of rooms of patients with CDI and comprehensive ward disinfection with sodium hypochlorite was done when three or more nosocomial CDI cases (defined as cases with positive toxin or with endoscopic or histological evidence of pseudomembranous colitis) remained elevated.⁶³ Within 4 months of the time infection prevention measures were implemented, the investigators also took several steps to reduce antibiotic use. Nosocomial CDI incidence fell abruptly within 1 month of the changes in antibiotic use.

In one study using **aldehydes** as part of a multiple-component intervention, a cluster of CDI in a surgical ward led to a hospitalwide surveillance and control program.⁵⁵ Control interventions included terminal room disinfection with 0.04 percent formaldehyde and 0.03 percent glutaraldehyde in wards with a cluster of two or more nosocomial CDI cases per month. During a 12-month period, the quarterly incidence of nosocomial CDI remained unchanged. *C. difficile* spores were recovered from 36.7 percent of the surfaces of case patient rooms versus 6.7 percent in control rooms. Subsequently, more intensive control measures were evaluated, which included daily meticulous room disinfection for each sporadic nosocomial CDI case. Surface disinfection reduced the contamination level fourfold ($p = 0.04$). In the following 12 months, the nosocomial CDI incidence fell to 0.3/1,000 admission (protective efficacy 73 percent, 95 percent CI, 46–87 percent). Multiple interventions, including disinfection, were used to control the outbreak. The study provides low evidence that disinfection, in this case with aldehydes, might have had a role in terminating the outbreak.

These ten studies provide low evidence that disinfection with a chemical compound that kills *C. difficile* spores in the hospital environment prevents CDI, at least in epidemic or hyperendemic settings. Decreased CDI incidence might have been from natural variation (regression to the mean) in some or all studies. As stated previously, disinfection was one of multiple interventions used to prevent CDI in seven studies; it is difficult to impossible to know which intervention or combination of interventions might have led to reduced CDI incidence.

Multiple Component Studies

Ten studies described the use of multiple preventive measures to control epidemic CDI, or endemic CDI that was felt to be excessive. Tables 5 and 6 list the categories of interventions in each of these articles. The number of interventions and the specific nature of any particular interventions varied widely. Studies employed between two and nine different types of interventions, including steps to optimize antimicrobial (six studies),⁵⁸⁻⁶³ enhanced surveillance (two studies),^{59,60} intensified staff education about infection prevention (three studies),^{60,62,63} new

isolation procedures (four studies),^{59,61,63,64} and “enteric precautions” (two studies).^{58,61} Two studies emphasized handwashing^{61,64} and one alcohol-based gel for hand disinfection.⁶⁰ Health care workers were required to wear gloves in three studies,^{61,62,64} and use of gowns for patient contact was required in two studies.^{61,64} Visitors were asked to comply with infection prevention procedures in one study.⁶⁴ New dedicated patient care equipment was purchased in two studies,^{60,63} and in one of these, cleaning of dedicated patient equipment was intensified. Disposable rectal thermometers were used in one study.⁶³ Intensified environmental cleaning was implemented in six studies.⁵⁹⁻⁶⁴ CDI patient movement was restricted in two studies.^{59,64}

Investigators often placed greater weight on one intervention over others because the timing of decreased CDI incidence appeared to follow implementation of a particular intervention. However, the time it takes for many interventions to become adopted in health care settings and the variance expected in disease incidence led us to conclude that it was not possible to attribute decreases in CDI incidence to a single intervention in any of these studies. Natural fluctuations are such that all outbreaks diminish after variable periods of time so that assigning causality to individual or a collection of prevention measures is impossible. The evidence from these studies that any single intervention or combination of interventions prevents CDI was low.

Harms

Harms, beyond cost, were not addressed in any study.

Risk Factors

Identified CDI risk factors can provide clues to researchers and health care providers for where to target prevention strategies. We identified one systematic review reviewed CDI risk factor literature through 1997²⁰ and 12 risk factor studies published after the review. Bignardi’s systematic review identified risk factors with “substantive” evidence: age, severity of underlying diseases, nonsurgical GI procedures, nasogastric tube, acid suppression medications, ICU, length of stay, duration of antibiotic course, and multiple antibiotics.²⁰ Five studies identified specific antibiotics or antibiotic classes with increased CDI risk^{111,168,169,176,177} (Table 7), and two studies found that antibiotic use in general was associated with increased risk for CDI.^{111,171} Consistent with Bignardi’s findings, the more recent literature also identified severe underlying disease as a risk factor in four studies^{112,166,167,171} and acid suppression in one.¹¹²

Sustainability

No studies addressed the sustainability of a prevention program.

Table 4. Prevention interventions

Author/Year Country	Study Design	Population	Intervention	Outcome	Findings	Quality Issues
Antibiotic Use						
Fowler, 2007 ⁴² UK	Prospective interrupted time series	Acute medical wards, elderly	Switch from broad to narrow spectrum antibiotics	CDI incidence	Incidence rate decreased (0.35, 95% CI 0.17 to 0.73)	No concurrent controls
Davey, 2005 ⁴¹ UK	Cochrane Review five included studies	Hospital inpatients	Improve antibiotic prescribing practices	CDI incidence	Four interventions were associated with significant reductions in CDI	Only one study was judged to be of "good" quality
O'Connor, 2004 ⁴⁴	Before–after	Geriatric unit N = 17 cases in 683 patients	Change in antibiotic policy; education, monitoring, feedback	CDI incidence	CDI rate decreased significantly. Use of restricted antibiotic decreased. RR 0.31 (95% CI 0.93 to 0.10)	Retrospective
Wilcox, 2004 ⁴³	Before–after time series	Elderly Medicine Unit inpatients	Change in antibiotic policy	CDI incidence	Use of restricted antibiotic decrease	No concurrent control
Ludlam, 1999 ⁴⁵ UK	Prospective before–after time series	Hospital N = 4,284	Change in antibiotic policy	CDI incidence	CDI rate decreased 50%. Use of restricted antibiotic decreased 92%	Patients on wards were antibiotic policy was unchanged acted as controls
Transmission Interruption – Gloves						
Johnson, 1990 ¹⁷⁸ USA	Controlled trial		Education program to use gloves	CDI incidence	CDI incidence decreased from 7.7 cases/1,000 patient discharges to 1.5/1,000 discharges	Not randomized or blinded
Transmission Interruption – Disposable Thermometers						
Brooks, 1992 ⁴⁷ and 1998 ⁴⁸ USA	Time series (before– after)	Hospital and long-term care	Single use thermometers	CDI incidence	Decrease in incidence: acute care – from 2.71/1,000 patient days to 1.76/1000 Long term-care – from 0.41/1,000 patient days to 0.11/1,000 patient days	No concurrent controls

Table 4. Prevention interventions (continued)

Author/Year Country	Study Design	Population	Intervention	Outcome	Findings	Quality Issues
Jernigan, 1998 ⁴⁹ USA	Crossover RCT	Hospital patients admitted to 20 nursing units	Disposable thermometers versus electronic thermometers	Rate of nosocomial CDI	CDI rates were reduced 44% (95% CI, 21 to 93) with disposable thermometers compared with electronic thermometers. Rates of nosocomial diarrhea or nosocomial infections did not differ significantly between the two groups.	Two wards elected not to use disposable thermometers
Transmission Interruption – Hand washing						
Kaier, 2009 ⁵² Germany	Before–after time series analysis	Tertiary care teaching hospital	Alcohol-based gel	CDI incidence	No association between alcohol-based hand rub and CDI incidence	Retrospective, no concurrent control
Vernaz, 2008 ⁶⁶ Switzerland	Before–after time series analysis	Primary and tertiary care teaching hospital	Promotional campaigns to encourage use of alcohol-based hand rub	CDI incidence	No association between alcohol-based hand rub and CDI incidence	Retrospective, no concurrent control
Rupp, 2008 ⁵⁰ USA	Controlled cross- over trial	Adult medical- surgical ICUs	Alcohol-based gel	CDI incidence	Use of gel adherence rates increased from 37% to 68%. No change in CDI rates	Not blinded
Gordin, 2005 ⁵¹ USA	Before–after	Hospital	Alcohol-based gel	CDI incidence	No change in CDI rates	
Transmission Interruption – Disinfection						
Hacek 2010 ⁶⁷	Before–after	Hospital patients	Hypochlorite solution for patient room cleaning	CDI incidence	48% reduction in CDI rates. (P<.0001, 95% CI 36–58%)	No concurrent controls
Mayfield, 2000 ⁵³ USA	Before–after	3 hospital units; one unit with high incidence, 2 with lower	Hypochlorite solution for patient room cleaning	CDI incidence	High incidence unit- CDI decreased from 8.6/1,000 patient days to 3.3/1,000 patient days. No change in other units	No concurrent controls

Table 4. Prevention interventions (continued)

Author/Year Country	Study Design	Population	Intervention	Outcome	Findings	Quality Issues
Kaatz, 1988 ⁵⁴ USA	Outbreak	Hospital patients	Hypochlorite solution for patient room cleaning	CDI incidence	Contamination decreased and the outbreak ended. Phosphate-buffered hypochlorite was effective for disinfection.	Before–after design in the setting of an epidemic
Struelens, 1991 ⁵⁵	Before–after	Hospital patients	Intensive cleaning measures, aldehydes	CDI incidence	Protective efficacy 73% (95% CI 46–87%)	No concurrent controls
Multiple Interventions						
Abbett, 2009 ⁵⁶ USA	Prospective before–after study	Hospital patients	Infection control practices, laboratory notification procedures, and steps coordinate infection control and environmental services aimed to decrease the transmission of <i>C. difficile</i> between patients (i.e., a prevention checklist)	CDI incidence	Use of a checklist of hospital interventions to decrease the incidence of healthcare-associated CDI	No concurrent control
Boyce, 2008 ⁵⁷ USA	Before–after time series	Hospital	Liquid vapor hydrogen peroxide decontamination system	CDI incidence	Nosocomial CDI incidence decreased and remained at lower levels	No concurrent control
Drudy, 2007 ⁶⁰ Ireland	Prospective time series (before–after)	Hospital patients	Antimicrobial use, enhanced surveillance, education, hand hygiene, equipment, intensified environmental cleaning	CDI incidence	CDI incidence decreased from a peak of 21 cases/1,000 patient admissions to 5/1,000 patient admissions	No concurrent controls

Table 4. Prevention interventions (continued)

Author/Year Country	Study Design	Population	Intervention	Outcome	Findings	Quality Issues
Valiquette, 2007 ⁶³ Canada	Retrospective time series (before–after)	Hospital patients	Antimicrobial use, education, isolation, equipment, intensified environmental cleaning	CDI incidence	Nonrestrictive measures to optimize antibiotic usage (leading to decreases in usage) led to a decrease in CDI incidence by 60%	Retrospective, no concurrent control
Whitaker, 2007 ⁶⁵ USA	Prospective time series (before–after)	Hospital patients	Antimicrobial use, education, isolation, automated report functions, and standardized nursing unit isolation processes	CDI incidence	66% reduction in the number of healthcare-associated CDI cases was achieved during the study	No concurrent controls
Zafar, 1998 ⁶⁴ USA	Prospective time series (before–after)	Hospital patients	Isolation, patient/staff movement, hand hygiene, patient room practices, intensified environmental cleaning	CDI incidence	Incidence of CDI decreased by 60% from 1990 to 1996 following use of comprehensive infection control measures.	No concurrent controls
McNulty, 1997 ⁶¹ UK	Retrospective time series (before–after)	Hospital patients, elderly care unit	Antimicrobial use, isolation, patient/staff movement, hand hygiene, patient room practices, intensified environmental cleaning	CDI incidence	Thirty-seven cases of CDI occurred in the period before and 16 in the period after policy change (combined approach of infection control and strict antibiotic policies).	Retrospective, no concurrent control
Cartmill, 1994 ⁵⁹ UK	Prospective time series (before–after)	Hospital patients	Antimicrobial use, enhanced surveillance, isolation, patient/staff movement, intensified environmental cleaning	CDI incidence	Subsequent to the intervention measures, there was a substantial and sustained decreased in the incidence of CDI	No concurrent controls

Table 4. Prevention interventions (continued)

Author/Year Country	Study Design	Population	Intervention	Outcome	Findings	Quality Issues
Pear, 1994 ⁶² USA	Prospective time series (before–after)	Hospital patients (Veterans Affairs)	Antimicrobial use, education, isolation, patient room practices, intensified environmental cleaning	CDI incidence	Nosocomial epidemic of CDI was controlled by analysis of antibiotic use patterns and by subsequent restriction of clindamycin	No concurrent controls
Brown, 1990 ⁵⁸ USA	Retrospective time series (before–after)	Hospital patients	Antimicrobial policy, isolation	CDI incidence	CDI attack rate dropped progressively	Retrospective, no concurrent control

CDI = *Clostridium difficile* infection; CI = confidence interval; ICU = intensive care unit; RR = relative risk

Table 5. (A) Studies of multiple interventions used together to reduce CDI incidence

Study	Type of Study	Epidemic or Excessive Incidence?	CDI Incidence Decreased After intervention?	Interventions									
				Improved Antimicrobial Use	Enhanced Surveillance, Analysis, and Reporting of CDI Data	Laboratory-Based Infection Prevention Alert System	Infection Prevention Education	Isolation (n=8)		Patient/Staff Movement (n=3)		Hand Hygiene (n=7)	
								Enteric Precautions	Isolation	CDI Patient Movement Restricted	Restriction of Nursing Cross-Cover	Enhanced Hand Washing	Alcohol-Based Rub or Gel
Abbett, 2009 ⁵⁶	Prospect time series (before–after)	Yes	Yes		X	X	X		X			X	
Boyce, 2008 ⁵⁷	Prospect time series (before–after)	Yes	Yes	X	X			X	X			X	
Brown, 1990 ⁵⁸	Retrospect time series (before–after)	Yes	Yes	X				X					
Cartmill, 1994 ⁵⁹	Prospect time series (before–after)	Yes	Yes	X	X				X	X			
Drudy, 2007 ⁶⁰	Prospect time series (before–after)	Yes	Yes	X	X		X						X
McMullen, 2007 ⁶⁸	Prospect time series (before–after)	Yes	Yes									X	
McNulty, 1997 ⁶¹	Retrospect time series (before–after)	Yes	Yes	X				X	X		X	X	
Pear, 1994 ⁶²	Prospect time series (before–after)	Yes	Yes	X			X						

Table 5. (A) Studies of multiple interventions used together to reduce CDI incidence (continued)

Study	Type of Study	Epidemic or Excessive Incidence?	CDI incidence Decreased After intervention?	Interventions									
				Improved Antimicrobial Use	Enhanced Surveillance, Analysis, and Reporting of CDI Data	Laboratory-Based Infection Prevention Alert System	Infection Prevention Education	Isolation (n=8)		Patient/Staff Movement (n=3)		Hand Hygiene (n=7)	
								Enteric Precautions	Isolation	CDI Patient Movement Restricted	Restriction of Nursing Cross-Cover	Enhanced Hand Washing	Alcohol-Based Rub or Gel
Valiquette, 2007 ⁶³	Retrospect time series (before–after)	Yes	Yes	X			X	X					
Whitaker, 2007 ⁶⁵	Prospect time series (before–after)	Yes	Yes	X	X		X	X			X		
Zafar, 1998 ⁶⁴	Prospect time series (before–after)	No	Yes					X	X		X		
Total number of studies evaluating specific intervention				8	5	1	5	3	7	2	1	6	1

CDI = Clostridium difficile infection

Table 6. (B) Studies of multiple interventions used together to reduce CDI incidence

Study	Type of Study	Interventions										
		Practices Within Patient Rooms (n=5)			Equipment (n=4)		Intensified Environmental Cleaning (n=10)					
		Gloves for Patient Contact	Gowns or Aprons for Patient Contact	Visitors Comply With Infection Prevention Practices	Dedicated Equipment, Equipment Cleaning	Disposable Rectal Thermometers	Room Cleaning With Hypochlorite	Ward Cleaning With Hypochlorite	Room Cleaning With Hydrogen Peroxide	Ward Cleaning With Hydrogen Peroxide	Room Cleaning With Detergent	Unspecified
Abbett, 2009 ⁵⁶	Prospect time series (before–after)		X	X	X		X					
Boyce, 2008 ⁵⁷	Prospect time series (before–after)						X		X	X		
Brown, 1990 ⁵⁸	Retrospect time series (before–after)											
Cartmill, 1994 ⁵⁹	Prospect time series (before–after)						X					
Drudy, 2007 ⁶⁰	Prospect time series (before–after)				X		X					
McMullen, 2007 ⁶⁸	Prospect time series (before–after)						X	X				
McNulty, 1997 ⁶¹	Retrospect time series (before–after)	X	X								X	
Pear, 1994 ⁶²	Prospect time series (before–after)	X										X
Valiquette, 2007 ⁶³	Retrospect time Series (before–after)				X	X	X		X	X		

Table 6. (B) Studies of multiple interventions used together to reduce CDI incidence (continued)

Study	Type of Study	Interventions										
		Practices Within Patient Rooms (n=5)			Equipment (n=4)		Intensified Environmental Cleaning (n=10)					
		Gloves for Patient Contact	Gowns or Aprons for Patient Contact	Visitors Comply With Infection Prevention Practices	Dedicated Equipment, Cleaning	Disposable Rectal Thermometers	Room Cleaning With Hypochlorite	Ward Cleaning With Hypochlorite	Room Cleaning With Hydrogen Peroxide	Ward Cleaning with Hydrogen Peroxide	Room Cleaning With Detergent	Unspecified
Whitaker, 2007 ⁶⁵	Prospect time series (before–after)			X	X		X	X				
Zafar, 1998 ⁶⁴	Prospect time series (before–after)	X	X	X								X
Total number of studies evaluating specific intervention		3	3	3	4	1	7	2	2	2	1	2

Table 7. Summary of risk factors for CDI

Study	Specific Antibiotic Use	General Antibiotic Use	Health Status or Disease Severity	Acid Suppression	Hospitalization in an ICU	Age	Miscellaneous
Peled, 2007 ¹¹²	NE	NE	Functional capacity score OR = 9.1	PPI OR = 6.1 Histamine blocker OR = 3.1	NE	NE	Hypoalbuminemia OR = 3.8 Leukocytosis OR = 2.7
Samore, 2006 ¹⁶⁹	Clindamycin OR = 4.2	NE	NE	NE	NE	NE	
Yearsley, 2006 ¹⁷¹	NE	OR = 13.1	NE	OR = 1.90	NE	NS	Female gender OR = 1.79
Vesta, 2005 ¹⁶⁶	NE	NS	Horn's Index P = 0.0022	NE	NE	NS	
Kyne, 2002 ¹⁶⁷	NS	NS	Severe underlying dz OR = 17.6	NS	NE	NS	
Mody, 2001 ¹⁶⁸	3 rd generation cephalosporins OR = 3.6	NE	NE	NE	NE	NE	
Schwaber, 2000 ¹⁷⁰	Cephalosporin P = 0.03; 3 rd generation cephalosporins P = 0.02	Greater number used P = 0.02	NE	NE	NE	NS	
Katz, 1997 ¹¹¹	Cephalosporin P = 0.001	Antibiotic use past 30 days P = 0.009; Antibiotic use prior to transfer/ admission P = 0.009	NE	NE	NE	NE	
Bignardi, 1998 ²⁰ Searched to March 1996		Duration of antibiotic course; multiple antibiotics	Severity of underlying diseases	Anti-ulcer medications	Yes	Yes	Non-surgical gastrointestinal procedures, nasogastric tube, hospital length of stay

dz = disease; ICU = intensive care unit; NE = not examined by multivariate analysis; NS = not significant factor; OR = odds ratio; PPI = proton pump inhibitor

Key Question 3. What are the Comparative Effectiveness and Harms of Different Antibiotic Treatments?

Search Results

Eleven randomized clinical trials were identified that evaluated different antimicrobials (or different doses of a single drug) available for treatment of CDI in the United States. These 11 studies, published from 1978 to 2009, ranged in size from 39 to 629 subjects. Table 8 provides a breakdown of the trial comparators. Vancomycin is the most frequently studied antimicrobial, examined in 8 of the 10 studies. The most frequent comparison was vancomycin versus metronidazole (three studies, one of which also included fusidic acid and teicoplanin treatment arms, which are not included in this analysis), followed by two studies of vancomycin versus bacitracin. The remaining comparisons (vancomycin vs. nitazoxanide, vancomycin vs. fidaxomicin, vancomycin high dose vs. low dose, vancomycin vs. placebo, metronidazole vs. nitazoxanide, and metronidazole vs. metronidazole plus rifampin) all occurred in single studies. Treatment duration was 10 days in 9 of 11 studies, with the other two having durations of 7 and 5 days. The typical study followup period was 21 to 31 days. The largest patient sample was 629; most studies were in the range of approximately 40 to 60 patients. (See Appendix Table C4.) Two studies that did not meet inclusion criteria merit brief mention: one¹⁷⁹ appears to report on the same subjects included in another publication,⁷⁸ while another¹⁸⁰ has been presented in abstract form only.

Table 8. Summary of trial comparators for 10 trials of antibiotic treatment of CDI

	Vancomycin	Metronidazole
Vancomycin	1 (N = 56) (dosing)	
Metronidazole	3 (N = 172 N = 62 N = 101)	
Nitazoxanide	1 (N = 50)	1 (N = 142)
Bacitracin	2 (N = 62 N = 42)	
Metronidazole + Rifampin		1 (N = 39)
Fidaxomicin	1 (N = 629)	
Placebo	1 (N = 44)	

Key Points

- Overall, study quality is low.
- Vancomycin and metronidazole, the most frequently clinically used antimicrobials, were the most frequently compared antimicrobials.
- Three RCT comparisons of vancomycin to metronidazole, with a total of 335 pooled subjects, found no significant differences in any examined outcome.
- One RCT comparing vancomycin to metronidazole, using a prespecified subgroup analysis of 69 patients, found a small but significant increase in the proportion of subjects with severe CDI who achieved initial clinical cure with vancomycin, using a treatment-received analysis. This difference was not significant using a strict intention-to-treat analysis.

- One study demonstrated that recurrence was significantly decreased with fidaxomicin versus vancomycin; initial cure was not significantly different between fidaxomicin and vancomycin.
- The decrease in recurrence seen with fidaxomicin use appeared to be limited to those patients with non-NAP1 strains.
- Harms were not reported with sufficient detail to compare the risks of any particular antimicrobial with another antimicrobial.
 - When harms were reported, they were generally not serious (nausea, emesis, etc.) and transient.

Minor Key Points

- No other head-to-head trial demonstrated superiority of any single antimicrobial for initial clinical cure, clinical recurrence, or mean days to resolution of diarrhea.
- Combination therapy with rifampin and metronidazole resulted in significantly higher mortality when compared to treatment with metronidazole only.
- Pooled data of 104 subjects comparing vancomycin to bacitracin showed significantly higher rates of organism or toxin clearance for vancomycin.
- No data were available to assess the importance of general patient characteristics or the strain of organism on the effectiveness of an antimicrobial.

Quality of the Studies

Overall study quality is low. Only two studies specified that the investigators (who also assessed outcomes) were blinded with respect to treatment.^{70,82} Quality summary tables are available in Appendix C of this report (see Appendix Tables C5 and C6). Strength of evidence is summarized in Appendix Tables C7 and C8.

Detailed Analysis

As vancomycin and metronidazole are the most frequently employed antimicrobials, and therefore of greatest interest to clinicians, results are broken into two sets: (1) vancomycin versus metronidazole and (2) all other comparisons of standard treatment trials.

Initial Cure

The percentage of subjects initially cured with vancomycin ranged from 84 percent to 94 percent among individual studies, with a mean value of 88 percent (Table 9). For subjects treated with metronidazole, the individual cure rates ranged from 73 percent to 94 percent, with a mean value of 81 percent. The relative risk for initial cure comparing vancomycin to metronidazole was 1.08 (95 percent CI 0.99 to 1.19).

Table 9. Initial clinical cure (# subjects / # randomized) for vancomycin versus metronidazole

Study	Vancomycin	Metronidazole	RR [95% CI]
Zar, 2007 ⁷⁰	69/82 (84)	66/90 (73)	1.15 [0.98 to 1.34]
<i>severe disease</i>	30/38 (79)	29/44 (66)	1.20 [0.92 to 1.57]
Wenisch, 1996 ⁷³	29/31 (94)	29/31 (94)	1.00 [0.88 to 1.14]
Teasley, 1983 ⁷⁶	51/56 (91)	39/45 (87)	1.05 [0.91 to 1.21]
Totals	149/169 (88)	134/166 (81)	1.08 [0.99 to 1.19]

CI = confidence interval; RR = relative risk

With the exception of vancomycin versus placebo, no other treatment comparison resulted in significant differences in initial clinical cure (Table 10).

Table 10. Initial clinical cure (# subjects / # randomized) for all other standard treatment trials

Study	Treatment 1	Treatment 2 / Control	Relative Risk [95% CI]
1. Vancomycin versus Nitazoxanide			
Musher, 2009 ⁶⁹	20/27 (74)	17/23 (74)	1.00 [0.72 to 1.39]
<i>severe disease</i>	7/10 (70)	8/10 (80)	0.88 [0.53 to 1.46]
2. Vancomycin versus bacitracin			
Dudley, 1986 ^{74*}	15/23 (65)	12/16 (75)	0.87 [0.58 to 1.31]
Young, 1985 ⁷⁷	18/21 (86)	16/21 (76)	1.13 [0.84 to 1.51]
Totals	33/44 (75)	28/37 (76)	1.01 [0.79 to 1.28]
4. Vancomycin versus fidaxomicin			
Louie, 2011 ⁷⁹	265/313 (85)	253/289 (88)	0.97 [0.91 to 1.04]
3. Vancomycin high-dose versus vancomycin low dose			
Fekety, 1989 ⁷⁵	22/28 (79)	24/28 (86)	0.92 [0.72 to 1.17]
4. Vancomycin versus placebo			
Keighley, 1978 ^{78*}	9/12 (75)	1/9 (11)	6.75 [1.03 to 44.08]
5. Metronidazole versus Nitazoxanide			
Musher, 2006 ⁷²	28/44 (64)	68/98 (69) 36/49 (73) 7-day 32/49 (65) 10-day	0.92 [0.71 to 1.19]
6. Metronidazole versus metronidazole plus rifampin			
Lagrotteria, 2006 ⁷¹	13/20 (65)	12/19 (63)	1.03 [0.64 to 1.65]

CI = confidence interval

Note: Treatment 1 is the first intervention listed in the first column, followed by treatment 2.

Clinical Recurrence

The percentage of subjects meeting the investigator-determined definition of recurrent disease (after meeting criteria for initial cure) ranged from 7 percent to 17 percent with vancomycin, with a mean value of 11 percent. For metronidazole the range was 5 percent to 21 percent, with a mean value of 12 percent. (Table 11) The relative risk for recurrence after vancomycin treatment compared to metronidazole was 0.92 (95 percent CI, 0.47 to 1.77)

Table 11. Clinical recurrence: # subjects / # initially cured (percent) for vancomycin versus metronidazole

Study	Vancomycin	Metronidazole	Relative Risk [95% CI]
Zar, 2007 ⁷⁰	5/69 (7)	9/66 (14)	2.29 [0.49 to 10.76]
<i>severe disease</i>	3/30 (10)	6/29 (21)	0.48 [0.13 to 1.75]
Wenisch, 1996 ⁷³	5/29 (17)	5/29 (17)	1.00 [0.32 to 3.09]
Teasley, 1983 ⁷⁶	6/51 (12)	2/39 (5)	0.53 [0.19 to 1.50]
Totals	16/149 (11)	16/134 (12)	0.92 [0.47 to 1.77]

CI = confidence interval

Only the comparison between fidaxomicin and vancomycin showed a statistically significant difference (15 percent vs. 25 percent, P = 0.005); in all other trials there was no significant difference in percentage of patients with recurrence. Between trial comparisons for the percentage of patients with recurrence are of uncertain relevance because of the variable definitions of recurrence and duration of followup. (Table 12).

Table 12. Clinical recurrence: # subjects / # initially cured (percent) for all other standard treatment trials

Study	Treatment 1	Treatment 2 / Control	Relative Risk [95% CI]
1. Vancomycin versus Nitazoxanide			
Musher, 2009 ⁶⁹	2/20 (10)	1/17 (6)	1.70 [0.17 to 17.16]
<i>severe disease</i>	1/10 (10)	1/10 (10)	1.00 [0.07 to 13.87]
2. Vancomycin versus bacitracin			
Dudley, 1986 ^{74*}	3/15 (20)	5/12 (42)	0.48 [0.14 to 1.62]
Young, 1985 ⁷⁷	6/18 (33)	5/12 (42)	0.80 [0.31 to 2.04]
Totals	9/33 (27)	10/24 (42)	0.65 [0.31 to 1.35]
3. Vancomycin high dose versus vancomycin low dose			
Fekety, 1989 ⁷⁵	4/22 (18)	5/24 (21)	0.87 [0.27 to 2.84]
4. Vancomycin versus fidaxomicin			
Louie, 2011 ⁷⁹	67/265 (25)	39/253 (15)	1.64 [1.15 to 2.34]
5. Vancomycin versus placebo			
Keighley, 1978 ^{78*}	NR	NR	
6. Metronidazole versus Nitazoxanide			
Musher, 2006 ⁷²	8/28 (29)	14/68 (21) 9/36 7-day 5/32 (3) 10-day	1.39 [0.66 to 2.93]
7. Metronidazole versus metronidazole plus rifampin			
Lagrotteria, 2006 ⁷¹	5/13 (38)	5/12 (42)	0.92 [0.35 to 2.41]

CI = confidence interval; NR = not reported

* Subjects without demonstrable *C. difficile* cytotoxin and/or positive culture for *C. difficile* were removed and not included in the efficacy analyses.

Note: Treatment 1 is the first intervention listed in the first column, followed by treatment 2.

Mean Days to Resolution of Diarrhea

Two of the three vancomycin versus metronidazole studies reported the mean time to resolution of diarrhea.^{73,76} No differences were seen between treatment arms (Table 13).

Table 13. Mean days to resolution of diarrhea/clinical improvement for vancomycin versus metronidazole

Study	Vancomycin	Metronidazole	WMD [95% CI]
Zar, 2007 ⁷⁰	Not reported	Not reported	
Wenisch, 1996 ⁷³	3.1 ± 1.1	3.2 ± 1.1	0.10 [-0.65 to 0.45]
Teasley, 1983 ⁷⁶	2.8 ± 1.8	2.4 ± 1.9	-0.40 [-0.35 to 1.15]
Totals			0.07 [-0.37 to 0.52]

CI = confidence interval; WMD = weighted mean differences

No other treatment comparison resulted in significant differences in mean days to resolution of diarrhea (Table 14).

Table 14. Mean days to resolution of diarrhea/clinical improvement for all other standard treatment trials

Study	Treatment 1	Treatment 2 / Control	WMD [95% CI]
1. Vancomycin Versus Nitazoxanide			
Musher, 2009 ⁶⁹	Not reported	Not reported	
2. Vancomycin Versus Bacitracin			
Dudley, 1986 ⁷⁴	Not reported	Not reported	
Young, 1985 ⁷⁷	4.3 ± 1.8	4.8 ± 1.8	-0.50 [-1.59 to 0.59]
Totals			-
3. Vancomycin High Dose Versus Vancomycin low Dose			
Fekety, 1989 ⁷⁵	4.3 ± 1.8	3.8 ± 1.4	0.50 [-0.44 to 1.44]
4. Vancomycin Versus Fidaxomicin			
Louie, 2011 ⁷⁹	Median 3.3	Median 2.4	p = NS
5. Vancomycin Versus Placebo			
Keighley, 1978 ⁷⁸	Not reported	Not reported	
6. Metronidazole Versus Nitazoxanide			
Musher, 2006 ⁷²	Not reported	Not reported	
7. Metronidazole Versus Metronidazole Plus Rifampin			
Lagrotteria, 2006 ⁷¹	6.6	7.0	p = 0.73

CI = confidence interval; NS = not statistically significant; WMD = weighted mean differences

Note: Treatment 1 is the first intervention listed in the first column, followed by treatment 2.

All-Cause Mortality

Mortality was rare overall, in part due to the short study-followup periods. There were five deaths in each arm among the 335 subjects enrolled in studies comparing vancomycin with metronidazole (Table 15). Wenisch⁷³ evaluated four drugs, including two not evaluated in this review, but did not provide mortality data by subject. Depending on in which study arm the mortalities occurred in the Wenisch study,⁷³ there were between 10 and 13 total deaths in studies comparing vancomycin to metronidazole. Even if all three deaths in this study occurred in one arm, the difference in mortality could not reach statistical significance.

Table 15. All-cause mortality (# subjects / # randomized) for vancomycin versus metronidazole

Study	Vancomycin	Metronidazole	Nitazoxanide	Bacitracin	Placebo
Zar, 2007 ⁷⁰	3/82 (4)	5/90 (6)			
Wenisch, 1996 ⁷³	3 subjects died within first days of therapy (treatment groups not noted)				
Teasley, 1983 ⁷⁶	2/56 (4)	0/45			

All-cause mortality was significantly higher for combination metronidazole plus rifampin versus metronidazole alone (32 percent versus 5 percent).⁷¹ There were no differences in all-cause mortality in any of the other treatment comparisons (Table 16).

Table 16. All-cause mortality (# subjects / # randomized) for all other standard treatment trials

Study	Vancomycin	Metronidazole	Nitazoxanide	Fidaxomicin	Bacitracin	Placebo
Musher, 2009 ⁶⁹		Overall mortality was 4% (2/49 subjects) (treatment groups not noted)				
Lagrotteria, 2006 ⁷¹		1/20 (5) 6/19 (32) + Rif				
Musher, 2006 ⁷²		1+/44*	3+/98*			
Fekety, 1989 ⁷⁵	1/28 HD 1/28 LD					
Dudley, 1986 ⁷⁴	0/31	1/31 (3)				
Young, 1985 ⁷⁷	0/21	0/21				
Keighley, 1978 ⁷⁸	0 "colitis"/12	0 "colitis"/12				
Louie, 2011 ^{79†}	21/323 (7)			16/300 (5)		

* A total of 13 deaths (9 percent) occurred, but only the 4 deaths above were denoted by treatment arm. † Numbers based on safety population.

Other Outcomes

Where the outcomes were reported, no differences were found between vancomycin and metronidazole for clearance of toxin,⁷³ laboratory-confirmed relapse,⁷³ or persistence of the organism⁷⁶ (Table 17). The clinical relevance of these outcomes is uncertain.

Table 17. Other outcomes (# subjects / # assessed) for vancomycin versus metronidazole

Study	Vancomycin	Metronidazole	Relative Risk [95% CI]
Zar, 2007 ⁷⁰	Not reported	Not reported	
Wenisch, 1996 ⁷³	CT at day 6 22/31 (71)	CT at day 6 22/31 (71)	1.00 [0.73 to 1.37]
	LR at day 30 9/31 (29)	LR at day 30 9/31 (29)	1.00 [0.46 to 2.18]
Teasley, 1983 ⁷⁶	P at day 21 11/43 (26)	P at day 21 14/35 (40)	0.64 [0.33 to 1.23]

CI = confidence interval; CT = clearance of toxin; LR = laboratory-confirmed-relapse; P = persistence

Pooled data of 104 subjects comparing vancomycin to bacitracin showed significantly higher rates of organism or toxin clearance for vancomycin.^{74,77} No other differences were found in reported outcomes (Table 18).

Harms

Reported adverse events were relatively uncommon, minor, and not associated with one drug compared with the other. One study reported two episodes of intolerance (nausea and vomiting) leading to subject withdrawal, one in each treatment arm.⁷⁶ Another reported a subject with emesis that developed while on metronidazole, which resolved when treatment was changed to vancomycin; in the same study, another subject developed nausea while on vancomycin, which resolved when treatment was changed to metronidazole.⁷⁰ The third study reported “gastrointestinal discomfort” (which did not result in cessation of therapy) in 10 percent of subjects receiving metronidazole, compared to none with vancomycin, a difference that did not reach significance.

Disease Severity

Only one study stratified patients by disease severity at the time of screening.⁷⁰ Severity was dichotomized into two outcomes: mild or severe disease. This trial stratified treatment based on disease severity (mild versus severe). Sixty-nine subjects, 31 who received vancomycin and 38 who received metronidazole, met the prespecified definition of severe disease. Patients with two or more of the following were considered to be severe: 60 years old or older, temperature above 38.3 degrees Celsius, albumin level less than 2.5 mg/dL, or peripheral white blood count greater than 15,000 cells/mm³ within 48 hours. Using a treatment-received analysis, the authors reported that initial cure was more common among those receiving vancomycin (97 percent versus 76 percent), with a relative risk for initial cure of 1.27 (95 percent CI, 1.05 to 1.53). In a subsequent response¹⁸¹ to several letters,¹⁸²⁻¹⁸⁴ they reported a revised result, which incorporated a modified intention-to-treat analysis (including subjects who died in the first 5 days of therapy), and reclassification of two subjects as being initially cured. This slightly changed the relative risk for initial cure to 1.28 (95 percent CI, 1.03 to 1.59). However, using a strict intention-to-treat analysis, which includes subjects intolerant of therapy, lost to followup, and early deaths, and the original classification of initial cure, the percentage cured with vancomycin versus metronidazole was 79 percent versus 66 percent. This corresponds to a relative risk for initial cure of 1.20 (95 percent CI, 0.92 to 1.57) (Table 9). This is minimally changed to 1.20 (95 percent CI, 0.93 to 1.54) if the two subjects initially classified as failures are reclassified as cures. No other significant differences in outcomes were found by disease severity.

C. *difficile* Strain

A single study assessed initial cure and recurrence by strain, categorized as North American pulsed-field gel electrophoresis type 1 (NAP1) versus non-NAP1.⁷⁹ Strain data was available for 324 of the 629 (51.5%) participants. For initial cure, no significant difference was observed, regardless of strain. However, among patients with non-NAP1 strains, those treated with fidaxomicin recurred less frequently than those treated with vancomycin (10 percent versus 28 percent; $P < 0.001$), whereas among patients with the NAP1 strain recurrence was similarly frequent regardless of treatment.

Patient Characteristics

Our search did not identify any evidence for comparative effectiveness by general patient characteristics such as age, gender, or treatment setting.

Resistance of Other Pathogens

The impact of treatment for CDI on other pathogens has not been addressed by the available studies that directly assigned subjects to different drugs. From observational studies, there is some evidence that treatment with either metronidazole or vancomycin can cause an increase in the incidence in the carriage of vancomycin resistant enterococci^{185,186} however, the magnitude of this effect and the clinical significance are uncertain.

Table 18. Outcomes for all standard treatment trials

Study	Vancomycin	Metronidazole	Fidaxomicin	Nitazoxanide	Bacitracin	Placebo
Clinical Initial Cure (# Subjects / # Randomized)						
Musher, 2009 ⁶⁹	20/27 (74)			17/23 (74)		
Zar, 2007 ⁷⁰	69/82 (84)	66/90 (73)				
Lagrotteria, 2006 ⁷¹		13/20 (65) 12/19 (63) + Rif				
Musher, 2006 ⁷²		28/44 (64)		68/98 (69)		
Wenisch, 1996 ⁷³	29/31 (94)	29/31 (94)			27/29 (93)	
de Lalla, 1992 ¹⁸⁷	20/24 (83)					
Fekety, 1989 ⁷⁵	22/28 (79) HD 24/28 (86) LD					
Dudley, 1986 ⁷⁴	15/23* (65)				12/16* (75)	
Young, 1985 ⁷⁷	18/21 (86)				16/21 (76)	
Teasley, 1983 ⁷⁶	51/56 (91)	39/45 (87)				
Keighley, 1978 ^{78*}	9/12* (75)					1/9* (11)
Louie, 2011 ⁷⁹	265/313 (85)		253/289 (88)			
Clinical Recurrence (# Subjects / # Initially Cured) for all Standard Treatment Trials						
Musher, 2009 ⁶⁹	2/20 (10)			1/17 (6)		
Zar, 2007 ⁷⁰	5/69 (7)	9/66 (14)				
Lagrotteria, 2006 ⁷¹		5/13 (38) 5/12 (42) + Rif				
Musher, 2006 ⁷²		8/28 (29)		14/68 (21)		
Wenisch, 1996 ⁷⁵	5/29 (16)	5/29 (16)			8/27 (30)	
de Lalla, 1992 ¹⁸⁶	4/20 (20)					
Fekety, 1989 ⁷⁵	4/22 (18) HD 5/24 (21) LD					
Dudley, 1986 ⁷⁴	3/15 (20)				5/12 (42)	
Young, 1985 ⁷⁷	6/18 (33)				5/12† (42)	
Teasley, 1983 ⁷⁶	6/51 (12)	2/39 (5)				
Keighley, 1978 ⁷⁸	Not reported	Not reported				
Louie, 2011 ⁷⁹	67/265 (25)		39/253 (15)			
All-cause Mortality (# Subjects / # Randomized) for all Standard Treatment Trials						
Musher, 2009 ⁶⁹		Overall mortality was 4% (2/49 subjects) (treatment groups not noted)				
Zar, 2007 ⁷⁰	3/82 (4)	5/90 (6)				
Lagrotteria, 2006 ⁷¹		1/20 (5) 6/19 (32) + Rif				
Musher, 2006 ⁷²	1+/44‡			3+/98‡		
Wenisch, 1996 ⁷³		3 subjects died within first days of therapy (treatment groups not noted)				
de Lalla, 1992 ¹⁸⁷		2 subjects died within first days of therapy (treatment groups not noted)				

Table 18. Outcomes for all standard treatment trials (continued)

Study	Vancomycin	Metronidazole	Fidaxomicin	Nitazoxanide	Bacitracin	Placebo
Fekety, 1989 ⁷⁵	1/28 HD 1/28 LD					
Dudley, 1986 ⁷⁴	0/31	1/31 (3)			1/31 (3)	
Young, 1985 ⁷⁷	0/21	0/21			0/21	
Teasley, 1983 ⁷⁶	2/56 (4)	0/45				
Keighley, 1978 ⁷⁸	0 "colitis"/12	0 "colitis"/12				
Louie, 2011 ⁷⁹	21/323 (7)		16/300 (5)			
Mean Days to Resolution of Diarrhea/Clinical Improvement						
Musher, 2009 ⁶⁹	NR			Not reported		
Zar, 2007 ⁷⁰	NR	Not reported				
Lagrotteria, 2006 ⁷¹		6.6 7.0 + Rif				
Musher, 2006 ⁷²		Not reported		Not reported		
Wenisch, 1996 ⁷³	3.1 ± 1.1	3.2 ± 1.1				
de Lalla, 1992 ¹⁸⁷	3.6 ± 1.7					
Fekety, 1989 ⁷⁵	4.3 ± 1.8 HD 3.8 ± 1.4 LD					
Dudley, 1986 ⁷⁴	Not reported				NR	
Young, 1985	4.3 ± 1.8				4.8 ± 1.8	
Teasley, 1983 ⁷⁶	2.8 ± 1.8	2.4 ± 1.9				
Keighley, 1978 ⁷⁸	Not reported					Not reported
Louie, 2011 ⁷⁹	Median 3.3		Median 2.4			
Clearance of Organism (CO) / Toxin (CT) or Laboratory-confirmed-relapse (LR) / Persistence (P) for Evaluable Subjects						
Musher, 2009 ⁶⁹	Not reported			Not reported		
Zar, 2007 ⁷⁰	Not reported	Not reported				
Lagrotteria, 2006 ⁷¹		LR 2 LR 4 (+ Rif)				
Musher, 2006 ⁷²		Not reported		Not reported		
Wenisch, 1996 ⁷³	CT 22/31 (71) LR 9/31 (29)	CT 22/31 (71) LR 9/31 (29)			CT 14/29 (48) LR 15/29 (52)	
de Lalla, 1992 ¹⁸⁷	P 9/20 (45)					
Fekety, 1989 ⁷⁵	CO 4/10 (40) HD CO 5/9 (56) LD					
Dudley, 1986 ⁷⁴	CO 11/14 (79) CT 12/14 (86)				CO 4/10 (40) CT 5/11 (45)	

Table 18. Outcomes for all standard treatment trials (continued)

Study	Vancomycin	Metronidazole	Fidaxomicin	Nitazoxanide	Bacitracin	Placebo
Young, 1985 ⁷⁷	CO 17/21 (81) CT 15/18 (83)				CO 11/21 (52) CT 10/19 (53)	
Teasley, 1983 ⁷⁶	P 11/43 (26)	P 14/35 (40)				
Keighley, 1978 ⁷⁸	CO 11/12 (92) CT 12/12 (100)					CO 1/9 (11) CT 3/9 (33)
Louie, 2011 ⁷⁹	Not reported		Not reported			

HD = high dose; LD = low dose; NR = not reported; Rif = Rifampin

* Subjects without demonstrable *C. difficile* cytotoxin and/or positive culture for *C. difficile* were removed and not included in the efficacy analyses.

† 4 subjects excluded with no reasons given.

‡ A total of 13 deaths (9 percent) occurred, but only the 4 deaths above were denoted by treatment arm.

Key Question 4. What are the Effectiveness and Harms of Nonstandard Adjunctive Interventions?

Search Results

A total of five RCTs on nonstandard adjunctive treatments of CDI (Table 19) and 13 studies that addressed prevention of CDI (Table 20) formed the basis of this analysis. Four of the studies on treatment of CDI compared a nonstandard intervention with an active control, that is, a standard antibiotic treatment for CDI, oral vancomycin or metronidazole.⁸⁰⁻⁸³ One study compared a nonstandard intervention with placebo.⁸⁴ All of the 13 prevention studies compared the nonstandard intervention to placebo rather than to another intervention, reflecting the current state of this area of science. Five of the 13 prevention studies analyzed antibiotic-acquired diarrhea as a primary outcome and CDI as a secondary outcome.^{83,85,87,89,188} Numerous published case reports, as well as nonexperimental studies, describe additional nonstandard approaches for treatment of CDI and their possible harms (Table 21).

Due to the heterogeneity of the interventions, quantitative analysis was not possible. We therefore provide a narrative review of the literature.

Key Points

- Overall, study quality was low.
- *C. difficile* immune whey in one study of 38 patients was similar to standard antibiotic treatment with metronidazole in treating recurrent CDI.
- Colestipol plus metronidazole in one study was not more effective than placebo plus metronidazole.
- Administration of a probiotic to treat CDI in critically ill patients increases risk for greater morbidity and mortality from fungemia without any known benefit.
- There is low-strength limited evidence that the nonstandard interventions in this review are not more effective than placebo for primary prevention of CDI.
- There is low-strength limited evidence from one subgroup analysis that a prebiotic may reduce diarrhea recurrence in patients treated for CDI more so than placebo with standard antibiotics.
- There is limited moderate-strength evidence from one study that monoclonal antibodies are effective in preventing recurrence of CDI.
- There is limited low-strength evidence from 6 case studies/series with 60 patients that fecal flora reconstitution is effective in treating recurrent CDI for up to 1 year.
- Data are inconclusive about the benefit of intravenous immunoglobulin as an adjuvant treatment for severe CDI.
- Definitions of CDI with regard to diarrhea, that is, number and consistency of stool, were inconsistent across studies.

Quality of the Studies

The level of the quality of the evidence is low. Several study limitations lowered the quality of their findings. Among the most common were lack of a power analysis, inadequate power to detect significant differences, lack of an intent-to-treat analysis, and failure to define allocation concealment. In one study, the findings of subjects with CDI at the start of a nonstandard

intervention were combined with those who developed CDI after the intervention.⁸⁴ The problem of a nonstandardized, incomplete, or unspecified definition of CDI has already been noted. In one study, a culture of *C. difficile* (which could have indicated a nontoxigenic strain of the organism) was accepted in place of, or in addition to, a toxin test for the definition of CDI for some patients.⁸⁴ Longer term followup for CDI incidence or recurrence sometimes relies on reports of diarrhea without retesting for *C. difficile* toxin. Although probiotics may have been intended solely for prevention of recurrent CDI in some studies, they were included among treatments for recurrent CDI because the probiotic was administered concurrently with a standard antibiotic during treatment and not after recurrent CDI was cured.^{80,83} Thus, it is not possible to restrict the effect of the probiotic for prevention of future CDI recurrence only. Whether the results of CDI as a secondary outcome are weaker than the primary outcome of AAD due to an underpowered subgroup analysis cannot be determined. There was known lack of adequate power for the primary outcome in one of these studies,⁸⁷ and no power analysis for the primary outcome was reported in the other four studies.^{83,85,89,188} There was lack of standardization of the active control in two studies, allowing subjects to receive an antibiotic for CDI as prescribed by their physicians.^{91,95} Summaries of study quality and strength of evidence are provided in Appendix Tables C9 and C10.

Detailed Analysis

Defining the Outcome of CDI

The operative definition of diarrhea, which is part of the definition of CDI, varied among the studies for prevention and treatment of CDI (Tables 19 and 20). Six of the studies defined diarrhea as three or more loose or liquid stools per day for 2 days.^{80,81,83-85,95} One study required that same number and consistency of stools but for only 1 day,⁸⁶ and another study did not require the three stools per day to be loose or liquid.⁸³ One study required two liquid stools on 3 or more days.⁹⁰ The most liberal definition of diarrhea was one to two loose stools per day.⁹¹ Diarrhea due to *C. difficile* was not explicitly defined in four studies (6 percent).^{82,87-89}

Treatment of CDI

The effectiveness of two types of nonstandard interventions were compared for treating CDI, agents that bind or absorb *C. difficile* toxins,^{82,84} and probiotics that aim to recolonize the intestinal flora with nonpathogenic bacteria^{80,81,83} (Table 19). All interventions were administered orally. Probiotics were the only intervention administered as an adjunct to standard antibiotic treatment for CDI;^{80,81,83} the other nonstandard interventions were administered independently. The probiotic in two studies contained *Sacchomyces boulardii*^{80,83} and in one it contained *Lactobacillus plantarum*.⁸¹

Subjects in the treatment studies had a mean age ranging from 58 to 67 years. Females comprised more than 70 percent of the sample in three of the six studies,^{80,81,83} and, in one study, the age and gender of subjects were not reported.⁸⁴ Subjects were hospital inpatients in two studies.^{80,83,84}

The findings of the studies in Table 19 are presented in the same direction, that is, as CDI resolution (versus treatment failure) to facilitate comparison and interpretation. In all studies of CDI treatment, the main outcome was the incidence of resolving CDI, which was defined as diarrhea in patients with a positive stool test for *C. difficile* toxin.

Treatment of Primary CDI

The rate of resolution of CDI was the lowest in the study comparing an absorptive resin (25 percent of subjects) to placebo (21 percent of subjects); no statistical results were reported.⁸⁴ Resolution rates for probiotic (81 percent of patients) compared to placebo (76 percent of patients) were not statistically different in another study.⁸³

Treatment of Recurrent CDI

In three comparative treatment studies the subjects recruited were treated for a recurrent (rather than an initial) episode of CDI.⁸⁰⁻⁸² A third study conducted a subanalysis of their subjects with recurrent CDI.⁸³ In all four studies, the nonstandard intervention was probiotic. There was no significant difference in the resolution of CDI between the interventions compared in three of the studies⁸⁰⁻⁸² based on reported statistics or those conducted by the reviewers. In the study that analyzed a subset of their patients with recurrent CDI, a significantly higher percentage of subjects on a standard antibiotic plus a probiotic resolved diarrhea compared to those on a standard antibiotic and a placebo.⁸³

Prevention of Primary CDI


The nonstandard interventions investigated for preventing CDI were (1) probiotics,⁸⁵⁻⁹⁰ (2) a prebiotic (oligofructose) that aims to support a normal ecology of bacteria,^{91,92} and (3) a monoclonal antibody to *C. difficile* toxins⁹⁵ (Table 20). Six different probiotics were tested, and in two of the eight studies, the probiotic contained more than one strain of bacteria.^{88,90} Seven of the 12 CDI prevention trials using nonstandard interventions focused on primary prevention, i.e., avoiding a first occurrence of CDI.⁸⁵⁻⁹¹ All of the studies of primary prevention of CDI investigated either a probiotic (six studies) or a prebiotic (one probiotic). Two studies that tested a nonstandard intervention for treating CDI also investigated its ability to prevent CDI recurrence.^{80,81}

Subjects in the primary prevention studies had a mean age of 47 to 77 years. Females comprised less than one-third of the sample in two studies^{85,89} and, in one study, the age and sex of the sample were not reported.⁸⁸ Subjects in all of the primary prevention studies were hospitalized patients.

The overall incidence of CDI across intervention groups was relatively low, ranging from 2 percent to 9 percent. Only one of seven studies, which investigated a mixture of two probiotics (*L. casei* and *S. thermophilus*), showed a significantly lower incidence of CDI diarrhea compared to placebo;⁹⁰ the investigators of this study acknowledged that the study was underpowered to detect a significant difference greater than by chance. In four studies, statistical testing was not reported.^{86,87,89,91} Based on reported statistics, or those conducted by the reviewers, there was no significant difference in the recurrence of CDI between any of the interventions and placebo in the six other studies.^{85-89,91}

There is disagreement in the research community regarding the appropriateness of pooling results of probiotics due to the heterogeneity of probiotic organisms used and variability in dosing. We provide a forest plot (Figure 5) of the effects of probiotics on overall incidence of CDI from the primary prevention probiotic trials for those who view such aggregation as reasonable. The pooled RR is 0.40 (95 percent CI, 0.20 to 0.83). The prebiotic trial showed no effect.

Figure 5. Overall incidence of CDI from probiotic primary prevention trials



CI = confidence interval; M-H = Mantel-Haenszel test

Prevention of Recurrence of CDI

Five studies investigated the effectiveness of a nonstandard intervention to prevent the recurrence of CDI (Table 20). Three studies investigated a probiotic,^{80,81,83} one a prebiotic,⁹² and one a monoclonal antibody to *C. difficile*.⁹⁵ The mean age of subjects ranged from 58 to 75 years. Females comprised 70 percent or more of the subjects in three studies.^{80,81,83} Hospital inpatients comprised the sample in two studies^{83,91} and were included along with nonhospitalized subjects in a second study.⁸⁰ The overall recurrence rate of CDI across intervention groups ranged from 6.5 percent to 34.5 percent.

A significantly lower rate of CDI recurrence was reported in two studies following administration of the prebiotic oligofructose⁹² or a monoclonal antibody to *C. difficile* toxins A and B.⁹⁵ In both studies, the recurrence rate of CDI was approximately three times as great in subjects on placebo compared with the intervention. There was no significant difference in the recurrence of CDI in subjects taking probiotics^{80,81} compared to controls. In one study comparing a probiotic versus placebo as adjuvants to standard antibiotics, no conclusions could be made since no statistical testing was conducted and findings of similar subgroups were not reported.⁸³ For example, patients with initial or recurrent CDI participated in the study but the recurrence rate was not reported by the type of CDI as enrollment for the probiotic group.⁸³

Additional Nonstandard Approaches

In addition to the nonstandard interventions for CDI addressed in this review, case reports, or nonexperimental studies reveal numerous other approaches for treating or preventing CDI (See Table 21; Appendix Table C11 is the evidence table). Use of other probiotics (for example, yogurt containing live bacterial cultures)^{93,189,190} and other cytotoxin absorbing resins^{191,192} have been reported.

Another approach under investigation for treatment of recurrent or refractory CDI is fecal flora reconstitution, which instills feces from a healthy donor into the colon of a patient with CDI. Six case studies/series have been published,^{96,97,128-130,193} four within the last 2 years.^{128-130,193} Of a total of 60 patients; 52 patients (87 percent) resolved diarrhea and experienced no further relapse during followup. Two studies reported relapse of diarrhea in 7 of 34 patients (21 percent). Followup periods ranged from 3 weeks to 8 years.

Other nonstandard interventions include a monoclonal antibody to *C. difficile* toxin A,¹⁹⁴ intravenous immunoglobulin,^{106,195-197} two nonstandard antibiotics, Tigecycline,¹⁹⁸ a *C. difficile* toxoid vaccine,¹⁹⁹ and a nontoxic strain of *C. difficile*.²⁰⁰

Potential Harms

Harmful effects of nonstandard interventions for CDI appear to be few, but not all studies or case reports included adverse effects in their finding (Tables 19–21). A serious potential harm associated with administration of probiotics for CDI in critically ill patients is fungemia.^{93,94} In one review of an outbreak, previous medical charts, and the literature, 46 percent of 60 critically ill patients who developed fungemia had been administered a probiotic, and 28 percent subsequently died.⁹³ In addition, McFarland reported finding 12 cases of *Lactobacillus* bacteremia in patients (mostly children) taking a probiotic containing *Lactobacillus*.¹¹ Minor adverse symptoms of probiotics and prebiotics were abdominal symptoms such as nausea, bloating, and vomiting, and they have not differed significantly from those of subjects receiving placebo or an active control.^{11,83,91} Headache (one subject), and abdominal pain, change in bowel habit, and polymyalgia rheumatica (one subject) occurred following *C. difficile* vaccination.¹⁹⁹ Hypotension, diarrhea, headache, nausea, and abdominal discomfort were reported after administration of a monoclonal antibody to *C. difficile* toxin A.¹⁹⁴

Table 19. Nonstandard intervention for treatment of initial and recurrent CDI

Study	Sample	Intervention/ Comparison and Method	Resolution of CDI (Diarrhea and CD Toxin Positive Stool)	Other Outcomes	Study Quality
<i>Nonstandard Intervention Versus Active Control for Recurrent CDI</i>					
<p>Mattila, 2008⁸² Scand J Infect Dis Finland</p>	<p>40 adults with ≥2 episodes of CDI in past 3 months and stool positive for <i>C. difficile</i> toxin</p> <p>38 completed the study (95%)</p> <p>Mean age: 61.3 (CDIW 56.4 vs. metronidazole 65.7) Gender: Male 47%</p>	<p><i>C. difficile</i> immune whey (CDIW) CDIW 200 ml liquid and placebo tablets three times per day x 14 d (n=18)</p> <p>Metronidazole 400 mg tablets and placebo liquid three times per day x 14 days (n=20)</p> <p>CD culture and toxin on days 0, 14, and 28 followup x 7 days</p> <p>Daily stool and symptom diary daily for 42 days</p> <p>Followup after day 28 used stool and symptom diary only</p>	<p>Response to study drugs at day 14 CDIW: 89% (16/18)</p> <p>Metronidazole: 100% (20/20)</p> <p>No statistical testing reported, Fisher's Exact test performed by reviewers p=0.22</p>	<p>Response to study drugs at day 28 (14 days after treatment)</p> <p>CDIW: 61% (11/18) Metronidazole:60% (12/20)</p>	<p>Allocation concealment: not defined Blinding: double Intention-to-treat analysis: no Withdrawals and dropouts adequately described: yes</p> <p>Notes: Sample size not achieved because of bankruptcy of sponsor</p> <p>Although CD culture and toxin were measured and stool diary data collected at day 14, the reported primary endpoint, "response to ...study drugs" was not defined nor defined in relation to these measures; the same is true for sustained response at day 28</p> <p>Secondary outcome of time to treatment failure through day 70 was measured by diarrhea only and not by CD toxin in stool</p> <p>CDIW had no local or systemic side effects</p>

Table 19. Nonstandard intervention for treatment of initial and recurrent CDI (continued)

Study	Sample	Intervention/ Comparison and Method	Resolution of CDI* (Diarrhea and CD Toxin Positive Stool)	Other Outcomes	Study Quality
<i>Adjuvant Nonstandard Intervention Versus Active Control for Recurrent CDI</i>					
<p>Surawicz, 2000⁸⁰ Clin Infectious Diseases United States</p>	<p>168 randomized adult inpatients and outpatients with recurrent CDI, 32 on high-dose vancomycin</p> <p>(This paper reported subgroup analysis of treatment of subjects on high-dose vancomycin only)</p> <p><i>Recurrent CDI subjects</i> Mean age (years): 61.6 Gender: Male (M) 41%</p>	<p>Probiotic-<i>Sacchomyces boulardii</i> (1 g/d) + high dose oral vancomycin (2g/d) (n=16)</p> <p>Placebo (1 g/d) + high dose oral vancomycin (2g/d) (n=16)</p> <p>Probiotic/placebo started on day 7–day 28 CDI was defined as diarrhea (≥3 loose/watery stools/s x 2 days or >8 loose stools/day within 48 hours) and positive CD assay (culture then toxin A or B) measured at multiple time points</p>	<p>Probiotic and vancomycin: 13/16 (81.3%)</p> <p>Placebo and vancomycin: 8/16 (50%)</p> <p>Fisher’s Exact test performed by reviewers p =0.06</p>		<p>Allocation concealment: adequate, centralized Blinding: double Intention-to-treat analysis: yes Withdrawals and dropouts adequately described: none reported</p>

Table 19. Nonstandard intervention for treatment of initial and recurrent CDI (continued)

Study	Sample	Intervention/ Comparison and Method	Resolution of CDI* (Diarrhea and CD Toxin Positive Stool)	Other Outcomes	Study Quality
<p>Wullt, 2003⁸¹ Scan J Infect Dis Sweden</p>	<p>29 adult patients with recurrent disease from 9 centers (positive CD toxin assay within 6 days of enrollment at least 1 prior episode CD diarrhea within past 2 months and ongoing diarrhea). 8 patients (28%) lost to followup were not included in analysis, 21 completed trial (72%) Mean age: 63.8 Gender: Male 5%</p>	<p>Probiotic-<i>Lactobacillus plantarum</i> in fruit drink with oats fermented by <i>L. plantarum</i> 299v (5 x 10¹⁰ cfu) x 38 days and Metronidazole (400 mg three times per day po) x 10 d Placebo fruit drink with chemically acidified oats and metronidazole Toxin testing on days 11–13 followup about diarrhea on days 37–41 and 70–75 Clinical cure was defined as no diarrhea (≥3 loose stools x 2 days) on days 5-10 of treatment:</p>	<p>Probiotic and metronidazole: 92% (11/12) Placebo and metronidazole: 100% (9/9) No statistical testing reported, Fisher's Exact test performed by reviewers p=1.0</p>		<p>Allocation concealment: Not defined Blinding: double Intention-to-treat analysis: no Withdrawals and dropouts adequately described: yes Notes: CD toxin not measured after day 11</p>

Table 19. Nonstandard intervention for treatment of initial and recurrent CDI (continued)

Study	Sample	Intervention/ Comparison and Method	Resolution of CDI* (Diarrhea and CD Toxin Positive Stool)	Other Outcomes	Study Quality
<p>McFarland, 1994⁸³ JAMA United States</p>	<p>124 in patients with active CDI and receiving standard antibiotic treatment (vancomycin or metronidazole)</p> <p>104 (84%) completed the study</p> <p>Mean age 58.1 Gender: Male 23%</p> <p>64 patients had initial CDI and 60 had recurrent CDI</p>	<p>Probiotic-Lyophilized <i>S. boulardii</i> 3x10¹⁰ cfu (1 g) orally in two 250 mg capsules/days x 4 weeks and standard therapy, vancomycin or metronidazole or both (n=57). Probiotic was given within 4 days of treatment</p> <p>Placebo and standard therapy, vancomycin or metronidazole or both (n=67).</p> <p>Both groups followed for 4 weeks and an additional 4 weeks</p> <p>CDI defined as diarrhea ≥3 stools/d x 2 consecutive days and 1 CD positive assay (culture, toxin A or toxin B)</p> <p>Treatment failure was defined as 2 consecutive days of diarrhea, and positive CD assay or pseudomembranes by endoscope at time of diarrhea, diarrhea no attributable to another cause</p>	<p>Resolution of CDI <u>Overall (all subjects, n=124)</u> Probiotic: 73.4% (42/57) Placebo: 55.2% (37/67) p = 0.05</p> <p><u>Subgroup analysis</u> Subjects treated for recurrent CD (n=60) Probiotic 65.4% (17/26) Placebo 35.3% (12/34) p=0.04</p> <p>Subjects treated for initial CD (n=64) Probiotic 81.3% (25/31) Placebo 75.5% (25/33) p=0.86</p>		<p>Allocation concealment: Adequate, blinded study drug kits Blinding: double Intention-to-treat analysis: yes Withdrawals and dropouts adequately described: yes</p> <p>Notes: No difference in nausea, pain, or vomiting</p>

Table 19. Nonstandard intervention for treatment of initial and recurrent CDI (continued)

Study	Sample	Intervention/ Comparison and Method	Resolution of CDI* (Diarrhea and CD Toxin Positive Stool)	Other Outcomes	Study Quality
Nonstandard Intervention Versus Placebo					
<p>Mogg, 1982⁸⁴ Br J Surg United Kingdom</p>	<p>48 patients on a single surgical unit with severe diarrhea after antibiotic treatment</p> <p>48 entered study and 10 withdrew (7 on resin and 3 on placebo), 38 analyzed (79%)</p> <p>No information on age and gender.</p> <p>Diarrhea defined as ≥ 3 loose stools/day or more than 1 L of drainage from colostomy</p> <p>Previous placebo group (n=22) from prior study of vancomycin and placebo on same unit.</p>	<p>Absorptive resin Colestipol 10 g every day mixed in fruit squash x 5 days (n=17)</p> <p>Placebo (sherbet) (n=21)</p> <p>Stool tested for CD cytotoxin at study start, on day 3 and last day of treatment (day 5)</p> <p>Outcome was defined as return of diarrheal stool to normal, (i.e., 2 solid stools in 24 hours) in stools that were positive for <i>C. difficile</i> OR its toxin</p>	<p>Colestipol: 3/12 (25%)</p> <p>Placebo: 3/14 (21%)</p>		<p>Allocation concealment: Possibly adequate ("identical placebo")</p> <p>Blinding: not reported</p> <p>Intention-to-treat analysis: no</p> <p>Withdrawals and dropouts adequately described: yes</p> <p>Notes: CD cytotoxin was not present in all subjects reported as cases</p> <p>No statistical testing</p> <p>Some historical controls included with concurrent controls</p> <p>CD treatment and prevention findings were combined (i.e., findings of subjects with <i>C. difficile</i> or its toxin in stool before receiving the intervention were combined with those who acquired these <i>during</i> the intervention)</p>

CD = Clostridium difficile; CDI = Clostridium difficile infection

Table 20. Probiotic or prebiotic interventions for prevention of initial and recurrent CDI

Study/Design	Sample	Intervention/Comparison and Method	<i>C. difficile</i> Diarrhea (Diarrhea and CD Toxin +)	Later Recurrence of CD Diarrhea	CD Toxin+	Notes of Study Quality and Side Effects
Primary Prevention of Initial CDI						
Surawicz, 1989 ⁸⁵ Gastroenterology United States RCT	318 hospitalized patients given new antibiotics 180 completed study, 138 had <i>C. difficile</i> tested Mean age: 46.5 years Gender: Male 69%	Probiotic: <i>Saccharomyces boulardii</i> (250 mg capsule with 1 g <i>S. boulardii</i> bid (n=116) Placebo bid (n=64) Stools collected for CD culture at entry, day 5 then q 10 d, end of study, and when have diarrhea (diarrhea ≥3 loose/watery stools/s x 2 d); CD culture + stools were tested for cytotoxin; need 3 stools tested for CD and ≥8 days of monitoring for inclusion	<u>Overall incidence of CDI:</u> Probiotic: 3/116 (2.6%) Placebo: 5/64 (7.8%) Fisher's Exact test performed by reviewers p=0.13 <u>Incidence of diarrhea in 48 patients had stools that were CD toxin+:</u> Probiotic: 3/32 (9.4%) Placebo: 5/16 (31%), test of significance between groups p=0.07			Allocation concealment: not defined Blinding: double Intention-to-treat analysis*: no, 138 not evaluated (43%) Withdrawals and dropouts adequately described: yes
McFarland, 1995 ¹⁸⁸ Am J Gastroenterol United States RCT	193 hospitalized adult patients receiving new beta-lactam antibiotic with or without another antibiotic and no diarrhea 129 (67%) completed study Mean age: 42 years Gender: Male 65%	Probiotic: Lyophilized <i>S. boulardii</i> 3x10 ¹⁰ cfu (1 g) orally in two 250 mg capsules/d within 72 hours of antibiotic and until max of 28 days (n=97) Placebo 1 g (undefined) (n=96) Followup for 7 days after stopping drug	<u>Overall incidence of AAD:</u> Probiotic: 3/97 (3.1%) Placebo: 4/96 (4.2%) Fisher's Exact test performed by reviewers p=0.72 <u>Development of ADD in 24 patients with positive CD assays:</u> Probiotic: 3/10 (30%) Placebo: 4/14 (29%) (The power of detecting a significant difference based on the sample size of 24 and the above rates was less than 3%)			Allocation concealment: adequate (appearance and odor of the capsules of interventions were identical, done centrally) Blinding: double Intention-to-treat analysis: yes Withdrawals and dropouts adequately described: yes Notes: 3 reviewers of diarrhea

Table 20. Probiotic or prebiotic interventions for prevention of initial and recurrent CDI (continued)

Study/ Design	Sample	Intervention/Comparison and Method	<i>C. difficile</i> Diarrhea (Diarrhea and CD Toxin +)	Later Recurrence of CD Diarrhea	CD Toxin+	Notes of Study Quality and Side Effects
Lewis, 1998 ⁸⁶ J Infect United Kingdom RCT	72 Hospitalized elderly (≥65 years) patients started on antibiotics Mean age (range): 74 (70-85) years Gender not reported ("no difference between sex")	Probiotic: <i>S. boulardii</i> (113 mg) (Ultra-Levure, Biocodex, Montrouge, FR) 2x/day (n=33) Placebo (undefined) 2x/day (n=36) Stool sample sent to lab every 4 th day or if diarrhea (≥3 loose stools in 24 hours) to test for CD toxin	<u>Overall incidence of CDI:</u> 4 patients had diarrhea stools that were CD toxin+ (not reported by treatment arm) No statistically significant difference in diarrhea stools with + CD toxin between probiotic and placebo (data and percents not reported)		CD toxin only Probiotic: 5/33 (15%) Placebo 3/36 (8%) No statistical testing done	Allocation concealment: adequate (pharmacy- controlled) Blinding: probably double, nursing staff blinded to treatment assignment Intention-to-treat analysis: no, 3 excluded Withdrawals and dropouts adequately described: yes
Thomas, 2001 ⁸⁷ Mayo Clinics United States RCT	302 hospitalized patients on antibiotics 267 (88%) completed study Mean age (range): 56 (18-93) years Gender: Male 54%	Probiotic: <i>Lactobacillus</i> GG (20 x 10 ⁹ cfu + inulin filler) (CAG Functional Foods, Nebraska) 1 capsule 2x/d x 14 d (n=133) Placebo (inulin filler) (n=134)	<u>Overall incidence of CDI:</u> Only 5 patients (1.9%) with positive CD toxin: Probiotic: 2/133 (1.5%) Placebo: 3/134 (2.2%), p >0.99		CD toxin in 1 st 21 days after enrollment per retrospective chart review data of patients with CD at hospital Probiotic: 5/133 (4%) Placebo: 3/134 (2%), no statistical testing	Allocation concealment: adequate (pharmacy- controlled) Blinding: double Intention-to-treat analysis: no Withdrawals and dropouts adequately described: yes Notes: CD results by randomized chart review How tested for CD toxin not reported No association of diarrhea with CD toxin+

Table 20. Probiotic or prebiotic interventions for prevention of initial and recurrent CDI (continued)

Study/ Design	Sample	Intervention/Comparison and Method	<i>C. difficile</i> Diarrhea (Diarrhea and CD Toxin +)	Later Recurrence of CD Diarrhea	CD Toxin+	Notes of Study Quality and Side Effects
Plummer, 2004 ⁸⁸ International Microbiol United Kingdom RCT	150 elderly hospitalized patients started on antibiotics 138 (92%) completed study Age and gender not reported	Probiotic: <i>Lactobacillus acidophilus</i> and <i>Bifidobacterium bifidum</i> , 2 x 10 ¹⁰ cfu in 1 capsule/d (Cultech, Saansea) for at least 20 of antibiotic therapy (n=69) Placebo (n=69) Start therapy within 36 hours of antibiotics, probiotic = 1.12 days after antibiotics placebo = 1.10 day Stools were cultured for <i>C. difficile</i> , then if culture +, CD toxins A and B were tested - at start of study - if diarrhea - after antibiotics completed during hospitalization or discharge	<u>CD diarrhea, 1st testing, during diarrhea and antibiotic tx in hospital:</u> Probiotic: 2/69 (3%) Placebo: 5/69 (7%), no statistical testing reported, Fisher's Exact test performed by reviewers p=0.44 Proportion developing diarrhea positive for CD toxins was 4.35% lower in probiotic group (95% CI of -0.132 to 0.038). <u>CD diarrhea, 2nd testing of same patients after antibiotics completed or at discharge:</u> Probiotic: 2/69 (3%) Placebo: 6/69 (9%)			Allocation concealment: not defined Blinding: double Intention-to-treat analysis: no Withdrawals and dropouts adequately described: no Notes: Diarrhea is undefined Study participation stopped if on antibiotics >20 days

Table 20. Probiotic or prebiotic interventions for prevention of initial and recurrent CDI (continued)

Study/ Design	Sample	Intervention/Comparison and Method	<i>C. difficile</i> Diarrhea (Diarrhea and CD Toxin +)	Later Recurrence of CD Diarrhea	CD Toxin+	Notes of Study Quality and Side Effects
Lewis, 2005 ⁹¹ Aliment Pharmacol Ther United Kingdom RCT	450 hospital patients ≥65 years prescribed a broad spectrum antibiotic within past 24 hours 15 (3.3%) patients withdrew or were withdrawn from study N=435 who finished Mean age (range): 77 (70–84) years Gender: Male 49%	Prebiotic: Oligofructose (12 g/d) (n=215) Placebo (sucrose 12 g/day) (n=220) Taken during antibiotics + 7 days after Follow up for additional 7 days <i>C difficile</i> toxin was measured if diarrhea (1-2 loose stools/day)	54 (12%) patients were culture-positive for <i>C. difficile</i> on study entry. Prebiotic: 19/213 (9%) Placebo: 21/220 (9.5%), no statistical testing reported, Fisher's Exact test performed by reviewers p=0.87			Allocation concealment: Unclear Blinding: double Intention-to-treat analysis: no Withdrawals and dropouts adequately described: yes Notes: Subjects were withdrawn from study if they experienced significant diarrhea (>3 stools/day) Stated intent to treat but some % are for N=433 not 435 or 450 who enrolled No increase in bloating, stool form or interval between stools by prebiotic

Table 20. Probiotic or prebiotic interventions for prevention of initial and recurrent CDI (continued)

Study/ Design	Sample	Intervention/Comparison and Method	<i>C. difficile</i> Diarrhea (Diarrhea and CD Toxin +)	Later Recurrence of CD Diarrhea	CD Toxin+	Notes of Study Quality and Side Effects
Can, 2006 ⁸⁹ Med Sci Monit Turkey RCT	151 adult inpatients between 25–50 years who had chemotherapy and antibiotics Gender: Male 95%	Probiotic: <i>S. boulardii</i> + antibiotics (β lactam) (n=73) Placebo + antibiotics(n=78) 2x/day started 48 hours or less after antibiotic therapy started for duration of antibiotic tx CD toxin A tested in those with diarrhea	<u>Overall incidence of CDI:</u> 8 patients had diarrhea, only two CD toxin + (both in the placebo group Probiotic: 0/73 (0%) Placebo: 2/78 (2.6%) Fisher's Exact test performed by reviewers $p=0.50$			Allocation concealment: not defined Blinding: double Intention-to-treat analysis: yes Withdrawals and dropouts adequately described: none reported Notes: Duration of probiotic may have been variable Diarrhea is undefined

Table 20. Probiotic or prebiotic interventions for prevention of initial and recurrent CDI (continued)

Study/ Design	Sample	Intervention/Comparison and Method	<i>C. difficile</i> Diarrhea (Diarrhea and CD Toxin +)	Later Recurrence of CD Diarrhea	CD Toxin+	Notes of Study Quality and Side Effects
Hickson, 2007 ⁹⁰ BMJ RCT	135 hospital patients taking antibiotics were given tx until tx was finished + 1 week; If discharged from hospital and stayed on antibiotics, they continued tx; CD testing and followup occurred for 4 weeks after tx ended 11/2002-1/2005 22 (16%) patients lost to followup and not included in the analyses 12 in probiotic group and 10 in placebo 4 pts not tested for CD (1 on probiotics and 3 on placebo) Mean age: 74 years Gender: Male 46%	Probiotic: <i>L. casei</i> DN-114 001 (<i>L. casei</i> imunitass, 1 x 10 ⁸ cfu/ml) + <i>S.thermophilus</i> (1 x 10 ⁸ cfu/ml) + <i>L. bulgaris</i> (1 x 10 ⁷ cfu/ml) in yogurt drink (Actimel, Danone, FR) (n=69) Placebo: sterile milkshake (Yazoo, Campina NE) (n=66) Drinks consumed during antibiotics therapy + 1 week CD toxins A and B tested in diarrheal stools CD diarrhea = CD toxins A and/or B and diarrhea stools (2 liquid stools/d x 3 or more days in an amount greater than normal for the patient)	<u>Overall incidence of CDI:</u> Probiotic: 0/57 Placebo: 9/53 (17%), p=0.001 Absolute risk reduction = 17% (95% CI 7% to 27%) NNT = 6 (4 to 14)			Allocation concealment: adequate (pharmacy - controlled) Blinding: double Intention-to-treat analysis: no Withdrawals and dropouts adequately described: yes Notes: Good compliance with drink, 75% for probiotic and 79% placebo Type CD toxin not specified No adverse events from either drink

Table 20. Probiotic or prebiotic interventions for prevention of initial and recurrent CDI (continued)

Study/ Design	Sample	Intervention/Comparison and Method	<i>C. difficile</i> Diarrhea (Diarrhea and CD Toxin +)	Later Recurrence of CD Diarrhea	CD Toxin+	Notes of Study Quality and Side Effects
Prevention of Recurrent CDI						
McFarland, 1994 ⁸³ JAMA United States	<p>124 in patients with active CDI and receiving standard antibiotic treatment (vancomycin or metronidazole)</p> <p>104 (84%) completed the study</p> <p>Mean age 58.1 Gender: Male 23%</p> <p>64 patients had initial CDI and 60 had recurrent CDI</p>	<p>Probiotic-Lyophilized <i>S. boulardii</i> 3x10¹⁰ cfu (1 g) orally in two 250 mg capsules/days x 4 weeks and standard therapy, vancomycin or metronidazole or both (n=57). Probiotic was given within 4 days of treatment</p> <p>Placebo and standard therapy, vancomycin or metronidazole or both (n=67).</p> <p>Both groups followed for 4 weeks and an additional 4 weeks</p> <p>CDI defined as diarrhea ≥3 stools/d x 2 consecutive days and 1 CD positive assay (culture, toxin A or toxin B)</p> <p>Treatment failure was defined as 2 consecutive days of diarrhea, and positive CD assay or pseudomembranes by endoscope at time of diarrhea, diarrhea no attributable to another cause</p>		<p>Probiotic: 41.3% (51/124) subjects with no recurrence</p> <p>Placebo: 24.3% (8/33) with initial CDI had CDI recurrence and 64.7% (22/34) with recurrent CDI had another recurrence</p> <p>no statistical testing</p>		<p>Allocation concealment: Adequate, blinded study drug kits Blinding: double Intention-to-treat analysis: yes Withdrawals and dropouts adequately described: yes</p> <p>Notes:</p> <p>The absence of CDI recurrence for the probiotic group was reported as a percent of the entire sample and not of the probiotic group.</p> <p>No difference in nausea, pain, or vomiting</p>

Table 20. Probiotic or prebiotic interventions for prevention of initial and recurrent CDI (continued)

Study/ Design	Sample	Intervention/Comparison and Method	<i>C. difficile</i> Diarrhea (Diarrhea and CD Toxin +)	Later Recurrence of CD Diarrhea	CD Toxin+	Notes of Study Quality and Side Effects
<p>Surawicz, 2000⁸⁰ CI Infectious Diseases United States</p> <p>RCT</p>	<p>32 randomized adult inpatients and outpatients, 32 with recurrent CDI</p> <p><i>CD disease subjects</i> Age: 61.6 Gender: Male 41%</p>	<p><i>CDI subjects</i> Probiotic: <i>S. boulardii</i> (1 g/d) + high dose oral vancomycin (2g/d) (n=16)</p> <p>Placebo (1 g/d) + high-dose oral vancomycin (2g/d) (n=16)</p> <p>Probiotic/placebo started on day 7 - day 28</p> <p>CDI = diarrhea + (≥3 loose/watery stools/s x 2 days or >8 loose stools/day within 48 hours) and positive CD assay (culture then toxin A or B) measured at multiple time points</p>		<p>Recurrence: Probiotic: 3/18 (17%) Placebo: 7/14 (50%), p=0.05</p>		<p>Allocation concealment: adequate, centralized Blinding: double Intention-to-treat analysis: yes Withdrawals and dropouts adequately described: none reported</p>
<p>Wullt, 2003⁸¹ Scan J infect Dis</p> <p>RCT</p>	<p>29 adult patients from 9 centers with + CD toxin assay within 6 days of enrollment at least 1 prior episode CDI diarrhea within past 2 months. And ongoing diarrhea 8 patients (28%) lost to followup were not included in analysis, 21 completed trial</p> <p>Mean age: 63.8 years Gender: Male 5%</p>	<p>Probiotic: <i>L. plantarum</i> in fruit drink with oats fermented by <i>L. plantarum</i> 299v (5×10^{10} cfu) x 38 days and Metronidazole (400 mg tid po) x 10 days Metronidazole + placebo fruit drink with chemically acidified oats</p>	<p><u>Clinical cure</u>: no diarrhea (≥ 3 loose stools x 2 days) on days 5-10 of tx</p> <p>Probiotic: 11/12 (92%)</p> <p>Placebo: 9/9 (100%)</p>	<p><u>Total recurrences</u>: Probiotic: 4/11 (36%)</p> <p>Placebo: 6/9 no statistical testing reported, Fisher's Exact test performed by reviewers p=0.37</p>	<p><u>CD toxin negative</u>:</p> <p>Probiotic: 7/1 2 (58%)</p> <p>Placebo: 5/9 (56%), p=.642</p>	<p>Allocation concealment: Not defined Blinding: double Intention-to-treat analysis: no Withdrawals and dropouts adequately described: yes</p>

Table 20. Probiotic or prebiotic interventions for prevention of initial and recurrent CDI (continued)

Study/ Design	Sample	Intervention/Comparison and Method	<i>C. difficile</i> Diarrhea (Diarrhea and CD Toxin +)	Later Recurrence of CD Diarrhea	CD Toxin+	Notes of Study Quality and Side Effects
Lewis, 2005 ⁹² Clin Gastroenterol Hepatol RCT	142 consecutive elderly (≥65 years) in patients with CDI and treated by their physician with metronidazole or vancomycin for 10 days (if treatment failure (diarrhea and CD toxin A and B) or intolerance with metronidazole). Mean age: 75 years Gender: Male 58%	Prebiotic: Oligofructose (12 g/d) (n=72) Placebo (sucrose 12 g/day) (n=70) Taken as soon as possible after dx of CD diarrhea and + 30 days after CDI diarrhea = 3 loose stools in 1 day and + CD toxin		<u>Relapse of diarrhea</u> (CD was not retested) Prebiotic: 6/72 (8.3%) Placebo: 24/70 (34.3%), p<0.0001		Allocation concealment: Not defined Blinding: single Intention-to-treat analysis: no, 1 was lost to followup and 8 never resolved diarrhea to be able to relapse and were excluded Withdrawals and dropouts adequately described: yes Notes: CD was not measured at diarrhea recurrence

Table 20. Probiotic or prebiotic interventions for prevention of initial and recurrent CDI (continued)

Study/ Design	Sample	Intervention/Comparison and Method	<i>C. difficile</i> Diarrhea (Diarrhea and CD Toxin +)	Later Recurrence of CD Diarrhea	CD Toxin+	Notes of Study Quality and Side Effects
<p>Lowy, 2010⁹⁵ N Eng J Med United States and Canada</p> <p>RCT</p>	<p>200 inpatients and outpatients were ≥18 years of age with diarrhea associated with a positive stool test for CD toxin(s) in the 14 days prior to enrollment and who were receiving either metronidazole or vancomycin</p> <p>Mean age (range): 64 (20-101) years Gender: Male 34% White race: 88% Black race: 6%</p> <p>Severe disease at enrollment: 40%</p>	<p>Monoclonal antibodies: intravenous infusion of fully human monoclonal antibodies against <i>C. difficile</i> toxins A (CDA1) and B (CDB1) x 1 (n=101)</p> <p>Placebo (0.9% sodium chloride) x 1 (n=99)</p> <p>Recurrence of <i>C. difficile</i> infection, was defined as a new episode of diarrhea associated with a new positive stool toxin test after the resolution of the initial CDI diarrheal episode and after discontinuation of metronidazole or vancomycin.</p> <p>Diarrhea was defined as three or more unformed stools per day for at least 2 consecutive days or more than six unformed stools in 1 day</p>		<p><u>Incidence of laboratory documented CDI - primary outcome:</u></p> <p>Monoclonal antibodies: 7/101 (7%); inpatient = 7/50, outpatient = 0/51 Placebo: 25/99 (25%); inpatient = 13/52, outpatient = 12/47, p=0.0004</p> <p>Recurrent diarrhea With/without laboratory confirmation of CDI and with/without antibiotic treatment for CDI</p> <p>Monoclonal antibodies: 28/101 (28%) Placebo: 49/99 (50%), p=0.0022</p>		<p>Allocation concealment: not defined Blinding: double and independent statistician and data and safety monitoring board Intention-to-treat analysis: yes Withdrawals and dropouts adequately described: yes</p> <p>Adverse events reported in 14 patients (antibody group = 9; placebo = 5) during infusion and in 11 patients (antibody group = 6; placebo = 5) during 2-hour period after infusion. All AE noted to be mild to moderate (headache reported most frequently)</p> <p>Death: antibody group = 7; placebo = 8 (p=0.79)</p>

CD = Clostridium difficile; CDI = Clostridium difficile infection; RCT = randomized controlled trial

Table 21. Summary of case studies/series and potential harms of nonstandard interventions for CDI

Intervention	# of Reports	Patient N	Type of CDI Patient	Study Aim	Outcome	Reported Adverse Events
Fecal flora reconstitution	6 ^{96,97,128-130,193}	60	Recurrent CDI	Treatment	73% – 100% symptom free, up to 1 year	1 case IBS
Cholestyramine	2 ^{191,192}	2	CDI with PMC	Treatment, primary CDI	1 patient rapid symptom relief	Not reported
IV hemoperfusion, vancomycin	1 ²⁰¹	2	CDI with PMC	Treatment, primary CDI	PMC resolved in 7 days	Not reported
Probiotics	3 ^{93,189,190}	5 (plus 57 from literature review)	4 ICU patients, 1 recurrent CDI (plus 41 patients with fungemia, 14 ICU)	Treatment		1 case <i>S. pneumoniae</i> and secondary <i>L. rhamnosus</i> septicemia and death. 46% fungemia patients previously given probiotics
Nontoxigenic <i>C. difficile</i> strain	1 ²⁰⁰	2	CDI patients failing antibiotic treatment	Treatment	Symptom decrease, 1 patient resolved	Constipation
Monoclonal antibody for <i>C. difficile</i> toxin A	1 ¹⁹⁴	30	Healthy young adults	Safety study		3 moderate AE (low BP, diarrhea), 18 mild AE (headache, nausea, loose stools, abdominal discomfort BP changes)
Intravenous Tigecycline	1 ¹⁹⁸	4	CDI with PMC	Treatment, severe refractory	Symptom decrease within 7 days	Not reported
<i>C. difficile</i> toxoid vaccines	2 ^{199,202}	3 (plus 30 healthy adults)	First CDI relapse	Treatment (safety study)		Mild headache, mild abdominal pain, rash, 1 CDI relapse patient polyarthritis
Intravenous immunoglobulin	4 ^{83,106,196,197}	37	CDI, recurrent, refractory, severely ill	Treatment	54% symptom resolution, of these, 20% patients had recurrence or toxin still present	1 case pulmonary edema

AE = adverse event; BP = blood pressure; CDI = *Clostridium difficile* infection; IBS = irritable bowel syndrome; ICU = intensive care unit; IV = intravenous; PMC = pseudomembranous colitis

Summary and Discussion

There is very limited high-quality evidence, to support the diagnostic, preventive, and treatment practices for *Clostridium difficile* infection (CDI) carried out by providers in hospital, long-term care, and outpatient settings. Inconsistency in definitions of diarrhea, severity, and resolution of symptoms contributes to the difficulty in drawing conclusions from the evidence. Table 22 provides a summary of the evidence and results presented in this review.

Diagnostic Testing (Key Question 1)

This review focused on comparing the sensitivity and specificity of diagnostic methods that rely, at least in part, on the most widely used commercial immunoassays for *C. difficile* toxin. Immunoassays that can detect both toxins A and B were of particular interest because hypothetically they are the most sensitive immunoassay for detecting toxins and they are very commonly used by laboratories in the United States. In addition, data from comparative evaluations that included newer commercial *C difficile* toxin gene detection tests were of interest.

In general, there is little evidence that the sensitivities of commonly used immunoassays for toxins A and B differ, and any differences in their percent of false positives (1 minus specificity) most likely are small (3 percent or less). However, the strength of the evidence is low due to the number of direct comparisons of the immunoassay that are available in the literature. The possibility exists that future research could impact the findings. Further, one article that examined eight tests is the sole source for many of the comparisons. The available comparative data doesn't rule out the possibility of larger differences between some of the immunoassays that have or have not been directly compared in adequate numbers. While the precision of the findings is such that we cannot rule out the possibility of differences in sensitivity on the order of 3 to 5 percent, it is unclear whether such differences would affect clinical decisionmaking.

Gene-based tests that used toxin B gene fragments tended to have better sensitivity than immunoassays for toxins A and B. Results, however, should be viewed with caution. Few studies contributed to the findings, and many direct comparisons were not found. Further, as mentioned above, the methodological differences between studies, including use of different reference tests, might have affected the toxin immunoassays more than the gene detection tests. Perhaps variation in the stability of the toxins in stool specimens as they were collected, stored, and processed contributed to the observed variation between studies in the estimates of the immunoassay's sensitivities, whereas detection via amplification of gene fragments could be less susceptible to specimen degradation. Use of a more sensitive toxigenic culture as the reference test may impact the estimated sensitivity of the immunoassays more than the toxin gene detection tests.²⁰³

These tests require varying skills, equipment, and time to carry out, and heterogeneity is a significant factor in reviewing the literature. Previous reviews by Planche et al.⁹⁸ and Crobach et al.⁹⁹ encountered difficulty comparing the sensitivities and specificities of the diagnostic tests in large part because there was too much variation between studies in the estimates of sensitivity and specificity of a particular test. Planche et al. used logistic regression with dummy variables to represent each immunoassay and found significant differences in sensitivity and specificity; however, the regression model did not include any covariates to try to account for the substantial heterogeneity between studies. We attempted to control for the heterogeneity between studies by examining the differences in sensitivity and specificity in stool samples tested within the same

lab and did not find strong evidence of differences between tests within several immunoassays for toxins type A and B. The extent of any publication bias for these comparisons is unknown.

A clinically important question is whether the potential differences in the accuracy of the diagnostic tests being employed in practice would translate into differences in clinical behaviors or patient outcomes. Indeed, how well clinicians actually know the sensitivity and specificity of the test(s) for toxigenic *C. difficile* employed by their laboratories and incorporate this information, along with estimates of the prior probability of CDI (using Bayes formula) into their patient care decisions is not clear.

Clinical diagnosis is important in outpatient settings, and primary care in particular, as well as inpatient settings. Outpatient clinicians will need to be alert to the possibility of CDI, given that CDI can manifest several months after hospital exposure or antibiotic use.

Prevention (Key Question 2)

Very little evidence connects prevention strategies and techniques directly to patient-related outcomes, such as CDI incidence. Available evidence is generally from before/after study designs or limited time series. Hospital settings with outbreaks or hyperendemic episodes further limit applicability of the findings, and leave open the question of the relative contribution of regression to the mean (i.e., that CDI rates returned to baseline rates even in the absence of effective interventions). The studies also varied in the degree to which they described CDI surveillance, diagnostic accuracy, or laboratory performance. In most, surveillance was passive and depended on a positive toxin test on a stool specimen sent by clinicians caring for a patient with diarrhea. Unknown numbers of cases might have been missed or misdiagnosed. Additionally, attention has not been given to describing a prevention strategy's potential harm (e.g., increase in other pathogens, reduction in direct patient care contact due to isolation or restrictive contact requirements, increased costs) or the long-term sustainability of a practice.

There is low-strength evidence that antibiotic prescribing practices appear to reduce CDI incidence, a finding consistent with the Cochrane review.⁴¹ None of the studies explicitly addressed the potential harms of changes in antibiotic use policy, but there are several theoretical harms. They include the possibility that preferred drugs will be less effective than drugs that physicians are discouraged from using, or drugs that are made unavailable for treating infections other than CDI. Preferred antimicrobials might have greater costs or greater toxicities unrelated to CDI. *C. difficile* strains might evolve to develop resistance to the preferred antibiotics, which might increase the likelihood that the recommended antibiotics might induce CDI.

While several studies found increased risk with specific antibiotics or antibiotic classes, the antibiotics that confer greater risk for CDI have changed over time and vary by location because of differences in prevalent toxigenic strains and especially the susceptibility patterns of those strains.¹⁰⁰ Clindamycin resistance was identified soon after the role of *C. difficile* in pathogenesis was discovered.^{46,101,102} More recently, quinolones have assumed greater importance because strains have become more resistant over time.¹⁰³

Fewer studies are available to support prevention practices aimed at breaking transmission. There was limited low-strength evidence that gloves, disposable thermometers, handwashing, and intensive disinfection solutions help to reduce CDI incidence. In addition, the presence and use of alcohol gel to prevent other hospital-acquired infections, such as MRSA, did not increase the rate of CDI incidence as might be expected if alcohol gel use replaced handwashing.

Similar to the antibiotic prescribing practice research, none of the studies aimed at breaking transmission addressed potential harms for other prevention practices. Costs of disinfection, time

to perform disinfection, and the possible harm to surfaces and equipment should be anticipated. Failures with vapor disinfection systems would be possible and might lead to toxic exposures of personnel or patients. Nor is there evidence to inform infection control professionals whether such practices are sustainable after an intervention period. That is, we cannot answer whether environmental cleaning staff will have developed professional habits that will continue when the intense monitoring related to an intervention period discontinues.

The potential for prevention research is often compromised by the swift uptake of newly described prevention strategies with the belief that these will improve institutional practices, health care quality, and reduce CDI morbidity and mortality. Current prevention strategies often rely on studies using intermediate outcomes such as process. Newly acquired strategies are then added to current practice, bundling them into multiple component interventions. When introduced in outbreak or hyperendemic situations, these “bundled” multipronged prevention efforts in natural settings have been associated with reduction in CDI incidence. The bundles appear to be beneficial, but from a research standpoint, it is challenging to design research that would tease out the relative contributions of single components to the overall bundled prevention strategies to determine which ones are essential or what might be added.

The realities of the environment and the habits of people who occupy those environments are complicated, and care must be taken to avoid assuming the effectiveness of preventive practices based on apparent logic. For example, handwashing is a logical and simple sounding strategy. Studies^{103,133,204} have shown that surfaces in and near the bed of a patient with CDI are often contaminated with *C. difficile*, and it is easy for health care workers to recontaminate their hands by touching one of these surfaces. However, if handwashing is performed using the same facilities as the patient, depending on the state of cleanliness in the room, handwashing may be negated the moment a surface is touched by the freshly washed hands. Further, *C. difficile* spores may persist for up to 5 months on some surfaces.²⁰⁵ This very issue of complexity is in part what drives the aforementioned practice of adding prevention components with what might be, under other conditions, considered minimal available evidence.

Standard Treatment (Key Question 3)

There is moderate evidence that the two most commonly used treatments, metronidazole and vancomycin, are similarly effective for the initial cure of CDI. Our results build upon, and are consistent with, the Cochrane Review completed by Bricker et al.¹⁰⁷ The total number of subjects from comparative studies on metronidazole and vancomycin is just 335 patients. This raises the possibility that, although a significant difference in effectiveness has not been detected, a true difference may exist.

In addition, there is moderate-strength evidence, based on a single large study, that fidaxomicin and vancomycin are similarly effective for initial cure of CDI, but that fidaxomicin use leads to significantly fewer recurrences. This difference in recurrence was observed only among non-NAP1 strains of *C. difficile*. There is no evidence for a difference in effectiveness for other agents, but again the possibility remains that such a difference exists. However, at this time any claims that one agent is superior to another for all cases of CDI are not supported by available evidence. The findings apply to general adult inpatients. Bias due to selectively reporting outcomes is possible if cut-points are changed for CDI definitions, that is, number or consistency of stools. The clinical differences of changes in cut-points are also unknown, however, so the clinical significance could remain.

We found insufficient evidence that vancomycin was superior to metronidazole for subjects classified as having severe disease. One subgroup analysis of a single trial used a prespecified analysis, and the severity classification appears to have been made before treatment allocation.⁷⁰ However, the superiority of vancomycin over metronidazole does not persist when a strict intention-to-treat analysis is used. An argument can be made that even small increases in effect size are important to a high-risk patient population where time is of the essence.¹⁰⁴ A study that has been presented in abstract form only would add to the data available for comparing metronidazole with vancomycin, but it has not yet been published in a peer-reviewed journal (See Table 23, study NCT00196794).

Outcome definitions varied significantly. For the assessment of initial cure, methods varied between only assessing symptoms, to a combination of symptoms and either laboratory values (stool studies, C-reactive protein levels, peripheral blood leukocyte count) or a physiologic measure (temperature). Similarly, definitions of resolved diarrhea ranged from greater than three formed stools in a 24-hour period⁷⁰ to greater than two formed stools daily⁷⁶ to “no loose stools.”⁷³ Assessment of recurrence in these studies was similarly complicated by variable definitions, followup periods (21 days in two, 30 days in the other), and lack of detail regarding whether active or passive surveillance was used to detect recurrence.

None of the randomized controlled trials (RCT) studies included data regarding any other organisms, either with regard to colonization or subsequent clinical infection. Selection of vancomycin-resistant enterococci (VRE) in particular has long been a concern when treating CDI; usually this concern has involved the use of vancomycin, but increasingly it has been recognized that other antimicrobials can also select for increased rates of VRE carriage.

Nonstandard Treatment (Key Question 4)

We sought to document the range of treatments under investigation for treatment and prevention of CDI, particularly recurrent CDI. Overall, definitions of CDI, interventions and measured outcomes are variable across the nonstandard prevention and treatment literature.

In attempts to expand treatment options for high rates of treatment nonresponse, treatment failure,²⁰⁶ relapse, and recurrence, researchers and clinicians are examining a number of potential lines of treatment options. The evidence for effectiveness of nonstandard interventions for treating CDI shows that probiotics, prebiotics, *C. difficile* immune whey, and colestipol are not more effective in treating CDI than standard antibiotic treatment with oral vancomycin or metronidazole or compared with placebo. The evidence supporting this conclusion is limited and of low strength. Administration of a probiotic to treat CDI in critically ill patients increases risk for greater morbidity and mortality from fungemia without any established benefit.

Prevention of CDI, both initial and recurrent cases, through interventions intended to improve gut flora and host immunity is also a very active topic in the literature. Indeed, the majority of ongoing trials accessed through ClinicalTrials.gov are of this type of research. (See the Future Research Needs section and Table 23 following this section.)

There is limited, low-strength evidence that the nonstandard prevention interventions are not more effective than placebo for primary prevention of CDI. There is limited evidence of moderate strength that administering the prebiotic oligofructose or a monoclonal antibody to *C. difficile* toxins A and B along with standard antibiotics for CDI are better than placebo and active control in preventing recurrence of CDI in patients treated for CDI. Although the studies for both treatment and prevention of CDI using a nonstandard intervention included components of experimental designs, few had adequate rigor to yield high quality findings or power to detect a

significant difference between the interventions (or placebo) compared. In some studies, a low rate of CDI precluded statistical testing. Study designs in which probiotics are administered along with standard antibiotics for recurrent CDI result in a combined treatment for recurrent CDI and do not allow for restricted investigation of probiotics as a prevention of CDI recurrence only.

There were five systematic reviews²⁰⁷⁻²¹⁰ and one meta-analysis²¹¹ about the effectiveness of probiotics for treating CDI, one systematic review about immunoglobulin treatment of CDI,²¹² and one systematic review included studies about prevention of CDI using probiotics²¹⁰ (Appendix Table C12).

The five systematic reviews on the effectiveness of probiotics for treating CDI included three to six studies. The authors of the systematic reviews determined that the variability in methods, such as types of probiotics, outcome measures, and types of subjects, did not support pooling estimates in a meta-analysis. The conclusions of the systematic reviews were that there was no evidence (two reviews), sparse evidence (two reviews), and insufficient evidence (one review) of any benefit of probiotics for CDI. The systematic review on probiotics that also addressed prevention of CDI included only one prevention study and concluded there was sparse evidence supporting this use of probiotics. The one meta-analysis of using probiotics for CDI included six studies²¹¹ and has been met with criticism. The criticism noted, among other points, the combination of findings from studies of treatment and prevention of adults and children, conducting a pooled analysis on results from heterogeneous outcome measures, analysis of results of studies with low quality due to flawed designs or methods, and lack of independent review as the investigator reviewed their own studies. The conclusion from the meta-analysis was that there was benefit in using a probiotic, especially one containing *S. boulardii*, for reducing recurrence of CDI. The one systematic review of immunoglobulin was based on four retrospective studies and five case reports and concluded no recommendations could be made.²¹² This conclusion is supported by the findings of a recent retrospective case series with the largest sample size to date, which showed a higher mortality rate than previously reported.¹⁰⁶ The authors suggested that the effect of immunoglobulin may be dependent upon the extent of systematic involvement in CDI.¹⁰⁶

Caution is recommended regarding new, nonstandard treatments, and not extrapolating study findings beyond the data. For example, one cannot assume if a probiotic treatment is effective for antibiotic-associated diarrhea that it will be effective for CDI. Likewise, attention should be paid to which patients were included and excluded in probiotic treatment studies. Such studies generally exclude high-risk patients. Thus, there is no evidence for the use of probiotics in high risk patients. During a Technical Expert Panel call it was noted that some intensive care units have banned probiotics in order to avoid the potential for fungemia and bacteremia in very ill patients.

Future Research

There are a number of important questions to be addressed regarding: (1) how to control both endemic infections and outbreaks; (2) what to do to prevent transmission after occurrence; (3) how to diagnose; (4) how to treat; and (5) how to change prevention strategies with outbreaks. Table 24 provides a summary of the research recommendations.

Diagnostic Tests

It is difficult to apply the available evidence from comparative studies to help select the best diagnostic test(s) for clinical applications. Estimates of sensitivity and specificity for many diagnostics tests for toxigenic *C. difficile* can vary greatly between laboratories. Further, there is no high-grade evidence from direct, within-laboratory comparisons of the performance of currently available diagnostic tests. The reviewed comparative studies did not clearly define the testing scenario, including the setting, disease prevalence, patient selection criteria, patient characteristics, or the signs and symptoms of the suspected CDI, making it difficult to judge to whom the study results might apply. Ultimately, the clinical importance of estimated differences in sensitivity (true positives), false positives, specificity (true negatives) and false negatives, depends on how these types of test results would affect clinical decisions and patient outcomes.²¹³

More research is needed to understand how test sensitivities and specificities are used to make decisions in clinical practice, and to define clinically meaningful differences based on their effects on clinical decisions and patient outcomes. Multicenter studies that (1) consistently use the most clinically relevant reference test, (2) use explicit clinical criteria to select patients and stool specimens to be tested, (3) randomly assign patients to different diagnostic tests, and (4) use key clinical outcomes as study endpoints are needed to fill this major gap in knowledge about diagnostic tests for toxigenic *C. difficile*.

Questions about whether the newer gene amplification and detection tests are more consistent across laboratories, and more sensitive than the currently used toxin immunoassays without substantial loss of specificity, need further study. Most importantly, studies are needed to demonstrate that use of tests that detect genetic residue related to *C. difficile* toxin production rather than the toxins per se lead to better patient outcomes.

Prevention

A number of potential prevention strategies can, and should, be investigated as a single intervention in a controlled trial in order to understand its potential contribution to a prevention program. However, the main obstacle to research in this area is the contextual setting.

Prevention happens within an institutional environment. It happens as a comprehensive approach for multiple potential hospital-acquired infectious agents and attending to multiple potential vectors of transmission and host susceptibility. Researchers and decisionmakers may need to consider another approach to inform decisionmaking: a collaborative research process in which consensus agreements are reached for minimum data sets and followup periods, and definitions of interventions are agreed to in order to facilitate pooling data across organizations. Efforts to establish and define minimum datasets for surveillance purposes have been undertaken jointly by the Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America.¹¹⁰ Lessons learned from this experience can guide future work in establishing expert and evidence-based minimum dataset projects, aligned with the needs of decisionmakers, consumers, and other stakeholders. Datasets of this nature could allow for employing more sophisticated epidemiological and decision analytic techniques to tease apart the relative contributions of different prevention strategies. Another approach to addressing lack of data to support prevention recommendations is to conduct studies that model *C. difficile* transmission and the impact the intervention has on interrupting transmission. This may have the additional benefit of identifying new, potentially more effective methods to prevent transmission

as well. The nature of the decisions faced by infection control professionals is qualitatively different than a physician's clinical decisions for an individual CDI patient. Decision analytic techniques may be particularly valuable in this venue.

Standard Treatment

The greatest needs for future studies for CDI treatment are consistent definitions and reporting of outcomes, a uniform and clinically relevant definition of disease severity, and trials with adequate power to detect clinically meaningful differences in outcomes. In particular, trials need to include adequate numbers of subjects to allow stratification by patient characteristics such as age, gender, and comorbid conditions in order to address questions regarding the most effective therapy for CDI. A well validated and clinically meaningful severity score would also assist in treatment decisions. Although most agents for CDI appear to be well tolerated, explicit reporting of adverse events by treatment allocation is another area where future research can improve our understanding of optimal management of this disease.

Although identifying the strain of *C. difficile* is of great relevance to researchers and can offer useful information to hospital epidemiologists, at present, strain identification is rarely performed in clinical settings. Thus, few clinicians treating CDI know which strain of *C. difficile* is causing an individual patient's disease and can at most make an assumption as to the strain type based on current epidemiology reported in the literature. This limitation makes any difference by strain in treatment efficacy of uncertain relevance.

Nonstandard Treatment

Additional research on nonstandard interventions as adjunctive or alternatives to standard antibiotics for preventing and treating CDI is needed and encouraged. Studies to prevent recurrence of *C. difficile* are a priority of prevention. As no single approach has been shown to be superior, promoting studies of different types of interventions is reasonable at this time.

Fecal flora reconstitution is one novel therapy for which continued research is supported. Findings of one fecal flora reconstitution case show that the colonic microbial profile of the donor temporarily resembles that of the normal donor, which might explain its beneficial effect.¹²⁶ Guidelines related to screening for safety and selecting donors that would need to be considered in future studies have been outlined.²¹⁴ Of all the nonstandard interventions, probiotics have been investigated in the most studies, and the results are not encouraging. Unlike fecal flora reconstitution, probiotics provide only a single or few strains of bacteria, and thus may be insufficient to correct alterations in the complex and extensive microbiome to the extent needed be therapeutic. The genomic mapping of indigenous microflora may offer new information to guide future formulation of a probiotic that can effectively target alterations in the microbiome in CDI and other diseases of the colon.^{215,216} A third strategy related to modifying microbial ecology in CDI for which additional research is supported is administration of a nontoxic strain of *C. difficile*. Colonization with nontoxic *C. difficile* in hamsters protects against *C. difficile* disease after challenge with a toxigenic strain. The nontoxic strain of *C. difficile* is thought to directly compete with toxigenic strains of *C. difficile*.

Developing agents to treat severe cases of refractory CDI is another area in need of research. Identifying new antibiotics may be one approach. Two of the larger case series of immunoglobulin use are in severely ill patients, and results are inconsistent.^{105,106} Whether immunoglobulin might confer greater benefit if initiated earlier in the course of CDI prior to extensive systemic involvement is an area for further study.

Studies are needed to determine whether some patients might be more likely to respond to nonstandard interventions. Sampling in current studies of nonstandard interventions varies considerably, ranging from individuals who are just starting antibiotics for infections other than *C. difficile*, to those who have had multiple failures of antibiotic treatment for CDI itself, to those who have had *C. difficile* in the past. Whether any one type of nonstandard intervention is effective in all of these types of cases is a question. More information is needed about patients who are at high risk for recurrence of CDI.

The effects of sequencing therapies (antibiotic as well as nonstandard) on the resolution of CDI merits further research. Studies show a variety of procedures for administering probiotics to prevent CDI, such as during standard antibiotic therapy or for a period after standard treatment is completed. Determining the optimal timing to introduce nonstandard interventions to possibly maximize their effect is recommended. For example, studies in hamsters indicate that timing of administration of a nontoxigenic strain of *C. difficile* for successful colonization as potential protection against disease differs depending on whether the animal is receiving antibiotics to which *C. difficile* is susceptible or resistant.²¹⁷

Methodological Improvements

It is essential that future studies of a nonstandard intervention for treatment or prevention of CDI be supported by a power analysis, adequate sample size, and an intent-to-treat analysis, in addition to other standard quality components of experimental design. Study designs must separate interventions for prevention versus treatment of recurrent CDI if this approach is desired. Multicenter studies may be necessary to achieve adequate sample sizes. Laboratory confirmation of a pathogenic *C. difficile* organism (e.g., by toxin testing) and clinical symptoms of disease (e.g., diarrhea) are essential not only for study eligibility but for determination of recurrence in long-term followup. Adoption of a standard definition of diarrhea as part of the definition of CDI is strongly recommended. Similarly, a standard definition of CDI resolution should be adopted. RCTs that compare more than one type of nonstandard intervention are suggested for efficiency.

Other organizations have also examined research gaps based on literature reviews and expert opinion. Key research issues identified during the *Clostridium difficile* Symposium on Emerging Issues and Research, convened in 2004, provides further information on research gaps.¹⁵² While many of the issues identified in the symposium are beyond the scope of this review, they merit mention. Table 23 provides a list of 23 relevant ongoing or recently completed trials not yet published for the diagnosis, prevention, and treatment of CDI. While there is considerable activity, none of the studies listed is expected to provide a definitive answer for any of the research needs discussed above. More studies that compare toxin gene detection tests to other diagnostic tests for toxigenic *C. difficile* are forthcoming and may support the notion that the gene detection tests are generally more sensitive.

Table 22. Summary of evidence

Key Questions	Level of Evidence	Summary/Conclusion/Comments
Key Question 1 - Diagnostics		
Immunoassays for toxins A and B	Low to moderate	Ten studies directly compared at least two immunoassays for toxins A and B, providing 16 pairwise comparisons of 7 different immunoassays. Comparative data were not found for many currently used tests. There were no statistical differences between the sensitivities of immunoassays that were compared, however, the estimates of the differences in sensitivity were not very precise and could not rule out substantial differences. Substantial differences in false positives, i.e. specificity, were not found among the tests that were compared.
Gene detection tests vs. immunoassays for toxins A and B	Low to moderate	Four studies compared at least one toxin gene detection test to at least one immunoassay for toxins A and B, providing a total of nine direct comparisons. Comparative data were not always available for the three currently available gene detection tests. The gene detection tests could be substantially more sensitive than many immunoassays for toxins A and B, with no or relatively modest loss of specificity.
Patient characteristics	Insufficient	Insufficient patient information was provided in reports of comparative data.
Key Question 2 - Prevention		
Antibiotic use	Low	Sixteen studies, including six bundled prevention practice studies, found appropriate prescribing practices are associated with decreased CDI incidence. Harms were not reported.
Gloves	Low	One controlled trial found use of gloves in hospital settings reduced CDI incidence.
Disposable thermometer	Low	Three time series/before–after studies, two with controls, found use of disposable thermometers in hospital settings reduced CDI incidence.
Handwashing/ alcohol gel	Low	No study examined whether handwashing reduced CDI incidence. Two studies, one controlled trial and one before/after study, of use alcohol gel to reduce MRSA transmission did not find significant differences in CDI incidence.
Disinfection	Low	Thirteen before–after studies of outbreaks or endemic hospital settings found intensive disinfection with a chemical compound that kills <i>C. difficile</i> spores reduced CDI incidence.
Sustainability	Insufficient	No evidence was available.
Risk factors	Low	Ten observational studies found evidence for antibiotic use, whether specific or general, increased risk of CDI. Severe underlying disease, acid suppression, and age are indicated as risk factors. A number of other potential factors may be indicated in single studies.
Multiple component strategies	Insufficient	Eleven time series/before–after studies examined bundles of prevention components in a single intervention. Data is insufficient to draw conclusions. Harms were not reported.

Table 22. Summary of evidence (continued)

Key Questions	Level of Evidence	Summary/Conclusion/Comments
Key Question 3 - Antibiotic Treatment		
Vancomycin versus Metronidazole	Moderate for clinical cure, low for all other outcomes	There were three head to head trials with a total of 335 subjects. Trials used various definitions of CDI patient and cure definitions, especially with regard to stool count and consistency. No significant differences in outcomes, including initial cure, clinical recurrence, mean days to resolved diarrhea, were found. Our results build upon, and are consistent with, the Cochrane Review completed by Bricker et al. ¹⁰⁶
Severe disease, vancomycin versus metronidazole	Insufficient	One RCT examined a prespecified subgroup of 69 subjects with severe CDI; improved clinical cure based on per-protocol analysis, but not with strict intention-to-treat analysis
Fidaxomicin versus vancomycin	Moderate	One large, high-quality RCT demonstrated decreased recurrence among those receiving fidaxomicin.
All other comparisons of standard treatments	Moderate for vancomycin vs. fidaxomicin, low for all other comparisons	There were eight trials examining: vancomycin versus bacitracin (two trials), vancomycin versus fidaxomicin, vancomycin versus nitazoxanide, vancomycin high versus low dose, vancomycin versus placebo, metronidazole versus nitazoxanide, and metronidazole versus metronidazole plus rifampin (one each). No differences.
Strain of organism	Low	One RCT (fidaxomicin versus vancomycin) demonstrated decreased recurrence among those receiving fidaxomicin when the infecting organism was a non-NAP1 strain.
Patient characteristics	Insufficient	No comparative data were available.
Resistance of other pathogens	Insufficient	No data were available.
Key Question 4 - Nonstandard Treatment		
Treating CDI, active control	Low	Probiotics, prebiotics, <i>C. difficile</i> immune whey, and colestipol, are not more effective in treating CDI than standard antibiotic treatment with oral vancomycin or metronidazole.
Treating CDI, placebo	Low	Administration of a probiotic with live bacteria to treat CDI in critically ill patients increases risk for greater morbidity and mortality from fungemia without any known benefit.
Treating recurrent CDI	Low	There is limited evidence from six case series that fecal flora reconstitution is effective in treating recurrent CDI for up to 1 year (3 weeks to 8 years).
Preventing CDI	Low	There is limited evidence that the nonstandard interventions in this review are not more effective than placebo for primary prevention of CDI.
Preventing recurrent CDI	Low to moderate	There is limited evidence from one subgroup analysis that a prebiotic may reduce diarrhea recurrence in patients treated for CDI more so than placebo with standard antibiotics. There is limited moderate strength evidence from one study that monoclonal antibodies are effective in preventing recurrence of CDI.

CDI = Clostridium difficile infection

Table 23. Trials from ClinicalTrials.gov and other sources

Intervention Comparator	Last Update, Estimated Completion	Sponsor	Study Design	Population	Primary Outcome	Code
<i>Not yet Recruiting – Diagnostic</i>						
PCR, EIA, or cytotoxin assay	Feb 2010, 2010	Hamilton Health Science, McMaster C. Lee, PI	Comparative	N=500 12+ years stool specimens	Test performance	NCT01066221
<i>Not yet Recruiting – Prevention</i>						
I: Lactobacillus acidophilus/ rhamnosus complex C: placebo	Jan 2010, 2012	Vancouver Island Health Authority, C. Harder	RCT double blind	N=200 60+ patients on antibiotics	CDI incidence	NCT01048567
I: Colostrum derived antibodies C: placebo	Aug 2009, 2012	Hadassah Medical Organization	RCT double blind 60 day followup Phase II, III	N=300 18+ patients symptomatic patient, lab-confirmed CDI	Recurrent CDI, new cases in close proximity	NCT00747071
<i>Recruiting – Prevention</i>						
I: Saccharomyces Boulardii C:Placebo	July 2012	Bernhard Nocht Institute for Tropical Medicine S. Ehrhardt, PI	RCT double blind, Phase III	N=1,520 18+ hospitalized patients	CDI incidence	NCT01143272
I: toxoid vaccine C: placebo	Apr 2011	Sanofi-Aventis	RCT double blind 9 week followup	N=650 18+ patients with one CDI episode within last 10 days, not currently treated for recurrent	Recurrent CDI	NCT00772343
I: Lactobacillus casei probiotic C: placebo	Apr 2010, 2012	University of Sussex, C. Rajkumar, PI	RCT double blind, 28 days, Phase II	N=1,200 55+ patients receiving antibiotics	Incidence and presence of toxin, prevent recurrence	NCT01087892
I: Clostridium butyricum MIYAIRI 588 Strain (CBM588) C: placebo)	Feb 2010, 2011	Osel, Inc. P. Lee, PI	RCT double blind, Phase II	N=200 18+ patients treated with vancomycin or metronidazole for CDI	Recurrent CDI	NCT01077245
I: Probiotic VSL#3 C: placebo	Sept 2009, Sept 2010	NHS, UK N. Haslam, PI	RCT double blind, 28 days, Phase II, III	N=450 18+ patients on antibiotics	CDI incidence	NCT00973908

Table 23. Trials from ClinicalTrials.gov and other sources (continued)

Intervention Comparator	Last Update, Estimated Completion	Sponsor	Study Design	Population	Primary Outcome	Code
I: Recombinant human lactoferrin C: placebo	Sept 2006	John Hopkins W. Greenough, PI	RCT double blind	N=300 18+ LTC patients on enteral tube feeding	Not reported	NCT00377078
I: Hospital ward physical design C: traditional ward design	Mar 2009	University of Calgary W. Ghali, PI	Prospective controlled trial	N=3,600 18+ patients	CDI incidence	NCT00563186
Recruiting – Treatment						
I: CB-183,315 two doses tested C: Vancomycin	Apr 2010, 2011	Cubist Pharmaceuticals	RCT double blinded, 3 arms, Phase II	N=210 18+ patients symptomatic patients, lab-confirmed, index or 1st recurrence	Not clear	NCT01085591
I: Loperamide (Imodium) C: placebo	Jan 2008, Dec 2009	VA Houston, D. Musher, PI	RCT double blind, Phase IV	N=120 18+ patients on antibiotics	Symptomatic treatment of diarrhea	NCT00591357
I: Nitazoxanide C: NA	Mar 2006	VA Houston, D. Musher, PI	Open label compassionate use Phase III	N=100 18+ patients with CDI who failed therapy	Resolution of symptoms	NCT00304356
Fecal bacteriology	Mar 2006	VA Houston D. Musher, PI	Retro observational cross-sectional	N=80 18+ patients with CDI, patients lab-confirmed without CDI, patients who fail therapy, hospitalized patients on antibiotic with no diarrhea		NCT00304876
Completed – Prevention						
I: Bio-K+ CL-1285 probiotic, Lactobacillus acidophilus, Lactobacillus casei C: placebo	Aug 2009	Bio-K Plus International, Inc. G. XingWang, PI	RCT double blind, Phase III	N=255 50-70 years, patients on antibiotic therapy	CDI incidence	NCT00958308

Table 23. Trials from ClinicalTrials.gov and other sources (continued)

Intervention Comparator	Last Update, Estimated Completion	Sponsor	Study Design	Population	Primary Outcome	Code
I: Lactobacillus acidophilus and casei C: placebo	Sept 2008	Bio-K Plus International, Inc. J. Dylewski, PI	RCT double blind	N=480 18+ patients on antibiotics	CDI incidence	NCT00328263
I: Polycationic disinfectant C: alcohol-based gel and regular disinfectant with quat/chloramines	Aug 2008	Helsinki University Soft protector TEKES, M. Kanerva, PI	Open label, parallel active control 6 months	3 experimental wards plus control wards	CDI incidence	NCT00566306
Completed – Treatment						
I: GT160-246 C: Vancomycin	Jul 2009	Genzyme	RCT double blinded, Phase II	N=300 18+ patient with mild to moderate CDI	Not reported	NCT00034294
I: Rifaximin C: Vancomycin	Dec 2009	Salix Pharmaceuticals A. Shaw, PI	RCT double blind, Phase III	N=300 18+ lab confirmed CDI	Resolution of baseline, recurrence	NCT00269399
I: OPT-80 C: Vancomycin	Feb 2010	Optimer Pharmaceuticals, YK Shue, PI	RCT double blind, Phase III	N=536 16+ patients with CDI	Cure rate, recurrence rate	NCT00468728
I: Lactobacillus CL placebo (both arms used metronidazole)	Mar 2006	VA Houston D. Musher	RCT double blind Phase IV	N=70 18+ patients lab confirmed CDI	Response to treatment	NCT00304863
Not ClinicalTrials.gov						
FECAL trial I: bacteriotherapy C: Standard antibiotic treatment		ZonMW, the Netherlands Organisation for Health Research and Development van Nood, PI	RCT, 10 week followup	N=120 18+ patients, proven relapse of CDI. Exclude ICU, immuno-compromised	Response to treatment	Netherlands. Non-citizens accepted if travel to Amsterdam

C = comparator; CDI = Clostridium difficile infection; EIA = enzyme immunoassay; I = intervention; ICU = intensive care unit; PCR = polymerase chain reaction; PI = Principal Investigator; RCT = randomized controlled trial

Table 24. Future research recommendations

Key Question	Research Gaps	Types of Studies Needed to Answer Questions	Future Research Recommendation
Key Question 1. How do different methods for detection of toxigenic <i>C. difficile</i> compare in their sensitivity, specificity, and predictive values?	Few direct comparisons are available. Methodological heterogeneity is an obstacle. Unknown what differences in sensitivity and specificity would alter clinician decisionmaking and patient outcomes. Unknown influence of patient and stool characteristics on differences in test sensitivity and specificity.	Comparison of diagnostic tests using same clinical samples in the same labs. Multicenter studies with well-documented patient samples.	Document stool sample characteristics, patient selection criteria, patient characteristics, signs and symptoms of suspected CDI and effects of differences on patient outcomes.
Key Question 2. What are effective prevention strategies?	Little evidence available with clinically important outcomes.	High-quality comparative studies evaluating effectiveness and harms of single and/or multicomponent prevention strategies, including cleaning, isolation, antibiotic restriction. Discrete simulation models.	Pool data from multiple participating hospital sites. Establish minimum data sets for observational data points that can inform models.
Key Question 3. What are the comparative effectiveness and harms of different antibiotic treatments?	Limited evidence available on whether vancomycin is more effective for severe CDI.	High-quality comparative studies with adequate power to detect significance in a priori subgroups.	A uniform and clinically relevant definition of severity. Subgroup analysis may include age, gender, comorbid conditions. Explicit reporting of adverse events.
Key Question 4. What are the effectiveness and harms of nonstandard adjunctive interventions?	Probiotics as a treatment adjuvant is not supported. Potential harms to seriously ill patients may outweigh potential benefits for further prevention research. Probiotics as prevention warrants further study. Further research of monoclonal antibodies for prevention is warranted. Further research of fecal transplant is warranted.	High-quality comparative studies with adequate power.	Placebo comparators would contribute indirect evidence that would help guide potential combination therapies. Quality research includes power analysis, intention to treat. Multicenter trials are likely needed to achieve adequate samples. Trials of probiotics for prevention are well represented in ongoing studies. Patient characteristics for subgroup analysis.
Umbrella issues			Adoption of standard definitions for diarrhea, CDI resolution.

CDI = Clostridium difficile infection

References and Included Studies

(The references below correspond to the footnotes in the body of the report. There is a separate set of references at the end of the evidence tables in Appendix C.)

1. Gravel D, Miller M, Simor A, et al. Health care-associated *Clostridium difficile* infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. *Clin Infect Dis* 2009 Mar 1; 48(5):568-76.
2. McDonald LC. Confronting *Clostridium difficile* in inpatient health care facilities. *Clin Infect Dis* 2007 Nov 15; 45(10):1274-6.
3. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *N Engl J Med* 2005 Dec 8; 353(23):2442-9.
4. Brandt LJ, Kosche KA, Greenwald DA, et al. *Clostridium difficile*-associated diarrhea in the elderly. *Am J Gastroenterol* 1999 Nov; 94(11):3263-6.
5. Hebuterne X. Gut changes attributed to ageing: effects on intestinal microflora. *Curr Opin Clin Nutr Metab Care* 2003 Jan; 6(1):49-54.
6. Kim J, Smathers SA, Prasad P, et al. Epidemiological features of *Clostridium difficile*-associated disease among inpatients at children's hospitals in the United States, 2001-2006. *Pediatrics* 2008 Dec; 122(6):1266-70.
7. Simor AE, Bradley SF, Strausbaugh LJ, et al. *Clostridium difficile* in long-term-care facilities for the elderly. *Infect Control Hosp Epidemiol* 2002 Nov; 23(11):696-703.
8. Laffan AM, Bellantoni MF, Greenough WB, 3rd, et al. Burden of *Clostridium difficile*-associated diarrhea in a long-term care facility. *J Am Geriatr Soc* 2006 Jul; 54(7):1068-73.
9. Jarvis WR, Schlosser J, Jarvis AA, et al. National point prevalence of *Clostridium difficile* in US health care facility inpatients, 2008. *Am J Infect Control* 2009 May; 37(4):263-70.
10. Kim KH. Isolation of *Clostridium difficile* from the environment and contacts of patients with antibiotic-associated colitis. *J Infect Dis* 1981; 143(1):42-50.
11. McFarland LV. Renewed interest in a difficult disease: *Clostridium difficile* infections--epidemiology and current treatment strategies. *Curr Opin Gastroenterol* 2009 Jan; 25(1):24-35.
12. Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of *Clostridium difficile* isolates from various patient populations. *Gastroenterol* 1981 Jul; 81(1):5-9.
13. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent *Clostridium difficile*-associated diarrhea. *J Infect Dis* 2008 Feb 1; 197(3):435-8.
14. Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. *J Clin Microbiol* 2004 Mar; 42(3):1203-6.
15. Aslam S, Musher DM. An update on diagnosis, treatment, and prevention of *Clostridium difficile*-associated disease. *Gastroenterol Clin North Am* 2006 Jun; 35(2):315-35.
16. Dial S, Alrasadi K, Manoukian C, et al. Risk of *Clostridium difficile* diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. *CMAJ* 2004 Jul 6; 171(1):33-8.
17. Dial S, Delaney JAC, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired *Clostridium difficile*-associated disease. *JAMA* 2005 Dec 21; 294(23):2989-95.

18. Aseeri M, Schroeder T, Kramer J, et al. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. *Am J Gastroenterol* 2008 Sep; 103(9):2308-13.
19. Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent *Clostridium difficile* infection. *Arch Intern Med* 2010 May 10; 170(9):772-8.
20. Bignardi GE. Risk factors for *Clostridium difficile* infection. *J Hosp Infect* 1998 Sep; 40(1):1-15.
21. Garey KW, Sethi S, Yadav Y, et al. Meta-analysis to assess risk factors for recurrent *Clostridium difficile* infection. *J Hosp Infect* 2008 Dec; 70(4):298-304.
22. Cunningham R, Dial S. Is over-use of proton pump inhibitors fuelling the current epidemic of *Clostridium difficile*-associated diarrhoea? *J Hosp Infect* 2008 Sep; 70(1):1-6.
23. Thibault A, Miller MA, Gaese C. Risk factors for the development of *Clostridium difficile*-associated diarrhea during a hospital outbreak. *Infect Control Hosp Epidemiol* 1991 Jun; 12(6):345-8.
24. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. *Am J Gastroenterol* 2007 Sep; 102(9):2047-56; quiz 57.
25. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial *Clostridium difficile* infection. *Arch Intern Med* 2010 May 10; 170(9):784-90.
26. Starr JM, Campbell A, Renshaw E, et al. Spatio-temporal stochastic modelling of *Clostridium difficile*. *J Hosp Infect* 2009 Jan; 71(1):49-56.
27. Gerding DN, Muto CA, Ownes RC, Jr. Measuresto control and prevent *Clostridium difficile* infection. *Clin Infect Dis* 2008 Jan 15; 46 Suppl 1:S43-9.
28. Severe *Clostridium difficile*-associated disease in populations previously at low risk--four states, 2005. *MMWR Morb Mortal Wkly Rep* 2005 Dec 2; 54(47):1201-5.
29. Hensgens MP, Goorhuis A, Notermans DW, et al. Decrease of hypervirulent *Clostridium difficile* PCR ribotype 027 in the Netherlands. *Euro Surveill* 2009; 14(45).
30. Belmares J, Johnson S, Parada JP, et al. Molecular epidemiology of *Clostridium difficile* over the course of 10 years in a tertiary care hospital. *Clin Infect Dis* 2009 Oct 15; 49(8):1141-7.
31. Alcalá L, Sánchez-Cambronero L, Catalan MP, et al. Comparison of three commercial methods for rapid detection of *Clostridium difficile* toxins A and B from fecal specimens. *J Clin Microbiol* 2008 Nov; 46(11):3833-5.
32. Eastwood K, Else P, Charlett A, et al. Comparison of nine commercially available *Clostridium difficile* toxin detection assays, a real-time PCR assay for *C. difficile* tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. *J Clin Microbiol* 2009 Oct; 47(10):3211-7.
33. Musher DM, Manhas A, Jain P, et al. Detection of *Clostridium difficile* toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay. *J Clin Microbiol* 2007 Aug; 45(8):2737-9.
34. Samra Z, Luzon A, Bishara J. Evaluation of two rapid immunochromatography tests for the detection of *Clostridium difficile* toxins. *Dig Dis Sci* 2008 Jul; 53(7):1876-9.
35. Sloan LM, Duresko BJ, Gustafson DR, et al. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of *Clostridium difficile* infection. *J Clin Microbiol* 2008 Jun; 46(6):1996-2001.
36. O'Connor D, Hynes P, Cormican M, et al. Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of *Clostridium difficile*-associated diarrhea. *J Clin Microbiol* 2001 Aug; 39(8):2846-9.
37. Kvach EJ, Ferguson D, Riska PF, et al. Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic *Clostridium difficile* infection. *J Clin Microbiol* 2010 Jan; 48(1):109-14.

38. Turgeon DK, Novicki TJ, Quick J, et al. Six rapid tests for direct detection of *Clostridium difficile* and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. *J Clin Microbiol* 2003 Feb; 41(2):667-70.
39. Miendje Deyi VY, Vandenberg O, Mascart G, et al. Diagnostic value of five commercial tests for the rapid diagnosis of *Clostridium difficile*-associated disease. *Clin Lab* 2008; 54(1-2):9-13.
40. Novak-Weekley SM, Marlowe EM, Miller JM, et al. *Clostridium difficile* testing in the clinical laboratory by use of multiple testing algorithms. *J Clin Microbiol* 2010 Mar; 48(3):889-93.
41. Davey P, Brown E, Fenelon L, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev* 2005; (4):CD003543.
42. Fowler S, Webber A, Cooper BS, et al. Successful use of feedback to improve antibiotic prescribing and reduce *Clostridium difficile* infection: a controlled interrupted time series. *J Antimicrob Chemother* 2007 May; 59(5):990-5.
43. Wilcox MH, Freeman J, Fawley W, et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of *Clostridium difficile* diarrhoea. *J Antimicrob Chemother* 2004 Jul; 54(1):168-72.
44. O'Connor KA, Kingston M, O'Donovan M, et al. Antibiotic prescribing policy and *Clostridium difficile* diarrhoea. *QJM* 2004 Jul; 97(7):423-9.
45. Ludlam H, Brown N, Sule O, et al. An antibiotic policy associated with reduced risk of *Clostridium difficile*-associated diarrhoea. *Age Ageing* 1999 Oct; 28(6):578-80.
46. Johnson S, Gerding DN, Olson MM, et al. Prospective, controlled study of vinyl glove use to interrupt *Clostridium difficile* nosocomial transmission. *Am J Med* 1990 Feb; 88(2):137-40.
47. Brooks SE, Veal RO, Kramer M, et al. Reduction in the incidence of *Clostridium difficile*-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. *Infect Control Hosp Epidemiol* 1992 Feb; 13(2):98-103.
48. Brooks S, Khan A, Stoica D, et al. Reduction in vancomycin-resistant *Enterococcus* and *Clostridium difficile* infections following change to tympanic thermometers. *Infect Control Hosp Epidemiol* 1998 May; 19(5):333-6.
49. Jernigan JA. A randomized crossover study of disposable thermometers for prevention of *Clostridium difficile* and other nosocomial infections. *Infect Control Hosp Epidemiol* 1998; 19(7):494-9.
50. Rupp ME, Fitzgerald T, Puumala S, et al. Prospective, controlled, cross-over trial of alcohol-based hand gel in critical care units. *Infect Control Hosp Epidemiol* 2008 Jan; 29(1):8-15.
51. Gordin FM, Schultz ME, Huber RA, et al. Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub. *Infect Control Hosp Epidemiol* 2005 Jul; 26(7):650-3.
52. Kaier K. Two time-series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant *Staphylococcus aureus* infection and *Clostridium difficile* infection. *Infect Control Hosp Epidemiol* 2009; 30(4):346-53.
53. Mayfield JL, Leet T, Miller J, et al. Environmental control to reduce transmission of *Clostridium difficile*. *Clin Infect Dis* 2000 Oct; 31(4):995-1000.
54. Kaatz GW, Gitlin SD, Schaberg DR, et al. Acquisition of *Clostridium difficile* from the hospital environment. *Am J Epidemiol* 1988 Jun; 127(6):1289-94.
55. Struelens MJ, Maas A, Nonhoff C, et al. Control of nosocomial transmission of *Clostridium difficile* based on sporadic case surveillance. *Am J Med* 1991 Sep 16; 91(3B):138S-44S.

56. Abbett SK, Yokoe DS, Lipsitz SR, et al. Proposed checklist of hospital interventions to decrease the incidence of healthcare-associated *Clostridium difficile* infection. *Infect Control Hosp Epidemiol* 2009 Nov; 30(11):1062-9.
57. Boyce JM, Havill NL, Otter JA, et al. Impact of hydrogen peroxide vapor room decontamination on *Clostridium difficile* environmental contamination and transmission in a healthcare setting. *Infect Control Hosp Epidemiol* 2008 Aug; 29(8):723-9.
58. Brown E, Talbot GH, Axelrod P, et al. Risk factors for *Clostridium difficile* toxin-associated diarrhea. *Infect Control Hosp Epidemiol* 1990 Jun; 11(6):283-90.
59. Cartmill TD, Panigrahi H, Worsley MA, et al. Management and control of a large outbreak of diarrhoea due to *Clostridium difficile*. *J Hosp Infect* 1994 May; 27(1):1-15.
60. Drudy D, Harnedy N, Fanning S, et al. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive *Clostridium difficile*. *Infect Control Hosp Epidemiol* 2007 Aug; 28(8):932-40.
61. McNulty C, Logan M, Donald IP, et al. Successful control of *Clostridium difficile* infection in an elderly care unit through use of a restrictive antibiotic policy. *J Antimicrob Chemother* 1997 Nov; 40(5):707-11.
62. Pear SM, Williamson TH, Bettin KM, et al. Decrease in nosocomial *Clostridium difficile*-associated diarrhea by restricting clindamycin use. *Ann Intern Med* 1994 Feb 15; 120(4):272-7.
63. Valiquette L, Cossette B, Garant MP, et al. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of *Clostridium difficile*-associated disease caused by the hypervirulent NAP1/027 strain. *Clin Infect Dis* 2007 Sep 1; 45 Suppl 2:S112-21.
64. Zafar AB, Gaydos LA, Furlong WB, et al. Effectiveness of infection control program in controlling nosocomial *Clostridium difficile*. *Am J Infect Control* 1998 Dec; 26(6):588-93.
65. Whitaker J, Brown BS, Vidal S, et al. Designing a protocol that eliminates *Clostridium difficile*: a collaborative venture. *Am J Infect Control* 2007 Jun; 35(5):310-4.
66. Vernaz N, Sax H, Pittet D, et al. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and *Clostridium difficile*. *J Antimicrob Chemother* 2008 Sep; 62(3):601-7.
67. Hacek DM, Ogle AM, Fisher A, et al. Significant impact of terminal room cleaning with bleach on reducing nosocomial *Clostridium difficile*. *Am J Infect Control* 2010 Jun; 38(5):350-3.
68. McMullen KM, Zack J, Coopersmith CM, et al. Use of hypochlorite solution to decrease rates of *Clostridium difficile*-associated diarrhea. *Infect Control Hosp Epidemiol* 2007 Feb; 28(2):205-7.
69. Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in *Clostridium difficile* infection: a randomized, double-blind study. *Clin Infect Dis* 2009 Feb 15; 48(4):e41-6.
70. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clin Infect Dis* 2007 Aug 1; 45(3):302-7.
71. Lagrotteria D, Holmes S, Smieja M, et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of *Clostridium difficile*-associated diarrhea. *Clin Infect Dis* 2006 Sep 1; 43(5):547-52.
72. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of *Clostridium difficile* colitis. *Clin Infect Dis* 2006 Aug 15; 43(4):421-7.
73. Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of *Clostridium difficile*-associated diarrhea. *Clin Infect Dis* 1996 May; 22(5):813-8.

74. Dudley MN, McLaughlin JC, Carrington G, et al. Oral bacitracin vs vancomycin therapy for *Clostridium difficile*-induced diarrhea. A randomized double-blind trial. *Arch Intern Med* 1986 Jun; 146(6):1101-4.
75. Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic-associated *Clostridium difficile* colitis with oral vancomycin: comparison of two dosage regimens. *Am J Med* 1989 Jan; 86(1):15-9.
76. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for *Clostridium-difficile*-associated diarrhoea and colitis. *Lancet* 1983 Nov 5; 2(8358):1043-6.
77. Young GP, Ward PB, Bayley N, et al. Antibiotic-associated colitis due to *Clostridium difficile*: double-blind comparison of vancomycin with bacitracin. *Gastroenterol* 1985 Nov; 89(5):1038-45.
78. Keighley MR, Burdon DW, Arabi Y, et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. *BMJ* 1978 Dec 16; 2(6153):1667-9.
79. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for *Clostridium difficile* infection. *N Engl J Med*. 2011 Feb 3; 364(5):422-31
80. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent *Clostridium difficile* disease: use of high-dose vancomycin combined with *Saccharomyces boulardii*. *Clin Infect Dis* 2000 Oct; 31(4):1012-7.
81. Wullt M, Hagslatt ML, Odenholt I. *Lactobacillus plantarum* 299v for the treatment of recurrent *Clostridium difficile*-associated diarrhoea: a double-blind, placebo-controlled trial. *Scand J Infect Dis* 2003; 35(6-7):365-7.
82. Mattila E, Anttila VJ, Broas M, et al. A randomized, double-blind study comparing *Clostridium difficile* immune whey and metronidazole for recurrent *Clostridium difficile*-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. *Scand J Infect Dis* 2008; 40(9):702-8.
83. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of *Saccharomyces boulardii* in combination with standard antibiotics for *Clostridium difficile* disease. *JAMA* 1994 Jun 22-29; 271(24):1913-8.
84. Mogg GA, George RH, Youngs D, et al. Randomized controlled trial of colestipol in antibiotic-associated colitis. *Br J Surg* 1982 Mar; 69(3):137-9.
85. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by *Saccharomyces boulardii*: a prospective study. *Gastroenterol* 1989 Apr; 96(4):981-8.
86. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of *Saccharomyces boulardii* in the prevention of antibiotic-related diarrhoea in elderly patients. *J Infect* 1998 Mar; 36(2):171-4.
87. Thomas MR, Litin SC, Osmon DR, et al. Lack of effect of *Lactobacillus GG* on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. *Mayo Clin Proc* 2001 Sep; 76(9):883-9.
88. Plummer S, Weaver MA, Harris JC, et al. *Clostridium difficile* pilot study: effects of probiotic supplementation on the incidence of *C. difficile* diarrhoea. *Int Microbiol* 2004 Mar; 7(1):59-62.
89. Can M, Besirbellioglu BA, Avci IY, et al. Prophylactic *Saccharomyces boulardii* in the prevention of antibiotic-associated diarrhea: a prospective study. *Med Sci Monit* 2006 Apr; 12(4):P19-22.
90. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic *Lactobacillus* preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. *BMJ* 2007 Jul 14; 335(7610):80.
91. Lewis S, Burmeister S, Cohen S, et al. Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea. *Aliment Pharmacol Ther* 2005 Feb 15; 21(4):469-77.
92. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of *Clostridium difficile*-associated diarrhea: a randomized, controlled study. *Clin Gastroenterol Hepatol* 2005 May; 3(5):442-8.

93. Munoz P, Bouza E, Cuenca-Estrella M, et al. *Saccharomyces cerevisiae* fungemia: an emerging infectious disease.[see comment]. *Clin Infect Dis* 2005 Jun 1; 40(11):1625-34.
94. Eriksson S, Aronsson B. Medical implications of nosocomial infection with *Clostridium difficile*. *Scand J Infect Dis* 1989; 21(6):733-4.
95. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against *Clostridium difficile* toxins. *N Engl J Med* 2010 Jan 21; 362(3):197-205.
96. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing *Clostridium difficile* diarrhoea in six patients. *Lancet* 1989 May 27; 1(8648):1156-60.
97. Persky SE, Brandt LJ. Treatment of recurrent *Clostridium difficile*-associated diarrhea by administration of donated stool directly through a colonoscope. *Am J Gastroenterol* 2000 Nov; 95(11):3283-5.
98. Planche T, Aghaizu A, Holliman R, et al. Diagnosis of *Clostridium difficile* infection by toxin detection kits: a systematic review. *Lancet Infect Dis* 2008 Dec; 8(12):777-84.
99. Crobach MJ, Dekkers OM, Wilcox MH, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing *Clostridium difficile*-infection (CDI). *Clin Microbiol Infect* 2009 Dec; 15(12):1053-66.
100. Samore MH, DeGirolami PC, Tlucko A, et al. *Clostridium difficile* colonization and diarrhea at a tertiary care hospital. *Clin Infect Dis* 1994 Feb; 18(2):181-7.
101. Samore MH, Venkataraman L, DeGirolami PC, et al. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial *Clostridium difficile* diarrhea. *Am J Med* 1996 Jan; 100(1):32-40.
102. Shim JK, Johnson S, Samore MH, et al. Primary symptomless colonisation by *Clostridium difficile* and decreased risk of subsequent diarrhoea. *Lancet* 1998 Feb 28; 351(9103):633-6.
103. McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of *Clostridium difficile* infection. *N Engl J Med* 1989 Jan 26; 320(4):204-10.
104. Gerding DN, Johnson S, Peterson LR, et al. *Clostridium difficile*-associated diarrhea and colitis. *Infect Control Hosp Epidemiol* 1995 Aug; 16(8):459-77.
105. Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe *Clostridium difficile*-associated diarrhea. *Am J Infect Control* 2007 Mar; 35(2):131-7.
106. Abougergi MS, Broor A, Cui W, et al. Intravenous immunoglobulin for the treatment of severe *Clostridium difficile* colitis: an observational study and review of the literature. *J Hosp Med (Online)* 2010 Jan; 5(1):E1-9.
107. Bricker E, Garg R, Nelson R, et al. Antibiotic treatment for *Clostridium difficile*-associated diarrhea in adults.[update in *Cochrane Database Syst Rev*. 2007;(3):CD004610; PMID: 17636768]. *Cochrane Database Syst Rev* 2005; (1):004610.
108. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of *Clostridium difficile* infection. *Clin Infect Dis* 2008 Jan 15; 46 Suppl 1:S12-8.
109. Peterson LR, Robicsek A. Does my patient have *Clostridium difficile* infection? *Ann Intern Med* 2009 Aug 4; 151(3):176-9.
110. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infect Control Hosp Epidemiol* 2010 May; 31(5):431-55.
111. Katz DA, Bates DW, Rittenberg E, et al. Predicting *Clostridium difficile* stool cytotoxin results in hospitalized patients with diarrhea. *J Gen Intern Med* 1997 Jan; 12(1):57-62.
112. Peled N, Pitlik S, Samra Z, et al. Predicting *Clostridium difficile* toxin in hospitalized patients with antibiotic-associated diarrhea. *Infect Control Hosp Epidemiol* 2007 Apr; 28(4):377-81.
113. Cooper GS, Lederman MM, Salata RA. A predictive model to identify *Clostridium difficile* toxin in hospitalized patients with diarrhea. *Am J Gastroenterol* 1996 Jan; 91(1):80-4.

114. Fekety R. Guidelines for the diagnosis and management of *Clostridium difficile*-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol* 1997 May; 92(5):739-50.
115. Gerding DN, Muto CA, Owens RC, Jr. Treatment of *Clostridium difficile* infection. *Clin Infect Dis* 2008 Jan 15; 46 Suppl 1:S32-42.
116. Pepin J. Vancomycin for the treatment of *Clostridium difficile* Infection: for whom is this expensive bullet really magic? *Clin Infect Dis* 2008 May 15; 46(10):1493-8.
117. HICPAC. Recommendations for preventing the spread of vancomycin resistance. *Infect Control Hosp Epidemiol* 1995 Feb; 16(2):105-13.
118. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. *N Engl J Med* 2000 Dec 28; 343(26):1925-32.
119. Olivas AD, Umanskiy K, Zuckerbraun B, et al. Avoiding colectomy during surgical management of fulminant *clostridium difficile* colitis. *Surg Infect (Larchmt)* 2010 Jun; 11(3):299-305.
120. van Nood E, Speelman P, Kuijper EJ, et al. Struggling with recurrent *Clostridium difficile* infections: is donor faeces the solution? *Euro Surveill* 2009; 14(34).
121. Jodlowski TZ, Oehler R, Kam LW, et al. Emerging therapies in the treatment of *Clostridium difficile*-associated disease. *Ann Pharmacother* 2006 Dec; 40(12):2164-9.
122. Stepan C, Surawicz CM. Treatment strategies for *C. difficile* associated diarrhea. *Acta Gastroenterologica Latinoamericana* 2007 Sep; 37(3):183-91.
123. Halsey J. Current and future treatment modalities for *Clostridium difficile*-associated disease. *Am J Health Syst Pharm* 2008 Apr 15; 65(8):705-15.
124. Bakken JS. Fecal bacteriotherapy for recurrent *Clostridium difficile* infection. *Anaerobe* 2009 Dec; 15(6):285-9.
125. Food and Agriculture Organization of the United Nations, World Health Organization. Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Cordoba, Argentina; 2001.
126. Khoruts A, Dicksved J, Jansson JK, et al. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent *Clostridium difficile*-associated diarrhea. *J Clin Gastroenterol* 2010 May-Jun; 44(5):354-60.
127. Floch M. Fecal bacteriotherapy, fecal transplant, and the microbiome. *J Clin Gastroenterol* 2010; 44(8):529-30.
128. Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic *Clostridium difficile* infection. *Clin Gastroenterol Hepatol* 2010 May; 8(5):471-3.
129. MacConnachie AA, Fox R, Kennedy DR, et al. Faecal transplant for recurrent *Clostridium difficile*-associated diarrhoea: a UK case series. *QJM* 2009 Nov; 102(11):781-4.
130. Yoon S, Brandt L. Treatment of refractory/recurrent *C. difficile*-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. *J Clin Gastroenterol* 2010; 44(8):562-6.
131. Dubberke ER, Gerding DN, Classen D, et al. Strategies to prevent *clostridium difficile* infections in acute care hospitals. *Infect Control Hosp Epidemiol* 2008 Oct; 29 Suppl 1:S81-92.
132. Jabbar U, Leischner J, Kasper D, et al. Effectiveness of alcohol-based hand rubs for removal of *Clostridium difficile* spores from hands. *Infect Control Hosp Epidemiol* 2010 Jun; 31(6):565-70.
133. Roberts K, Smith CF, Snelling AM, et al. Aerial dissemination of *Clostridium difficile* spores. *BMC Infectious Diseases* 2008; 8:7.
134. Chang TW, Lauermann M, Bartlett JG. Cytotoxicity assay in antibiotic-associated colitis. *J Infect Dis* 1979 Nov; 140(5):765-70.

135. Riegler M, Sedivy R, Pothoulakis C, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. *J Clin Invest* 1995 May; 95(5):2004-11.
136. Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. *Nature* 2009 Apr 30; 458(7242):1176-9.
137. Wilkins TD, Lyerly DM. Clostridium difficile testing: after 20 years, still challenging. *J Clin Microbiol* 2003 Feb; 41(2):531-4.
138. Brazier JS. The diagnosis of Clostridium difficile-associated disease. *J Antimicrob Chemother* 1998 May; 41 Suppl C:29-40.
139. Bouza E, Pelaez T, Alonso R, et al. "Second-look" cytotoxicity: an evaluation of culture plus cytotoxin assay of Clostridium difficile isolates in the laboratory diagnosis of CDAD. *J Hosp Infect* 2001 Jul; 48(3):233-7.
140. Delmee M. Laboratory diagnosis of Clostridium difficile disease. *Clin Microbiol Infect* 2001 Aug; 7(8):411-6.
141. Fenner L, Widmer AF, Goy G, et al. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. *J Clin Microbiol* 2008 Jan; 46(1):328-30.
142. Ticehurst JR, Aird DZ, Dam LM, et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. *J Clin Microbiol* 2006 Mar; 44(3):1145-9.
143. Wren MW, Sivapalan M, Kinson R, et al. Laboratory diagnosis of clostridium difficile infection. An evaluation of tests for faecal toxin, glutamate dehydrogenase, lactoferrin and toxigenic culture in the diagnostic laboratory. *Br J Biomed Sci* 2009; 66(1):1-5.
144. Bartlett JG, Perl TM. The new Clostridium difficile--what does it mean? *N Engl J Med* 2005 Dec 8; 353(23):2503-5.
145. McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. *Nat Clin Pract Gastroenterol Hepatol* 2008 Jan; 5(1):40-8.
146. al-Barrak A, Embil J, Dyck B, et al. An outbreak of toxin A negative, toxin B positive Clostridium difficile-associated diarrhea in a Canadian tertiary-care hospital. *Can Commun Dis Rep* 1999 Apr 1; 25(7):65-9.
147. Samra Z, Talmor S, Bahar J. High prevalence of toxin A-negative toxin B-positive Clostridium difficile in hospitalized patients with gastrointestinal disease. *Diagn Microbiol Infect Dis* 2002 Jul; 43(3):189-92.
148. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. *World J Gastroenterol* 2009 Apr 7; 15(13):1554-80.
149. Yucesoy M, McCoubrey J, Brown R, et al. Detection of toxin production in Clostridium difficile strains by three different methods. *Clin Microbiol Infect* 2002 Jul; 8(7):413-8.
150. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. *N Engl J Med* 1994 Jan 27; 330(4):257-62.
151. Lamontagne F, Labbe AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. *Ann Surg* 2007 Feb; 245(2):267-72.
152. Zhanel G, Hammond G. Key research issues in Clostridium difficile. *Can J Infect Dis Med Microbiol* 2005 Sep; 16(5):282-5.
153. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. *N Engl J Med* 2005 Dec 8; 353(23):2433-41.
154. Courvalin P. Vancomycin resistance in gram-positive cocci. *Clin Infect Dis* 2006 Jan 1; 42 Suppl 1:S25-34.
155. Whiting PF, Weswood ME, Rutjes AW, et al. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. *BMC Med Res Methodol* 2006; 6:9.
156. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med Res Methodol* 2003 Nov 10; 3:25.

157. Higgins JP, Green S. *Cochrane Handbook for Systematic Reviews of Interventions*. The Cochrane Collaboration 2008; Version 5.0.2 [updated September 2009].
158. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. *Lancet* 2002 Feb 16; 359(9306):614-8.
159. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. *J Clin Epidemiol* 2010 May; 63(5):513-23.
160. Review Manager [computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2008.
161. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003 Sep 6; 327(7414):557-60.
162. Tang NS, Li HQ, Tang ML. A comparison of methods for the construction of confidence interval for relative risk in stratified matched-pair designs. *Stat Med* 2010 Jan 15; 29(1):46-62.
163. van den Berg RJ, Vaessen N, Endtz HP, et al. Evaluation of real-time PCR and conventional diagnostic methods for the detection of *Clostridium difficile*-associated diarrhoea in a prospective multicentre study. *J Med Microbiol* 2007 Jan; 56(Pt 1):36-42.
164. Alcalá L, Marin M, Madrid M, et al. Comparison of ImmunoCard Toxins A&B and the new semiautomated Vidas *Clostridium difficile* Toxin A&B tests for diagnosis of *C. difficile* infection. *J Clin Microbiol* 2010 Mar; 48(3):1014-5.
165. Swindells J, Brenwald N, Reading N, et al. Evaluation of diagnostic tests for *Clostridium difficile* infection. *J Clin Microbiol* 2010 Feb; 48(2):606-8.
166. Vesta KS, Wells PG, Gentry CA, et al. Specific risk factors for *Clostridium difficile*-associated diarrhea: a prospective, multicenter, case control evaluation. *Am J Infect Control* 2005 Oct; 33(8):469-72.
167. Kyne L, Sougioultzis S, McFarland LV, et al. Underlying disease severity as a major risk factor for nosocomial *Clostridium difficile* diarrhea. *Infect Control Hosp Epidemiol* 2002 Nov; 23(11):653-9.
168. Mody LR, Smith SM, Dever LL. *Clostridium difficile*-associated diarrhea in a VA medical center: clustering of cases, association with antibiotic usage, and impact on HIV-infected patients. *Infect Control Hosp Epidemiol* 2001 Jan; 22(1):42-5.
169. Samore MH, Venkataraman L, DeGirolami PC, et al. Genotypic and phenotypic analysis of *Clostridium difficile* correlated with previous antibiotic exposure. *Microb Drug Resist* 2006; 12(1):23-8.
170. Schwaber MJ, Simhon A, Block C, et al. Factors associated with nosocomial diarrhea and *Clostridium difficile*-associated disease on the adult wards of an urban tertiary care hospital. *Eur J Clin Microbiol Infect Dis* 2000 Jan; 19(1):9-15.
171. Yearsley KA, Gilby LJ, Ramadas AV, et al. Proton pump inhibitor therapy is a risk factor for *Clostridium difficile*-associated diarrhoea. *Aliment Pharmacol Ther* 2006 Aug 15; 24(4):613-9.
172. Carling P, Fung T, Killion A, et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. *Infect Control Hosp Epidemiol* 2003 Sep; 24(9):699-706.
173. Climo MW, Israel DS, Wong ES, et al. Hospital-wide restriction of clindamycin: effect on the incidence of *Clostridium difficile*-associated diarrhea and cost. *Ann Intern Med* 1998 Jun 15; 128(12 Pt 1):989-95.
174. Khan R, Cheesbrough J. Impact of changes in antibiotic policy on *Clostridium difficile*-associated diarrhoea (CDAD) over a five-year period in a district general hospital. *J Hosp Infect* 2003 Jun; 54(2):104-8.
175. Otter JA, Puchowicz M, Ryan D, et al. Feasibility of routinely using hydrogen peroxide vapor to decontaminate rooms in a busy United States hospital. *Infect Control Hosp Epidemiol* 2009 Jun; 30(6):574-7.

176. Starr JM, Martin H, McCoubrey J, et al. Risk factors for *Clostridium difficile* colonisation and toxin production. *Age Ageing* 2003 Nov; 32(6):657-60.
177. Winston DJ, Lazarus HM, Beveridge RA, et al. Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. *Clin Infect Dis* 2001 Feb 1; 32(3):381-90.
178. Johnson S, Clabots CR, Linn FV, et al. Nosocomial *Clostridium difficile* colonisation and disease. *Lancet* 1990 Jul 14; 336(8707):97-100.
179. Mogg GA, Arabi Y, Youngs D, et al. Therapeutic trials of antibiotic associated colitis. *Scand J Infect Dis Supplement* 1980; (Suppl 22):41-5.
180. Proceedings of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sept 17–20; Chicago.
181. Zar F, Davis M. Reply to Bishara et al., Huggan et al., and Lawrence et al.. *Clin Infect Dis* 2007; 45(12):1649-51.
182. Lawrence SJ, Dubberke ER, Johnson S, et al. *Clostridium difficile*-associated disease treatment response depends on definition of cure. *Clin Infect Dis* 2007 Dec 15; 45(12):1648; author reply 9-51.
183. Huggan PJ, Murdoch DR. Vancomycin therapy for severe *Clostridium difficile*-associated diarrhea. *Clin Infect Dis* 2007 Dec 15; 45(12):1647-8; author reply 9-51.
184. Bishara J, Wattad M, Paul M. Vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea. *Clin Infect Dis* 2007 Dec 15; 45(12):1646-7; author reply 9-51.
185. Al-Nassir WN, Sethi AK, Li Y, et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of *Clostridium difficile*-associated disease. *Antimicrob Agents Chemother* 2008 Jul; 52(7):2403-6.
186. Lam S, Singer C, Tucci V, et al. The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study. *Am J Infect Control* 1995 Jun; 23(3):170-80.
187. de Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and *Clostridium difficile*-associated diarrhea. *Antimicrob Agents Chemother* 1992 Oct; 36(10):2192-6.
188. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhea by *Saccharomyces boulardii* compared with placebo. *Am J Gastroenterol* 1995 Mar; 90(3):439-48.
189. MacGregor G, Smith AJ, Thakker B, et al. Yoghurt biotherapy: contraindicated in immunosuppressed patients? *Postgrad Med J* 2002 Jun; 78(920):366-7.
190. Pakyz A. A case of recurrent *Clostridium difficile* diarrhea. *Consult Pharm* 2007 Mar; 22(3):249-53.
191. McDonald GB, Vracko R. Systemic absorption of oral cholestyramine. *Gastroenterol* 1984 Jul; 87(1):213-5.
192. Kunimoto D, Thomson AB. Recurrent *Clostridium difficile*-associated colitis responding to cholestyramine. *Digestion* 1986; 33(4):225-8.
193. Rohlke F, Surawicz C, Stollman N. Fecal flora reconstitution for recurrent *Clostridium difficile* infection: results and methodology. *J Clin Gastroenterol* 2010; 44(8):567-70.
194. Taylor CP, Tummala S, Molrine D, et al. Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to *Clostridium difficile* toxin A. *Vaccine* 2008 Jun 25; 26(27-28):3404-9.
195. McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent *Clostridium difficile* diarrhea. *Dis Colon Rectum* 2006 May; 49(5):640-5.
196. Hassoun A, Ibrahim F. Use of intravenous immunoglobulin for the treatment of severe *Clostridium difficile* colitis. *Am J Geriatr Pharmacother* 2007 Mar; 5(1):48-51.
197. Murphy C, Vernon M, Cullen M. Intravenous immunoglobulin for resistant *Clostridium difficile* infection. *Age Ageing* 2006 Jan; 35(1):85-6.

198. Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory *Clostridium difficile* infection. *Clin Infect Dis* 2009 Jun 15; 48(12):1732-5.
199. Sougioultzis S, Kyne L, Drudy D, et al. *Clostridium difficile* toxoid vaccine in recurrent *C. difficile*-associated diarrhea. *Gastroenterol* 2005 Mar; 128(3):764-70.
200. Seal D, Borriello SP, Barclay F, et al. Treatment of relapsing *Clostridium difficile* diarrhoea by administration of a non-toxigenic strain. *Eur J Clin Microbiol* 1987 Feb; 6(1):51-3.
201. Kimura Y, Sato K, Tokuda H, et al. Effects of combination therapy with direct hemoperfusion using polymyxin B-immobilized fiber and oral vancomycin on fulminant pseudomembranous colitis with septic shock. *Dig Dis Sci* 2007 Mar; 52(3):675-8.
202. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a *Clostridium difficile* toxoid vaccine administered to healthy adults. *Infect Immun* 2001 Feb; 69(2):988-95.
203. Tenover F, Novak-Weekley S, Woods C, et al. Impact of strain type on detection of toxigenic *Clostridium difficile*: comparison of molecular diagnostic and enzyme immunoassay approaches. *J Clin Microbiol* 2010; 48(10):3719-24.
204. Bettin K, Clabots C, Mathie P, et al. Effectiveness of liquid soap vs. chlorhexidine gluconate for the removal of *Clostridium difficile* from bare hands and gloved hands. *Infect Control Hosp Epidemiol* 1994 Nov; 15(11):697-702.
205. Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. *BMC Infect Dis* 2006; 6:130.
206. Kelly CP, LaMont JT. *Clostridium difficile*-more difficult than ever. *N Engl J Med* 2008 Oct 30; 359(18):1932-40.
207. Pillai A, Nelson R. Probiotics for treatment of *Clostridium difficile*-associated colitis in adults. *Cochrane Database Syst Rev* 2008; (1):CD004611.
208. Eddins C, Gray M. Are probiotic or synbiotic preparations effective for the management of *clostridium difficile*-associated or radiation-induced diarrhea? *J Wound Ostomy Continence Nurs* 2008 Jan-Feb; 35(1):50-8.
209. Segarra-Newnham M. Probiotics for *Clostridium difficile*-associated diarrhea: focus on *Lactobacillus rhamnosus* GG and *Saccharomyces boulardii*. *Ann Pharmacother* 2007 Jul; 41(7):1212-21.
210. Dendukuri N, Costa V, McGregor M, et al. Probiotic therapy for the prevention and treatment of *Clostridium difficile*-associated diarrhea: a systematic review. *CMAJ* 2005 Jul 19; 173(2):167-70.
211. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of *Clostridium difficile* disease. *Am J Gastroenterol* 2006 Apr; 101(4):812-22.
212. O'Horo J, Safdar N. The role of immunoglobulin for the treatment of *Clostridium difficile* infection: a systematic review. *Int J Infect Dis* 2009 Nov; 13(6):663-7.
213. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. *BMJ* 2008 May 17; 336(7653):1106-10.
214. Bakken JS. Resolution of recurrent *Clostridium difficile*-associated diarrhea using staggered antibiotic withdrawal and kefir. *Minn Med* 2009 Jul; 92(7):38-40.
215. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. *Nature* 2007 Oct 18; 449(7164):804-10.
216. Hattori M, Taylor TD. The human intestinal microbiome: a new frontier of human biology. *DNA Res* 2009 Feb; 16(1):1-12.
217. Merrigan MM, Sambol SP, Johnson S, et al. New approach to the management of *Clostridium difficile* infection: colonisation with non-toxigenic *C. difficile* during daily ampicillin or ceftriaxone administration. *Int J Antimicrob Agents* 2009 Mar; 33 Suppl 1:S46-50.

Abbreviations

AAD	Antibiotic-associated disease
AE	Adverse effects
AHRQ	Agency for Healthcare Research and Quality
AMED	Allied and Complementary Medicine
CDI	<i>Clostridium difficile</i> infection
CI	Confidence interval
GDH	Glutamate dehydrogenase enzyme
GI	Gastrointestinal
GRADE	Grading of Recommendations, Assessment, Development, and Evaluation
ICU	Intensive care unit
MeSH	Medical Subject Headings
MRSA	Methicillin-resistant <i>Staphylococcus aureus</i>
PCR	Polymerase chain reaction
RCT	Randomized controlled trial
RR	Relative risk
TEP	Technical expert panel
VRE	Vancomycin-resistant enterococci
WMD	Weighted mean differences

Glossary of Terms

CDI – *C. difficile* infection.

Colonization – *C. difficile* becomes established in the intestine. Technically, colonized individuals may or may not have CDI, since an individual with an infection is necessarily colonized by the organism. However, the term is often used in the literature to denote asymptomatic colonization.

False Negative Fraction – Fraction of tested stool specimens that had a positive reference test and a negative result for the diagnostic method being evaluated. The false negative fraction is equal to one minus the sensitivity.

False Positive Fraction – Fraction of tested stool specimens that had a negative reference test and a positive result for the diagnostic method being evaluated. The false positive fraction is equal to one minus the specificity.

Gene Detection Test – Methods of amplifying (replicating) specific parts of genetic material (DNA) in samples usually using the polymerase chain reaction (PCR) followed by detection of the highly replicated gene fragment.

Hypersporulation – Accelerated rate of spore production.

Hypervirulent – Strains of CDI that include increased toxin production, an additional binary toxin, hypersporulation, and high-level resistance to fluoroquinolone antibiotics.²⁷

Immunoassay – Test that is based on interactions between added animal antibodies against the specific substance to be detected, e.g. *C. difficile* toxins or glutamate dehydrogenase. Different tests use varying methods to isolate and detect the antibody/antigen complexes formed in the specimen being tested. Commonly referred to as enzyme immunoassay (EIA) in the literature.

Negative Predictive Value – Fraction of tested stool specimens that were negative for the diagnostic method being evaluated and negative on the reference test. Depends on the prevalence of toxigenic *C. difficile* in the tested specimens.

Nonstandard Therapy – Therapies other than treatment with antibiotics for CDI, such as probiotics, prebiotics, monoclonal antibodies, and fecal flora reconstitution.

Positive Predictive Value – Fraction of tested stool specimens that were positive for the diagnostic method being evaluated and positive on the reference test. Depends on the prevalence of toxigenic *C. difficile* in the tested specimens.

Prebiotics – Nondigestible foods that create environments healthy for bacteria growth.

Probiotics – Living microorganisms, including bacteria or yeast, which are believed to restore microbial balance to gastrointestinal flora when administered in adequate amounts.

Recurrent CDI – Recurrence of symptoms within 8 to 10 weeks after cessation of specific antibiotic therapy, with exclusion of other enteropathogens and a positive diagnostic test for toxigenic *C. difficile*.¹¹⁹

Sensitivity – Fraction of tested stool specimens that had a positive reference test and a positive result for the diagnostic method being evaluated. Sensitivity is also called the true positive fraction.

Severe CDI – Definitions vary in the literature, but generally refer to a CDI diagnosis in combination with more complex manifestations of disease or in patients with other significant risk-factors such as age, signs of infections, or comorbidities.

Specificity – Fraction of tested stool specimens that had a negative reference test and a negative result for the diagnostic method being evaluated. Specificity is also called the true negative fraction.

Appendix A. Technical Expert Panel Members and Affiliation

Marcel Salive, M.D., M.P.H.	Division of Medical and Surgical Services Centers for Medicare and Medicaid Services Baltimore, Maryland
Erik Dubberke, M.D., SHEA	School of Medicine Washington University St. Louis, Missouri
Christina Surawicz, M.D.	Professor of Medicine University of Washington School of Medicine Seattle, Washington
Dale Gerding, M.D.	Associate Chief of Staff Hines VA Hospital Hines, Illinois
Michael Wilson, M.D.	Department of Pathology & Laboratory Services Denver Health Medical Center Denver, Colorado

Appendix B. Search Strategies

Search string for C Difficile (general)

Database: Ovid MEDLINE

Search Strategy:

- 1 difficile.mp.
- 2 limit 1 to (english language and humans)
- 3 limit 2 to ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)")
- 4 randomized controlled trial.pt.
- 5 controlled clinical trial.pt.
- 6 randomized.ab.
- 7 placebo.ab.
- 8 drug therapy.fs.
- 9 randomly.ab.
- 10 trial.ab.
- 11 groups.ab.
- 12 or/4-11
- 13 (animals not (humans and animals)).sh.
- 14 12 not 13
- 15 3 and 14
- 16 limit 15 to (addresses or bibliography or biography or dictionary or directory or duplicate publication or editorial or interview or introductory journal article or lectures or legal cases or legislation or letter or news or newspaper article or patient education handout or portraits)
- 17 15 not 16
- 18 Cohort studies/ or comparative study/ or follow-up studies/ or prospective studies/ or risk factors/ or cohort.mp. or compared.mp. or groups.mp. or multivariate.mp.
- 19 limit 18 to (comment or editorial or historical article or interview or letter)
- 20 18 not 19
- 21 3 and 20
- 22 17 or 21

Search string for C Difficile (Diagnostic)

Database: Ovid MEDLINE

Search Strategy:

- 1 difficile.mp.
- 2 diagnostic accuracy.mp.
- 3 (enzyme adj2 immunoassay\$.mp.
- 4 Immunoenzyme techniques/
- 5 enzyme linked immunosorbent assay/
- 6 feces/
- 7 faeces analysis.mp.
- 8 fecal.mp.
- 9 stool culture.mp.
- 10 exp "Sensitivity and Specificity"/
- 11 cytotoxicity test, immunologic/
- 12 cell cytotoxicity assay.mp.
- 13 pcr.mp. or polymerase chain reaction/
- 14 immunochromatography.mp.
- 15 or/2-14
- 16 1 and 15

- 17 limit 16 to (english language and humans and ("young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)"))
- 18 limit 17 to (addresses or bibliography or biography or dictionary or directory or duplicate publication or editorial or interactive tutorial or interview or introductory journal article or lectures or legal cases or legislation or letter or news or newspaper article or patient education handout or portraits)
- 19 limit 17 to in vitro
- 20 17 not (18 or 19)

Appendix C. Evidence Tables

Appendix Table C1.	Summary of matched comparisons of select assays for <i>C. difficile</i> toxins.....	C-2
Appendix Table C2.	Grade of evidence for comparisons of diagnostic tests for toxigenic <i>C. difficile</i>	C-7
Appendix Table C3.	Description of studies evaluating risk factors for CDI	C-9
Appendix Table C4.	Evidence table for standard antibiotic treatments.....	C-13
Appendix Table C5.	Assessment of study quality of individual metronidazole trials	C-21
Appendix Table C6.	Assessment of study quality of individual vancomycin trials.....	C-22
Appendix Table C7.	Summary of strength of evidence for CDI—Key Question 3c: Vancomycin studies	C-23
Appendix Table C8.	Summary of strength of evidence for CDI—Key Question 3c: Metronidazole studies	C-24
Appendix Table C9.	Assessment of study quality of individual nonstandard treatment trials	C-25
Appendix Table C10.	Summary of evidence for CDI—Key Question 4	C-26
Appendix Table C11.	Case studies/series and potential harms of nonstandard interventions for CDI	C-27
Appendix Table C12.	Reviews and meta-analyses	C-35
References for Appendix Tables		C-38

Appendix Table C1. Summary of matched comparisons of select† assays for *C. difficile* toxins

Study	Patients/ Site	Tested Specimens	Reference Standard/ % Positive in Sample	Tests Compared	True Positive/ False Positive‡	PPV/ NPV
Swindells 2010 ¹	n=? Patients over 65 yrs old who developed diarrhea at least 48 hrs after admission Birmingham City Hospital, UK ?spectrum ?selection	n=150 fresh liquid stool specimens stored < 48 hrs at 2-8 ° C ; Independent, blinded operators; No tests were repeated	Toxigenic culture using CTA on cultured organisms 12.0%	GeneOhm <i>C.</i> <i>difficile</i> (tcdB), Becton Dickinson GeneXpert <i>C. difficile</i> (tcdB), Cepheid VIDAS <i>C. difficile</i> Tox A/B, bioMerieux	17/18=94.4% 1/132=0.8% 18/18=100% 1/132=0.8% 8/18=44.4% 0/132=0%	17/18=94.4% 131/132=99.2% 18/19=94.7% 131/131=100% 8/8=100% 132/142=93.0%
Kvach, 2010 ²	n=341 in hospital with suspected CDI; Yale-New Haven Hospital, CT ?spectrum ?selection	n=400 fresh liquid or semisolid that were either GDH positive or negative; Some frozen at -20° C for < week after two-step GDH/CTA to do other tests; Excluded if patient being treated for CDI or retested within 7 days; ?blinded	If not all positive or negative on 3 tests, then toxigenic culture using Premier Toxin A/B test of cultured organisms 26.2%	GeneOhm <i>C.</i> <i>difficile</i> (tcdB), Becton Dickinson Tox A/B II, Techlab	96/105=91.4% 0/295=0% 70/105=66.7% 1/295=0.3%	96/96=100% 295/304=97.0% 70/71=98.6% 294/329=89.4%
Alcala 2010 ³	n=412 ?suspected CDI Madrid, Spain ?spectrum ?selection	n= 487 ?fresh ?consistency ?blinded equivocal results were called negative	CTA followed by toxigenic culture if negative 12.7%	Premier ImmunoCard Toxins A&B, Meridian VIDAS <i>C. difficile</i> Tox A/B, bioMerieux	42/62=67.7% 21/425=4.9% 43/62=69.4% 8/425=1.9%	42/63=66.7% 404/424=95.3% 43/51=84.3% 417/436=95.6%

Appendix Table C1. Summary of matched comparisons of select† assays for *C. difficile* toxins (continued)

Study	Patients/ Site	Tested Specimens	Reference Standard/ % Positive in Sample	Tests Compared	True Positive/ False Positive‡	PPV/ NPV
Eastwood, 2009 ⁴	?n CDI suspected with some previously diagnosed CDI; Leeds Teaching Hospitals, London, UK ?spectrum ?selection	n=600 only 558 for GeneOhm test; fresh, unformed refrigerated except for GeneOHm that were frozen at -20° C for < 8 months; ?blinded;	CTA of specimen and cultured organisms when stool CTA was negative 20.8%	GeneOhm <i>C. difficile</i> (tcdB), Becton Dickinson Premier Toxin A&B, Meridian Premier ImmunoCard Toxins A&B, Meridian Tox A/B II, Techlab Tox A/B Quik Chek, Techlab ProSpecT Toxin A/B, Remel Xpect Toxin A/B, Remel VIDAS <i>C. difficile</i> Tox A/B	92/103=89.3% 16/449=3.6% 101/125=80.8% 12/475=2.5% 86/115=74.8% 2/444=0.4% 100/125=80.0% 19/475=4.0% 93/125=74.4% 3/473=0.6% 102/125=81.6% 32/475=6.7% 86/117=73.5% 3/475=0.6% 100/116=86.2% 2/464=0.4%	92/108=85.2% 433/444=97.5% 101/113=89.4% 463/487=95.1% 86/88=97.7% 442/471=93.8% 100/119=84.0% 456/481=94.8% 93/96=96.9% 470/502=93.6% 102/134=76.1% 443/466=92.9% 86/89=96.6% 472/503=93.8% 100/102=98.0% 462/478=96.6%
Novak-Weekley, 2009 ⁵	n = 432 suspected CDI; patients under 2 years old excluded; Southern CA Permanente Medical Labs; ?spectrum ?selection	n = 432 ?fresh Unformed, refrigerated; ?blinded;	Toxigenic culture using CTA on cultured organisms 16.7%	GeneXpert <i>C. difficile</i> (tcdB), Cepheid Premier Toxins A&B, Meridian 1 st <i>C. difficile</i> CHEK- 60 (GDH), Techlab; if positive, then Premier Toxins A&B	68/72=94.4% 13/356=3.7% 42/72=58.3% 19/360=5.3% 40/72=55.6% 6/360=1.7%	68/81=84.0% 343/347=98.8% 42/61=68.9% 341/371=91.9% 40/46=87.0% 354/386=91.7%

Appendix Table C1. Summary of matched comparisons of select† assays for *C. difficile* toxins (continued)

Study	Patients/ Site	Tested Specimens	Reference Standard/ % Positive in Sample	Tests Compared	True Positive/ False Positive‡	PPV/ NPV
Alcala, 2008 ⁶	n=305 mixture of suspected CDI and positive samples by CTA; Hospital General Universitario Gregorio Maranon, Madrid, Spain ?spectrum ?selection	n=367 fresh refrigerated; ?consistency ?blinded ?indeterminate results	CTA of specimen and cultured organisms when direct CTA was negative 27.8%	ImmunoCard Toxins A&B, Meridian Xpect <i>C. diff.</i> toxin A/B, Remel TOX A/B QUIK CHEK, Techlab	68/102=66.7% 13/265=4.9% 50/102=49.0% 11/265=4.2% 56/102=54.9% 12/265=4.5%	68/81=83.9% 252/265=88.1% 50/61=81.9% 254/306=83.0% 56/68=82.4% 253/299=84.6%
Miendje Deyi, 2008 ⁷	n=91 Age 65-99 avg. 81 yrs; suspected CDI; 2 university hospitals in Brussels, Belgium; 1 hospital had recent outbreak of <i>C. difficile</i> ; ?spectrum ?selection	n=100 frozen at -70° C; ?consistency tested blindly on same day in same lab ?indeterminate results	CTA 23.0%	ImmunoCard Toxins A&B, Meridian Xpect <i>C. diff.</i> toxin A/B, Remel TOX A/B QUIK CHEK, Techlab	21/23=91.3% 0/77=0% 21/23=91.3% 0/77=0% 22/23=95.7% 0/77=0%	21/21=100% 77/79=97.5% 21/21=100% 77/79=97.5% 22/22=100% 77/78=98.7%
Samra, 2008 ⁸	n=200 hospitalized patients with diarrhea; Rabin Medical Center, Israel ?spectrum ?selection	n= 200 fresh or refrigerated diarrhea; randomly selected from positive and negative results; ?blinded ?indeterminate results	In-house PCR for toxin B gene 47.0%	Tox A/B II, Techlab Tox A/B Quik Chek, Techlab Immunocard Toxin A&B, Meridian	88/94=93.6% 6/106=5.7% 89/94=94.7% 3/106=2.8% 89/94=94.7% 3/106=2.8%	88/94=93.6% 100/106=94.3% 89/92=96.7% 103/108=95.4% 89/92=96.7% 103/108=95.4%

Appendix Table C1. Summary of matched comparisons of select† assays for *C. difficile* toxins (continued)

Study	Patients/ Site	Tested Specimens	Reference Standard/ % Positive in Sample	Tests Compared	True Positive/ False Positive‡	PPV/ NPV
Sloan, 2008 ⁹	n=200 suspected CDI; Mayo Clinic, Rochester, MN ?spectrum ?selection	n=200 soft or liquid; fresh or frozen < 48 hrs. ?blinded; ?indeterminate results	Toxigenic culture using toxin A and B gene detection for cultured organisms 22.0%	Premier Toxin A&B, Meridian ImmunoCard Toxin A&B, Meridian Xpect <i>C. diff.</i> toxin A/B, Remel	21/44=47.7% 3/156=1.9% 21/44=47.7% 2/156=1.3% 21/44=47.7% 25/156=16.0%	21/24=87.5% 153/176=86.9% 21/23=91.3% 154/177=87.0% 21/46=45.6% 131/154=85.1%
Musher, 2007 ¹⁰	?n inpatients suspected CDI; Michael E. DeBakey VA Medical Center, Houston, TX ?spectrum ?selection	n=446 ?fresh ?consistency ?blinded ?indeterminate results <i>Part 2</i> n=131 Convenience sample; Fresh; ?consistency ?blinded ?indeterminate results	CTA 17.0% CTA 41.2%	Premier Toxin A&B, Meridian ImmunoCard Toxin A & B, Meridian ----- Premier Toxin A&B, Meridian C. difficile TOX A/B II, TechLab ProSpecT Clostridium difficile toxin A/B, Remel	75/76=98.7% 10/370=2.7% 73/76=96.1% 4/370=1.1% ----- 52/54=96.3% 5/77=6.5% 52/54=96.3% 10/77=13.0% 49/54=90.7% 2/77=2.6%	75/85=88.2% 360/361=99.7% 73/77=94.8% 366/369=99.2% ----- 52/57=91.2% 72/74=97.3% 52/62=83.9% 67/69=97.1% 49/51=96.1% 75/80=93.8%
van den Berg, 2007 ¹¹	n=450 all with diarrhea, some suspected CDI others not but inpatients for at least 72 hours; from 4 medical centers in The Netherlands; ?spectrum ?selection	n=547 diarrhea frozen at - 20° C; ?blinded	CTA 5.7%	Premier Toxins A&B, Meridian VIDAS <i>C. difficile</i> Tox A II, bioMerieux Vitek	30/31=96.8% 29/509=5.7% 26/31=83.8% 15/509=2.9%	30/59=50.8% 480/481=99.8% 26/41=63.4% 494/499=99.0%

Appendix Table C1. Summary of matched comparisons of select† assays for *C. difficile* toxins (continued)

Study	Patients/ Site	Tested Specimens	Reference Standard/ % Positive in Sample	Tests Compared	True Positive/ False Positive‡	PPV/ NPV
Turgeon, 2003 ¹²	n=1003 Consecutive samples, all suspected CDI; Childrens, university & cancer centers in Seattle, WA; 45% stem cell transplant patients ?spectrum ?selection	n=1003 any consistency; fresh for CTA, rest frozen at -20° C; ?interim time ?blinded ?indeterminate results	CTA 10.1%	Premier Cytoclone A/B, Meridian <i>C. diff</i> Tox A/B, Techlab	74/101=73.3% 8/898=0.9% 78/101=77.2% 5/902=0.6%	74/82=90.2% 890/917=97.1% 78/83=94.0% 897/902=99.4%
O'Connor, 2001 ¹³	n=133 Adults, consecutive samples, CDI suspected; Multiple health centers in Galway County area of Ireland ?spectrum ?selection	n=200 92% liquid or unformed; -20° C for CTA, then frozen at 84° C; ?blinded	CTA 30.5%	Premier Toxins A&B, Meridian <i>C. diff</i> Tox A/B II, Techlab	50/61=82.0% 1/139=0.7% 49/61=80.3% 1/139=0.7%	50/51=98.0% 138/149=92.6% 49/50=98.0% 138/150=92.0%

CDI = *C. difficile* infection; CTA = cytotoxicity assay using cultured test cells, true + is sensitivity/false + is 1 – specificity; PPV/NPV = positive/negative predictive value based on prevalence of *C. difficile* in tested sample; GDH = glutamate dehydrogenase.

? Indicates issues identified by the quality assessment of diagnostic accuracy studies (QUADAS) criteria.

‡ Varying numbers of indeterminate results are excluded from estimates of true and false positives when possible, thus denominators are not constant for all methods compared within a study.

† Presumably available and used in the United States, and at least one comparator is an immunoassay for toxins A and B.

Appendix Table C2. Grade of evidence for comparisons of diagnostic tests for toxigenic *C. difficile*

Comparison	Difference in Sensitivity (True Positives)		Difference in False Positives (1 – Specificity)	
	Ratings†	Overall Evidence Grade	Ratings†	Overall Evidence Grade
<i>Immunoassays for Toxins A & B</i>				
Premier Toxin A&B, Meridian Tox A/B II, TechLab	Consistent, Imprecise	Low	Inconsistent, Precise	Low
Tox A/B QUIK CHEK, TechLab ImmunoCard A&B, Meridian	Consistent, Imprecise	Low	Consistent, Precise	Moderate
Premier Toxin A&B, Meridian ImmunoCard A&B, Meridian	Consistent, Imprecise	Low	Consistent, Precise	Moderate
Tox A/B QUIK CHEK, TechLab Xpect Toxin A/B, Remel	Consistent, Imprecise	Low	Consistent, Precise	Moderate
Tox A/B QUIK CHEK, TechLab Tox A/B II, TechLab	Consistent, Imprecise	Low	Consistent, Imprecise	Low
Premier Toxin A&B, Meridian ProSpecT Toxin A/B, Remel	Consistent, Imprecise	Low	Inconsistent, Imprecise	Low
Premier Toxin A&B, Meridian Xpect Toxin A/B, Remel	Consistent, Imprecise	Low	Inconsistent, Imprecise	Low
Tox A/B II, TechLab ImmunoCard A&B, Meridian	Consistent, Imprecise	Low	Consistent, Imprecise	Low
Premier Toxin A&B, Meridian <i>C. diff</i> Tox A/B, VIDAS	Inconsistent Imprecise	Low	Consistent Precise	Moderate
Premier Toxin A&B, Meridian Tox A/B QUIK CHEK, TechLab	Single study, Imprecise	Low	Single study, Precise	Low
Tox A/B QUIK CHEK, TechLab ProSpecT Toxin A/B, Remel	Single study, Imprecise	Low	Single study, Imprecise	Low
Tox A/B QUIK CHEK, TechLab <i>C. diff</i> Tox A/B, VIDAS	Single study, Imprecise	Low	Single study, Precise	Low
Xpect Toxin A/B, Remel ProSpecT Toxin A/B, Remel	Single study, Imprecise	Low	Single study, Imprecise	Low
Xpect Toxin A/B, Remel <i>C. diff</i> Tox A/B, VIDAS	Single study, Imprecise	Low	Single study, Precise	Low
ProSpecT Toxin A/B, Remel <i>C. diff</i> Tox A/B, VIDAS	Single study, Imprecise	Low	Single study, Imprecise	Low
ImmunoCard A&B, Meridian <i>C. diff</i> Tox A/B, VIDAS	Single study Imprecise	Low	Single study, Imprecise	Low
<i>Gene Detection Tests vs. Immunoassays for Toxins A & B</i>				
GeneOhm, Becton Dickinson Tox A/B II, TechLab	Inconsistent, Imprecise	Low	Consistent, Precise	Moderate
GeneOhm, Becton Dickinson <i>C. diff</i> Tox A/B, VIDAS	Inconsistent, Imprecise	Low	Inconsistent, Imprecise	Low
GeneOhm, Becton Dickinson Premier Toxin A&B, Meridian	Single study, Imprecise	Low	Single study, Imprecise	Low
GeneOhm, Becton Dickinson ImmunoCard A&B, Meridian	Single study, Imprecise	Low	Single study, Imprecise	Low
GeneOhm, Becton Dickinson Tox A/B QUIK CHEK, TechLab	Single study, Imprecise	Low	Single study, Imprecise	Low
GeneOhm, Becton Dickinson ProSpecT Toxin A/B, Remel	Single study, Imprecise	Low	Single study, Imprecise	Low
GeneOhm, Becton Dickinson Xpect Toxin A/B, Remel	Single study, Imprecise	Low	Single study, Imprecise	Low

Appendix Table C2. Grade of evidence for comparisons of diagnostic tests for toxigenic *C. difficile* (continued)

Comparison	Difference in Sensitivity (True Positives)		Difference in False Positives (1 – Specificity)	
	Ratings†	Overall Evidence Grade	Ratings†	Overall Evidence Grade
GeneXpert, Cepheid Premier Toxin A&B, Meridian	Single study, Imprecise	Low	Single study, Imprecise	Low
GeneXpert, Cepheid 2-Stage test using CHEK-60 for GDH, then if positive Premier Toxin A&B, Meridian	Single study, Imprecise	Low	Single study, Imprecise	Low

† Consistency refers to the variation between estimates from different studies. Precision refers to the width of the overall confidence interval. The risk of bias was considered to be low for all comparisons. All the evidence is only indirectly related to clinical decisions and the effect of differences on patient health outcomes is not known.

Appendix Table C3. Description of studies evaluating risk factors for CDI

Study/Origin	Study Type	Objective	Population	Methods	Results
Peled, 2007 ¹⁴ Israel	Prospective cohort study	Compare the clinical characteristics of patients who developed CDI versus patients with a negative stool assay for <i>C. difficile</i> toxin	217 patients with ADD. <i>C. difficile</i> toxin positive (n=52): n=52; mean age 72 years; Male-female ratio 1:26 <i>C. difficile</i> toxin negative (n=165): mean age 66 (p=0.21 vs. toxin pos.); Male-female ratio 1:11	Diarrhea was defined as the passage of ≥3 unformed stools for ≥2 consecutive days. Toxin assay: enzyme immunoassay for <i>C. difficile</i> toxin A/B (TechLab). Analysis (controlling for confounding): Stepwise logistic regression	Significant factors for CDI: watery diarrhea (OR=17.1, p=0.000), functional capacity score of 2 or 3 (requiring assistance in daily activities or bedridden) (OR=9.14, p=0.000), use of a proton pump inhibitor (OR=6.1, p=0.024), hypoalbuminemia (OR=3.8, p=0.001), histamine blocker (OR=3.1, p=0.024) leukocytosis (OR=2.7, p=0.004). Stepwise logistic regression analysis predicted a positive result for <i>C. difficile</i> toxin with 95% specificity and 68% sensitivity.
Samore, 2006 ¹⁵ United States	Prospective case series	Analyze <i>C. difficile</i> susceptibility results and genotypes in relation to antibiotic exposures that precipitated CDI	83 patients with nosocomial CDI. Mean age 66 years; female 43% Median length of stay before onset of CDI was 10 days (range, 2–95). <i>C. difficile</i> isolates were recovered from patients in 10 different hospital wards and 3 intensive care units. The wards with the largest number of cases were vascular surgery (n=15) and general surgery/liver transplantation (n =14).	Prospective surveillance and collection of stool isolates. Isolates were genotyped by pulsed-field gel electrophoresis and restriction enzyme analysis. Analysis: multivariable logistic regression	Clindamycin exposure was strongly associated with CDI caused by isolates that exhibited multiple resistance to clindamycin, erythromycin, and trovafloxacin (prevalence OR 4.2; 95%CI: 1.1 to 16.8)

Appendix Table C3. Description of studies evaluating risk factors for CDI (continued)

Study/ Origin	Study Type	Objective	Population	Methods	Results
Yearsley, 2006 ¹⁶ United Kingdom	Prospective case-control	Association between acid suppression therapy and risk of CDI	<p>N=308 hospital inpatients. CDI group (n=155): Mean age 79 years (range 37– 102); Female 61% Received antibiotics: 92% Received PPI: 40% Received acid suppression: 41%</p> <p>Control group (n=153): Mean age 79 years (range 43–99); female 55% Received antibiotics: 50%, p<001 (vs. case) Received PPI: 25%, p=0.004 Received acid suppression: 26%, p=0.005</p>	<p>Cases with CDI were mostly were recruited from general medical wards. Control was chosen as a person on the same ward whose birthday was closest to that of the index patient.</p> <p>Analysis: Logistic regression</p>	<p>CDI was independently associated with: antibiotic use (OR 13.1, 95%CI: 6.6 to 26.1); acid suppression therapy (OR 1.90, 95%CI: 1.10 to 3.29); and female gender (OR 1.79, 95%CI: 1.06 to 3.04).</p>
Vesta, 2005 ¹⁷ United States	Prospective observational case control, multicenter, study	Risk factors associated with the development of nosocomial CDI, particularly with the use of antibiotics	<p>144 hospitalized patients with diarrhea requiring a <i>C. difficile</i> toxin test as part of their routine clinical workup, Cases (n=72) Mean age 56 years; Female 43%</p> <p>Controls (n=72) Mean age 56 years; Female 43%</p>	<p>Case patients had nosocomial diarrhea and positive <i>C. difficile</i> toxin tests. Control were patients with stool negative for <i>C. difficile</i> toxin and were individually matched with cases based on hospital, sex, age (within 4 years), and duration of hospital stay up to the time of stool sampling (within 4 days).</p> <p>Analysis: multivariate logistic regression analysis to identify independent risk factors for the development of CDI (not performed)</p>	<p>There were no significant differences in antibiotic use between cases and controls. Patient severity, classified by Horn's Index, was significantly different between cases and controls (p=0.0022).</p>

Appendix Table C3. Description of studies evaluating risk factors for CDI (continued)

Study/Origin	Study Type	Objective	Population	Methods	Results
Kyne, 2002 ¹⁸ United States	Prospective cohort series	Determine the diagnostic accuracy of an index of underlying disease severity (Horn's index) in identifying patients with a high probability of having nosocomial CDI as a complication of antimicrobial therapy	252 inpatients and receiving antibiotics. Mean age 74 years; female 60%; Disease severity (Horn's index) 1 (mild) 30% (n=76) 2 (moderate) 37% (n=93) 3 (severe) 22% (n=55) 4 (extremely severe) 11% (n=28) 28 (11%) of the patients had CDI	CDI defined as diarrhea (≥ 3 unformed stools for ≥ 2 days) not attributed to any other cause that occurred in association with a positive stool test for <i>C. difficile</i> . Horn's index as a measure of the severity of underlying disease at the time of admission to the hospital, rated as follows: mild=1; moderate =2 (more severe disease but uncomplicated recovery expected); severe (major illness or complications or multiple conditions requiring treatment) =3; extremely severe (catastrophic illness that may lead to death) =4. Analysis: stepwise multivariable logistic regression	Extremely severe underlying disease was associated with CDI (OR 17.6 95%CI: 5.8 to 53.5). Sensitivity, specificity, and positive and negative predictive values of a Horn's index score of 3 or more (severe to extremely severe disease) as a predictor of nosocomial <i>C. difficile</i> diarrhea were 79%, 73%, 27%, and 96%, respectively.
Mody, 2001 ¹⁹ United States	Prospective case control	Evaluate risk factors and clustering of CDI cases over 2 years	252 patients from a Veterans Affairs Medical Center with unformed stools and positive stool <i>C. difficile</i> cytotoxin assays over the 24-month period; 98 patients served as control. No information on age. 45 cases (17.8%) and 19 controls (19.4%) were HIV-infected.	Cases were patients with CDI. Controls were patients with unformed stools and <i>C. difficile</i> negative toxin test. Stools for cytotoxin assays were frozen and sent on ice to a reference laboratory. Analysis: logistic regression	Third-generation cephalosporins were the antibiotics most strongly associated with CDI (OR 3.63 95%CI 1.56 to 9.80). The association of third-generation cephalosporin use was particularly striking in HIV-infected patients (p=0.0004 when HIV status was included in the model). 34 (76%) of 45 HIV-infected patients with CDI died during their hospitalization.

Appendix Table C3. Description of studies evaluating risk factors for CDI (continued)

Study/Origin	Study Type	Objective	Population	Methods	Results
Schwaber, 2000 ²⁰ Israel	Prospective case control	Determine factors associated with the development of nosocomial diarrhea and the acquisition of CDI	136 hospital inpatients, 98 with nosocomial diarrhea and 38 controls. 59.9 ±17.5 years, whereas that of the controls was 56.3 ±19.9 years <i>Clostridium difficile</i> toxin B was identified in the stool of 13 cases.	Diarrhea defined as ≥3 loose or watery stools in a 24 h, lasting for ≥ 3 days, beginning ≥ 2 days after admission. Toxin assay: cell-culture cytotoxin test in a culture of human fibroblasts. Analysis: No multivariate analyses reported.	Factors associated with the presence of <i>C. difficile</i> toxin B as compared to other causes of nosocomial diarrhea were: greater number of individual antibiotics used during hospitalization (p=0.02); cephalosporin use (p=0.03), more specifically, a third generation cephalosporin (p=0.02). Among patients with nosocomial diarrhea, those who <i>C. difficile</i> toxin positive had a significantly higher total antibiotic burden (as antibiotic days) than those with diarrhea due to other causes (p=0.01).
Katz, 1997 ²¹ United States	Prospective case series	Develop predictors for diagnosis of CDAD	609 adult inpatients tested for <i>C. difficile</i> cytotoxin <i>C. difficile</i> toxin positive (n=49) Mean age 58 years; Female 57% <i>C. difficile</i> toxin negative (n=49) Mean age 58 Female 57%	Relevant clinical symptoms, signs, and antibiotic exposure were recorded before reporting of assay results. Toxin assay: procedure by Chang Analysis: logistic regression	Potential contributing causes of diarrhea (toxin+ vs. toxin-) Antibiotic use past 30 days: 98% vs. 84% (p=0.009) Cephalosporin use: 73% vs. 49% (p=0.001) Antibiotic use prior to admission/transfer: 51% vs. 32% (p=0.009) Antacid use: 20% vs. 10%, p=0.04. Prior antibiotic use and significant diarrhea were significantly greater in <i>C. difficile</i> toxin positive patients.

ADD = antibiotic-associated diarrhea; ASA = American Society of Anesthesiologists; CDI = *C. difficile* infection; HIV = Human immunodeficiency virus; OR = odds ratio; PPI = proton pump inhibitor

Appendix Table C4. Evidence table for standard antibiotic treatments

Study / Region / Funding Source	Population / Age or Age Range / % Women / Ethnicity / Inclusion Criteria	Sample Size (N) / Intervention(s) / Control (s) / Study Duration	Outcomes Evaluated	Study Quality
1. Newly Identified Trials				
<p>Louie 2011²²</p> <p>Region: Canada and USA</p> <p>Funding source: Industry</p> <p>The first draft of the manuscript was written by one of the authors who is a part-time employee of the study sponsor, Optimer Pharmaceuticals</p>	<p>Population: Adults with acute symptoms of CDI and a positive result on a stool toxin test</p> <p>Mean age: 62 % women: 56</p> <p>Inclusion criteria: 16 years of age or older with a diagnosis of CDI, defined by the presence of diarrhea (a change in bowel habits, with >3 unformed bowel movements in the 24-hour period before randomization) and <i>C. difficile</i> toxin A, B, or both in a stool specimen obtained within 48 hours before randomization.</p>	<p>N=629</p> <p>Intervention 1: Fidaxomicin 200 mg 2 times/day (n=302)</p> <p>Intervention 2: Vancomycin 125 mg 4 times/day (n=327)</p> <p>Treatment duration: 10 days Followup period: 30 days</p>	<p>a. Clinical cure, defined by the resolution of diarrhea (i.e., three or fewer unformed stools for 2 consecutive days), with maintenance of resolution for the duration of therapy and no further requirement (in the investigator's opinion) for therapy for CDI as of the second day after the end of the course of therapy.</p> <p>b. Clinical recurrence, defined by the reappearance of more than three diarrheal stools per 24-hour period within 4 weeks after the cessation of therapy; <i>C. difficile</i> toxin A or B, or both, in stool; and a need for retreatment for CDI</p> <p>c. Median time to resolution of diarrhea</p> <p>d. All-cause mortality</p> <p>e. Adverse events</p>	<p>Allocation concealment: adequate</p> <p>Blinding: double</p> <p>Intention-to-treat analysis: modified (subjects withdrawing before treatment, had ≤3 bowel motions in 24 hours, or tested negative for <i>C. difficile</i> toxin were excluded)</p> <p>Withdrawals and dropouts reported: yes</p>

Appendix Table C4. Evidence table for standard antibiotic treatments (continued)

Study / Region / Funding Source	Population / Age or Age Range / % Women / Ethnicity / Inclusion Criteria	Sample Size (N) / Intervention(s) / Control (s) / Study Duration	Outcomes Evaluated	Study Quality
<p>Musher, 2009²³</p> <p>Region: USA</p> <p>Funding source: Department of Veterans Affairs</p>	<p>Population: Mild or severe symptomatic inpatient adults with comorbid conditions</p> <p>Mean age: 63 % women: 35 Ethnicity: White 69%; black 31% (45% in nitazoxanide group, 19% in vancomycin group)</p> <p>Inclusion criteria: EIA results positive for <i>C. difficile</i> toxin (Premier Toxins A & B; Meridian Bioscience), ≥3 loose stools within 24 h and ≥1 of the following additional findings: fever (temperature, 138.37C), abdominal pain, and/or leukocytosis</p> <p>Severity: patients with ≥2 points were considered to have severe CDI based on an assessment score developed for this study. One point each was given for age ≥60 years, >7 stools/day, temperature >38.3 C, albumin level <2.5 mg/dL, or peripheral WBC count >15,000 cells/mm³</p>	<p>N=50 (severe 41%, n=20)</p> <p>Intervention 1: Vancomycin 125 mg 4 times/day (n=27)</p> <p>Intervention 2: Nitazoxanide 500 mg 2 times/day + placebo pill (n=23)</p> <p>Treatment duration: 10 days Followup period: 21 days</p>	<p>a. End-of-treatment response (cure), # of patients (defined as complete resolution of all symptoms and signs attributable to CDI during the 3 days after completion of therapy)</p> <p>b. Relapse, # of patients (defined as a return of symptoms after an initial response but within 31 days after the onset of treatment with <i>C. difficile</i> toxin detected in stool by EIA or patient was re-treated empirically for CDI and responded to treatment.</p> <p>c. All-cause mortality</p> <p>d. Adverse events</p>	<p>Allocation concealment: adequate (sequentially numbered identical packages)</p> <p>Blinding: double</p> <p>Intention-to-treat analysis (all subjects randomized included in the analyses): partially, one subject was found to have IBD (an exclusion criteria) and was removed</p> <p>Withdrawals and dropouts reported: 9 (18%)</p>

Appendix Table C4. Evidence table for standard antibiotic treatments (continued)

Study / Region / Funding Source	Population / Age or Age Range / % Women / Ethnicity / Inclusion Criteria	Sample Size (N) / Intervention(s) / Control (s) / Study Duration	Outcomes Evaluated	Study Quality
<p>Zar, 2007²⁴</p> <p>Region: USA</p> <p>Funding source: none stated</p>	<p>Population: Mild or severe symptomatic inpatient adults with comorbid conditions</p> <p>Mean age: 58 (47% <60 years) % women: 45</p> <p>Inclusion criteria: <i>Clostridium difficile</i>-associated diarrhea (CDI), testing positive for <i>C. difficile</i> cytotoxin</p> <p>Severity: patients with ≥2 points were considered to have severe CDI based on an assessment score developed for this study. One point each was given for age >60 years, temperature >38.3 C, albumin level <2.5 mg/dL, or peripheral WBC count >15,000 cells/mm³ within 48 h of enrollment. Two points were given for endoscopic evidence of pseudo-membranous colitis or treatment in the intensive care. All patients had received antimicrobial treatment prior to onset of CDI (>90% within 14 days)</p>	<p>N=172 (mild 54%, severe 46% based on 150 patients completing trial)</p> <p>Intervention 1: Vancomycin (liquid) 125 mg 4 times/day + placebo pill (n=82)</p> <p>Intervention 2: Metronidazole (oral) 250 mg 4 times/day plus placebo liquid (n=90)</p> <p>Treatment duration: 10 days Followup period: 21 days</p>	<p>a. Cure, # of patients (defined as resolution of diarrhea by day 6 of treatment and a negative result of a <i>C. difficile</i> toxin A assay at days 6 and 10 of treatment)</p> <p>b. Relapse, # of patients (defined as recurrence of <i>C. difficile</i> toxin A-positive diarrhea by day 21 after initial cure)</p> <p>c. All-cause mortality</p>	<p>Allocation concealment: adequate (controlled by pharmacy)</p> <p>Blinding: double</p> <p>Intention-to-treat analysis: no, completers only</p> <p>Withdrawals and dropouts reported: 22 (13%)</p>

Appendix Table C4. Evidence table for standard antibiotic treatments (continued)

Study / Region / Funding Source	Population / Age or Age Range / % Women / Ethnicity / Inclusion Criteria	Sample Size (N) / Intervention(s) / Control (s) / Study Duration	Outcomes Evaluated	Study Quality
2. Trials Included in Cochrane Systematic Review²⁴				
<p>Lagrotteria, 2006²⁶</p> <p>Region: Canada</p> <p>Funding source: The Physicians' Services Incorporated Foundation</p>	<p>Population: Symptomatic adults (95% inpatients and 5% outpatients)</p> <p>Mean age: 69 years women: 59%</p> <p>Inclusion criteria: diagnosis of CDI on the basis of the Society for Healthcare Epidemiology of America definition, laboratory confirmation of the presence of <i>C. difficile</i> toxins A and B using an enzyme immunoassay, and no other etiology for diarrhea</p>	<p>N=39</p> <p>Intervention 1: Metronidazole 500 mg 3 times/day (n=20)</p> <p>Intervention 2: Metronidazole 500 mg 3 times/day and rifampin 300 mg 2 times/day (n=19)</p> <p>Treatment duration: 10 days Followup period: 30 days</p>	<p>a. Clinical improvement (cure) at study day 10, # (%) of patients (defined as becoming asymptomatic during the treatment course. Failure defined as persistent symptoms and signs after 10 days of antimicrobial therapy)</p> <p>b. Experienced relapse by study day 40, # (%) of patients (defined as recurrence of diarrhea in the followup period for those patients who initially experienced a clinical cure)</p> <p>c. Laboratory-confirmed relapse by study day 40, # of patients</p> <p>d. Time to clinical improvement (days)</p> <p>e. Time to relapse (days)</p> <p>f. All-cause mortality</p> <p>g. Adverse events</p>	<p>Allocation concealment: unclear (numbered packages)</p> <p>Blinding: single (study staff)</p> <p>Intention-to-treat analysis: yes</p> <p>Withdrawals and dropouts reported: 7 (18%)</p>

Appendix Table C4. Evidence table for standard antibiotic treatments (continued)

Study / Region / Funding Source	Population / Age or Age Range / % Women / Ethnicity / Inclusion Criteria	Sample Size (N) / Intervention(s) / Control (s) / Study Duration	Outcomes Evaluated	Study Quality
<p>Musher, 2006²⁷</p> <p>Region: USA</p> <p>Funding source: Romark Pharmaceuticals</p>	<p>Population: Symptomatic adults, a substantial proportion had severe, comorbid conditions</p> <p>Mean age: 68 women: 24% Ethnicity: White 77%; black 17%; Hispanic 6%</p> <p>Inclusion criteria: inpatients >18 years of age with diarrhea (defined as ≥ 3 unformed stools within a 24-h period), an enzyme immunoassay result positive for <i>C. difficile</i> toxin, and ≥ 1 of the following findings: fever, abdominal pain, or leukocytosis</p>	<p>N=142</p> <p>Intervention 1: Metronidazole 250 mg 4 times/day (n=44)</p> <p>Intervention 2: Nitazoxanide 500 mg 2 times/day for 7 days (n=49)</p> <p>Intervention 3: Nitazoxanide 500 mg 2 times/day (n=49)</p> <p>Treatment duration: 10 days unless noted Followup period: 31 days</p>	<p>a. Response to therapy, assessed 3 ways: (1) time to resolution of symptoms of colitis; (2) complete clinical response at the end of 7 days of treatment, defined as return of normal stool pattern and absence of fever, abdominal pain, or leukocytosis, unless some other explanation was apparent; and (3) sustained clinical response 31 days after the beginning of treatment</p> <p>b. All-cause mortality</p> <p>c. Adverse events</p>	<p>Allocation concealment: not defined</p> <p>Blinding: double</p> <p>Intention-to-treat analysis: no</p> <p>Withdrawals and dropouts reported: 32 (23%)</p>
<p>Wullt, 2004²⁸ Noren 2006²⁹</p> <p>Region: Sweden</p> <p>Funding source: Region Skåne and the Scandinavian Society of Antimicrobial Chemotherapy, and Leo Pharma AB</p>	<p>Population: Symptomatic adult inpatients (51%) or outpatients (49%) on enrollment</p> <p>Mean age: 59 % women: 39</p> <p>Inclusion criteria: age >18 years, lack of hypersensitivity to fusidic acid or metronidazole, a positive <i>C. difficile</i> toxin assay from feces within 6 days before enrolment, and a history of ongoing diarrhea (diarrhea defined as three or more loose stools per day for at least 2 days)</p>	<p>N=131</p> <p>Intervention 1: Metronidazole 400 mg 3 times/day (n=64)</p> <p>Intervention 2: Fusidic acid 250 mg 3 times/day (n=67)</p> <p>Treatment duration: 7 days Followup period: 33 days</p>	<p>a. Clinical cure (defined as cessation of diarrhea within 5–8 days of initiating treatment, and clinical failure as persistence of diarrhea on days 5–8)</p> <p>b. Clinical recurrence, defined as the reappearance of diarrhea on days 8–40 in clinically cured patients who had completed 7 days of treatment</p> <p>c. Adverse events</p>	<p>Allocation concealment: adequate (coded containers of identical appearance)</p> <p>Blinding: double</p> <p>Intention-to-treat analysis: no</p> <p>Withdrawals and dropouts reported: 17 (13%)</p>

Appendix Table C4. Evidence table for standard antibiotic treatments (continued)

Study / Region / Funding Source	Population / Age or Age Range / % Women / Ethnicity / Inclusion Criteria	Sample Size (N) / Intervention(s) / Control (s) / Study Duration	Outcomes Evaluated	Study Quality
<p>Wenisch, 1996³⁰</p> <p>Region: Austria</p> <p>Funding source: none stated</p>	<p>Population: Symptomatic adults hospitalized for a minimum of 5 days</p> <p>Mean age: 42 % women: 48</p> <p>Inclusion criteria: age of >18 years and the presence of CDI. Diarrhea was defined as >3 loose stools per day. CDI was diagnosed on the basis of the results of a <i>C. difficile</i> toxin assay and/or endoscopic evidence of typical colitis, with the finding of granulocytes in stools</p>	<p>N=126</p> <p>Intervention 1: Metronidazole 500 mg 3 times/day (n=31)</p> <p>Intervention 2: Fusidic acid 500 mg 3 times/day (n=29)</p> <p>Intervention 3: Vancomycin 500 mg 3 times/day (n=31)</p> <p>Intervention 4: Teicoplanin (injection) 400 mg 2 times/day (n=28)</p> <p>Treatment duration: 10 days Followup period: 30 days</p>	<p>a. Clinical cure, # of patients (defined as no loose stools, gastro-intestinal symptoms, or fever and normalization of serum levels of C-reactive protein and leukocyte counts)</p> <p>b. Clinical failure (defined as persistence of diarrhea after 6 days of treatment)</p> <p>c. Clinical relapse (defined as the reappearance of CDI and other symptoms during the followup period)</p> <p>d. Adverse events</p>	<p>Allocation concealment: not defined</p> <p>Blinding: none stated, teicoplanin administered as an injection, the other drugs orally</p> <p>Intention-to-treat analysis: no</p> <p>Withdrawals and dropouts reported: 7 (6%)</p>
<p>de Lalla, 1992³¹</p> <p>Region: Italy</p> <p>Funding source: none stated</p>	<p>Population: Symptomatic adult inpatients</p> <p>Mean age (range): 47 (18 to 83) % women: 70</p> <p>Inclusion criteria: age of >18 years, presence of symptoms (diarrhea, sometimes combined with fever and abdominal pain), and stool culture and/or a rapid diagnostic test positive for <i>C difficile</i> and/or colonoscopic demonstration of the typical endoscopic picture of pseudomembranous colitis</p>	<p>N=51</p> <p>Intervention 1: Vancomycin 500 mg 4 times/day (n=24)</p> <p>Intervention 2: Teicoplanin 100 mg 2 times/day (n=27)</p> <p>Study duration: 10 days Followup period: 30 days</p>	<p>a. Cure, # of patients (defined as elimination of symptoms and signs were)</p> <p>b. Failure, # patients (defined persistence of diarrhea after 6 days of treatment)</p> <p>c. Relapse (defined as reappearance of diarrhea and other symptoms in the 1-month followup period)</p> <p>d. All-cause mortality</p> <p>e. Adverse events</p>	<p>Allocation concealment: not defined</p> <p>Blinding: none stated</p> <p>Intention-to-treat analysis: no</p> <p>Withdrawals and dropouts reported: 5 (10%)</p>

Appendix Table C4. Evidence table for standard antibiotic treatments (continued)

Study / Region / Funding Source	Population / Age or Age Range / % Women / Ethnicity / Inclusion Criteria	Sample Size (N) / Intervention(s) / Control (s) / Study Duration	Outcomes Evaluated	Study Quality
<p>Fekety, 1989³²</p> <p>Region: USA</p> <p>Funding source: NIH and Upjohn Company</p>	<p>Population: Moderately or severely ill symptomatic inpatients adults (plus one infant)</p> <p>Mean age/range: 54 (1 to 76) % women: gender not reported</p> <p>Inclusion criteria: antibiotic associated diarrhea plus at least one stool specimen that demonstrated both <i>C difficile</i> and its cytotoxin. All patients were moderately or severely ill, or unresponsive to supportive therapy (patients with mild illness as judged physicians were treated supportively, and not entered into the study)</p>	<p>N=56</p> <p>Intervention 1: Vancomycin 500 mg 4 times/day (n=22)</p> <p>Intervention 2: Vancomycin 125 mg 4 times/day (n=24)</p> <p>Study duration: 10 days</p> <p>Followup period: up to 6 weeks after treatment</p>	<p>a. Treatment response (cure) based diarrhea resolution (defined as patients stating their bowel function is normal, or when they were having ≤ 3 movements a day and their stools were semiformal) Patients whose diarrhea ceased within 7 days after treatment were considered to have a good response; patients whose diarrhea ceased but after 7 days of treatment were considered simply to have responded</p> <p>b. Mean duration of symptoms, days</p> <p>c. Adverse events</p>	<p>Allocation concealment: not defined</p> <p>Blinding: physicians were blinded to treatment assignment</p> <p>Intention-to-treat analysis: no</p> <p>Withdrawals and dropouts reported: 10 (18%)</p>
<p>Dudley, 1986³³</p> <p>Region: USA</p> <p>Funding source: Upjohn Company</p>	<p>Population: Symptomatic adult inpatients</p> <p>Mean age: 69 % women: 60 (evaluable subjects (n=30) only for age and gender)</p> <p>Inclusion criteria: antibiotic associated diarrhea (≥ 4 loose stools were passed for ≥ 2 consecutive days, signs and symptoms of <i>C difficile</i>-induced diarrhea and its cytotoxin</p>	<p>N=62</p> <p>Intervention 1: Vancomycin 500 mg 4 times/day (n=31)</p> <p>Intervention 2: Bacitracin 25,000 mg 4 times/day (n=31)</p> <p>Study duration: 10 days</p> <p>Followup period: up to 60 days</p>	<p>a. Treatment response (cure) based diarrhea resolution (defined as ≤ 4 loose stools were passed for ≥ 2 consecutive days)</p> <p>b. Treatment failure (defined as diarrhea and other symptoms worsened and were crossed over to the alternative drug in a blinded manner. Patients worsening after 5 days of the crossed over therapy were considered failures and removed from the study)</p> <p>c. All-cause mortality</p> <p>d. Adverse events</p>	<p>Allocation concealment: adequate (coded amber bottles prepared by pharmacy)</p> <p>Blinding: double</p> <p>Intention-to-treat analysis: no</p> <p>Withdrawals and dropouts reported: 32 (52%)</p>

Appendix Table C4. Evidence table for standard antibiotic treatments (continued)

Study / Region / Funding Source	Population / Age or Age Range / % Women / Ethnicity / Inclusion Criteria	Sample Size (N) / Intervention(s) / Control (s) / Study Duration	Outcomes Evaluated	Study Quality
<p>Young, 1985³⁴</p> <p>Region: Australia</p> <p>Funding source: Upjohn Company and the McGauran Trust</p>	<p>Population: Symptomatic adult inpatients</p> <p>Mean age: 62 (gender not reported)</p> <p>Inclusion criteria: antibiotic associated diarrhea (≥ 4 loose stools were passed for ≥ 2 consecutive days, signs and symptoms of <i>C difficile</i>-induced diarrhea and its cytotoxin</p>	<p>N=42</p> <p>Intervention 1: Vancomycin 125 mg 4 times/day (n=21)</p> <p>Intervention 2: Bacitracin 20,000 mg 4 times/day (n=21)</p> <p>Study duration: 7 days</p> <p>Followup period: 28 days</p>	<p>a. Treatment response (cure) based diarrhea resolution (defined as < 3 times/day by the time the last capsule was given. Day of resolution defined as first day of < 3 stools, provide frequency did not go above > 2)</p> <p>b. Treatment relapse</p> <p>c. Mean days to 50% improvement</p>	<p>Allocation concealment: adequate (identical red capsules and sealed codes held in pharmacy)</p> <p>Blinding: double</p> <p>Intention-to-treat analysis: yes for initial therapy</p> <p>Withdrawals and dropouts reported: all completed initial treatment</p>
<p>Teasley, 1983³⁵</p> <p>Region: USA</p> <p>Funding source: Veterans Affairs and Searle Laboratories</p>	<p>Population: Symptomatic inpatient adults</p> <p>Mean age: 65 % women: 1</p> <p>Inclusion criteria: <i>C difficile</i>-associated diarrhea and its cytotoxin. All patients had received antimicrobial treatment 14-55 days prior to diarrhea</p>	<p>N=101</p> <p>Intervention 1: Vancomycin 500 mg 4 times/day (n=56)</p> <p>Intervention 2: Metronidazole 250 mg 4 times/day (n=45)</p> <p>Study duration: 10 days</p> <p>Followup period: 21 days</p>	<p>a. Cure (defined as diarrhea resolved within 6 days of treatment, toleration of complete treatment course, and no relapse in the 21-day followup period)</p> <p>b. Treatment response based diarrhea resolution (defined as < 2 stools formed /day)</p> <p>c. Treatment failure (defined as ≤ 4 loose stools/day after 6 days of treatment.</p> <p>d. Treatment relapse (defined as recurrence with 21 days of diarrhea with ≤ 4 loose stools/day for a minimum of 2 days)</p>	<p>Allocation concealment: not defined</p> <p>Blinding: none stated</p> <p>Intention-to-treat analysis: no</p> <p>Withdrawals and dropouts reported: 7 (7%)</p>

Appendix Table C4. Evidence table for standard antibiotic treatments (continued)

Study / Region / Funding Source	Population / Age or Age Range / % Women / Ethnicity / Inclusion Criteria	Sample Size (N) / Intervention(s) / Control (s) / Study Duration	Outcomes Evaluated	Study Quality
<p>Keighley, 1978³⁶</p> <p>Region: UK</p> <p>Funding source: none stated</p>	<p>Population: Symptomatic adult inpatients. Subjects with evidence of cytotoxins separated with from subjects with <i>C difficile</i> on culture</p> <p>Age and gender not reported</p> <p>Inclusion criteria: postoperative diarrhea (≥3 loose stools/day or colostomy output >1 liter/day. All patients had received antimicrobial treatment prior to diarrhea</p>	<p>N=44</p> <p>Intervention: Vancomycin 125 mg 4 times/day (n=22)</p> <p>Control: Placebo (n=22)</p> <p>Study duration: 5 days</p> <p>Followup period: unclear, up to 29 days in the control group</p>	<p>a. Treatment response based diarrhea resolution (defined as normal stool, improved, same, or worse. Normal was defined as 1 solid stool/day, the others were not described)</p> <p>b. Adverse events</p>	<p>Allocation concealment: adequate (identical looking placebo and based code held in pharmacy)</p> <p>Blinding: unclear if double (“identical looking placebo”)</p> <p>Intention-to-treat analysis: yes</p> <p>Withdrawals and dropouts reported: all completed initial treatment</p>

Appendix Table C5. Assessment of study quality of individual metronidazole trials

Study	Allocation Concealment	Blinding	Intention-to-Treat Analysis	Withdrawals and Dropouts Reported	Study Quality Good, Fair, or Poor
<i>Versus Vancomycin</i>					
Zar 2007 ²⁴ (n=172), subset with severe disease (46% based on 150 completing trial)	Adequate	Double	Completers only	22 (13%)	Fair
Wenisch 1996 ³⁰ (n=62)	Not defined	None stated	No	7 (6%)*	Poor
Teasley 1983 ³⁵ (n=101)	Not defined	None stated	No	7 (7%)	Poor
<i>Versus Nitazoxanide</i>					
Musher 2006 ²⁷ (n=142)	Not defined	Double	No	32 (23%)	Poor
<i>Versus Metronidazole Plus Rifampin</i>					
Lagrotteria ²⁶ (n=39)	Unclear (numbered packages but no further detail)	Single (study staff)	Yes	7 (18%)	Fair

* Based on all subjects, 4-arm trial.

Appendix Table C6. Assessment of study quality of individual vancomycin trials

Study	Allocation Concealment	Blinding	Intention-to-Treat Analysis	Withdrawals and Dropouts Reported	Study Quality Good, Fair, or Poor
<i>Versus Metronidazole</i>					
Zar, 2007 ²⁴ (n=172), subset with severe disease (46% based on 150 completing trial)	Adequate	Double	No, completers only	22 (13%)	Fair
Wenisch, 1996 ³⁰ (n=62)	Not defined	None stated	No	7 (6%)*	Poor
Teasley, 1983 ³⁵ (n=101)	Not defined	None stated	No	7 (7%)	Poor
<i>Versus Nitazoxanide</i>					
Musher, 2009 ²³ (n=50), subset of 20 with severe disease	Adequate	Double	Partially, one subject removed	9 (18%)	Good
<i>Versus Fidaxomicin</i>					
Louie, 2011 ²³	Adequate	Double	Partially	33 (5%)	Good
<i>Versus Bacitracin</i>					
Dudley, 1986 ³³ (n=62)	Adequate	Double	No	32 (52%)	Fair
Young, 1985 ³⁴ (n=42)	Adequate	Double	Yes for initial therapy	None	Good
<i>Versus Placebo</i>					
Keighley, 1978 ³⁶ (n=44)	Adequate	Unclear ("identical placebo")	Yes	All completed initial treatment	Good

* Based on all subjects, 4-arm trial.

Appendix Table C7. Summary of strength of evidence for CDI—Key Question 3c: vancomycin studies

Key Question, # Studies (# Participants)	Study Design	Risk of Bias	Consistency	Directness	Precision	Overall Grade/ Conclusion
<i>Versus Metronidazole</i>						
Initial clinical cure; 3 (335)	RCT	High	Consistent	Direct	Imprecise	Low
Clinical recurrence; 3 (283)	RCT	High	Consistent	Direct	Imprecise	Low
Initial clinical cure, severe disease; 1 (69)	RCT	Medium	Unknown	Direct	Precise	Low
Clinical recurrence, severe disease; 1 (59)	RCT	Medium	Unknown	Direct	Imprecise	Insufficient
<i>Versus Nitazoxanide</i>						
Initial clinical cure; 1 (50)	RCT	Low	Unknown	Direct	Imprecise	Low
Clinical recurrence; 1 (37)	RCT	Low	Unknown	Direct	Imprecise	Low
Initial clinical cure, severe disease; 1 (20)	RCT	Low	Unknown	Direct	Imprecise	Insufficient
Clinical recurrence, severe disease; 1 (15)	RCT	Low	Unknown	Direct	Imprecise	Insufficient
<i>Versus Fidaxomicin</i>						
Initial clinical cure; 1 (629)	RCT	Low	Unknown	Direct	Precise	Moderate
Clinical recurrence; 1 (518)	RCT	Low	Unknown	Direct	Precise	Moderate
<i>Versus Bacitracin</i>						
Initial clinical cure; 2 (81)	RCT	Low	Consistent	Direct	Imprecise	Low
Clinical recurrence; 2 (37)	RCT	Low	Consistent	Direct	Imprecise	Low
<i>Versus Placebo</i>						
Initial clinical cure; 1 (21)	RCT	Low	Unknown	Direct	Precise	Moderate

RCT = randomized controlled trial

Appendix Table C8. Summary of strength of evidence for CDI—Key Question 3c: metronidazole studies

Key Question, # Studies (# Participants)	Study Design	Risk of Bias	Consistency	Directness	Precision	Overall Grade/ Conclusion
<i>Versus Vancomycin</i>						
Initial clinical cure; 3 (335)	RCT	High	Consistent	Direct	Imprecise	Low
Clinical recurrence; 3 (283)	RCT	High	Consistent	Direct	Imprecise	Low
Initial clinical cure, severe disease; 1 (69)	RCT	Medium	Unknown	Direct	Precise	Low
Clinical recurrence, severe disease; 1 (59)	RCT	Medium	Unknown	Direct	Imprecise	Insufficient
<i>Versus Nitazoxanide</i>						
Initial clinical cure; 1 (142)	RCT	High	Unknown	Direct	Imprecise	Low
Clinical recurrence; 1 (97)	RCT	High	Unknown	Direct	Imprecise	Low
<i>Versus Metronidazole Plus Rifampin</i>						
Initial clinical cure; 1 (142)	RCT	Medium	Unknown	Direct	Imprecise	Low
Clinical recurrence; 1 (97)	RCT	Medium	Unknown	Direct	Imprecise	Low

RCT = randomized controlled trial

Appendix Table C9. Assessment of study quality of individual nonstandard treatment trials

Study	Allocation Concealment	Blinding	Intention-to-Treat Analysis	Withdrawals and Dropouts Adequately Described	Study Quality <i>Good, Fair or Poor</i>
<i>Adjuvant Probiotics (With Standard Therapy) Versus Placebo (With Standard Therapy)</i>					
Wullt, 2003 ³⁷ (n=29)	Not defined	Double	No	Yes	Fair
Surawicz, 2000 ³⁸ (n=168, 32 with recurrent CDI)	Adequate	Double	Yes	Yes (none reported)	Good
McFarland, 1994 ³⁹ (n=124)	Adequate	Double	Yes	Yes	Good
<i>C. difficile Immune Whey Versus Active Control (Metronidazole)</i>					
Mattila, 2008 ⁴⁰ (n=40)	Not defined	Double	No	Yes	Fair
<i>Absorptive Resin Versus Active Placebo</i>					
Mogg, 1982 ⁴¹ (n=48)	Possibly adequate	None stated	No	Yes	Fair

CDI = Clostridium difficile infection

Appendix Table C10. Summary of evidence for CDI—Key Question 4

Key Question, # Studies (# Participants)	Study Design	Risk of Bias	Consistency	Directness	Precision	Overall Grade/ Conclusion
<i>Probiotics and Prebiotics (Adjuvant to Standard Care) Versus Placebo and Standard Care</i>						
Resolution of CDI; 3 (185*)	RCT	Low	Consistent	Direct	Imprecise	Low
Prevention of CDI; 8 (1756)	RCT	Low	Consistent	Direct	Imprecise	Low
Prevention of recurrence of CDI; 3 (339)	RCT	Medium	Consistent	Direct	Imprecise	Low
<i>Monoclonal Antibodies (Adjuvant to Standard Care) Versus Placebo and Standard Care</i>						
Prevention of recurrence of CDI; 1 (200)	RCT	Medium	Unknown	Direct	Imprecise	Low
Resolution of CDI; 1 (n=40)	RCT	Medium	Unknown	Direct	Imprecise	Low
<i>Colestipol (an Absorptive Resin) Versus Placebo</i>						
Resolution of CDI; 1 (n=48)	RCT	Medium	Unknown	Direct	Imprecise	Low

CDI = C. difficile infection; RCT = randomized controlled trial

* Includes only patients with C. difficile positive stools. Some trials, particularly the prevention studies, enrolled patients who were negative for C. difficile.

Appendix Table C11. Case studies/series and potential harms of nonstandard interventions for CDI

Study/ Study Focus	Subject/Study Details	Interventions	Clinical Diarrhea Outcomes	CD Toxin, CD Culture, or Other	Adverse Effects (AE) Harms
McDonald, 1984 ⁴² Treatment	Male, age 76 years Tx for diarrhea and PSC per sigmoidoscopy	Cholestyramine (toxin absorbing resin) 12 grams(g)/day (d)orally	PMC resolved at autopsy	CD toxin + stools for 1 month after symptomatic relief CD culture + stools for 1 month	Cholestyramine particles in arterial and venous vessel walls at autopsy Ulcerated esophagus was likely portal
Kunimoto, 1986 ⁴³ Treatment for recurrent CDI	Female, age 38 years with PMC and CD cytotoxin and 4 recurrences of symptoms after vancomycin and metronidazole	Cholestyramine 12 day/orally x 12 months.	"Rapid symptoms relief"		Not reported
Kimura, 2007 ⁴⁴ Treatment	2 men, age 71 and 54 years with PMC by colonoscopy, CD toxin A and septic shock	IV "hemoperfusion" agent: Vancomycin (2 g/d) orally + polymixin B- immobilized fiber 80- 100 mg/d IV x 7-14 days		CD toxin became negative after 7 days PMC resolved after 7 days	Not reported
Tvede, 1989 ⁴⁵ Treatment for chronic relapsing CDI	6 patients with chronic relapsing CDI 1 male and 5 females, age 6-72 years 6 previously treated with vancomycin, 1 treated with cholestyramine and vancomycin and 5 were treated with metronidazole also	Fecal flora reconstitution: enema of fresh feces from a healthy relative 1 patient Enema of mixture of 10 strains of bacteria: <i>E.</i> <i>coli</i> (1109 & 1108-1), <i>Cl</i> <i>innocuum</i> , <i>Cl ramosum</i> , <i>Bact. Ovatus</i> , <i>Bact.</i> <i>vulgatus</i> , <i>Cl</i> <i>bifermentans</i> , <i>Bact.</i> <i>Thetaiotaomicron</i> , <i>Peptostreptococcus</i> <i>productus</i> , <i>Cl bifermentans</i>		All had stools negative for CD toxin after enema and at 1 yr followup All had stools negative for CD culture after enema and at 1 yr followup	Not reported

Appendix Table C11. Case studies/series and potential harms of nonstandard interventions for CDI (continued)

Study/ Study Focus	Subject/Study Details	Interventions	Clinical Diarrhea Outcomes	CD Toxin, CD Culture, or Other	Adverse Effects (AE) Harms
Persky 2000 ⁴⁶ Treatment for recurrent CDI	Female, age 60 years who failed vancomycin treatment of CDI	Fecal flora reconstitution: enema of fresh feces from a healthy relative 1 patient	Diarrhea resolved	Stools negative for CD toxin	Not reported
Macconnachie, 2009 ⁴⁷ Treatment for recurrent CDI	15 patients with recurrent CDI which was defined as relapse of loose stool following antibiotic treatment for CD toxin positive stool 14 females, age = 81.5 (68-95) years (median [range]) 11 were inpatients and 4 were newly readmitted after recent discharge; all had several comorbidities and were seriously ill Retrospective chart review	Fecal flora reconstitution: Stool from healthy relatives administered by nasogastric tube Donors were administered a proton pump inhibitor and oral vancomycin (125 mg 4 times/d) up to 12 hours prior to reconstitution	11 (73%) with diarrhea were symptom free of diarrhea at followup and 4 had a relapse of diarrhea Followup was at 16 (4– 24) weeks (median [range])		Reported as none
Rohlke, 2010 ⁴⁸ Treatment for recurrent CDI	19 patients with recurrent CDI defined as CD toxin positivity and symptoms after at least 3 courses of antibiotic treatment 17 females, mean age = 49 years	Fecal flora reconstitution: Stool from healthy relatives, partners, or housemates administered via colonoscopy	18 (95%) became free of symptoms after initial treatment for 6–60 mos. 3 (17%) redeveloped symptoms after 6–48 mos.		Not reported

Appendix Table C11. Case studies/series and potential harms of nonstandard interventions for CDI (continued)

Study/ Study Focus	Subject/Study Details	Interventions	Clinical Diarrhea Outcomes	CD Toxin, CD Culture, or Other	Adverse Effects (AE) Harms
<p>Yoon, 2010⁴⁹</p> <p>Treatment for recurrent or refractory CDI</p>	<p>12 patients with refractory or recurrent CDI Defined as having diarrhea and symptoms of cramps and fever and a history of a positive CD toxin assay despite treatment with antibiotics</p> <p>9 females; age = 66 (30–68) years (mean (range))</p> <p>Retrospective chart review</p>	<p>Fecal flora reconstitution: Stool from healthy relatives or friend administered via colonoscopy</p>	<p>12 (100%) had cessation of diarrhea and other symptoms within 3–5 days. Follow-up ranged 3 wks to 8 years. No relapse reported.</p>		<p>Reported as none</p>
<p>Silverman, 2010⁵⁰</p> <p>Treatment for recurrent CDI</p>	<p>7 patients recurrent CDI defined as with diarrhea after a positive stool toxin test and antibiotic treatment</p> <p>50% females, age range = 30–88 years; all lived at home after developing CDI in hospital</p> <p>Patients were treated with a standard antibiotic and probiotic (<i>S. boulardii</i>) up to 24–48 hours before procedure</p>	<p>Fecal flora reconstitution: Donor stools from relatives were infused by low-volume enema by self or family member</p>	<p>7 (100%) were free of diarrhea for up to 14 mos. followup</p>		<p>One patient developed infectious irritable bowel symptoms (alternating constipation and diarrhea) but <i>C. difficile</i> toxin test was negative</p>

Appendix Table C11. Case studies/series and potential harms of nonstandard interventions for CDI (continued)

Study/ Study Focus	Subject/Study Details	Interventions	Clinical Diarrhea Outcomes	CD Toxin, CD Culture, or Other	Adverse Effects (AE) Harms
MacGregor, 2002 ⁵¹ Treatment	Female, age 42 years with multiple health problems then respiratory failure and critically ill Developed CDI, toxin positive Failed metronidazole switched to vancomycin and yogurt added	Probiotic: yogurt with live cultures (supermarket brand) + vancomycin			<i>S. pneumoniae</i> and secondary <i>L. rhamnosus</i> septicemia and death
Pakyz, 2007 ⁵² Treatment for recurrent CDI	Female, age 87 years with recurrent diarrhea and <i>C. difficile</i> antigen in stool	Probiotic: lacinex (lactobacillus) 1 g orally 3x/day + Metronidazole	Loose watery stools continued for 5 days	CD antigen in stools remained even with symptomatic relief on vancomycin. Switched to oral vancomycin with symptomatic relief	Not reported
Munoz, 2005 ⁵³ Treatment	Case studies + Retrospective chart review of ICU pts + review of 57 patients literature review. 3 ICU patients 3 ICU patients (females in 70s) with <i>S. cerevisiae</i> fungemia Charts of 41 (with 14 ICU) patients over 1 month of fungemia outbreak were reviewed	Probiotic: 3 cases were treated with Ultralevura for CDI 2/41 patients without fungemia received probiotic		Probiotic cultures grew heavy yeast (>1 million cfu/ml) Mortality: 28% (17/60)	60 patients total with fungemia, 28/47 (60%) in ICU, 26 (46%) were treated with the probiotic

Appendix Table C11. Case studies/series and potential harms of nonstandard interventions for CDI (continued)

Study/ Study Focus	Subject/Study Details	Interventions	Clinical Diarrhea Outcomes	CD Toxin, CD Culture, or Other	Adverse Effects (AE) Harms
Seal, 1987 ⁵⁴ Treatment	2 patients, age 88 and 76 years, with CDI toxin positive, who failed antibiotic treatment.	Nontoxigenic strain of <i>C. difficile</i> (M-1) previously shown to protect hamsters One ml was suspended in 50 ml of milk to yield ~10 ⁷ CFU of <i>C. difficile</i> /ml. Given as a single oral dose on 3 successive days.	Symptoms decreased in 2 patients and CD toxin was (1) eventually 1 patient had a relapse of CD toxin and diarrhea x 2d 17 d after improvement		Constipation in 1 patient
Taylor, 2008 ⁵⁵ Phase 2 safety study	30 subjects, mean age 27.5 years (range 20-53) 33% male 5 cohorts of 6 subjects each	Monoclonal antibody to CD toxin A (CDAI)			No serious AEs possibly, probably or definitely associated to CDI 3 moderate severity AEs (low BP, diarrhea) 18 mild severity (headache, nausea, loose stools, abdominal discomfort, BP changes)
Herpers, 2009 ⁵⁶ Treatment for severe refractory CDI	4 patients with diarrhea, positive <i>C. difficile</i> toxin stool and pseudomembranes as well as septic or hypovolemic shock and other serious health problems 2 males, 59 and 36 years old and 2 females, 36 and 82 years old	Intravenous tigecycline 100 mg x 1 dose then 50 mg twice/day for 7-24 days 3 patients were treated with standard antibiotics along with tigecycline		Clinical signs (e.g., diarrhea) improved within 7 d <i>C. difficile</i> toxin became negative in 3 patients within 7 d and after continued oral vancomycin in 1 patient in 2 weeks No recurrence was reported in 3 weeks	

Appendix Table C11. Case studies/series and potential harms of nonstandard interventions for CDI (continued)

Study/ Study Focus	Subject/Study Details	Interventions	Clinical Diarrhea Outcomes	CD Toxin, CD Culture, or Other	Adverse Effects (AE) Harms
<p>Sougioultzis, 2005⁵⁷</p> <p>Treatment CD Vaccine</p>	<p>Subject 1: Male, age 51 years Subject 2: Female, age 71 years Subject 3: Female, age 33 years</p> <p>All had ≥3 unformed bowel movements per day for ≥2 days, associated with a positive stool toxin test for <i>C. difficile</i> (either tissue culture cytotoxin assay or toxin A or B enzyme immunoassay) that occurred within 30 days of discontinuation of therapy with metronidazole or oral vancomycin that had been administered for treatment of a prior episode of CDI</p>	<p><i>C difficile</i> toxoid vaccine form purified toxins A and B, injected IM at the deltoid region on 4 occasions, on days 0, 7, 28, and 56.</p>		<p>Subjects discontinued treatment with oral vancomycin after their fourth and final inoculation with the <i>C difficile</i> toxoid vaccine</p> <p>One of the 3 subjects did not show increase in serum antitoxin antibodies or serum toxin neutralizing activity</p>	<p>No AE that were definitely or probably related to vaccination. Adverse events that were possibly related to vaccination included a mild headache (subject 1) and mild abdominal pain (subject 2). Subject 2 also reported transient polyarthralgia after the fourth inoculation and later developed atypical polyarthritits with a normal erythrocyte sedimentation rate, a negative rheumatoid factor test, and slightly elevated C-reactive protein.</p> <p>Approximately 2 months after completion of the study, a clinical diagnosis of polymyalgia rheumatica was made by a rheumatologist</p>

Appendix Table C11. Case studies/series and potential harms of nonstandard interventions for CDI (continued)

Study/ Study Focus	Subject/Study Details	Interventions	Clinical Diarrhea Outcomes	CD Toxin, CD Culture, or Other	Adverse Effects (AE) Harms
Kotloff, 2001 ⁵⁸ Randomized, double-blind, Phase 1 study of CD vaccine	30 healthy adults (no ages reported)	Vaccine, 6.25, 25 or 100 mg given IM Five subjects at each dose level received soluble toxoid vaccine, and five subjects received an equivalent dose of toxoid adsorbed to alum.			No serious adverse events during the study: rash = 8 (subjects); abdominal pain = 6; athralgia = 2; diarrhea = 2 All subjects had local pain at injection site, especially those who received toxoid adsorbed to alum, pruritus (without urticaria) at the site of injection n = 6
McPherson, 2006 ⁵⁹ Treatment for recurrent or refractory CDI	14 patients with diarrhea and <i>C. difficile</i> toxin positive stools despite standard antibiotics Age = 79 (54–91) years (median [range])	Intravenous immunoglobulin (IVIG) 150–400 mg/kg x 1-2 doses	9 /14 (64%) resolved diarrhea 3/9 surviving had a recurrence		Reported as none
Murphy 2006 ⁶⁰ Treatment for recurrent CDI	1 female age 57 years with recurrent and refractory diarrhea and <i>C. difficile</i> toxin-positive stools after standard antibiotics and <i>S. boulardii</i> probiotic	IVIG 400 mg x 3 days	Diarrhea resolved but stools remained positive for <i>C. difficile</i> toxin		Reported as none

Appendix Table C11. Case studies/series and potential harms of nonstandard interventions for CDI (continued)

Study/ Study Focus	Subject/Study Details	Interventions	Clinical Diarrhea Outcomes	CD Toxin, CD Culture, or Other	Adverse Effects (AE) Harms
Hassoun 2007 ⁶¹ Treatment	<p>1 male age 72 years with diarrhea, abdominal pain, nausea and ulcerative colitis by colonoscopy after chemotherapy for cancer</p> <p>Treatment included numerous antibiotics including oral vancomycin</p>	<p>IVIg 400 mg for 1 dose</p>	<p>Diarrhea and clinical symptoms and bowel dilatation resolved within 7 days</p>	<p>Hassoun 2007 Treatment</p>	<p>1 male age 72 years with diarrhea, abdominal pain, nausea and ulcerative colitis by colonoscopy after chemotherapy for cancer</p> <p>Treatment included numerous antibiotics including oral vancomycin</p>
Abougergi, 2010 ⁶² Treatment	<p>21 patients with <i>C. difficile</i> colitis defined as <i>C. difficile</i> cytotoxin positive feces + diarrhea + other symptoms of abdominal pain and/or distention or fever + a leukoid reaction (white blood count of 20,000 cell/mm³ or more) + radiographic evidence of colitis or pseudomembranes by colonoscopy or sigmoidoscopy</p> <p>13 females and 8 males; age = 68 years (13) (mean [SD])</p> <p>All patients were seriously ill with sepsis and other comorbidities</p> <p>Retrospective chart review</p>	<p>IVIg as an adjuvant treatment to standard antibiotics</p> <p>Dose: mode of 250 mg/kg for 1–3 days (dose range = 200–1,250 mg/kg)</p>	<p>9 patients (43%) survived with resolution of clinical symptoms of <i>C. difficile</i> colitis</p>		<p>Pulmonary edema in 1 patient</p>

CD = *C. difficile*; CDI = *C. difficile* infection; IM = intramuscular; IVIG = intravenous immunoglobulin; PMC = PMC = pseudomembranous colitis

Appendix Table C12. Reviews and meta-analyses

Study	Title/Question Patient Population	# of Studies Patient N	Comparators	Outcomes Followup	Results
Diagnosis					
Planche, 2008 ⁶³ Searched 1994 to Nov 2007	Diagnosis of <i>Clostridium difficile</i> infection by toxin detection kits. Toxins A & B All inpatients	18 trials N=62 to 2,891 Meta-analysis	ELISA (Meridian, Techlab), Rapid antigen capture (Techlab), Rapid CI (Remel), EIA (BioMerieux) Rapid EIA (Meridian) compared to cell culture w/neutralisable toxin	Sensitivity, specificity	No test met acceptable criteria (sensitivity IQR >90%, and false positivity below 3%). No difference in diagnostic performance of commercially available tests. Most had higher specificity than sensitivity. Differences between tests likely due to assay threshold cutoff.
Prevention					
Garey, 2008 ⁶⁴ Searched 1966 to Aug 2007	Assess risk factors for recurrent CDI Adult inpatients	3 RCT, 9 observational Meta-analysis	Patients with recurrent versus patients with one episode only.	Studies generally 1 to 3 months	Continued use of non- <i>C. difficile</i> antibiotics after CDI diagnosis: OR 4.23 (2.10-8.55), use of antacid medication: OR 2.15 (1.13-4.08), older age: OR 1.62 (1.11 – 2.36). (Many risk factors not included in analysis due to limited literature.)
Bignardi, 1998 ⁶⁵ Searched to March 1996	Assess risk factors for CDI NR	49 studies	<i>C. difficile</i> cases versus individuals without diarrhea	CDI, <i>C. difficile</i> carrier	Risk factors with “substantive” evidence: age, severity of underlying diseases, nonsurgical gastrointestinal procedures, nasogastric tube, anti-ulcer medications, ICU, LoS, duration of antibiotic course, multiple antibiotics
Leonard, 2007 ⁶⁶ Searched 1966 thru 2005	Risk of enteric infection in patients taking acid suppression Primarily inpatient	25 observational studies N=1,382 Meta-analysis	Use of PPI or H2RA versus multiple control group types	Presence of enteric infection	PPI: OR 2.05 (1.47-2.85); H2RA: OR 1.48 (1.06 – 2.06); Overall: OR 1.95 (1.48-2.58). Significant heterogeneity between studies. ORs for other enteric infections were even greater. Index cases?
Kramer, 2006 ⁶⁷ Searched 1966 through 2005	How long do nosocomial pathogens persist on inanimate surfaces	NR number Experimental data		Range of reported duration of persistence	CDI spores: 5 months. Overall, high inoculum in cold rooms with higher humidity persist longest. No quality check.
Thomas, 2001 ⁶⁸ Searched 1966 to 2001	Antibiotics and hospital-acquired <i>C.difficile</i> -associated diarrhea Adult inpatients	48 observational studies	Use of antibiotics versus multiple control group types	Study quality	General study quality precludes meta-analysis of observational studies for relationships between antibiotics and <i>C. diff.</i> 2 studies provide valid evidence for cephalosporin, penicillin, and clindamycin.

Appendix Table C12. Reviews and meta-analyses (continued)

Study	Title/Question Patient Population	# of Studies Patient N	Comparators	Outcomes Followup	Results
Davey, 2005 ⁶⁹ Cochrane Searched Jan 1980 thru Jul 2005	Interventions to improve antibiotic prescribing practices for hospital inpatients Hospitals/units for all inpatients	66 studies, RCT to time series	60 interventions to improve prescribing practices versus usual processes	Presence of Gram negative-resistant bacteria, CDI, vancomycin-resistant enterococci, MRSA	Both persuasive and restrictive interventions were effective overall.
Treatment					
Koo, 2009 ⁷⁰ Searched thru Dec 2007	Antimotility agents for CDI treatment Adult inpatients	1 retrospective 19 case reports/series N = 55	With or without antibiotic use	Adverse events, clinical resolution	All patients with documented complications or mortality received antimotility drugs alone initially. 23 patients who received concurrent antibiotics did not experience complications. (Use of antimotility did not appear to shorten disease course in the 23 patients.)
Pillai, 2008 ⁷¹ Cochrane Searched 1966 thru Oct 2007	Probiotics for treatment of <i>C. difficile</i> -associated colitis in adults Adults with recurrent CDI	4 trials	Use of probiotics, multiple forms, versus placebo	Resolution of diarrhea, negative stool for toxin assay or culture	Insufficient evidence to support use. Studies were small and lacked power.
Eddins, 2008 ⁷² Jan 1996 thru Sept 2007	Probiotic or symbiotics for ADD, CDI, or radiation-induced diarrhea All patients	CDI:1 systematic review, 6 trials	Narrative		Sparse evidence may reduce risk for CDI or recurrence.
Segarra-Newnham, 2007 ⁷³ Searched 1970 thru March 2007	Probiotics for <i>C. difficile</i> -associated diarrhea: focus on <i>Lactobacillus rhamnosus</i> GG and <i>Saccharomyces boulardii</i>	7 articles, care report to blinded trials	Narrative		Sparse evidence. Risks may outweigh benefits for debilitated and immunosuppressed patients, which are those most at risk for recurrent CDI.
McFarland, 2006 ⁷⁴ Searched 1977 to 2005	Probiotics for prevention of antibiotic associated diarrhea and treatment of <i>C. difficile</i> disease Primarily inpatient	31 trials; ADD 25, CDI 6 N = 3,164 Meta-analysis	Use of probiotics, multiple forms, versus placebo	New diarrhea episode associated with positive culture or toxin assay within 1 month of antibiotic exposure	ADD prevention: RR 0.43 (0.31–0.58). CDI treatment: RR 0.59 (0.41–0.85) Most benefit in CDI seen in treatment of patients with recurrent CDI, <i>S. boulardii</i> was effective agent.

Appendix Table C12. Reviews and meta-analyses (continued)

Study	Title/Question Patient Population	# of Studies Patient N	Comparators	Outcomes Followup	Results
Dendukuri, 2005 ⁷⁵ Searched up thru Mar 2005	Probiotic therapy for the prevention and treatment of <i>C. difficile</i> -associated diarrhea Adult inpatients	1 prevention trial, 3 treatment	Probiotics versus placebo; <i>L. acidophilus</i> , <i>L. plantarum</i> , <i>L. GG</i> , <i>Bifidocaterium bifidum</i> , <i>S. boulardii</i> (5)	Prevention of AAD 11 days to 8 weeks	No differences between groups for prevention. Only one found improvement for treatment. Subgroup analysis suggests limited to recurrent CDI. Dose was same as used in pediatric studies with positive results. Variability in CDI definition.
Nelson, 2007 ²⁵ Cochrane Searched 1966 thru April 2007	Antibiotic treatment for <i>C. difficile</i> -associated diarrhea (and need for stopping causative) in adults Inpatients	12 trials Meta-analysis	8 antibiotics, 1 placebo controlled	Resolution/ negative tests, recurrence/ positive tests, surgery, death	No single antibiotic clearly superior; teicoplanin showed some benefits over vancomycin, fusidic acid, metronidazole. Mild cases may be self-limiting without treatment. For prevention of spread, teicoplanin showed best bacteriologic cure.
Zimmerman, 1997 ⁷⁶ Searched 1978 thru 1996	Antibiotic treatment of <i>C. difficile</i> infection	9 trials Meta-analysis	5 antibiotics, 2 placebo controlled	Clinical resolution of diarrhea, relapse, negative test for toxin Average 1 month	Coolestipol no better than placebo, but of other 4, no significant differences between types or doses of antibiotics for clinical resolution. Teicoplanin better than fusidic acid for relapse. Unclear if higher dose of teicoplanin reduces relapse.

References for Appendix Tables

Note that reference numbers for evidence tables in this appendix are different from those in the body of the report.

1. Swindells J, Brenwald N, Reading N, et al. Evaluation of diagnostic tests for *Clostridium difficile* infection. *J Clin Microbiol* 2010 Feb; 48(2):606-8.
2. Kvach EJ, Ferguson D, Riska PF, et al. Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic *Clostridium difficile* infection. *J Clin Microbiol* 2010 Jan; 48(1):109-14.
3. Alcalá L, Marin M, Madrid M, et al. Comparison of ImmunoCard Toxins A&B and the new semiautomated Vidas *Clostridium difficile* Toxin A&B tests for diagnosis of *C. difficile* infection. *J Clin Microbiol* 2010 Mar; 48(3):1014-5.
4. Eastwood K, Else P, Charlett A, et al. Comparison of nine commercially available *Clostridium difficile* toxin detection assays, a real-time PCR assay for *C. difficile* tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. *J Clin Microbiol* 2009 Oct; 47(10):3211-7.
5. Novak-Weekley SM, Marlowe EM, Miller JM, et al. *Clostridium difficile* testing in the clinical laboratory by use of multiple testing algorithms. *J Clin Microbiol* 2010 Mar; 48(3):889-93.
6. Alcalá L, Sanchez-Cambronero L, Catalan MP, et al. Comparison of three commercial methods for rapid detection of *Clostridium difficile* toxins A and B from fecal specimens. *J Clin Microbiol* 2008 Nov; 46(11):3833-5.
7. Miendje Deyi VY, Vandenberg O, Mascart G, et al. Diagnostic value of five commercial tests for the rapid diagnosis of *Clostridium difficile*-associated disease. *Clin Lab* 2008; 54(1-2):9-13.
8. Samra Z, Luzon A, Bishara J. Evaluation of two rapid immunochromatography tests for the detection of *Clostridium difficile* toxins. *Dig Dis Sci* 2008 Jul; 53(7):1876-9.
9. Sloan LM, Duresko BJ, Gustafson DR, et al. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of *Clostridium difficile* infection. *J Clin Microbiol* 2008 Jun; 46(6):1996-2001.
10. Musher DM, Manhas A, Jain P, et al. Detection of *Clostridium difficile* toxin: comparison of enzyme immunoassay results with results obtained by cytotoxicity assay. *J Clin Microbiol* 2007 Aug; 45(8):2737-9.
11. van den Berg RJ, Vaessen N, Endtz HP, et al. Evaluation of real-time PCR and conventional diagnostic methods for the detection of *Clostridium difficile*-associated diarrhoea in a prospective multicentre study. *J Med Microbiol* 2007 Jan; 56(Pt 1):36-42.
12. Turgeon DK, Novicki TJ, Quick J, et al. Six rapid tests for direct detection of *Clostridium difficile* and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. *J Clin Microbiol* 2003 Feb; 41(2):667-70.
13. O'Connor D, Hynes P, Cormican M, et al. Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of *Clostridium difficile*-associated diarrhea. *J Clin Microbiol* 2001 Aug; 39(8):2846-9.
14. Peled N, Pitlik S, Samra Z, et al. Predicting *Clostridium difficile* toxin in hospitalized patients with antibiotic-associated diarrhea. *Infect Control Hosp Epidemiol* 2007 Apr; 28(4):377-81.
15. Samore MH, Venkataraman L, DeGirolami PC, et al. Genotypic and phenotypic analysis of *Clostridium difficile* correlated with previous antibiotic exposure. *Microb Drug Resist* 2006; 12(1):23-8.

16. Yearsley KA, Gilby LJ, Ramadas AV, et al. Proton pump inhibitor therapy is a risk factor for *Clostridium difficile*-associated diarrhoea. *Aliment Pharmacol Ther* 2006 Aug 15; 24(4):613-9.
17. Vesta KS, Wells PG, Gentry CA, et al. Specific risk factors for *Clostridium difficile*-associated diarrhea: a prospective, multicenter, case control evaluation. *Am J Infect Control* 2005 Oct; 33(8):469-72.
18. Kyne L, Sougioultzis S, McFarland LV, et al. Underlying disease severity as a major risk factor for nosocomial *Clostridium difficile* diarrhea. *Infect Control Hosp Epidemiol* 2002 Nov; 23(11):653-9.
19. Mody LR, Smith SM, Dever LL. *Clostridium difficile*-associated diarrhea in a VA medical center: clustering of cases, association with antibiotic usage, and impact on HIV-infected patients. *Infect Control Hosp Epidemiol* 2001 Jan; 22(1):42-5.
20. Schwaber MJ, Simhon A, Block C, et al. Factors associated with nosocomial diarrhea and *Clostridium difficile*-associated disease on the adult wards of an urban tertiary care hospital. *Eur J Clin Microbiol Infect Dis* 2000 Jan; 19(1):9-15.
21. Katz DA, Bates DW, Rittenberg E, et al. Predicting *Clostridium difficile* stool cytotoxin results in hospitalized patients with diarrhea. *J Gen Intern Med* 1997 Jan; 12(1):57-62.
22. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for *Clostridium difficile* infection. *N Engl J Med*. 2011 Feb 3; 364(5):422-31
23. Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in *Clostridium difficile* infection: a randomized, double-blind study. *Clinic Infect Dis* 2009 Feb 15; 48(4):e41-6.
24. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clinic Infect Dis* 2007 Aug 1; 45(3):302-7.
25. Nelson R. Antibiotic treatment for *Clostridium difficile*-associated diarrhea in adults.[update of Cochrane Database Syst Rev 2005;(1):CD004610; PMID: 15674956]. *Cochrane Database Syst Rev* 2007; (3):004610.
26. Lagrotteria D, Holmes S, Smieja M, et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of *Clostridium difficile*-associated diarrhea. *Clinic Infect Dis* 2006 Sep 1; 43(5):547-52.
27. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of *Clostridium difficile* colitis. *Clinic Infect Dis* 2006 Aug 15; 43(4):421-7.
28. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of *Clostridium difficile*-associated diarrhoea. *J Antimicrob Chemother* 2004 Jul; 54(1):211-6.
29. Noren T, Wullt M, Akerlund T, et al. Frequent emergence of resistance in *Clostridium difficile* during treatment of *C. difficile*-associated diarrhea with fusidic acid. *Antimicrob Agents Chemother* 2006 Sep; 50(9):3028-32.
30. Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of *Clostridium difficile*-associated diarrhea. *Clinic Infect Dis* 1996 May; 22(5):813-8.
31. de Lalla F, Nicolini R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and *Clostridium difficile*-associated diarrhea. *Antimicrob Agents Chemother* 1992 Oct; 36(10):2192-6.
32. Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic-associated *Clostridium difficile* colitis with oral vancomycin: comparison of two dosage regimens. *Am J Med* 1989 Jan; 86(1):15-9.
33. Dudley MN, McLaughlin JC, Carrington G, et al. Oral bacitracin vs vancomycin therapy for *Clostridium difficile*-induced diarrhea. A randomized double-blind trial. *Arch Intern Med* 1986 Jun; 146(6):1101-4.

34. Young GP, Ward PB, Bayley N, et al. Antibiotic-associated colitis due to *Clostridium difficile*: double-blind comparison of vancomycin with bacitracin. *Gastroenterol* 1985 Nov; 89(5):1038-45.
35. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for *Clostridium-difficile*-associated diarrhoea and colitis. *Lancet* 1983 Nov 5; 2(8358):1043-6.
36. Keighley MR, Burdon DW, Arabi Y, et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. *BMJ* 1978 Dec 16; 2(6153):1667-9.
37. Wullt M, Hagslatt ML, Odenholt I. *Lactobacillus plantarum* 299v for the treatment of recurrent *Clostridium difficile*-associated diarrhoea: a double-blind, placebo-controlled trial. *Scand J Infect Dis* 2003; 35(6-7):365-7.
38. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent *Clostridium difficile* disease: use of high-dose vancomycin combined with *Saccharomyces boulardii*. *Clinic Infect Dis* 2000 Oct; 31(4):1012-7.
39. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of *Saccharomyces boulardii* in combination with standard antibiotics for *Clostridium difficile* disease. *JAMA* 1994 Jun 22-29; 271(24):1913-8.
40. Mattila E, Anttila VJ, Broas M, et al. A randomized, double-blind study comparing *Clostridium difficile* immune whey and metronidazole for recurrent *Clostridium difficile*-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. *Scand J Infect Dis* 2008; 40(9):702-8.
41. Mogg GA, George RH, Youngs D, et al. Randomized controlled trial of colestipol in antibiotic-associated colitis. *Br J Surg* 1982 Mar; 69(3):137-9.
42. McDonald GB, Vracko R. Systemic absorption of oral cholestyramine. *Gastroenterol* 1984 Jul; 87(1):213-5.
43. Kunitomo D, Thomson AB. Recurrent *Clostridium difficile*-associated colitis responding to cholestyramine. *Digestion* 1986; 33(4):225-8.
44. Kimura Y, Sato K, Tokuda H, et al. Effects of combination therapy with direct hemoperfusion using polymyxin B-immobilized fiber and oral vancomycin on fulminant pseudomembranous colitis with septic shock. *Dig Dis Sci* 2007 Mar; 52(3):675-8.
45. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing *Clostridium difficile* diarrhoea in six patients. *Lancet* 1989 May 27; 1(8648):1156-60.
46. Persky SE, Brandt LJ. Treatment of recurrent *Clostridium difficile*-associated diarrhea by administration of donated stool directly through a colonoscope. *Am J Gastroenterol* 2000 Nov; 95(11):3283-5.
47. MacConnachie AA, Fox R, Kennedy DR, et al. Faecal transplant for recurrent *Clostridium difficile*-associated diarrhoea: a UK case series. *QJM* 2009 Nov; 102(11):781-4.
48. Rohlke F, Surawicz C, Stollman N. Fecal flora reconstitution for recurrent *clostridium difficile* infection: results and methodology. *Journal of Clinical Gastroenterol* 2010; 44(8):567-70.
49. Yoon S, Brandt L. Treatment of refractory/recurrent *C. difficile*-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. *J Clin Gastroenterol* 2010; 44(8):562-6.
50. Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic *Clostridium difficile* infection. *Clin Gastroenterol Hepatol* 2010 May; 8(5):471-3.
51. MacGregor G, Smith AJ, Thakker B, et al. Yoghurt biotherapy: contraindicated in immunosuppressed patients? *Postgrad Med J* 2002 Jun; 78(920):366-7.
52. Pakyz A. A case of recurrent *Clostridium difficile* diarrhea. *Consult Pharm* 2007 Mar; 22(3):249-53.

53. Munoz P, Bouza E, Cuenca-Estrella M, et al. *Saccharomyces cerevisiae* fungemia: an emerging infectious disease.[see comment]. *Clinic Infect Dis* 2005 Jun 1; 40(11):1625-34.
54. Seal D, Borriello SP, Barclay F, et al. Treatment of relapsing *Clostridium difficile* diarrhoea by administration of a non-toxigenic strain. *Eur J Clin Microbiol* 1987 Feb; 6(1):51-3.
55. Taylor CP, Tummala S, Molrine D, et al. Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to *Clostridium difficile* toxin A. *Vaccine* 2008 Jun 25; 26(27-28):3404-9.
56. Herpers BL, Vlamincx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory *Clostridium difficile* infection. *Clinic Infect Dis* 2009 Jun 15; 48(12):1732-5.
57. Sougioultzis S, Kyne L, Drudy D, et al. *Clostridium difficile* toxoid vaccine in recurrent *C. difficile*-associated diarrhea. *Gastroenterol* 2005 Mar; 128(3):764-70.
58. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a *Clostridium difficile* toxoid vaccine administered to healthy adults. *Infect Immun* 2001 Feb; 69(2):988-95.
59. McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent *Clostridium difficile* diarrhea. *Dis Colon Rectum* 2006 May; 49(5):640-5.
60. Murphy C, Vernon M, Cullen M. Intravenous immunoglobulin for resistant *Clostridium difficile* infection. *Age Ageing* 2006 Jan; 35(1):85-6.
61. Hassoun A, Ibrahim F. Use of intravenous immunoglobulin for the treatment of severe *Clostridium difficile* colitis. *Am J Geriatr Pharmacother* 2007 Mar; 5(1):48-51.
62. Abougergi MS, Broor A, Cui W, et al. Intravenous immunoglobulin for the treatment of severe *Clostridium difficile* colitis: an observational study and review of the literature. *J Hosp Med (Online)* 2010 Jan; 5(1):E1-9.
63. Planche T, Aghaizu A, Holliman R, et al. Diagnosis of *Clostridium difficile* infection by toxin detection kits: a systematic review. *Lancet Infect Dis* 2008 Dec; 8(12):777-84.
64. Garey KW, Sethi S, Yadav Y, et al. Meta-analysis to assess risk factors for recurrent *Clostridium difficile* infection. *J Hosp Infect* 2008 Dec; 70(4):298-304.
65. Bignardi GE. Risk factors for *Clostridium difficile* infection. *J Hosp Infect* 1998 Sep; 40(1):1-15.
66. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. *Am J Gastroenterol* 2007 Sep; 102(9):2047-56; quiz 57.
67. Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. *BMC Infect Dis* 2006; 6:130.
68. Thomas MR, Litin SC, Osmon DR, et al. Lack of effect of *Lactobacillus* GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. *May Clinic Proc* 2001 Sep; 76(9):883-9.
69. Davey P, Brown E, Fenelon L, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev* 2005; (4):CD003543.
70. Koo HL, Koo DC, Musher DM, et al. Antimotility agents for the treatment of *Clostridium difficile* diarrhea and colitis. *Clinic Infect Dis* 2009 Mar 1; 48(5):598-605.
71. Pillai A, Nelson R. Probiotics for treatment of *Clostridium difficile*-associated colitis in adults. *Cochrane Database Syst Rev* 2008; (1):CD004611.
72. Eddins C, Gray M. Are probiotic or synbiotic preparations effective for the management of *clostridium difficile*-associated or radiation-induced diarrhea? *J Wound Ostomy Continence Nurs* 2008 Jan-Feb; 35(1):50-8.
73. Segarra-Newnham M. Probiotics for *Clostridium difficile*-associated diarrhea: focus on *Lactobacillus rhamnosus* GG and *Saccharomyces boulardii*. *Ann Pharmacother* 2007 Jul; 41(7):1212-21.

74. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. *Am J Gastroenterol* 2006 Apr; 101(4):812-22.
75. Dendukuri N, Costa V, McGregor M, et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. *CMAJ* 2005 Jul 19; 173(2):167-70.
76. Zimmerman MJ, Bak A, Sutherland LR. Review article: treatment of Clostridium difficile infection. *Aliment Pharmacol Ther* 1997 Dec; 11(6):1003-12.

Appendix D. Excluded Studies

Excluded References – C Difficile (General Search)

1. Treatment of *Clostridium difficile* associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. *Scand J Infect Dis* 1994; 26(3):309-16. *Not eligible comparator*
2. Abbett SK, Yokoe DS, Lipsitz SR, et al. Proposed checklist of hospital interventions to decrease the incidence of healthcare-associated *Clostridium difficile* infection. *Infect Control Hosp Epidemiol* 2009 Nov; 30(11):1062-9. *Not relevant to key questions*
3. Abrahamsson TR, Sinkiewicz G, Jakobsson T, et al. Probiotic lactobacilli in breast milk and infant stool in relation to oral intake during the first year of life. *Journal of Pediatric Gastroenterology & Nutrition* 2009 Sep; 49(3):349-54. *Not included population*
4. Abrahao C, Carman RJ, Hahn H, et al. Similar frequency of detection of *Clostridium perfringens* enterotoxin and *Clostridium difficile* toxins in patients with antibiotic-associated diarrhea. *European J Clin Microbiol & Infectious Diseases* 2001 Sep; 20(9):676-7. *Not included treatment type*
5. Abreu MT, Harpaz N. Diagnosis of colitis: making the initial diagnosis.[see comment]. *Clin Gastroenterol Hepatol* 2007 Mar; 5(3):295-301. *Not included publication type*
6. Akhtar AJ, Shaheen M. Increasing incidence of *clostridium difficile*-associated diarrhea in African-American and Hispanic patients: association with the use of proton pump inhibitor therapy. *Journal of the National Medical Association* 2007 May; 99(5):500-4. *Not included study design*
7. Akhtar AJ, Shaheen M. Increasing incidence of *clostridium difficile*-associated diarrhea in African-American and Hispanic patients: association with the use of proton pump inhibitor therapy. *Journal of the National Medical Association* 2007 May; 99(5):500-4. *Duplicate listing*
8. Albright JB, Bonatti H, Mendez J, et al. Early and late onset *Clostridium difficile*-associated colitis following liver transplantation. *Transplant International* 2007 Oct; 20(10):856-66. *Not included study design*
9. Aldeyab MA, Harbarth S, Vernaz N, et al. Quasiexperimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of *Clostridium difficile*-associated diarrhea in hospitalized patients. *Antimicrob Agents Chemother* 2009 May; 53(5):2082-8. *Not included study design*
10. Aldeyab MA, Harbarth S, Vernaz N, et al. Quasiexperimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of *Clostridium difficile*-associated diarrhea in hospitalized patients. *Antimicrob Agents Chemother* 2009 May; 53(5):2082-8. *Duplicate listing*
11. Al-Eidan FA, McElnay JC, Scott MG, et al. *Clostridium difficile*-associated diarrhoea in hospitalised patients. *Journal of Clinical Pharmacy & Therapeutics* 2000 Apr; 25(2):101-9. *Not on topic*
12. Alestig K, Carlberg H, Nord CE, et al. Effect of cefoperazone on faecal flora. *J Antimicrob Chemother* 1983 Aug; 12(2):163-7. *Not on topic*
13. Ali SO, Welch JP, Dring RJ. Early surgical intervention for fulminant pseudomembranous colitis. *American Surgeon* 2008 Jan; 74(1):20-6. *Not included population*
14. Altaie SS, Meyer P, Dryja D. Comparison of two commercially available enzyme immunoassays for detection of *Clostridium difficile* in stool specimens. *J Clin Microbiol* 1994 Jan; 32(1):51-3. *Not relevant to key questions*

15. Altiparmak MR, Trablus S, Pamuk ON, et al. Diarrhoea following renal transplantation. *Clinical transplantation* 2002 Jun; 16(3):212-6. *Not included study design*
16. Al-Tureihi FI, Hassoun A, Wolf-Klein G, et al. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. *Journal of the American Medical Directors Association* 2005 Mar-Apr; 6(2):105-8. *Not included study design*
17. Ambrose NS, Burdon DW, Keighley MR. A prospective randomized trial to compare mezlocillin and metronidazole with cefuroxime and metronidazole as prophylaxis in elective colorectal operations. *J Hosp Infect* 1983 Dec; 4(4):375-82. *Not included population*
18. Ament ME, Berquist W, Vargas J. Advances in ulcerative colitis. *Pediatrician* 1988; 15(1-2):45-57. *Not on topic*
19. Anand A, Bashey B, Mir T, et al. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. *Am J Gastroenterol* 1994 Apr; 89(4):519-23. *Not included study design*
20. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. *Clinic Infect Dis* 1993 Jul; 17(1):109-13. *Not included study design*
21. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. *Gut* 2008 Feb; 57(2):205-10. *Not included population*
22. Anastasi JK, Capili B. HIV and diarrhea in the era of HAART: 1998 New York State hospitalizations. *Am J Infect Control* 2000 Jun; 28(3):262-6. *Not included study design*
23. Anastasi JK, Capili B. HIV and diarrhea in the era of HAART: 1998 New York State hospitalizations. *Am J Infect Control* 2000 Jun; 28(3):262-6. *Duplicate listing*
24. Andrews CN, Raboud J, Kassen BO, et al. Clostridium difficile-associated diarrhea: predictors of severity in patients presenting to the emergency department. *Can J Gastroenterol* 2003 Jun; 17(6):369-73. *Not included study design*
25. Ang CW, Heyes G, Morrison P, et al. The acquisition and outcome of ICU-acquired Clostridium difficile infection in a single centre in the UK. *Journal of Infection* 2008 Dec; 57(6):435-40. *Not included study design*
26. Ang P, Cheong WK, Khoo KS. Pseudomembranous colitis in a patient treated with paclitaxel for carcinoma of the breast: a case report. *Ann Acad Med Singapore* 2000 Jan; 29(1):132-4. *Not included publication type*
27. Antoine M, Khitrik-Palchuk M, Saif MW. Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. *Jop: Journal of the Pancreas [Electronic Resource]* 2007; 8(6):783-9. *Not included publication type*
28. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature.[see comment]. *Clinic Infect Dis* 2002 Sep 15; 35(6):690-6. *Not included study design*
29. Aradhyula S, Manian FA, Hafidh SA, et al. Significant absorption of oral vancomycin in a patient with clostridium difficile colitis and normal renal function. *Southern medical journal* 2006 May; 99(5):518-20. *Not included publication type*
30. Arango JI, Restrepo A, Schneider DL, et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. *Bone marrow transplantation* 2006 Mar; 37(5):517-21. *Not on topic*
31. Archimandritis A, Souyioultzis S, Katsorida M, et al. Clostridium difficile colitis associated with a 'triple' regimen, containing clarithromycin and metronidazole, to eradicate Helicobacter pylori. *Journal of internal medicine* 1998 Mar; 243(3):251-3. *Not included publication type*

32. Aronsson B, Blomback M, Eriksson S, et al. Low levels of coagulation inhibitors in patients with *Clostridium difficile* infection. *Infection* 1992 Mar-Apr; 20(2):58-60. *Not on topic*
33. Aronsson B, Granstrom M, Mollby R, et al. Serum antibody response to *Clostridium difficile* toxins in patients with *Clostridium difficile* diarrhoea. *Infection* 1985 May-Jun; 13(3):97-101. *Not included study design*
34. Aronsson B, Mollby R, Nord CE. *Clostridium difficile* and antibiotic associated diarrhoea in Sweden. *Scand J Infect Dis Supplement* 1982; 35:53-8. *Not included study design*
35. Aronsson B, Mollby R, Nord CE. Diagnosis and epidemiology of *Clostridium difficile* enterocolitis in Sweden. *J Antimicrob Chemother* 1984 Dec; 14(Suppl D):85-95. *Not included study design*
36. Aroori S, Blencowe N, Pye G, et al. *Clostridium difficile*: how much do hospital staff know about it? *Annals of the Royal College of Surgeons of England* 2009 Sep; 91(6):464-9. *Not included study design*
37. Arrich J, Sodeck GH, Sengolge G, et al. *Clostridium difficile* causing acute renal failure: case presentation and review. *World Journal of Gastroenterology* 2005 Feb 28; 11(8):1245-7. *Not included publication type*
38. Arsura EL, Fazio RA, Wickremesinghe PC. Pseudomembranous colitis following prophylactic antibiotic use in primary cesarean section. *American Journal of Obstetrics & Gynecology* 1985 Jan 1; 151(1):87-9. *Not included publication type*
39. Aseeri M, Schroeder T, Kramer J, et al. Gastric acid suppression by proton pump inhibitors as a risk factor for *clostridium difficile*-associated diarrhea in hospitalized patients. *Am J Gastroenterol* 2008 Sep; 103(9):2308-13. *Not included study design*
40. Ash L, Baker ME, O'Malley CM, Jr., et al. Colonic abnormalities on CT in adult hospitalized patients with *Clostridium difficile* colitis: prevalence and significance of findings. *AJR.American Journal of Roentgenology* 2006 May; 186(5):1393-400. *Not included study design*
41. Asha NJ, Tompkins D, Wilcox MH. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to *Clostridium difficile*, *Clostridium perfringens*, and *Staphylococcus aureus*. *J Clin Microbiol* 2006 Aug; 44(8):2785-91. *Not included study design*
42. Aziz EE, Ayis S, Gould FK, et al. Risk factors for the development of *Clostridium difficile* toxin-associated diarrhoea: a pilot study. *Pharmacoepidemiology & Drug Safety* 2001 Jun-Jul; 10(4):303-8. *Not included study design*
43. Bacci S, St-Martin G, Olesen B, et al. Outbreak of *Clostridium difficile* 027 in North Zealand, Denmark, 2008-2009. *Bulletin European sur les Maladies Transmissibles = European Communicable Disease Bulletin*. 2009 2009.; 14(16). *Not relevant to key questions*
44. Bacon AE, 3rd, Fekety R. Immunoglobulin G directed against toxins A and B of *Clostridium difficile* in the general population and patients with antibiotic-associated diarrhea. *Diagnostic Microbiology & Infectious Disease* 1994 Apr; 18(4):205-9. *Not included population*
45. Bahadursingh AN, Vagefi PA, Longo WE. Fulminant *Clostridium difficile* colitis in a patient with spinal cord injury: case report. *Journal of Spinal Cord Medicine* 2004; 27(3):266-8. *Not included publication type*
46. Baines SD, O'Connor R, Saxton K, et al. Activity of vancomycin against epidemic *Clostridium difficile* strains in a human gut model. *J Antimicrob Chemother* 2009 Mar; 63(3):520-5. *Not included publication type*
47. Bajaj JS, Ananthkrishnan AN, Hafeezullah M, et al. *Clostridium difficile* is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. *Am J Gastroenterol* 2010 Jan; 105(1):106-13. *Not relevant to key questions*
48. Bakken JS. Resolution of recurrent *Clostridium difficile*-associated diarrhea using staggered antibiotic withdrawal and kefir. *Minnesota medicine* 2009 Jul; 92(7):38-40. *Background*

49. Balamurugan R, Balaji V, Ramakrishna BS. Estimation of faecal carriage of *Clostridium difficile* in patients with ulcerative colitis using real time polymerase chain reaction. *Indian Journal of Medical Research* 2008 May; 127(5):472-7. *Not included study design*
50. Banning M. Ageing and the gut. *Nursing Older People* 2008 Feb; 20(1):17-21. *Not included publication type*
51. Barany P, Stenvinkel P, Nord CE, et al. *Clostridium difficile* infection--a poor prognostic sign in uremic patients? *Clinical nephrology* 1992 Jul; 38(1):53-7. *Not included study design*
52. Barbut F, Beaugerie L, Delas N, et al. Comparative value of colonic biopsy and intraluminal fluid culture for diagnosis of bacterial acute colitis in immunocompetent patients. *Infectious Colitis Study Group. Clinic Infect Dis* 1999 Aug; 29(2):356-60. *Not included study design*
53. Barbut F, Corthier G, Charpak Y, et al. Prevalence and pathogenicity of *Clostridium difficile* in hospitalized patients. A French multicenter study. *Arch Intern Med* 1996 Jul 8; 156(13):1449-54. *Not included study design*
54. Barbut F, Decre D, Burghoffer B, et al. Antimicrobial susceptibilities and serogroups of clinical strains of *Clostridium difficile* isolated in France in 1991 and 1997. *Antimicrob Agents Chemother* 1999 Nov; 43(11):2607-11. *Not included population*
55. Barbut F, Decre D, Lalande V, et al. Clinical features of *Clostridium difficile*-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. *Journal of medical microbiology* 2005 Feb; 54(Pt 2):181-5. *Not included study design*
56. Barbut F, Gariazzo B, Bonne L, et al. Clinical features of *Clostridium difficile*-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004. *Infect Control Hosp Epidemiol* 2007 Feb; 28(2):131-9. *Not included study design*
57. Barbut F, Leluan P, Antoniotti G, et al. Value of routine stool cultures in hospitalized patients with diarrhea. *European J Clin Microbiol & Infectious Diseases* 1995 Apr; 14(4):346-9. *Not included study design*
58. Barbut F, Mario N, Meyohas MC, et al. Investigation of a nosocomial outbreak of *Clostridium difficile*-associated diarrhoea among AIDS patients by random amplified polymorphic DNA (RAPD) assay. *J Hosp Infect* 1994 Mar; 26(3):181-9. *Not included study design*
59. Barbut F, Meynard JL, Guiguet M, et al. *Clostridium difficile*-associated diarrhea in HIV-infected patients: epidemiology and risk factors. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology* 1997 Nov 1; 16(3):176-81. *Not included study design*
60. Barbut F, MPMDBJKEPIESGoCd. Prospective study of *Clostridium difficile* infections in Europe with phenotypic and genotypic characterisation of the isolates. *Clinical Microbiology & Infection* 2007 Nov; 13(11):1048-57. *Not relevant to key questions*
61. Barker HC, Haworth CS, Williams D, et al. *Clostridium difficile* pancolitis in adults with cystic fibrosis. *Journal of Cystic Fibrosis* 2008 Sep; 7(5):444-7. *Not included publication type*
62. Barriere SL. Review of in vitro activity, pharmacokinetic characteristics, safety, and clinical efficacy of cefprozil, a new oral cephalosporin. *Ann Pharmacother* 1993 Sep; 27(9):1082-9. *Not included study design*
63. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea.[see comment]. *New England Journal of Medicine* 2002 Jan 31; 346(5):334-9. *Not included publication type*
64. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of *Clostridium difficile* infection. *Clinic Infect Dis* 2008 Jan 15; 46(Suppl 1):S12-8. *Background*
65. Bassaris HP, Lianou PE, Legakis NJ, et al. Interaction between *Clostridium difficile* and polymorphonuclear leucocytes from the elderly and post-operative cancer patients: phagocytosis and bactericidal function. *Medical Microbiology & Immunology* 1984; 173(1):49-55. *Not included population*

66. Bate G. Comparison of Minitek Anaerobe II, API An-Ident, and RapID ANA systems for identification of *Clostridium difficile*. *American Journal of Clinical Pathology* 1986 Jun; 85(6):716-8. *Not included study design*
67. Battle EH, Elliott SY. Three cases of hemorrhagic colitis in West Virginia due to *Escherichia coli* O157:H7. *West Virginia Medical Journal* 1995 Nov-Dec; 91(7):320-1. *Not included publication type*
68. Bauer MP, Goorhuis A, Koster T, et al. Community-onset *Clostridium difficile*-associated diarrhoea not associated with antibiotic usage--two case reports with review of the changing epidemiology of *Clostridium difficile*-associated diarrhoea. *Netherlands Journal of Medicine* 2008 May; 66(5):207-11. *Not included publication type*
69. Bauer MP, Veenendaal D, Verhoef L, et al. Clinical and microbiological characteristics of community-onset *Clostridium difficile* infection in The Netherlands. *Clinical Microbiology & Infection* 2009 Dec; 15(12):1087-92. *Not relevant to key questions*
70. Bauer TM, Lalvani A, Fehrenbach J, et al. Derivation and validation of guidelines for stool cultures for enteropathogenic bacteria other than *Clostridium difficile* in hospitalized adults. *JAMA* 2001 Jan 17; 285(3):313-9. *Not on topic*
71. Bauwens JE, McFarland LV, Melcher SA. Recurrent *Clostridium difficile* disease following ciprofloxacin use. *Ann Pharmacother* 1997 Sep; 31(9):1090. *Not included publication type*
72. Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent *Clostridium difficile*-associated diarrhea in hospitalized patients. *Infect Control Hosp Epidemiol* 2008 Jan; 29(1):44-50. *Not included study design*
73. Beaugerie L, Flahault A, Barbut F, et al. Antibiotic-associated diarrhoea and *Clostridium difficile* in the community. *Aliment Pharmacol Ther* 2003 Apr 1; 17(7):905-12. *Not included study design*
74. Beaugerie L, Metz M, Barbut F, et al. *Klebsiella oxytoca* as an agent of antibiotic-associated hemorrhagic colitis. *Clin Gastroenterol Hepatol* 2003 Sep; 1(5):370-6. *Not included publication type*
75. Beaugerie L, Ngo Y, Goujard F, et al. Etiology and management of toxic megacolon in patients with human immunodeficiency virus infection. *Gastroenterol* 1994 Sep; 107(3):858-63. *Not included publication type*
76. Beaujean DJ, Blok HE, Vandenbroucke-Grauls CM, et al. Surveillance of nosocomial infections in geriatric patients. *J Hosp Infect* 1997 Aug; 36(4):275-84. *Not included study design*
77. Beaulieu M, Williamson D, Pichette G, et al. Risk of *Clostridium difficile*-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit. *Infect Control Hosp Epidemiol* 2007 Nov; 28(11):1305-7. *Not included study design*
78. Beck A, McNeil C, Abdelsayed G, et al. *Salmonella pseudomembranous* colitis. *Connecticut medicine* 2007 Jun-Jul; 71(6):339-42. *Not included publication type*
79. Beloosesky Y, Grosman B, Marmelstein V, et al. Convulsions induced by metronidazole treatment for *Clostridium difficile*-associated disease in chronic renal failure. *American Journal of the Medical Sciences* 2000 May; 319(5):338-9. *Not included publication type*
80. Ben-Horin S, Margalit M, Bossuyt P, et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and *clostridium difficile* infection. *Clin Gastroenterol Hepatol* 2009 Sep; 7(9):981-7. *Not included study design*
81. Bennett RG, Greenough WB, 3rd. Approach to acute diarrhea in the elderly. *Gastroenterology clinics of North America* 1993 Sep; 22(3):517-33. *Not included publication type*
82. Bennett RG, Laughon BE, Mundy LM, et al. Evaluation of a latex agglutination test for *Clostridium difficile* in two nursing home outbreaks. *J Clin Microbiol* 1989 May; 27(5):889-93. *Not included population*

83. Berman L, Carling T, Fitzgerald TN, et al. Defining surgical therapy for pseudomembranous colitis with toxic megacolon. *J Clin Gastroenterol* 2008 May-Jun; 42(5):476-80. *Not included publication type*
84. Bilgrami S, Feingold JM, Dorsky D, et al. Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone marrow transplantation 1999 May; 23(10):1039-42. *Not included study design*
85. Biller P, Shank B, Lind L, et al. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. *Infect Control Hosp Epidemiol* 2007 Feb; 28(2):198-201. *Not included study design*
86. Bingley PJ, Harding GM. Clostridium difficile colitis following treatment with metronidazole and vancomycin. *Postgrad Med J* 1987 Nov; 63(745):993-4. *Not included publication type*
87. Bingley PJ, Harding GM. Clostridium difficile colitis following treatment with metronidazole and vancomycin. *Postgrad Med J* 1987 Nov; 63(745):993-4. *Duplicate listing*
88. Birnbaum J, Bartlett JG, Gelber AC. Clostridium difficile: an under-recognized cause of reactive arthritis? *Clinical rheumatology* 2008 Feb; 27(2):253-5. *Not included publication type*
89. Bishara J, Peled N, Pitlik S, et al. Mortality of patients with antibiotic-associated diarrhoea: the impact of Clostridium difficile. *J Hosp Infect* 2008 Apr; 68(4):308-14. *Not included study design*
90. Bishara J, Peled N, Pitlik S, et al. Mortality of patients with antibiotic-associated diarrhoea: the impact of Clostridium difficile. *J Hosp Infect* 2008 Apr; 68(4):308-14. *Duplicate listing*
91. Bixquert Jimenez M. Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last? *Revista Espanola de Enfermedades Digestivas* 2009 Aug; 101(8):553-64. *Not relevant to key questions*
92. Bliss DZ, Johnson S, Savik K, et al. Fecal incontinence in hospitalized patients who are acutely ill. *Nursing research* 2000 Mar-Apr; 49(2):101-8. *Not included study design*
93. Bliss DZ, Johnson S, Savik K, et al. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. *Annals of Internal Medicine* 1998 Dec 15; 129(12):1012-9. *Not included study design*
94. Bloedt K, Riecker M, Poppert S, et al. Evaluation of new selective culture media and a rapid fluorescence in situ hybridization assay for identification of Clostridium difficile from stool samples. *Journal of medical microbiology* 2009 Jul; 58(Pt 7):874-7. *Not included population*
95. Blossom DB, Lewis FM, McDonald LC. The changing spectrum of clostridium difficile associated disease: implications for dentistry. *Journal of the American Dental Association* 2008 Jan; 139(1):42-7. *Not included publication type*
96. Blot E, Escande MC, Besson D, et al. Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. *J Hosp Infect* 2003 Mar; 53(3):187-92. *Not included study design*
97. Blum RN, Berry CD, Phillips MG, et al. Clinical illnesses associated with isolation of dysgonic fermenter 3 from stool samples. *J Clin Microbiol* 1992 Feb; 30(2):396-400. *Not included publication type*
98. Bobulsky GS, Al-Nassir WN, Riggs MM, et al. Clostridium difficile skin contamination in patients with C. difficile-associated disease. *Clinic Infect Dis* 2008 Feb 1; 46(3):447-50. *Not on topic*
99. Bodey G, Abi-Said D, Rolston K, et al. Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. *European J Clin Microbiol & Infectious Diseases* 1996 Aug; 15(8):625-34. *Not on topic*
100. Bolton RP. Clostridium difficile-associated colitis after neomycin treated with metronidazole. *BMJ* 1979 Dec 8; 2(6203):1479-80. *Not included publication type*

101. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to *Clostridium difficile*. *Gut* 1986 Oct; 27(10):1169-72. *Not included study design*
102. Bombassaro AM, Wetmore SJ, John MA. *Clostridium difficile* colitis following antibiotic prophylaxis for dental procedures. *Journal (Canadian Dental Association)* 2001 Jan; 67(1):20-2. *Not included publication type*
103. Bonatti H, Brandacher G, Margreiter R, et al. Infectious complications in three double hand recipients: experience from a single center. *Transplantation proceedings* 2009 Mar; 41(2):517-20. *Not included publication type*
104. Bond F, Payne G, Borriello SP, et al. Usefulness of culture in the diagnosis of *Clostridium difficile* infection. *European J Clin Microbiol & Infectious Diseases* 1995 Mar; 14(3):223-6. *Not included population*
105. Bond JH. Office-based management of diarrhea. *Geriatrics* 1982 61-4; Feb; 37(2):52-5. *Not included publication type*
106. Borriello SP, Barclay FE. An in-vitro model of colonisation resistance to *Clostridium difficile* infection. *Journal of medical microbiology* 1986 Jun; 21(4):299-309. *Not included population*
107. Bouza E, Burillo A, Munoz P. Antimicrobial therapy of *Clostridium difficile*-associated diarrhea. *Medical Clinics of North America* 2006 Nov; 90(6):1141-63. *Not included publication type*
108. Bouza E, Perez MJ, Munoz P, et al. Continuous aspiration of subglottic secretions in the prevention of ventilator-associated pneumonia in the postoperative period of major heart surgery. *Chest* 2008 Nov; 134(5):938-46. *Not on topic*
109. Bouza E, Perez MJ, Munoz P, et al. Continuous aspiration of subglottic secretions in the prevention of ventilator-associated pneumonia in the postoperative period of major heart surgery. *Chest* 2008 Nov; 134(5):938-46. *Duplicate listing*
110. Bouza E, Sousa D, Munoz P, et al. Bloodstream infections: a trial of the impact of different methods of reporting positive blood culture results. *Clinic Infect Dis* 2004 Oct 15; 39(8):1161-9. *Not on topic*
111. Bouza E, Torres MV, Radice C, et al. Direct E-test (AB Biodisk) of respiratory samples improves antimicrobial use in ventilator-associated pneumonia. *Clinic Infect Dis* 2007 Feb 1; 44(3):382-7. *Not on topic*
112. Boyce JM, Havill NL, Otter JA, et al. Widespread environmental contamination associated with patients with diarrhea and methicillin-resistant *Staphylococcus aureus* colonization of the gastrointestinal tract. *Infect Control Hosp Epidemiol* 2007 Oct; 28(10):1142-7. *Not included study design*
113. Brandt LJ, Kosche KA, Greenwald DA, et al. *Clostridium difficile*-associated diarrhea in the elderly. *Am J Gastroenterol* 1999 Nov; 94(11):3263-6. *Background*
114. Brazier JS, Borriello SP. Microbiology, epidemiology and diagnosis of *Clostridium difficile* infection. *Current Topics in Microbiology & Immunology* 2000; 250:1-33. *Not included publication type*
115. Brennen C, Wagener MM, Muder RR. Vancomycin-resistant *Enterococcus faecium* in a long-term care facility. *Journal of the American Geriatrics Society* 1998 Feb; 46(2):157-60. *Not included publication type*
116. Brettle RP, Poxton IR, Murdoch JM, et al. *Clostridium difficile* in association with sporadic diarrhoea. *BMJ Clinical Research Ed* 1982 Jan 23; 284(6311):230-3. *Not included publication type*
117. Bricker E, Garg R, Nelson R, et al. Antibiotic treatment for *Clostridium difficile*-associated diarrhea in adults. [update in *Cochrane Database Syst Rev*. 2007;(3):CD004610; PMID: 17636768]. *Cochrane Database Syst Rev* 2005; (1):004610. *Background*
118. Brismar B, Edlund C, Nord CE. Effect of ceftibuten on the normal intestinal microflora. *Infection* 1993 Nov-Dec; 21(6):373-5. *Not included study design*

119. Brismar B, Edlund C, Nord CE. Impact of cefpodoxime proxetil and amoxicillin on the normal oral and intestinal microflora. *Eur J Clin Microbiol Infect Dis* 1993 Sep; 12(9):714-9. *Not included study design*
120. Brown EA, Talbot GH, Provencher M, et al. Anaerobic bacteremia in patients with acute leukemia. *Infect Control Hosp Epidemiol* 1989 Feb; 10(2):65-9. *Not included publication type*
121. Brown RJ, Batts DH, Hughes GS, et al. Comparison of oral cefpodoxime proxetil and penicillin V potassium in the treatment of group A streptococcal pharyngitis/tonsillitis. The Cefpodoxime Pharyngitis Study Group. *Clinical therapeutics* 1991 Sep-Oct; 13(5):579-88. *Not on topic*
122. Bruce D, Ritchie C, Jennings LC, et al. Clostridium difficile-associated colitis: cross infection in predisposed patients with renal failure. *New Zealand Medical Journal* 1982 Apr 28; 95(706):265-7. *Not included publication type*
123. Buchner AM, Sonnenberg A. Medical diagnoses and procedures associated with clostridium difficile colitis. *Am J Gastroenterol* 2001 Mar; 96(3):766-72. *Not included study design*
124. Buchner AM, Sonnenberg A. Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans. *Dig Dis Sci* 2002 Jan; 47(1):201-7. *Not included study design*
125. Buggy BP, Fekety R, Silva J, Jr. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. *J Clin Gastroenterol* 1987 Apr; 9(2):155-9. *Not included study design*
126. Bulstrode NW, Bradbury AW, Barrett S, et al. Clostridium difficile colitis after aortic surgery. *European Journal of Vascular & Endovascular Surgery* 1997 Sep; 14(3):217-20. *Not included study design*
127. Bulusu M, Narayan S, Shetler K, et al. Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. *Am J Gastroenterol* 2000 Nov; 95(11):3137-41. *Not on topic*
128. Burdon DW. Treatment of pseudomembranous colitis and antibiotic-associated diarrhoea. *J Antimicrob Chemother* 1984 Dec; 14(Suppl D):103-9. *Not included study design*
129. Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. *Lancet Neurology* 2009 Mar; 8(3):244-53. *Not on topic*
130. Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. *Lancet Neurology* 2009 Mar; 8(3):244-53. *Duplicate listing*
131. Butterworth SA, Koppert E, Clarke A, et al. Recent trends in diagnosis and treatment of Clostridium difficile in a tertiary care facility. *American Journal of Surgery* 1998 May; 175(5):403-7. *Not included publication type*
132. Byl B, Jacobs F, Struelens MJ, et al. Extraintestinal Clostridium difficile infections. *Clinic Infect Dis* 1996 Apr; 22(4):712. *Not included study design*
133. Byrd RP, Jr., Roy TM, Ossorio MA, et al. Delayed onset of pseudomembranous colitis after rifampin therapy. *Southern medical journal* 1997 Jun; 90(6):644-6. *Not included publication type*
134. Byrn JC, Maun DC, Gingold DS, et al. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. *Archives of Surgery* 2008 discussion 155; Feb; 143(2):150-4. *Not included study design*
135. Cadle RM, Mansouri MD, Darouiche RO. Vancomycin-induced elevation of liver enzyme levels. *Ann Pharmacother* 2006 Jun; 40(6):1186-9. *Not included study design*
136. Cadle RM, Mansouri MD, Logan N, et al. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. *American Journal of Health-System Pharmacy* 2007 Nov 15; 64(22):2359-63. *Not included study design*

137. Calame W, Weseler AR, Viebke C, et al. Gum arabic establishes prebiotic functionality in healthy human volunteers in a dose-dependent manner. *British Journal of Nutrition* 2008 Dec; 100(6):1269-75. *Not included study design*
138. Calame W, Weseler AR, Viebke C, et al. Gum arabic establishes prebiotic functionality in healthy human volunteers in a dose-dependent manner. *British Journal of Nutrition* 2008 Dec; 100(6):1269-75. *Duplicate listing*
139. Calfee DP. Clostridium difficile: a reemerging pathogen. *Geriatrics* 2008 Sep 1; 63(9):10-21. *Not included publication type*
140. Camilleri M, Toouli J, Herrera MF, et al. Intra-abdominal vagal blocking (VBLOC therapy): clinical results with a new implantable medical device. *Surgery* 2008 Jun; 143(6):723-31. *Not on topic*
141. Candiotta A, Pascoli I, Gritti A, et al. Toxic megacolon complicating a Clostridium difficile infection in a pregnant woman. *Journal of Medical Microbiology* 2010 Jan; 59(Pt 1):124-6. *Not relevant to key questions*
142. Cappell MS, Philogene C. Clostridium difficile infection is a treatable cause of diarrhea in patients with advanced human immunodeficiency virus infection: a study of seven consecutive patients admitted from 1986 to 1992 to a university teaching hospital. *Am J Gastroenterol* 1993 Jun; 88(6):891-7. *Not included study design*
143. Carbone J, Sarmiento E, Palomo J, et al. The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections. *Transplantation proceedings* 2007 Sep; 39(7):2385-8. *Not on topic*
144. Carbonell AM, Kercher KW, Matthews BD, et al. The laparoscopic repair of suprapubic ventral hernias. *Surgical endoscopy* 2005 Feb; 19(2):174-7. *Not on topic*
145. Carignan A, Allard C, Pepin J, et al. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. *Clinic Infect Dis* 2008 Jun 15; 46(12):1838-43. *Not included study design*
146. Carmeli Y, Eliopoulos G, Mozaffari E, et al. Health and economic outcomes of vancomycin-resistant enterococci. *Arch Intern Med* 2002 Oct 28; 162(19):2223-8. *Not on topic*
147. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. *Emerging Infectious Diseases* 2002 Aug; 8(8):802-7. *Not on topic*
148. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. *Emerging Infectious Diseases* 2002 Aug; 8(8):802-7. *Duplicate listing*
149. Carpenter DR, Zielinski DA. How do you treat--and control--C. difficile infection? *American Journal of Nursing* 1992 Sep; 92(9):22-4. *Not included publication type*
150. Carrer M, Vazquez GJ, Lebron RI, et al. The microbial etiologies of diarrhea in hospitalized patients from the Puerto Rico Medical Center Hospitals. *Puerto Rico health sciences journal* 2005 Mar; 24(1):41-4. *Not on topic*
151. Cartmill TD, Shrimpton SB, Panigrahi H, et al. Nosocomial diarrhoea due to a single strain of Clostridium difficile: a prolonged outbreak in elderly patients. *Age Ageing* 1992 Jul; 21(4):245-9. *Not included study design*
152. Cascinu S, Catalano G. Have enteric infections a role in 5-fluorouracil-associated diarrhea? *Supportive Care in Cancer* 1995 Sep; 3(5):322-3. *Not included study design*
153. Causey MW, Spencer MP, Steele SR. Clostridium difficile enteritis after colectomy. *American Surgeon* 2009 Dec; 75(12):1203-6. *Not relevant to key questions*
154. Cerquetti M, Molinari A, Sebastianelli A, et al. Characterization of surface layer proteins from different Clostridium difficile clinical isolates. *Microbial pathogenesis* 2000 Jun; 28(6):363-72. *Not on topic*

155. Chachaty E, Depitre C, Mario N, et al. Presence of *Clostridium difficile* and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo. *Antimicrob Agents Chemother* 1992 Sep; 36(9):2009-13. *Not on topic*
156. Chakrabarti S, Lees A, Jones SG, et al. *Clostridium difficile* infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. *Bone marrow transplantation* 2000 Oct; 26(8):871-6. *Not included study design*
157. Chan S, Kelly M, Helme S, et al. Outcomes following colectomy for *Clostridium difficile* colitis. *International Journal Of Surgery* 2009 Feb; 7(1):78-81. *Not included study design*
158. Chandok N, Kamath PS. Working out the bug in the accordion. *Gastroenterol* 2009 Jul; 137(1):e5-6. *Not included publication type*
159. Chang AY, Hui L, Asbury R, et al. Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer. *Cancer Chemotherapy & Pharmacology* 1999; 44(Suppl):S26-8. *Not on topic*
160. Chang KC, Leung CC, Yew WW, et al. Analyses of fluoroquinolones and *Clostridium difficile*-associated diarrhoea in tuberculosis patients. *International Journal of Tuberculosis & Lung Disease* 2009 Mar; 13(3):341-6. *Not on topic*
161. Chang TW, Gorbach SL, Bartlett JG, et al. Bacitracin treatment of antibiotic-associated colitis and diarrhea caused by *Clostridium difficile* toxin. *Gastroenterol* 1980 Jun; 78(6):1584-6. *Not included study design*
162. Chang VT, Nelson K. The role of physical proximity in nosocomial diarrhea. *Clinic Infect Dis* 2000 Sep; 31(3):717-22. *Not included study design*
163. Changela U, Cannon JP, Aneziokoro C, et al. Risk factors and mortality associated with *Clostridium difficile*-associated diarrhoea at a VA hospital. *International journal of antimicrobial agents* 2004 Dec; 24(6):562-6. *Not included study design*
164. Chaudhry R, Joshy L, Kumar L, et al. Changing pattern of *Clostridium difficile* associated diarrhoea in a tertiary care hospital: a 5 year retrospective study. *Indian Journal of Medical Research* 2008 Apr; 127(4):377-82. *Not included study design*
165. Chaun H. Colonic disorders in adult cystic fibrosis. *Can J Gastroenterol* 2001 Sep; 15(9):586-90. *Not included publication type*
166. Chemaly RF, Hanmod SS, Jiang Y, et al. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. *Medicine* 2009 Jul; 88(4):211-20. *Not on topic*
167. Cheng SH, Lu JJ, Young TG, et al. *Clostridium difficile*--associated diseases: comparison of symptomatic infection versus carriage on the basis of risk factors, toxin production, and genotyping results. *Clinic Infect Dis* 1997 Jul; 25(1):157-8. *Not included population*
168. Cherifi S, Robberecht J, Miendje Y. *Saccharomyces cerevisiae* fungemia in an elderly patient with *Clostridium difficile* colitis. *Acta Clinica Belgica* 2004 Jul-Aug; 59(4):223-4. *Not included study design*
169. Cherry RD, Portnoy D, Jabbari M, et al. Metronidazole: an alternate therapy for antibiotic-associated colitis. *Gastroenterol* 1982 May; 82(5 Pt 1):849-51. *Not included study design*
170. Chi DS, Waltzman RJ, Barakat RR, et al. Primary intravenous paclitaxel and platinum chemotherapy for high-risk Stage I epithelial ovarian carcinoma. *European journal of gynaecological oncology* 1999; 20(4):277-80. *Not on topic*
171. Choban PS, Heckler R, Burge JC, et al. Increased incidence of nosocomial infections in obese surgical patients. *American Surgeon* 1995 Nov; 61(11):1001-5. *Not on topic*
172. Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with *Clostridium difficile*-associated disease. *QJM* 2008 Jun; 101(6):445-8. *Not included study design*

173. Christensen PD, Starklint H, Tvede M, et al. Excessive hypercalcaemia and mixed connective tissue disease. *Acta Medica Scandinavica* 1986; 220(3):285-8. *Not included publication type*
174. Church JM, Fazio VW. The significance of quantitative results of *C. difficile* cultures and toxin assays in patients with diarrhea. *Dis Colon Rectum* 1985 Nov; 28(11):765-9. *Not included study design*
175. Church JM, Fazio VW. A role for colonic stasis in the pathogenesis of disease related to *Clostridium difficile*. *Dis Colon Rectum* 1986 Dec; 29(12):804-9. *Not included study design*
176. Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between *Clostridium difficile* and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. *Am J Gastroenterol* 2009 May; 104(5):1162-9. *Not included study design*
177. Cleary RK, Grossmann R, Fernandez FB, et al. Metronidazole may inhibit intestinal colonization with *Clostridium difficile*. *Dis Colon Rectum* 1998 Apr; 41(4):464-7. *Not included population*
178. Cloud J, Noddin L, Pressman A, et al. *Clostridium difficile* strain NAP-1 is not associated with severe disease in a nonepidemic setting. *Clin Gastroenterol Hepatol* 2009 Aug; 7(8):868-73.e2. *Not included study design*
179. Cober ED, Malani PN. *Clostridium difficile* infection in the "oldest" old: clinical outcomes in patients aged 80 and older. *Journal of the American Geriatrics Society* 2009 Apr; 57(4):659-62. *Not included study design*
180. Cohen SH, Tang YJ, Hansen B, et al. Isolation of a toxin B-deficient mutant strain of *Clostridium difficile* in a case of recurrent *C. difficile*-associated diarrhea. *Clin Infect Dis* 1998 Feb; 26(2):410-2. *Not included study design*
181. Colarian J. *Clostridium difficile* colitis following antiviral therapy in the acquired immunodeficiency syndrome. *Am J Med* 1988 Jun; 84(6):1081. *Not included study design*
182. Cooper GS, Lederman MM, Salata RA. A predictive model to identify *Clostridium difficile* toxin in hospitalized patients with diarrhea. *Am J Gastroenterol* 1996 Jan; 91(1):80-4. *Background*
183. Cope A, Anderson J, Wilkins E. *Clostridium difficile* toxin-induced reactive arthritis in a patient with chronic Reiter's syndrome. *Eur J Clin Microbiol Infect Dis* 1992 Jan; 11(1):40-3. *Not included study design*
184. Costas M, Holmes B, Ganner M, et al. Identification of outbreak-associated and other strains of *Clostridium difficile* by numerical analysis of SDS-PAGE protein patterns. *Epidemiology & Infection* 1994 Aug; 113(1):1-12. *Not included study design*
185. Cox GJ, Matsui SM, Lo RS, et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. *Gastroenterol* 1994 Nov; 107(5):1398-407. *Not on topic*
186. Cozart JC, Kalangi SS, Clench MH, et al. *Clostridium difficile* diarrhea in patients with AIDS versus non-AIDS controls. Methods of treatment and clinical response to treatment. *J Clin Gastroenterol* 1993 Apr; 16(3):192-4. *Not included study design*
187. Crabtree T, Aitchison D, Meyers BF, et al. *Clostridium difficile* in cardiac surgery: risk factors and impact on postoperative outcome. *Annals of Thoracic Surgery* 2007 Apr; 83(4):1396-402. *Not included study design*
188. Crabtree TD, Pelletier SJ, Gleason TG, et al. Clinical characteristics and antibiotic utilization in surgical patients with *Clostridium difficile*-associated diarrhea. *American Surgeon* 1999 discussion 511-2; Jun; 65(6):507-11. *Not included study design*
189. Crabtree TD, Pelletier SJ, Raymond DP, et al. Effect of changes in surgical practice on the rate and detection of nosocomial infections: a prospective analysis. *Shock* 2002 Apr; 17(4):258-62. *Not on topic*
190. Crogan NL, Evans BC. *Clostridium difficile*: an emerging epidemic in nursing homes. *Geriatric nursing* 2007 May-Jun; 28(3):161-4. *Not included publication type*

191. Cronberg S, Castor B, Thoren A. Fusidic acid for the treatment of antibiotic-associated colitis induced by *Clostridium difficile*. *Infection* 1984 Jul-Aug; 12(4):276-9. *Not relevant to key questions*
192. Crum-Cianflone N. *Clostridium innocuum* Bacteremia in a patient with acquired immunodeficiency syndrome. *American Journal of the Medical Sciences* 2009 Jun; 337(6):480-2. *Not on topic*
193. Crum-Cianflone N. *Clostridium innocuum* Bacteremia in a patient with acquired immunodeficiency syndrome. *American Journal of the Medical Sciences* 2009 Jun; 337(6):480-2. *Duplicate listing*
194. Cudmore MA, Silva J, Jr., Fekety R, et al. *Clostridium difficile* colitis associated with cancer chemotherapy. *Arch Intern Med* 1982 Feb; 142(2):333-5. *Not included study design*
195. Cunney RJ, Magee C, McNamara E, et al. *Clostridium difficile* colitis associated with chronic renal failure. *Nephrology Dialysis Transplantation* 1998 Nov; 13(11):2842-6. *Not included study design*
196. Cuzzolin L, Zambrieri D, Donini M, et al. Influence of radiotherapy on intestinal microflora in cancer patients. *Journal of Chemotherapy* 1992 Jun; 4(3):176-9. *Not included study design*
197. Cuzzolin L, Zambrieri D, Donini M, et al. Influence of radiotherapy on intestinal microflora in cancer patients. *Journal of Chemotherapy* 1992 Jun; 4(3):176-9. *Duplicate listing*
198. D'Agata EM, Mount DB, Thayer V, et al. Hospital-acquired infections among chronic hemodialysis patients. *American Journal of Kidney Diseases* 2000 Jun; 35(6):1083-8. *Not included study design*
199. Dalton BR, Lye-Maccannell T, Henderson EA, et al. Proton pump inhibitors increase significantly the risk of *Clostridium difficile* infection in a low-endemicity, non-outbreak hospital setting. *Aliment Pharmacol Ther* 2009 Mar 15; 29(6):626-34. *Not on topic*
200. Daniele B, Rossi GB, Losito S, et al. Ischemic colitis associated with paclitaxel. *J Clin Gastroenterol* 2001 Aug; 33(2):159-60. *Not included publication type*
201. Danna PL, Urban C, Bellin E, et al. Role of candida in pathogenesis of antibiotic-associated diarrhoea in elderly inpatients. *Lancet* 1991 Mar 2; 337(8740):511-4. *Not on topic*
202. Dansinger ML, Johnson S, Jansen PC, et al. Protein-losing enteropathy is associated with *Clostridium difficile* diarrhea but not with asymptomatic colonization: a prospective, case-control study. *Clinic Infect Dis* 1996 Jun; 22(6):932-7. *Not included study design*
203. Daw NC, Santana VM, Iacono LC, et al. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. *Journal of Clinical Oncology* 2004 Mar 1; 22(5):829-37. *Not on topic*
204. De Andres S, Ferreiro D, Ibanez M, et al. *Clostridium difficile* colitis associated with valaciclovir. *Pharmacy World & Science* 2004 Feb; 26(1):8-9. *Not included study design*
205. De La Cochetiere MF, Durand T, Lalande V, et al. Effect of antibiotic therapy on human fecal microbiota and the relation to the development of *Clostridium difficile*. *Microbial ecology* 2008 Oct; 56(3):395-402. *Not included study design*
206. de Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and *Clostridium difficile*-associated diarrhea. *Antimicrob Agents Chemother* 1992 Oct; 36(10):2192-6. *Not included treatment type*
207. de Lalla F, Santoro D, Rinaldi E, et al. Teicoplanin in the treatment of infections by staphylococci, *Clostridium difficile* and other gram-positive bacteria. *J Antimicrob Chemother* 1989 Jan; 23(1):131-42. *Not included study design*
208. de Leeuw P, de Mot H, Dugernier T, et al. Primary infection of ascitic fluid with *Clostridium difficile*. *Journal of Infection* 1990 Jul; 21(1):77-80. *Not included publication type*

209. Debast SB, Vaessen N, Choudry A, et al. Successful combat of an outbreak due to *Clostridium difficile* PCR ribotype 027 and recognition of specific risk factors. *Clinical Microbiology & Infection* 2009 May; 15(5):427-34. *Not relevant to key questions*
210. Delmee M, Ramboer I, Van Broeck J, et al. Epidemiology of *Clostridium difficile* toxinotype III, PCR-ribotype 027 associated disease in Belgium, 2006. *Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2006; 11(9):E060914.2. *Not included study design*
211. Depitre C, Avesani V, Delmee M, et al. Detection of *Clostridium difficile* toxins in stools. Comparison between a new enzyme immunoassay for toxin A and other routine tests. *Gastroenterologie clinique et biologique* 1993; 17(4):283-6. *Not relevant to key questions*
212. Deptula A, Kruszynska E, Mikucka A, et al. Toxin A-producing *Clostridium difficile* as an aetiological factor of post-traumatic wound infection. *Journal of medical microbiology* 2009 Jul; 58(Pt 7):963-4. *Not included publication type*
213. Dettenkofer M, Ebner W, Bertz H, et al. Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation. *Bone marrow transplantation* 2003 May; 31(9):795-801. *Not included study design*
214. Dhalla IA, Mamdani MM, Simor AE, et al. Are broad-spectrum fluoroquinolones more likely to cause *Clostridium difficile*-associated disease? *Antimicrob Agents Chemother* 2006 Sep; 50(9):3216-9. *Not included study design*
215. Dhawan B, Chaudhry R, Sharma N. Incidence of *Clostridium difficile* infection: a prospective study in an Indian hospital. *J Hosp Infect* 1999 Dec; 43(4):275-80. *Not included study design*
216. Dial S, Alrasadi K, Manoukian C, et al. Risk of *Clostridium difficile* diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. *CMAJ* 2004 Jul 6; 171(1):33-8. *Not included study design*
217. Dial S, Delaney JA, Schneider V, et al. Proton pump inhibitor use and risk of community-acquired *Clostridium difficile*-associated disease defined by prescription for oral vancomycin therapy. *CMAJ* 2006 Sep 26; 175(7):745-8. *Not included study design*
218. Dial S, Kezouh A, Dascal A, et al. Patterns of antibiotic use and risk of hospital admission because of *Clostridium difficile* infection. *CMAJ* 2008 Oct 7; 179(8):767-72. *Not included study design*
219. Dial S, Kezouh A, Dascal A, et al. Patterns of antibiotic use and risk of hospital admission because of *Clostridium difficile* infection. *CMAJ* 2008 Oct 7; 179(8):767-72. *Duplicate listing*
220. Dickinson RJ, O'Connor HJ, Pinder I, et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. *Gut* 1985 Dec; 26(12):1380-4. *Not included population*
221. Diep JT, Kerr LD, Sarebahi S, et al. Opportunistic infections mimicking gastrointestinal vasculitis in systemic lupus erythematosus. *JCR: Journal of Clinical Rheumatology* 2007 Aug; 13(4):213-6. *Not included study design*
222. Dignan CR, Greenson JK. Can ischemic colitis be differentiated from *C difficile* colitis in biopsy specimens?[see comment]. *American Journal of Surgical Pathology* 1997 Jun; 21(6):706-10. *Not included study design*
223. Djuretic T, Ryan MJ, Fleming DM, et al. Infectious intestinal disease in elderly people. *Communicable Disease Report.CDR Review* 1996 Jul 19; 6(8):R107-12. *Not included study design*
224. Do AN, Fridkin SK, Yechouren A, et al. Risk factors for early recurrent *Clostridium difficile*-associated diarrhea. *Clinic Infect Dis* 1998 Apr; 26(4):954-9. *Not included study design*
225. Donskey CJ, Ray AJ, Hoeny CK, et al. Colonization and infection with multiple nosocomial pathogens among patients colonized with vancomycin-resistant *Enterococcus*. *Infect Control Hosp Epidemiol* 2003 Apr; 24(4):242-5. *Not included study design*

226. Drees M, Snyderman DR, O'Sullivan CE. Repeated enzyme immunoassays have limited utility in diagnosing *Clostridium difficile*. *Eur J Clin Microbiol Infect Dis* 2008 May; 27(5):397-9. *Not included study design*
227. Drummond LJ, McCoubrey J, Smith DG, et al. Changes in sensitivity patterns to selected antibiotics in *Clostridium difficile* in geriatric in-patients over an 18-month period. *Journal of medical microbiology* 2003 Mar; 52(Pt 3):259-63. *Not included study design*
228. Dubberke ER, Butler AM, Hota B, et al. Multicenter study of the impact of community-onset *Clostridium difficile* infection on surveillance for *C. difficile* infection. *Infect Control Hosp Epidemiol* 2009 Jun; 30(6):518-25. *Not included study design*
229. Dubberke ER, Butler AM, Reske KA, et al. Attributable outcomes of endemic *Clostridium difficile*-associated disease in nonsurgical patients. *Emerging Infectious Diseases* 2008 Jul; 14(7):1031-8. *Not included study design*
230. Dubberke ER, Butler AM, Reske KA, et al. Attributable outcomes of endemic *Clostridium difficile*-associated disease in nonsurgical patients. *Emerging Infectious Diseases* 2008 Jul; 14(7):1031-8. *Duplicate listing*
231. Dubberke ER, McMullen KM, Mayfield JL, et al. Hospital-associated *Clostridium difficile* infection: is it necessary to track community-onset disease? *Infect Control Hosp Epidemiol* 2009 Apr; 30(4):332-7. *Not included study design*
232. Dubberke ER, Reske KA, McDonald LC, et al. ICD-9 codes and surveillance for *Clostridium difficile*-associated disease. *Emerging Infectious Diseases* 2006 Oct; 12(10):1576-9. *Not included study design*
233. Dubberke ER, Reske KA, Olsen MA, et al. Short- and long-term attributable costs of *Clostridium difficile*-associated disease in nonsurgical inpatients. *Clinic Infect Dis* 2008 Feb 15; 46(4):497-504. *Not included study design*
234. Dubberke ER, Reske KA, Olsen MA, et al. Evaluation of *Clostridium difficile*-associated disease pressure as a risk factor for *C difficile*-associated disease. *Arch Intern Med* 2007 May 28; 167(10):1092-7. *Not included study design*
235. Dubberke ER, Reske KA, Yan Y, et al. *Clostridium difficile*-associated disease in a setting of endemicity: identification of novel risk factors. *Clinic Infect Dis* 2007 Dec 15; 45(12):1543-9. *Not included study design*
236. Edlund C, Alvan G, Barkholt L, et al. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. *J Antimicrob Chemother* 2000 Nov; 46(5):741-9. *Not on topic*
237. Edlund C, Stark C, Nord CE. The relationship between an increase in beta-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances. *J Antimicrob Chemother* 1994 Jul; 34(1):127-38. *Not on topic*
238. Ehrenpreis ED, Lievens MW, Craig RM. *Clostridium difficile*-associated diarrhea after norfloxacin. *J Clin Gastroenterol* 1990 Apr; 12(2):188-9. *Not included publication type*
239. Eidhin DN, Ryan AW, Doyle RM, et al. Sequence and phylogenetic analysis of the gene for surface layer protein, *slpA*, from 14 PCR ribotypes of *Clostridium difficile*. *Journal of medical microbiology* 2006 Jan; 55(Pt 1):69-83. *Not included study design*
240. Elmer GW. Probiotics: "living drugs". *American Journal of Health-System Pharmacy* 2001 Jun 15; 58(12):1101-9. *Not included publication type*
241. Elmer GW, McFarland LV. Biotherapeutic agents in the treatment of infectious diarrhea. *Gastroenterology clinics of North America* 2001 Sep; 30(3):837-54. *Not included publication type*
242. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections.[see comment]. *JAMA* 1996 Mar 20; 275(11):870-6. *Not included study design*

243. Emery EA, Ahmad S, Koethe JD, et al. Banana flakes control diarrhea in enterally fed patients. *Nutrition in Clinical Practice* 1997 Apr; 12(2):72-5. *Not on topic*
244. Emoto M, Kawarabayashi T, Hachisuga MD, et al. Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. *Gynecologic oncology* 1996 Jun; 61(3):369-72. *Not included publication type*
245. Enzensberger R, Shah PM, Knothe H. Impact of oral ciprofloxacin on the faecal flora of healthy volunteers. *Infection* 1985 Nov-Dec; 13(6):273-5. *Not on topic*
246. Eriksson S, Aronsson B. Medical implications of nosocomial infection with Clostridium difficile. *Scand J Infect Dis* 1989; 21(6):733-4. *Background*
247. Eron LJ, Goldenberg RI, Park CH, et al. Ceftazidime therapy of serious bacterial infections. *Antimicrob Agents Chemother* 1983 Feb; 23(2):236-41. *Not on topic*
248. Eron LJ, Park CH, Hixon DL, et al. Ceftazidime in patients with Pseudomonas infections. *J Antimicrob Chemother* 1983 Jul; 12(Suppl A):161-9. *Not on topic*
249. Fan YJ, Chen SJ, Yu YC, et al. A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial. *Journal of Zhejiang University. Science. B* 2006 Dec; 7(12):987-91. *Not included population*
250. Farrell RJ, LaMont JT. Pathogenesis and clinical manifestations of Clostridium difficile diarrhea and colitis. *Current Topics in Microbiology & Immunology* 2000; 250:109-25. *Not included publication type*
251. Farver DK, Hedge DD, Lee SC. Ramoplanin: a lipoglycopeptide antibiotic. *Ann Pharmacother* 2005 May; 39(5):863-8. *Not included publication type*
252. Fass RJ, Plouffe JF, Russell JA. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. *Am J Med* 1989 Nov 30; 87(5A):164S-8S. *Not on topic*
253. Fawley WN, Wilcox MH. Molecular epidemiology of endemic Clostridium difficile infection. *Epidemiology & Infection* 2001 Jun; 126(3):343-50. *Not included study design*
254. Fekety R. Recent advances in management of bacterial diarrhea. *Reviews of infectious diseases* 1983 Mar-Apr; 5(2):246-57. *Not included publication type*
255. Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. *Clinic Infect Dis* 1997 Mar; 24(3):324-33. *Not included study design*
256. Fekety R, O'Connor R, Silva J. Rifampin and pseudomembranous colitis. *Reviews of infectious diseases* 1983 Jul-Aug; 5(Suppl 3):S524-7. *Not included study design*
257. Fekety R, Silva J, Buggy B, et al. Treatment of antibiotic-associated colitis with vancomycin. *J Antimicrob Chemother* 1984 Dec; 14(Suppl D):97-102. *Not included study design*
258. Feldman RJ, Kallich M, Weinstein MP. Bacteremia due to Clostridium difficile: case report and review of extraintestinal C. difficile infections. *Clinic Infect Dis* 1995 Jun; 20(6):1560-2. *Not included publication type*
259. Fenner L, Frei R, Gregory M, et al. Epidemiology of Clostridium difficile-associated disease at University Hospital Basel including molecular characterisation of the isolates 2006-2007. *Eur J Clin Microbiol Infect Dis* 2008 Dec; 27(12):1201-7. *Not included study design*
260. Fernandez A, Anand G, Friedenber F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. *J Clin Gastroenterol* 2004 May-Jun; 38(5):414-8. *Not included study design*
261. Ferroni A, Merckx J, Ancelle T, et al. Nosocomial outbreak of Clostridium difficile diarrhea in a pediatric service. *Eur J Clin Microbiol Infect Dis* 1997 Dec; 16(12):928-33. *Not included study design*
262. Fille M, Larcher C, Dierich MP, et al. Evaluation of four methods for detection of Clostridium difficile or C. difficile toxin: cytotoxin assay, culture, latex agglutination, and a new rapid immunoassay (C. difficile toxin A test). *Zeitschrift fur Gastroenterologie* 1998 Feb; 36(2):143-9. *Not included population*

263. Fitzpatrick F, McIlvenny G, Oza A, et al. Hospital infection society prevalence survey of Healthcare Associated Infection 2006: comparison of results between Northern Ireland and the Republic of Ireland. *J Hosp Infect* 2008 Jul; 69(3):265-73. *Not included study design*
264. Fletcher KR, Cinalli M. Identification, optimal management, and infection control measures for *Clostridium difficile*-associated disease in long-term care. *Geriatric nursing* 2007 quiz 182; May-Jun; 28(3):171-81. *Not included study design*
265. Follmar KE, Condron SA, Turner II, et al. Treatment of metronidazole-refractory *Clostridium difficile* enteritis with vancomycin. *Surgical Infections* 2008 Apr; 9(2):195-200. *Not included study design*
266. Forward LJ, Tompkins DS, Brett MM. Detection of *Clostridium difficile* cytotoxin and *Clostridium perfringens* enterotoxin in cases of diarrhoea in the community. *Journal of medical microbiology* 2003 Sep; 52(Pt 9):753-7. *Not included study design*
267. Foulke GE, Silva J, Jr. *Clostridium difficile* in the intensive care unit: management problems and prevention issues. *Critical care medicine* 1989 Aug; 17(8):822-6. *Not included study design*
268. Francioli P, Clement M, Geroulanos S, et al. Ceftazidime in severe infections: a Swiss multicentre study. *J Antimicrob Chemother* 1983 Jul; 12(Suppl A):139-46. *Not on topic*
269. Freeman HJ, Rabeneck L, Owen D. Survival after necrotizing enterocolitis of leukemia treated with oral vancomycin. *Gastroenterol* 1981 Oct; 81(4):791-4. *Not on topic*
270. Freeman J, Baines SD, Saxton K, et al. Effect of metronidazole on growth and toxin production by epidemic *Clostridium difficile* PCR ribotypes 001 and 027 in a human gut model. *J Antimicrob Chemother* 2007 Jul; 60(1):83-91. *Not included population*
271. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. *Journal of Clinical Oncology* 1995 Jan; 13(1):165-76. *Not on topic*
272. Frenz MB, McIntyre AS. Reducing delays in the diagnosis and treatment of *Clostridium difficile* diarrhoea. *QJM* 2003 Aug; 96(8):579-82. *Not on topic*
273. Friedenber F, Fernandez A, Kaul V, et al. Intravenous metronidazole for the treatment of *Clostridium difficile* colitis. *Dis Colon Rectum* 2001 Aug; 44(8):1176-80. *Not included study design*
274. Funada H, Ishizaki T, Kuroda T, et al. Cefotaxime-associated diarrhea and *Clostridium difficile*. *Japanese Journal of Antibiotics* 1984 Apr; 37(4):555-7. *Not included publication type*
275. Furrie E, Senok AC, Frank DN, et al. Pondering probiotics. *Clinical Immunology* 2006 Oct; 121(1):19-22. *Not included publication type*
276. Gadducci A, Gargini A, Palla E, et al. Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature. *Anticancer Research* 2005 May-Jun; 25(3c):2509-13. *Not included publication type*
277. Garbutt JM, Littenberg B, Evanoff BA, et al. Enteric carriage of vancomycin-resistant *Enterococcus faecium* in patients tested for *Clostridium difficile*. *Infect Control Hosp Epidemiol* 1999 Oct; 20(10):664-70. *Not included study design*
278. Garcia C, Samalvides F, Vidal M, et al. Epidemiology of *Clostridium difficile*-associated diarrhea in a Peruvian tertiary care hospital. *American Journal of Tropical Medicine & Hygiene* 2007 Nov; 77(5):802-5. *Not included study design*
279. Garcia-Osogobio S, Takahashi T, Gamboa-Dominguez A, et al. Toxic pseudomembranous colitis in a patient with ulcerative colitis. *Inflammatory bowel diseases* 2000 Aug; 6(3):188-90. *Not included publication type*
280. Garey KW, Dao-Tran TK, Jiang ZD, et al. A clinical risk index for *Clostridium difficile* infection in hospitalised patients receiving broad-spectrum antibiotics. *J Hosp Infect* 2008 Oct; 70(2):142-7. *Not included study design*

281. Garey KW, Graham G, Gerard L, et al. Prevalence of diarrhea at a university hospital and association with modifiable risk factors. *Ann Pharmacother* 2006 Jun; 40(6):1030-4. *Not included study design*
282. Garey KW, Jiang ZD, Yadav Y, et al. Peripartum *Clostridium difficile* infection: case series and review of the literature. *American Journal of Obstetrics & Gynecology* 2008 Oct; 199(4):332-7. *Not included study design*
283. Garey KW, Sethi S, Yadav Y, et al. Meta-analysis to assess risk factors for recurrent *Clostridium difficile* infection. *J Hosp Infect* 2008 Dec; 70(4):298-304. *Background*
284. Garibaldi RA. Residential care and the elderly: the burden of infection. *J Hosp Infect* 1999 Dec; 43(Suppl):S9-18. *Not included publication type*
285. Garner CE, Smith S, de Lacy Costello B, et al. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. *FASEB Journal* 2007 Jun; 21(8):1675-88. *Not on topic*
286. Gellad ZF, Alexander BD, Liu JK, et al. Severity of *Clostridium difficile*-associated diarrhea in solid organ transplant patients. *Transplant Infectious Disease* 2007 Dec; 9(4):276-80. *Not included study design*
287. Gentry LO. Role for newer beta-lactam antibiotics in treatment of osteomyelitis. *Am J Med* 1985 Jun 7; 78(6A):134-9. *Not on topic*
288. George WL, Rolfe RD, Harding GK, et al. *Clostridium difficile* and cytotoxin in feces of patients with antimicrobial agent-associated pseudomembranous colitis. *Infection* 1982; 10(4):205-8. *Not included study design*
289. Gerding DN, Olson MM, Peterson LR, et al. *Clostridium difficile*-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. *Arch Intern Med* 1986 Jan; 146(1):95-100. *Not included study design*
290. Geroulanos S, Donfried B, Schumacher F, et al. Cefuroxime versus ceftriaxone prophylaxis in cardiovascular surgery. *Drugs Under Experimental & Clinical Research* 1985; 11(3):201-5. *Not on topic*
291. Ghai S, Ghai V, Sunderji S. Fulminant postcesarean *Clostridium difficile* pseudomembranous colitis. *Obstetrics & Gynecology* 2007 Feb; 109(2 Pt2):541-3. *Not included publication type*
292. Ghai S, Ghai V, Sunderji S. Fulminant postcesarean *Clostridium difficile* pseudomembranous colitis. *Obstetrics & Gynecology* 2007 Feb; 109(2 Pt2):541-3. *Duplicate listing*
293. Gifford AH, Kirkland KB. Risk factors for *Clostridium difficile*-associated diarrhea on an adult hematology-oncology ward. *Eur J Clin Microbiol Infect Dis* 2006 Dec; 25(12):751-5. *Not included study design*
294. Gill VJ, Travis LB, Williams DY. Clinical and microbiological observations on CDC group DF-3, a gram-negative coccobacillus. *J Clin Microbiol* 1991 Aug; 29(8):1589-92. *Not on topic*
295. Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and *Corynebacterium* spp. *Antimicrob Agents Chemother* 2004 Jun; 48(6):2149-52. *Not included population*
296. Gonzalez-Valencia G, Munoz O, Torres JF. Toxigenicity and adherence in *Clostridium difficile* strains isolated from patients with and without diarrhoea. *Archivos de Investigacion Medica* 1991 Apr-Jun; 22(2):189-96. *Not included study design*
297. Goorhuis A, Bakker D, Corver J, et al. Emergence of *Clostridium difficile* infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. *Clinic Infect Dis* 2008 Nov 1; 47(9):1162-70. *Not included study design*
298. Goorhuis A, Van der Kooi T, Vaessen N, et al. Spread and epidemiology of *Clostridium difficile* polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. *Clinic Infect Dis* 2007 Sep 15; 45(6):695-703. *Not included study design*

299. Gopal Rao G, Mahankali Rao CS, Starke I. Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy. *J Antimicrob Chemother* 2003 Mar; 51(3):697-701. *Not on topic*
300. Gopal Rao G, Patel M. Urinary tract infection in hospitalized elderly patients in the United Kingdom: the importance of making an accurate diagnosis in the post broad-spectrum antibiotic era. *J Antimicrob Chemother* 2009 Jan; 63(1):5-6. *Not included study design*
301. Gopal Rao G, Patel M. Urinary tract infection in hospitalized elderly patients in the United Kingdom: the importance of making an accurate diagnosis in the post broad-spectrum antibiotic era. *J Antimicrob Chemother* 2009 Jan; 63(1):5-6. *Duplicate listing*
302. Gorbach SL. Clostridium difficile settles in a nursing home. *Hospital Practice (Office Edition)* 1989 152, 157-60; Feb 15; 24(2):145-9. *Not included publication type*
303. Gorbach SL, Cornick NA, Silva M. Effect of bismuth subsalicylate on fecal microflora. *Reviews of infectious diseases* 1990 Jan-Feb; 12(Suppl 1):S21-3. *Not on topic*
304. Gorenek L, Dizer U, Besirbellioglu B, et al. The diagnosis and treatment of Clostridium difficile in antibiotic-associated diarrhea. *Hepato-gastroenterology* 1999 Jan-Feb; 46(25):343-8. *Not relevant to key questions*
305. Gorschluter M, Glasmacher A, Hahn C, et al. Clostridium difficile infection in patients with neutropenia. *Clinic Infect Dis* 2001 Sep 15; 33(6):786-91. *Not included study design*
306. Gorschluter M, Marklein G, Hofling K, et al. Abdominal infections in patients with acute leukaemia: a prospective study applying ultrasonography and microbiology. *British journal of haematology* 2002 May; 117(2):351-8. *Not included study design*
307. Gould PC, Khawaja FI, Rosenthal WS. Antibiotic-associated hemorrhagic colitis. *Am J Gastroenterol* 1982 Jul; 77(7):491-3. *Not included study design*
308. Gravel D, Miller M, Simor A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. *Clinic Infect Dis* 2009 Mar 1; 48(5):568-76. *Background*
309. Gravel D, Miller M, Simor A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. *Clinic Infect Dis* 2009 Mar 1; 48(5):568-76. *Duplicate listing*
310. Greenstein AJ, Byrn JC, Zhang LP, et al. Risk factors for the development of fulminant Clostridium difficile colitis. *Surgery* 2008 May; 143(5):623-9. *Not included study design*
311. Griebie M, Adams GL. Clostridium difficile colitis following head and neck surgery. Report of cases. *Archives of Otolaryngology* 1985 Aug; 111(8):550-3. *Not included study design*
312. Grube BJ, Heimbach DM, Marvin JA. Clostridium difficile diarrhea in critically ill burned patients. *Archives of Surgery* 1987 Jun; 122(6):655-61. *Not relevant to key questions*
313. Grundfest-Broniatowski S, Quader M, Alexander F, et al. Clostridium difficile colitis in the critically ill. *Dis Colon Rectum* 1996 Jun; 39(6):619-23. *Not on topic*
314. Guenter PA, Settle RG, Perlmutter S, et al. Tube feeding-related diarrhea in acutely ill patients. *Jpen: Journal of Parenteral & Enteral Nutrition* 1991 May-Jun; 15(3):277-80. *Not relevant to key questions*
315. Gujja D, FriedenberG FK. Predictors of serious complications due to Clostridium difficile infection. *Aliment Pharmacol Ther* 2009 Mar 15; 29(6):635-42. *Not on topic*
316. Gunderson CC, Gupta MR, Lopez F, et al. Clostridium difficile colitis in lung transplantation. *Transplant Infectious Disease* 2008 Jul; 10(4):245-51. *Not on topic*

317. Hackford AW, Tally FP, Reinhold RB, et al. Prospective study comparing imipenem-cilastatin with clindamycin and gentamicin for the treatment of serious surgical infections. *Archives of Surgery* 1988 Mar; 123(3):322-6. *Not on topic*
318. Hackford AW, Tally FP, Reinhold RB, et al. Prospective study comparing imipenem-cilastatin with clindamycin and gentamicin for the treatment of serious surgical infections. *Archives of Surgery* 1988 Mar; 123(3):322-6. *Duplicate listing*
319. Hafiz S, McEntegart MG, Morton RS, et al. Clostridium defficiel in the urogenital tract of males and females. *Lancet* 1975 Feb 22; 1(7904):420-1. *Not on topic*
320. Halim HA, Peterson GM, Friesen WT, et al. Case-controlled review of Clostridium difficile-associated diarrhoea in southern Tasmania. *Journal of Clinical Pharmacy & Therapeutics* 1997 Oct-Dec; 22(5-6):391-7. *Not relevant to key questions*
321. Hall C, Curran F, Burdon DW, et al. A randomized trial to compare amoxicillin/clavulanate with metronidazole plus gentamicin in prophylaxis in elective colorectal surgery. *J Antimicrob Chemother* 1989 Nov; 24(Suppl B):195-202. *Not relevant to key questions*
322. Hall J, Horsley M. Diagnosis and management of patients with Clostridium difficile-associated diarrhoea.[see comment]. *Nursing Standard* 2007 quiz 58; Jul 25-31; 21(46):49-56. *Not relevant to key questions*
323. Hall J, Horsley M. Diagnosis and management of patients with Clostridium difficile-associated diarrhoea. *Nursing Standard* 2007 quiz 58; Jul 25-31; 21(46):49-56. *Not included publication type*
324. Hall JF, Berger D. Outcome of colectomy for Clostridium difficile colitis: a plea for early surgical management. *American Journal of Surgery* 2008 Sep; 196(3):384-8. *Not included treatment type*
325. Hall JF, Berger D. Outcome of colectomy for Clostridium difficile colitis: a plea for early surgical management. *American Journal of Surgery* 2008 Sep; 196(3):384-8. *Duplicate listing*
326. Hannah A, Scott AM, Akhurst T, et al. Abnormal colonic accumulation of fluorine-18-FDG in pseudomembranous colitis. *Journal of Nuclear Medicine* 1996 Oct; 37(10):1683-5. *Not on topic*
327. Harbarth S, Samore MH, Carmeli Y. Antibiotic prophylaxis and the risk of Clostridium difficile-associated diarrhoea. *J Hosp Infect* 2001 Jun; 48(2):93-7. *Not relevant to key questions*
328. Hardt C, Berns T, Treder W, et al. Univariate and multivariate analysis of risk factors for severe Clostridium difficile-associated diarrhoea: importance of comorbidity and serum C-reactive protein. *World Journal of Gastroenterology* 2008 Jul 21; 14(27):4338-41. *Not on topic*
329. Hardt C, Berns T, Treder W, et al. Univariate and multivariate analysis of risk factors for severe Clostridium difficile-associated diarrhoea: importance of comorbidity and serum C-reactive protein. *World Journal of Gastroenterology* 2008 Jul 21; 14(27):4338-41. *Duplicate listing*
330. Harrahill M. Clostridium difficile colitis following an open fracture: complications occur, even with straightforward trauma and straightforward decisions. *Journal of Emergency Nursing* 2003 Jun; 29(3):294-6. *Not relevant to key questions*
331. Harsch IA, Hahn EG, Konturek PC. Pseudomembranous colitis after eradication of Helicobacter pylori infection with a triple therapy. *Medical Science Monitor* 2001 Jul-Aug; 7(4):751-4. *Not on topic*
332. Harter C, Schulze B, Goldschmidt H, et al. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. *Bone marrow transplantation* 2006 Feb; 37(4):373-9. *Not relevant to key questions*
333. Hartley MG, Hudson MJ, Swarbrick ET, et al. Sulphasalazine treatment and the colorectal mucosa-associated flora in ulcerative colitis. *Aliment Pharmacol Ther* 1996 Apr; 10(2):157-63. *Not on topic*

334. Hashimoto M, Sugawara Y, Tamura S, et al. Clostridium difficile-associated diarrhea after living donor liver transplantation. World Journal of Gastroenterology 2007 Apr 14; 13(14):2072-6. *Not relevant to key questions*
335. Hassoun A, Ibrahim F. Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis. Am J Geriatr Pharmacother 2007 Mar; 5(1):48-51. *Not relevant to key questions*
336. Hastie KJ, Weymont G, Lewis DA. An outbreak of Clostridium difficile associated diarrhoea in urological practice: a potential consequence of excessive antibiotic prophylaxis? Journal of the Royal College of Surgeons of Edinburgh 1989 Jun; 34(3):146-8. *Not relevant to key questions*
337. Hawker PC, Hine KR, Burdon DW, et al. Fatal pseudomembranous colitis despite eradication of Clostridium difficile. BMJ Clinical Research Ed 1981 Jan 10; 282(6258):109-10. *Not relevant to key questions*
338. Hayakawa T, Imaeda H, Nakamura M, et al. Association of pseudomembranous colitis with Henoch-Schonlein purpura. Journal of gastroenterology 2005 Jun; 40(6):641-5. *Not on topic*
339. Hayetian FD, Read TE, Brozovich M, et al. Ileal perforation secondary to Clostridium difficile enteritis: report of 2 cases. Archives of Surgery 2006 Jan; 141(1):97-9. *Not included publication type*
340. Heard SR, Wren B, Barnett MJ, et al. Clostridium difficile infection in patients with haematological malignant disease. Risk factors, faecal toxins and pathogenic strains. Epidemiology & Infection 1988 Feb; 100(1):63-72. *Not relevant to key questions*
341. Hecht JR, Olinger EJ. Clostridium difficile colitis secondary to intravenous vancomycin. Dig Dis Sci 1989 Jan; 34(1):148-9. *Not relevant to key questions*
342. Heimburger DC, Sockwell DG, Geels WJ. Diarrhea with enteral feeding: prospective reappraisal of putative causes. Nutrition 1994 Sep-Oct; 10(5):392-6. *Not relevant to key questions*
343. Helgason KO, Raby SJ, Kamel HM, et al. Cytomegalovirus colitis in a critically ill patient following elective repair of an abdominal aortic aneurysm. Anaesthesia & Intensive Care 2008 Jan; 36(1):107-9. *Not on topic*
344. Henrich TJ, Krakower D, Bitton A, et al. Clinical risk factors for severe Clostridium difficile-associated disease. Emerging Infectious Diseases 2009 Mar; 15(3):415-22. *Not relevant to key questions*
345. Herpers BL, Vlamincx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009 Jun 15; 48(12):1732-5. *Not relevant to key questions*
346. Heyland DK, Dodek P, Muscedere J, et al. Critical care medicine 2008 Mar; 36(3):737-44. *Not on topic*
347. Hirschhorn LR, Trnka Y, Onderdonk A, et al. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994 Jan; 169(1):127-33. *Not relevant to key questions*
348. Hitchcock J, Jepson AP, Main J, et al. Establishment of an outpatient and home parenteral antimicrobial therapy service at a London teaching hospital: a case series. J Antimicrob Chemother 2009 Sep; 64(3):630-4. *Not on topic*
349. Hogenauer C, Langner C, Beubler E, et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. New England Journal of Medicine 2006 Dec 7; 355(23):2418-26. *Not on topic*
350. Hooker M. Clostridium difficile. Clinical journal of oncology nursing 2007 Dec; 11(6):801-4. *Not on topic*
351. Hopkins MJ, Macfarlane GT. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. Journal of medical microbiology 2002 May; 51(5):448-54. *Not relevant to key questions*

352. Hopkins MJ, Sharp R, Macfarlane GT. Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. *Gut* 2001 Feb; 48(2):198-205. *Not relevant to key questions*
353. Hopkins MJ, Sharp R, Macfarlane GT. Variation in human intestinal microbiota with age. *Digestive & Liver Disease* 2002 Sep; 34(Suppl 2):S12-8. *Not relevant to key questions*
354. Hossain M, Crook TJ, Keoghane SR. Clostridium difficile in urology. *Annals of the Royal College of Surgeons of England* 2008 Jan; 90(1):36-9. *Not on topic*
355. Hossain M, Crook TJ, Keoghane SR. Clostridium difficile in urology. *Annals of the Royal College of Surgeons of England* 2008 Jan; 90(1):36-9. *Duplicate listing*
356. Howitt JR, Grace JW, Schaefer MG, et al. Clostridium difficile-positive stools: a retrospective identification of risk factors. *Am J Infect Control* 2008 Sep; 36(7):488-91. *Duplicate listing*
357. Howitt JR, Grace JW, Schaefer MG, et al. Clostridium difficile-positive stools: a retrospective identification of risk factors. *Am J Infect Control* 2008 Sep; 36(7):488-91. *Not relevant to key questions*
358. Hsu MS, Wang JT, Huang WK, et al. Prevalence and clinical features of Clostridium difficile-associated diarrhea in a tertiary hospital in northern Taiwan. *Journal of Microbiology, Immunology & Infection* 2006 Jun; 39(3):242-8. *Not relevant to key questions*
359. Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. *Gastroenterol* 2009 Apr; 136(4):1206-14. *Not relevant to key questions*
360. Hu MY, Maroo S, Kyne L, et al. A prospective study of risk factors and historical trends in metronidazole failure for Clostridium difficile infection. *Clin Gastroenterol Hepatol* 2008 Dec; 6(12):1354-60. *Duplicate listing*
361. Hu MY, Maroo S, Kyne L, et al. A prospective study of risk factors and historical trends in metronidazole failure for Clostridium difficile infection. *Clin Gastroenterol Hepatol* 2008 Dec; 6(12):1354-60. *Not relevant to key questions*
362. Husain A, Aptaker L, Spriggs DR, et al. Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. *Gynecologic oncology* 1998 Oct; 71(1):104-7. *Not relevant to key questions*
363. Hutin Y, Molina JM, Casin I, et al. Risk factors for Clostridium difficile-associated diarrhoea in HIV-infected patients. *AIDS* 1993 Nov; 7(11):1441-7. *Not relevant to key questions*
364. Ibrahim EH, Mehringer L, Prentice D, et al. Early versus late enteral feeding of mechanically ventilated patients: results of a clinical trial. *Jpen: Journal of Parenteral & Enteral Nutrition* 2002 May-Jun; 26(3):174-81. *Not on topic*
365. Imase K, Takahashi M, Tanaka A, et al. Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota. *Microbiology & Immunology* 2008 Mar; 52(3):156-61. *Not relevant to key questions*
366. Impallomeni M, Galletly NP, Wort SJ, et al. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. *BMJ* 1995 Nov 18; 311(7016):1345-6. *Not relevant to key questions*
367. Incavo SJ, Muller DL, Krag MH, et al. Vertebral osteomyelitis caused by Clostridium difficile. A case report and review of the literature. *Spine* 1988 Jan; 13(1):111-3. *Duplicate listing*
368. Incavo SJ, Muller DL, Krag MH, et al. Vertebral osteomyelitis caused by Clostridium difficile. A case report and review of the literature. *Spine* 1988 Jan; 13(1):111-3. *Not relevant to key questions*

369. Indra A, Schmid D, Huhulescu S, et al. Characterization of clinical *Clostridium difficile* isolates by PCR ribotyping and detection of toxin genes in Austria, 2006-2007. *Journal of medical microbiology* 2008 Jun; 57(Pt 6):702-8. *Not relevant to key questions*
370. Iseman DT, Hamza SH, Eloubeidi MA. Pseudomembranous (*Clostridium difficile*) colitis. *Gastrointestinal endoscopy* 2002 Dec; 56(6):907. *Not relevant to key questions*
371. Issa M, Vijayapal A, Graham MB, et al. Impact of *Clostridium difficile* on inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2007 Mar; 5(3):345-51. *Not relevant to key questions*
372. Itani KM, Wilson SE, Awad SS, et al. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. *New England Journal of Medicine* 2006 Dec 21; 355(25):2640-51. *Not on topic*
373. Ito Y, Moriwaki H, Muto Y, et al. Effect of lactulose on short-chain fatty acids and lactate production and on the growth of faecal flora, with special reference to *Clostridium difficile*. *Journal of medical microbiology* 1997 Jan; 46(1):80-4. *Not on topic*
374. Jain S, Koirala J, Castro-Pavia F. Isolated gastrointestinal histoplasmosis: case report and review of the literature. *Southern medical journal* 2004 Feb; 97(2):172-4. *Not on topic*
375. Jansen JM, Bartelsman JF. Fulminant *Clostridium difficile* colitis. *Gut* 2008 24; Jan; 57(1):15. *Not relevant to key questions*
376. Jarvis B, Shevchuk YM. Recurrent *Clostridium difficile* diarrhea associated with mitoxantrone and etoposide: a case report and review. *Pharmacotherapy* 1997 May-Jun; 17(3):606-11. *Not relevant to key questions*
377. Jarvis W, Nunez-Montiel O, Thompson F, et al. Comparison of bacterial isolation, cytotoxicity assay, and counterimmunoelectrophoresis for the detection of *Clostridium difficile* and its toxin. *J Infect Dis* 1983 Apr; 147(4):778. *Not relevant to key questions*
378. Jen MH, Holmes AH, Bottle A, et al. Descriptive study of selected healthcare-associated infections using national Hospital Episode Statistics data 1996-2006 and comparison with mandatory reporting systems. *J Hosp Infect* 2008 Dec; 70(4):321-7. *Not on topic*
379. Jennings LJ, Hanumadass M. Silver sulfadiazine induced *Clostridium difficile* toxic megacolon in a burn patient: case report. *Burns* 1998 Nov; 24(7):676-9. *Not included study design*
380. Jensen GL, Bross JE, Bourbeau PP, et al. Risk factors for *Clostridium difficile* stool cytotoxin b among critically ill patients: role of sucralfate. *J Infect Dis* 1994 Jul; 170(1):227-30. *Not relevant to key questions*
381. Jewkes J, Larson HE, Price AB, et al. Aetiology of acute diarrhoea in adults. *Gut* 1981 May; 22(5):388-92. *Not included study design*
382. Jiang ZD, DuPont HL, Garey K, et al. A common polymorphism in the interleukin 8 gene promoter is associated with *Clostridium difficile* diarrhea. *Am J Gastroenterol* 2006 May; 101(5):1112-6. *Not relevant to key questions*
383. Jiang ZD, Garey KW, Price M, et al. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with *Clostridium difficile*-associated diarrhea. *Clin Gastroenterol Hepatol* 2007 Aug; 5(8):964-8. *Not relevant to key questions*
384. Jillella AP, Ustun C, Robach E, et al. Infectious complications in patients receiving mobilization chemotherapy for autologous peripheral blood stem cell collection. *Journal of hematotherapy & stem cell research* 2003 Apr; 12(2):155-60. *Not on topic*
385. Job ML, Jacobs NF, Jr. Drug-induced *Clostridium difficile*-associated disease. *Drug Safety* 1997 Jul; 17(1):37-46. *Not included publication type*

386. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing *Clostridium difficile* infection. *Dig Dis Sci* 2010 Feb; 55(2):415-20. *Not relevant to key questions*
387. Johal SS, Hammond J, Solomon K, et al. *Clostridium difficile* associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. *Gut* 2004 May; 53(5):673-7. *Not relevant to key questions*
388. Johal SS, Lambert CP, Hammond J, et al. Colonic IgA producing cells and macrophages are reduced in recurrent and non-recurrent *Clostridium difficile* associated diarrhoea. *Journal of clinical pathology* 2004 Sep; 57(9):973-9. *Not relevant to key questions*
389. Johnson DK, Balmaseda MT. Pseudomembranous colitis in spinal cord injury. *Archives of Physical Medicine & Rehabilitation* 1985 Jun; 66(6):394-6. *Not on topic*
390. Johnson EM, Remucal MJ, Gillingham KJ, et al. Complications and risks of living donor nephrectomy. *Transplantation* 1997 Oct 27; 64(8):1124-8. *Not on topic*
391. Johnson S, Gerding DN, Janoff EN. Systemic and mucosal antibody responses to toxin A in patients infected with *Clostridium difficile*. *J Infect Dis* 1992 Dec; 166(6):1287-94. *Not relevant to key questions*
392. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic *Clostridium difficile* carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. *Annals of Internal Medicine* 1992 Aug 15; 117(4):297-302. *Not relevant to key questions*
393. Johnson S, Sambol SP, Brazier JS, et al. International typing study of toxin A-negative, toxin B-positive *Clostridium difficile* variants. *J Clin Microbiol* 2003 Apr; 41(4):1543-7. *Not relevant to key questions*
394. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent *Clostridium difficile*-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. *Clinic Infect Dis* 2007 Mar 15; 44(6):846-8. *Not relevant to key questions*
395. Johnson S, Schriever C, Patel U, et al. Rifaximin Redux: treatment of recurrent *Clostridium difficile* infections with rifaximin immediately post-vancomycin treatment. *Anaerobe* 2009 Dec; 15(6):290-1. *Not relevant to key questions*
396. Jones EM, MacGowan AP. Back to basics in management of *Clostridium difficile* infections. *Lancet* 1998 Aug 15; 352(9127):505-6. *Not relevant to key questions*
397. Jones S, Yu VL, Johnson JT, et al. Pharmacokinetic and therapeutic trial of sultamicillin in acute sinusitis. *Antimicrob Agents Chemother* 1985 Dec; 28(6):832-3. *Not on topic*
398. Joseph R, Demeyer D, Vanrenterghem D, et al. First isolation of *Clostridium difficile* PCR ribotype 027, toxinotype III in Belgium. *Euro Surveillance: Bulletin European sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2005 Oct; 10(10):E051020.4. *Not relevant to key questions*
399. Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe *clostridium difficile*-associated diarrhea. *Am J Infect Control* 2007 Mar; 35(2):131-7. *Duplicate listing*
400. Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe *clostridium difficile*-associated diarrhea. *Am J Infect Control* 2007 Mar; 35(2):131-7. *Not relevant to key questions*
401. Jung K, Aronsson B. Rapid diagnosis of *Clostridium difficile*-associated diarrhoea using a latex agglutination test. *APMIS* 1990 Jul; 98(7):652-4. *Not relevant to key questions*

402. Karasawa T, Nojiri T, Hayashi Y, et al. Laboratory diagnosis of toxigenic *Clostridium difficile* by polymerase chain reaction: presence of toxin genes and their stable expression in toxigenic isolates from Japanese individuals. *Journal of gastroenterology* 1999 Feb; 34(1):41-5. *Not relevant to key questions*
403. Karlstrom O, Fryklund B, Tullus K, et al. A prospective nationwide study of *Clostridium difficile*-associated diarrhea in Sweden. The Swedish *C. difficile* Study Group. *Clinic Infect Dis* 1998 Jan; 26(1):141-5. *Not relevant to key questions*
404. Katchar K, Taylor CP, Tummala S, et al. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent *Clostridium difficile*-associated disease. *Clin Gastroenterol Hepatol* 2007 Jun; 5(6):707-13. *Not relevant to key questions*
405. Kato H, Kato N, Watanabe K, et al. Identification of toxin A-negative, toxin B-positive *Clostridium difficile* by PCR. *J Clin Microbiol* 1998 Aug; 36(8):2178-82. *Not relevant to key questions*
406. Kato H, Kita H, Karasawa T, et al. Colonisation and transmission of *Clostridium difficile* in healthy individuals examined by PCR ribotyping and pulsed-field gel electrophoresis. *Journal of medical microbiology* 2001 Aug; 50(8):720-7. *Not relevant to key questions*
407. Katz DA, Bates DW, Rittenberg E, et al. Predicting *Clostridium difficile* stool cytotoxin results in hospitalized patients with diarrhea. *J Gen Intern Med* 1997 Jan; 12(1):57-62. *Duplicate listing*
408. Katz DA, Lynch ME, Littenberg B. Clinical prediction rules to optimize cytotoxin testing for *Clostridium difficile* in hospitalized patients with diarrhea. *Am J Med* 1996 May; 100(5):487-95. *Not relevant to key questions*
409. Kaukoranta-Tolvanen SS, Renkonen OV, Gordin A, et al. Effect of erythromycin acistrate and erythromycin stearate on human colonic microflora. *Scand J Infect Dis* 1989; 21(6):717-20. *Not included population*
410. Kawamura Y, Fujiwara H, Mishima N, et al. First *Streptococcus agalactiae* isolates highly resistant to quinolones, with point mutations in *gyrA* and *parC*. *Antimicrob Agents Chemother* 2003 Nov; 47(11):3605-9. *Not on topic*
411. Kawecki D, Chmura A, Pacholczyk M, et al. Bacterial infections in the early period after liver transplantation: etiological agents and their susceptibility. *Medical Science Monitor* 2009 Dec; 15(12):CR628-37. *Not relevant to key questions*
412. Kawecki D, Chmura A, Pacholczyk M, et al. Detection of *Clostridium difficile* in stool samples from patients in the early period after liver transplantation. *Transplantation proceedings* 2007 Nov; 39(9):2812-5. *Not on topic*
413. Kazakova SV, Ware K, Baughman B, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of *Clostridium difficile*. *Arch Intern Med* 2006 Dec 11-25; 166(22):2518-24. *Not relevant to key questions*
414. Kelly CP. A 76-year-old man with recurrent *Clostridium difficile*-associated diarrhea: review of *C. difficile* infection.[see comment]. *JAMA* 2009 Mar 4; 301(9):954-62. *Not relevant to key questions*
415. Kelly CP. A 76-year-old man with recurrent *Clostridium difficile*-associated diarrhea: review of *C. difficile* infection. *JAMA* 2009 Mar 4; 301(9):954-62. *Not included publication type*
416. Kelly CP, Chetham S, Keates S, et al. Survival of anti-*Clostridium difficile* bovine immunoglobulin concentrate in the human gastrointestinal tract. *Antimicrob Agents Chemother* 1997 Feb; 41(2):236-41. *Not relevant to key questions*
417. Kelly MT, Champagne SG, Sherlock CH, et al. Commercial latex agglutination test for detection of *Clostridium difficile*-associated diarrhea. *J Clin Microbiol* 1987 Jul; 25(7):1244-7. *Not relevant to key questions*
418. Kenneally C, Rosini JM, Skrupky LP, et al. Analysis of 30-day mortality for *clostridium difficile*-associated disease in the ICU setting. *Chest* 2007 Aug; 132(2):418-24. *Not relevant to key questions*

419. Kent KC, Rubin MS, Wroblewski L, et al. The impact of *Clostridium difficile* on a surgical service: a prospective study of 374 patients. *Annals of Surgery* 1998 Feb; 227(2):296-301. *Not relevant to key questions*
420. Kerr RB, McLaughlin DI, Sonnenberg LW. Control of *Clostridium difficile* colitis outbreak by treating asymptomatic carriers with metronidazole. *Am J Infect Control* 1990 Oct; 18(5):332-5. *Not relevant to key questions*
421. Kerr RB, McLaughlin DI, Sonnenberg LW. Control of *Clostridium difficile* colitis outbreak by treating asymptomatic carriers with metronidazole. *Am J Infect Control* 1990 Oct; 18(5):332-5. *Duplicate listing*
422. Keven K, Basu A, Re L, et al. *Clostridium difficile* colitis in patients after kidney and pancreas-kidney transplantation. *Transplant Infectious Disease* 2004 Mar; 6(1):10-4. *Not on topic*
423. Khan MA, Brunt EM, Longo WE, et al. Persistent *Clostridium difficile* colitis: a possible etiology for the development of collagenous colitis. *Dig Dis Sci* 2000 May; 45(5):998-1001. *Not relevant to key questions*
424. Kilic A, Schuchert MJ, Pennathur A, et al. Minimally invasive myotomy for achalasia in the elderly. *Surgical endoscopy* 2008 Apr; 22(4):862-5. *Not on topic*
425. Kim KA, Wry P, Hughes E, Jr., et al. *Clostridium difficile* small-bowel enteritis after total proctocolectomy: a rare but fatal, easily missed diagnosis. Report of a case. *Dis Colon Rectum* 2007 Jun; 50(6):920-3. *Not on topic*
426. Kim SW, Peck KR, Jung SI, et al. *Pseudomonas aeruginosa* as a potential cause of antibiotic-associated diarrhea. *Journal of Korean medical science* 2001 Dec; 16(6):742-4. *Not on topic*
427. Kimura Y, Sato K, Tokuda H, et al. Combination therapy with direct hemoperfusion using polymyxin B-immobilized fiber and oral vancomycin improves fulminant pseudomembranous colitis by reducing the elevated endogenous cannabinoids and inflammatory cytokines: report of a case. *Hepato-gastroenterology* 2008 May-Jun; 55(84):956-8. *Not relevant to key questions*
428. Klarin B, Wullt M, Palmquist I, et al. *Lactobacillus plantarum* 299v reduces colonisation of *Clostridium difficile* in critically ill patients treated with antibiotics. *Acta Anaesthesiologica Scandinavica* 2008 Sep; 52(8):1096-102. *Not relevant to key questions*
429. Kleinkauf N, Weiss B, Jansen A, et al. Confirmed cases and report of clusters of severe infections due to *Clostridium difficile* PCR ribotype 027 in Germany. *Euro Surveillance: Bulletin European sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2007 Nov; 12(11):E071115.2. *Not on topic*
430. Klipfel AA, Schein M, Fahoum B, et al. Acute abdomen and *Clostridium difficile* colitis: still a lethal combination. *Digestive surgery* 2000; 17(2):160-3. *Not relevant to key questions*
431. Knudsen JD, Tvede M. Demonstration of toxin A and B by polymerase chain reaction and McCoy cell assay in clinical isolates of *Clostridium difficile* from Denmark. *APMIS* 1993 Jan; 101(1):18-22. *Not relevant to key questions*
432. Kocar IH, Caliskaner Z, Pay S, et al. *Clostridium difficile* infection in patients with reactive arthritis of undetermined etiology. *Scandinavian journal of rheumatology* 1998; 27(5):357-62. *Not relevant to key questions*
433. Kofsky P, Rosen L, Reed J, et al. *Clostridium difficile*--a common and costly colitis. *Dis Colon Rectum* 1991 Mar; 34(3):244-8. *Not on topic*
434. Koga H, Aoyagi K, Yoshimura R, et al. Can quinolones cause hemorrhagic colitis of late onset? Report of three cases. *Dis Colon Rectum* 1999 Nov; 42(11):1502-4. *Not on topic*

435. Koh TH, Tan AL, Tan ML, et al. Epidemiology of *Clostridium difficile* infection in a large teaching hospital in Singapore. *Pathology* 2007 Aug; 39(4):438-42. *Not relevant to key questions*
436. Komatsu M, Kato H, Aihara M, et al. High frequency of antibiotic-associated diarrhea due to toxin A-negative, toxin B-positive *Clostridium difficile* in a hospital in Japan and risk factors for infection. *European J Clin Microbiol & Infectious Diseases* 2003 Sep; 22(9):525-9. *Not relevant to key questions*
437. Koning CJ, Jonkers DM, Stobberingh EE, et al. The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxicillin. *Am J Gastroenterol* 2008 Jan; 103(1):178-89. *Not relevant to key questions*
438. Koss K, Clark MA, Sanders DS, et al. The outcome of surgery in fulminant *Clostridium difficile* colitis. *Colorectal Disease* 2006 Feb; 8(2):149-54. *Not relevant to key questions*
439. Kreisel D, Savel TG, Silver AL, et al. Surgical antibiotic prophylaxis and *Clostridium difficile* toxin positivity. *Archives of Surgery* 1995 Sep; 130(9):989-93. *Not relevant to key questions*
440. Krogsgaard K, Boesgaard S, Aldershvile J, et al. Cytomegalovirus infection rate among heart transplant patients in relation to anti-thymocyte immunoglobulin induction therapy. *Copenhagen Heart Transplant Group. Scand J Infect Dis* 1994; 26(3):239-47. *Not on topic*
441. Kuipers EJ, Surawicz CM. *Clostridium difficile* infection. *Lancet* 2008 May 3; 371(9623):1486-8. *Not included publication type*
442. Kumar B, Vaishnavi C, Sandhu K, et al. *Clostridium difficile* toxin assay in psoriatic patients. *Tropical Gastroenterology* 2004 Oct-Dec; 25(4):164-7. *Not relevant to key questions*
443. Kunin CM, Dobbins JJ, Melo JC, et al. Infectious complications in four long-term recipients of the Jarvik-7 artificial heart. *JAMA* 1988 Feb 12; 259(6):860-4. *Not on topic*
444. Kuntz JL, Cavanaugh JE, Becker LK, et al. *Clostridium difficile*-associated disease in patients in a small rural hospital. *Infect Control Hosp Epidemiol* 2007 Nov; 28(11):1236-9. *Not relevant to key questions*
445. Kurd MF, Pulido L, Joshi A, et al. *Clostridium difficile* infection after total joint arthroplasty: who is at risk? *Journal of Arthroplasty* 2008 Sep; 23(6):839-42. *Not relevant to key questions*
446. Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial diarrhea due to *Clostridium difficile*. *Clinic Infect Dis* 2002 Feb 1; 34(3):346-53. *Not relevant to key questions*
447. Kyne L, Merry C, O'Connell B, et al. Simultaneous outbreaks of two strains of toxigenic *Clostridium difficile* in a general hospital. *J Hosp Infect* 1998 Feb; 38(2):101-12. *Not relevant to key questions*
448. Kyne L, Merry C, O'Connell B, et al. Factors associated with prolonged symptoms and severe disease due to *Clostridium difficile*. *Age Ageing* 1999 Mar; 28(2):107-13. *Not relevant to key questions*
449. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of *Clostridium difficile* and serum levels of IgG antibody against toxin A. *New England Journal of Medicine* 2000 Feb 10; 342(6):390-7. *Not relevant to key questions*
450. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent *Clostridium difficile* diarrhoea. *Lancet* 2001 Jan 20; 357(9251):189-93. *Not relevant to key questions*
451. Labbe AC, Poirier L, Maccannell D, et al. *Clostridium difficile* infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. *Antimicrob Agents Chemother* 2008 Sep; 52(9):3180-7. *Duplicate listing*
452. Labbe AC, Poirier L, Maccannell D, et al. *Clostridium difficile* infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. *Antimicrob Agents Chemother* 2008 Sep; 52(9):3180-7. *Not relevant to key questions*

453. Lahn M, Tyler G, Daubener W, et al. Improvement of *Clostridium difficile* isolation by heat-shock and typing of the isolated strains by SDS-PAGE. *European journal of epidemiology* 1993 May; 9(3):327-34. *Not relevant to key questions*
454. Lai KK, Melvin ZS, Menard MJ, et al. *Clostridium difficile*-associated diarrhea: epidemiology, risk factors, and infection control. *Infect Control Hosp Epidemiol* 1997 Sep; 18(9):628-32. *Not relevant to key questions*
455. Lam MY, Feller ER, Lonks JR, et al. Inflammatory bowel disease potpourri: a vignette-based discussion. *Medicine & Health, Rhode Island* 2009 Apr; 92(4):121-4. *Not relevant to key questions*
456. Lam S, Singer C, Tucci V, et al. The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study. *Am J Infect Control* 1995 Jun; 23(3):170-80. *Duplicate listing*
457. Lambert ML, Mertens K, Ramboer I, et al. Nation-wide prospective surveillance of *Clostridium difficile* infections in hospitals in Belgium, July 2007-June 2008. *Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2009; 14(14):2-4. *Not relevant to key questions*
458. LaMont JT, Trnka YM. Therapeutic implications of *Clostridium difficile* toxin during relapse of chronic inflammatory bowel disease. *Lancet* 1980 Feb 23; 1(8165):381-3. *Not on topic*
459. Lamontagne F, Labbe AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant *Clostridium difficile* colitis during an epidemic caused by a hypervirulent strain. *Annals of Surgery* 2007 Feb; 245(2):267-72. *Background*
460. Larson AM, Fung AM, Fang FC. Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic *Clostridium difficile*. *J Clin Microbiol* 2010 Jan; 48(1):124-30. *Not relevant to key questions*
461. Lau SK, Woo PC, Leung KW, et al. Emergence of cotrimoxazole- and quinolone-resistant *Campylobacter* infections in bone marrow transplant recipients. *Eur J Clin Microbiol Infect Dis* 2002 Feb; 21(2):127-9. *Not on topic*
462. Lauritsen K, Laursen LS, Bukhave K, et al. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and *Clostridium difficile* colitis. *Gastroenterol* 1988 Jul; 95(1):11-7. *Not on topic*
463. Law EJ, Kanavage CB, Assad R, et al. Massive haemorrhage due to rectosigmoid ulcers in a patient with extensive burns. *Burns* 1992 Apr; 18(2):167-9. *Not on topic*
464. Lawrence SJ, Puzniak LA, Shadel BN, et al. *Clostridium difficile* in the intensive care unit: epidemiology, costs, and colonization pressure. *Infect Control Hosp Epidemiol* 2007 Feb; 28(2):123-30. *Not relevant to key questions*
465. Le D, Rusin W, Hill B, et al. Post-operative antibiotic use in nonperforated appendicitis. *American Journal of Surgery* 2009 Dec; 198(6):748-52. *Not relevant to key questions*
466. Leal J, Gregson DB, Ross T, et al. Epidemiology of *Clostridium* species bacteremia in Calgary, Canada, 2000-2006. *Journal of Infection* 2008 Sep; 57(3):198-203. *Not on topic*
467. Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody correlates with protection from recurrent *Clostridium difficile* infection (CDI). *Vaccine* 2010 Jan 22; 28(4):965-9. *Not relevant to key questions*
468. LeBlanc L, Pepin J, Toulouse K, et al. Fluoroquinolones and risk for methicillin-resistant *Staphylococcus aureus*, Canada. *Emerging Infectious Diseases* 2006 Sep; 12(9):1398-405. *Not on topic*
469. Lee JS, Auyeung TW. A comparison of two feeding methods in the alleviation of diarrhoea in older tube-fed patients: a randomised controlled trial. *Age Ageing* 2003 Jul; 32(4):388-93. *Not on topic*
470. Lee KS, Shin WG, Jang MK, et al. Who are susceptible to pseudomembranous colitis among patients with presumed antibiotic-associated diarrhea? *Dis Colon Rectum* 2006 Oct; 49(10):1552-8. *Not on topic*

471. Leffler DA, Lamont JT. A 69-year-old woman presenting to the hospital with 48 hours of abdominal pain and diarrhea. *Clin Gastroenterol Hepatol* 2009 Oct; 7(10):1046-8. *Not relevant to key questions*
472. Lemann F, Chambon C, Barbut F, et al. Arbitrary primed PCR rules out *Clostridium difficile* cross-infection among patients in a haematology unit. *J Hosp Infect* 1997 Feb; 35(2):107-15. *Not relevant to key questions*
473. Leung AC, Orange G, McLay A, et al. *Clostridium difficile*-associated colitis in uremic patients. *Clinical nephrology* 1985 Nov; 24(5):242-8. *Not on topic*
474. Levett PN. *Clostridium difficile* in habitats other than the human gastro-intestinal tract. *Journal of Infection* 1986 May; 12(3):253-63. *Not included publication type*
475. Levy DG, Stergachis A, McFarland LV, et al. Antibiotics and *Clostridium difficile* diarrhea in the ambulatory care setting. *Clinical therapeutics* 2000 Jan; 22(1):91-102. *Not relevant to key questions*
476. Lew MA, Kehoe K, Ritz J, et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. *Journal of Clinical Oncology* 1995 Jan; 13(1):239-50. *Not on topic*
477. Lewis R. Investigation of *Clostridium difficile* diarrhoea in a district general hospital: room for improvement? *J Hosp Infect* 1987 Nov; 10(3):243-7. *Not on topic*
478. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of *Clostridium difficile*-associated diarrhea: a randomized, controlled study. *Clin Gastroenterol Hepatol* 2005 May; 3(5):442-8. *Not relevant to key questions*
479. Lidman C, Burman LG, Lagergren A, et al. Limited value of routine microbiological diagnostics in patients hospitalized for community-acquired pneumonia. *Scand J Infect Dis* 2002; 34(12):873-9. *Not on topic*
480. Linden SK, Florin TH, McGuckin MA. Mucin dynamics in intestinal bacterial infection. *PLoS ONE [Electronic Resource]* 2008; 3(12):e3952. *Not on topic*
481. Linden SK, Florin TH, McGuckin MA. Mucin dynamics in intestinal bacterial infection. *PLoS ONE [Electronic Resource]* 2008; 3(12):e3952. *Duplicate listing*
482. Linneberg A, Ostergaard C, Tvede M, et al. IgG antibodies against microorganisms and atopic disease in Danish adults: the Copenhagen Allergy Study. *Journal of Allergy & Clinical Immunology* 2003 Apr; 111(4):847-53. *Not on topic*
483. Lode H, Von der Hoh N, Ziege S, et al. Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. *Scand J Infect Dis* 2001; 33(12):899-903. *Not on topic*
484. Lofgren RP, Tadlock LM, Soltis RD. Acute oligoarthritis associated with *Clostridium difficile* pseudomembranous colitis. *Arch Intern Med* 1984 Mar; 144(3):617-9. *Not on topic*
485. Long S, Fenelon L, Fitzgerald S, et al. First isolation and report of clusters of *Clostridium difficile* PCR 027 cases in Ireland. *Euro Surveillance: Bulletin European sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2007 Apr; 12(4):E070426.3. *Not on topic*
486. Longo WE, Mazuski JE, Virgo KS, et al. Outcome after colectomy for *Clostridium difficile* colitis. *Dis Colon Rectum* 2004 Oct; 47(10):1620-6. *Not included treatment type*
487. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *New England Journal of Medicine* 2005 Dec 8; 353(23):2442-9. *Background*
488. Loosli J, Gyr K, Stalder H, et al. Etiology of acute infectious diarrhea in a highly industrialized area of Switzerland. *Gastroenterol* 1985 Jan; 88(1 Pt 1):75-9. *Not on topic*
489. Louie T, Miller M, Donskey C, et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with *Clostridium difficile* infection. *Antimicrob Agents Chemother* 2009 Jan; 53(1):223-8. *Duplicate listing*

490. Louthier J. Enteric precautions for *Clostridium difficile*. *American Journal of Nursing* 1996 Apr; 96(4):19. *Not relevant to key questions*
491. Lowe DO, Mamdani MM, Kopp A, et al. Proton pump inhibitors and hospitalization for *Clostridium difficile*-associated disease: a population-based study. *Clinic Infect Dis* 2006 Nov 15; 43(10):1272-6. *Not relevant to key questions*
492. Loy CE. Antibiotic-associated diarrhoea: an overlooked aetiology? *British journal of biomedical science* 2005; 62(4):166-9. *Not on topic*
493. Lu SS, Schwartz JM, Simon DM, et al. *Clostridium difficile*-associated diarrhea in patients with HIV positivity and AIDS: a prospective controlled study. *Am J Gastroenterol* 1994 Aug; 89(8):1226-9. *Not on topic*
494. Lumpkins K, Bochicchio GV, Joshi M, et al. *Clostridium difficile* infection in critically injured trauma patients. *Surgical Infections* 2008 Oct; 9(5):497-501. *Not on topic*
495. Lundeen SJ, Otterson MF, Binion DG, et al. *Clostridium difficile* enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy. *Journal of Gastrointestinal Surgery* 2007 Feb; 11(2):138-42. *Not included treatment type*
496. MacGowan AP, Feeney R, Brown I, et al. Health care resource utilization and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop *Clostridium difficile*-associated diarrhoea. *J Antimicrob Chemother* 1997 Apr; 39(4):537-41. *Not relevant to key questions*
497. MacGregor G, Smith AJ, Thakker B, et al. Yoghurt biotherapy: contraindicated in immunosuppressed patients? *Postgrad Med J* 2002 Jun; 78(920):366-7. *Duplicate listing*
498. Magee JT, Brazier JS, Hosein IK, et al. An investigation of a nosocomial outbreak of *Clostridium difficile* by pyrolysis mass spectrometry. *Journal of medical microbiology* 1993 Nov; 39(5):345-51. *Not relevant to key questions*
499. Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. *Am J Gastroenterol* 2005 Feb; 100(2):373-82. *Not on topic*
500. Manabe YC, Vinetz JM, Moore RD, et al. *Clostridium difficile* colitis: an efficient clinical approach to diagnosis. *Annals of Internal Medicine* 1995 Dec 1; 123(11):835-40. *Background*
501. Manian FA, Aradhyula S, Greisnauer S, et al. Is it *Clostridium difficile* infection or something else? A case-control study of 352 hospitalized patients with new-onset diarrhea. *Southern medical journal* 2007 Aug; 100(8):782-6. *Not relevant to key questions*
502. Mann SD, Pitt J, Springall RG, et al. *Clostridium difficile* infection--an unusual cause of refractory pouchitis: report of a case. *Dis Colon Rectum* 2003 Feb; 46(2):267-70. *Not on topic*
503. Mantzaris GJ, Archavlis E, Christoforidis P, et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. *Am J Gastroenterol* 1997 Mar; 92(3):454-6. *Not on topic*
504. Marciniak C, Chen D, Stein AC, et al. Prevalence of *Clostridium difficile* colonization at admission to rehabilitation. *Archives of Physical Medicine & Rehabilitation* 2006 Aug; 87(8):1086-90. *Not on topic*
505. Marcon AP, Gamba MA, Vianna LA. Nosocomial diarrhea in the intensive care unit. *Brazilian Journal of Infectious Diseases* 2006 Dec; 10(6):384-9. *Not relevant to key questions*
506. Marinella MA, Burdette SD, Bedimo R, et al. Leukemoid reactions complicating colitis due to *Clostridium difficile*. *Southern medical journal* 2004 Oct; 97(10):959-63. *Not relevant to key questions*
507. Markowitz JE, Brown KA, Mamula P, et al. Failure of single-toxin assays to detect *Clostridium difficile* infection in pediatric inflammatory bowel disease. *Am J Gastroenterol* 2001 Sep; 96(9):2688-90. *Not included population*

508. Marra AR, Edmond MB, Wenzel RP, et al. Hospital-acquired Clostridium difficile-associated disease in the intensive care unit setting: epidemiology, clinical course and outcome. BMC Infectious Diseases 2007; 7:42. *Not relevant to key questions*
509. Marrie TJ, Faulkner RS, Badley BW, et al. Pseudomembranous colitis: isolation of two species of cytotoxic clostridia and successful treatment with vancomycin. CMAJ 1978 Nov 4; 119(9):1058-60. *Not relevant to key questions*
510. Marrie TJ, Furlong M, Faulkner RS, et al. Clostridium difficile: epidemiology and clinical features. Canadian Journal of Surgery 1982 Jul; 25(4):438-42. *Not on topic*
511. Martinusen S, Chen D, Frighetto L, et al. Comparison of cefoxitin and ceftizoxime in a hospital therapeutic interchange program. CMAJ 1993 Apr 1; 148(7):1161-9. *Not on topic*
512. Martirosian G, Wize J, Sokol-Leszczyńska B, et al. Comparison of Delmee and Polish serogroup-specific Clostridium difficile strains. Acta Microbiologica Polonica 1993; 42(3-4):251-7. *Not on topic*
513. Marts BC, Longo WE, Vernava AM, 3rd, et al. Patterns and prognosis of Clostridium difficile colitis. Dis Colon Rectum 1994 Aug; 37(8):837-45. *Not on topic*
514. Marx CE, Morris A, Wilson ML, et al. Fecal leukocytes in stool specimens submitted for Clostridium difficile toxin assay. Diagnostic Microbiology & Infectious Disease 1993 May-Jun; 16(4):313-5. *Not on topic*
515. Mathai MG, Shanthaveerapa HN, Byrd RP, Jr., et al. Fatal pseudomembranous colitis in a continent urinary neobladder. Journal of the Kentucky Medical Association 2002 Jun; 100(6):234-7. *Not on topic*
516. Matute AJ, Schurink CA, Krijnen RM, et al. Double-blind, placebo-controlled study comparing the effect of azithromycin with clarithromycin on oropharyngeal and bowel microflora in volunteers. Eur J Clin Microbiol Infect Dis 2002 Jun; 21(6):427-31. *Not on topic*
517. Mayfield JL, Leet T, Miller J, et al. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000 Oct; 31(4):995-1000. *Not relevant to key questions*
518. Mayumi T, Takezawa J, Takahashi H, et al. IL-15 is elevated in the patients of postoperative enterocolitis. Cytokine 1999 Nov; 11(11):888-93. *Not on topic*
519. McCarter MD, Abularrage C, Velasco FT, et al. Diarrhea and Clostridium difficile-associated diarrhea on a surgical service. Archives of Surgery 1996 Dec; 131(12):1333-7. *Not on topic*
520. McCarthy J, Stingemore N. Clostridium difficile infection of a prosthetic joint presenting 12 months after antibiotic-associated diarrhoea. Journal of Infection 1999 Jul; 39(1):94-6. *Not on topic*
521. McCullough JM, Dielman DG, Peery D. Oral vancomycin-induced rash: case report and review of the literature. DICP 1991 Dec; 25(12):1326-8. *Not relevant to key questions*
522. McCusker ME, Harris AD, Perencevich E, et al. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerging Infectious Diseases 2003 Jun; 9(6):730-3. *Not relevant to key questions*
523. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerging Infectious Diseases 2006 Mar; 12(3):409-15. *Not relevant to key questions*
524. McDonald M, Ward P, Harvey K. Antibiotic-associated diarrhoea and methicillin-resistant Staphylococcus aureus. Medical Journal of Australia 1982 May 29; 1(11):462-4. *Not on topic*
525. McEllistrem MC, Carman RJ, Gerding DN, et al. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005 Jan 15; 40(2):265-72. *Not relevant to key questions*
526. McErlean A, Kelly O, Bergin S, et al. The importance of microbiological investigations, medications and artificial feeding in diarrhoea evaluation. Irish journal of medical science 2005 Jan-Mar; 174(1):21-5. *Not on topic*

527. McFarland LV. Epidemiology of infectious and iatrogenic nosocomial diarrhea in a cohort of general medicine patients. *Am J Infect Control* 1995 Oct; 23(5):295-305. *Not on topic*
528. McFarland LV. Epidemiology of infectious and iatrogenic nosocomial diarrhea in a cohort of general medicine patients. *Am J Infect Control* 1995 Oct; 23(5):295-305. *Duplicate listing*
529. McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and *Clostridium difficile* infections. *Anaerobe* 2009 Dec; 15(6):274-80. *Not relevant to key questions*
530. McFarland LV, Brandmarker SA, Guandalini S. Pediatric *Clostridium difficile*: a phantom menace or clinical reality? *Journal of Pediatric Gastroenterology & Nutrition* 2000 Sep; 31(3):220-31. *Not included population*
531. McFarland LV, Clarridge JE, Beneda HW, et al. Fluoroquinolone use and risk factors for *Clostridium difficile*-associated disease within a Veterans Administration health care system. *Clinic Infect Dis* 2007 Nov 1; 45(9):1141-51. *Not relevant to key questions*
532. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent *Clostridium difficile* disease. *Am J Gastroenterol* 2002 Jul; 97(7):1769-75. *Not relevant to key questions*
533. McFarland LV, Stamm WE. Review of *Clostridium difficile*-associated diseases. *Am J Infect Control* 1986 Jun; 14(3):99-109. *Not included publication type*
534. McFarland LV, Stamm WE. Review of *Clostridium difficile*-associated diseases. *Am J Infect Control* 1986 Jun; 14(3):99-109. *Duplicate listing*
535. McFarland LV, Surawicz CM, Greenberg RN, et al. Possible role of cross-transmission between neonates and mothers with recurrent *Clostridium difficile* infections. *Am J Infect Control* 1999 Jun; 27(3):301-3. *Not relevant to key questions*
536. McFarland LV, Surawicz CM, Greenberg RN, et al. Possible role of cross-transmission between neonates and mothers with recurrent *Clostridium difficile* infections. *Am J Infect Control* 1999 Jun; 27(3):301-3. *Duplicate listing*
537. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhea by *Saccharomyces boulardii* compared with placebo. *Am J Gastroenterol* 1995 Mar; 90(3):439-48. *Not relevant to key questions*
538. McFarland LV, Surawicz CM, Rubin M, et al. Recurrent *Clostridium difficile* disease: epidemiology and clinical characteristics. *Infect Control Hosp Epidemiol* 1999 Jan; 20(1):43-50. *Not relevant to key questions*
539. McGuire T, Dobesh P, Klepser D, et al. Clinically important interaction between statin drugs and *Clostridium difficile* toxin? *Medical Hypotheses* 2009 Dec; 73(6):1045-7. *Not relevant to key questions*
540. McMurdo ME, Argo I, Phillips G, et al. Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women. *J Antimicrob Chemother* 2009 Feb; 63(2):389-95. *Not on topic*
541. McMurdo ME, Argo I, Phillips G, et al. Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women. *J Antimicrob Chemother* 2009 Feb; 63(2):389-95. *Duplicate listing*
542. McNeeley SG, Jr., Anderson GD, Sibai BM. *Clostridium difficile* colitis associated with single-dose cefazolin prophylaxis. *Obstetrics & Gynecology* 1985 Nov; 66(5):737-8. *Not included study design*
543. McNeeley SG, Jr., Anderson GD, Sibai BM. *Clostridium difficile* colitis associated with single-dose cefazolin prophylaxis. *Obstetrics & Gynecology* 1985 Nov; 66(5):737-8. *Duplicate listing*
544. McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent *Clostridium difficile* diarrhea. *Dis Colon Rectum* 2006 May; 49(5):640-5. *Not relevant to key questions*

545. Meadowcroft AM, Diaz PR, Latham GS. Clostridium difficile toxin-induced colitis after use of clindamycin phosphate vaginal cream. *Ann Pharmacother* 1998 Mar; 32(3):309-11. *Not on topic*
546. Meijer-Severs GJ, Van Santen E, Meijer BC. Short-chain fatty acid and organic acid concentrations in feces of healthy human volunteers and their correlations with anaerobe cultural counts during systemic ceftriaxone administration. *Scandinavian journal of gastroenterology* 1990 Jul; 25(7):698-704. *Not on topic*
547. Meijer-Severs GJ, van Santen E, Puister SM, et al. The effect of FCE 22891, a new oral penem, on faecal flora anaerobes and their fermentation end products in patients with chronic obstructive pulmonary disease. *Infection* 1993 Sep-Oct; 21(5):311-7. *Not on topic*
548. Mermel LA, Osborn TG. Clostridium difficile associated reactive arthritis in an HLA-B27 positive female: report and literature review. *Journal of Rheumatology* 1989 Jan; 16(1):133-5. *Not relevant to key questions*
549. Messinger-Rapport BJ, Morley JE, Thomas DR, et al. Intensive session: New approaches to medical issues in long-term care. *Journal of the American Medical Directors Association* 2007 Sep; 8(7):421-33. *Not relevant to key questions*
550. Methe H, Kim JO, Kofler S, et al. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. *Arteriosclerosis, Thrombosis & Vascular Biology* 2005 Jul; 25(7):1439-45. *Not on topic*
551. Meyer AM, Ramzan NN, Loftus EV, Jr., et al. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. *J Clin Gastroenterol* 2004 Oct; 38(9):772-5. *Not on topic*
552. Millard G. Further experience with augmentin in the treatment of skin infections. *Scottish medical journal* 1982; 27(Spec):S35-8. *Not on topic*
553. Miller AT, Tabrizian P, Greenstein AJ, et al. Long-term follow-up of patients with fulminant Clostridium difficile colitis. *Journal of Gastrointestinal Surgery* 2009 May; 13(5):956-9. *Not relevant to key questions*
554. Miller JM, Walton JC, Tordecilla LL. Recognizing and managing Clostridium difficile-associated diarrhea. *MEDSURG Nursing* 1998 352-6; Dec; 7(6):348-9. *Not included publication type*
555. Miller M, Gravel D, Mulvey M, et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. *Clin Infect Dis* 2010 Jan 15; 50(2):194-201. *Not relevant to key questions*
556. Miller SD, Blake M, Miliotis M, et al. Antibiotic-associated diarrhoea and pseudomembranous colitis caused by Clostridium difficile. A review of 40 cases. *South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde* 1983 Jun 11; 63(24):936-9. *Not relevant to key questions*
557. Miller SD, Koornhof HJ. Clostridium difficile colitis associated with the use of antineoplastic agents. *European J Clin Microbiol* 1984 Feb; 3(1):10-3. *Not on topic*
558. Milstone EB, McDonald AJ, Scholhamer CF, Jr. Pseudomembranous colitis after topical application of clindamycin. *Archives of Dermatology* 1981 Mar; 117(3):154-5. *Not on topic*
559. Modena S, Gollamudi S, Friedenber F. Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile-associated diarrhea. *J Clin Gastroenterol* 2006 Jan; 40(1):49-54. *Not relevant to key questions*
560. Mogg GA, Keighley MR, Burdon DW, et al. Antibiotic-associated colitis--a review of 66 cases. *Br J Surg* 1979 Oct; 66(10):738-42. *Not on topic*

561. Morales Chamorro R, Serrano Blanch R, Mendez Vidal MJ, et al. Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil. *Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies & of the National Cancer Institute of Mexico* 2005 Jul; 7(6):258-61. *Not on topic*
562. Morelli MS, Rouster SD, Giannella RA, et al. Clinical application of polymerase chain reaction to diagnose *Clostridium difficile* in hospitalized patients with diarrhea. *Clin Gastroenterol Hepatol* 2004 Aug; 2(8):669-74. *Not relevant to key questions*
563. Morgan RJ, Jr., Doroshov JH, Venkataraman K, et al. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support. *Clinical Cancer Research* 1997 Dec; 3(12 Pt 1):2337-45. *Not on topic*
564. Morimoto Y, Nomura K, Tsutsumi Y, et al. *Clostridium difficile*-associated diarrhea with hematochezia is associated with ulcer formation. *Scandinavian journal of gastroenterology* 2008 Aug; 43(8):967-70. *Not relevant to key questions*
565. Morris AM, Jobe BA, Stoney M, et al. *Clostridium difficile* colitis: an increasingly aggressive iatrogenic disease?[see comment]. *Archives of Surgery* 2002 Oct; 137(10):1096-100. *Not relevant to key questions*
566. Morris JG, Jr., Jarvis WR, Nunez-Montiel OL, et al. *Clostridium difficile*. Colonization and toxin production in a cohort of patients with malignant hematologic disorders. *Arch Intern Med* 1984 May; 144(5):967-9. *Not on topic*
567. Moshkowitz M, Ben Baruch E, Kline Z, et al. Clinical manifestations and outcome of Pseudomembranous colitis in an elderly population in Israel. *Israel Medical Association Journal: Imaj* 2004 Apr; 6(4):201-4. *Not relevant to key questions*
568. Moshkowitz M, Ben-Baruch E, Kline Z, et al. Risk factors for severity and relapse of pseudomembranous colitis in an elderly population. *Colorectal Disease* 2007 Feb; 9(2):173-7. *Not relevant to key questions*
569. Moskovitz M, Bartlett JG. Recurrent pseudomembranous colitis unassociated with prior antibiotic therapy. *Arch Intern Med* 1981 Apr; 141(5):663-4. *Not relevant to key questions*
570. Munoz P, Palomo J, Yanez J, et al. Clinical microbiological case: a heart transplant recipient with diarrhea and abdominal pain. Recurring *C. difficile* infection. *Clinical Microbiology & Infection* 2001 458-9; Aug; 7(8):451-2. *Not relevant to key questions*
571. Munro R, Foldes M, Morris G. An evaluation of a rapid latex test for the diagnosis of *Clostridium difficile*-associated diarrhea. *Pathology* 1988 Oct; 20(4):349-52. *Not relevant to key questions*
572. Murphy C, Vernon M, Cullen M. Intravenous immunoglobulin for resistant *Clostridium difficile* infection. *Age Ageing* 2006 Jan; 35(1):85-6. *Not relevant to key questions*
573. Musher DM, Logan N, Mehendiratta V, et al. *Clostridium difficile* colitis that fails conventional metronidazole therapy: response to nitazoxanide. *J Antimicrob Chemother* 2007 Apr; 59(4):705-10. *Not relevant to key questions*
574. Mwachari C, Batchelor BI, Paul J, et al. Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya. *Journal of Infection* 1998 Jul; 37(1):48-53. *Not relevant to key questions*
575. Mwachari C, Batchelor BI, Paul J, et al. Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya. *Journal of Infection* 1998 Jul; 37(1):48-53. *Duplicate listing*
576. Mylotte JM, Graham R, Kahler L, et al. Epidemiology of nosocomial infection and resistant organisms in patients admitted for the first time to an acute rehabilitation unit. *Clinic Infect Dis* 2000 Mar; 30(3):425-32. *Not relevant to key questions*
577. Nadelman RB, Arlin Z, Wormser GP. Life-threatening complications of empiric ceftriaxone therapy for 'seronegative Lyme disease'. *Southern medical journal* 1991 Oct; 84(10):1263-5. *Not on topic*

578. Nair S, Yadav D, Corpuz M, et al. Clostridium difficile colitis: factors influencing treatment failure and relapse--a prospective evaluation. *Am J Gastroenterol* 1998 Oct; 93(10):1873-6. *Not relevant to key questions*
579. Nanke Y, Kotake S, Akama H, et al. Pancytopenia and colitis with Clostridium difficile in a rheumatoid arthritis patient taking methotrexate, antibiotics and non-steroidal anti-inflammatory drugs. *Clinical rheumatology* 2001; 20(1):73-5. *Not on topic*
580. Nasereddin LM, Bakri FG, Shehabi AA. Clostridium difficile infections among Jordanian adult hospitalized patients. *Am J Infect Control* 2009 Dec; 37(10):864-6. *Not relevant to key questions*
581. Nash SV, Bourgeault R, Sands M. Colonic disease associated with a positive assay for Clostridium difficile toxin: a retrospective study. *J Clin Gastroenterol* 1997 Sep; 25(2):476-9. *Not relevant to key questions*
582. Nathanson DR, Sheahan M, Chao L, et al. Intracolonic use of vancomycin for treatment of clostridium difficile colitis in a patient with a diverted colon: report of a case. *Dis Colon Rectum* 2001 Dec; 44(12):1871-2. *Not included treatment type*
583. Navarro-Llavat M, Domenech E, Bernal I, et al. Prospective, observational, cross-sectional study of intestinal infections among acutely active inflammatory bowel disease patients. *Digestion* 2009; 80(1):25-9. *Not on topic*
584. Navon JD, Weinberg AC, Ahlering TE. Continent urinary diversion using a Modified Indiana Pouch in elderly patients. *American Surgeon* 1994 Oct; 60(10):786-8. *Not on topic*
585. Nawaz A, Mohammed I, Ahsan K, et al. Clostridium difficile colitis associated with treatment of Helicobacter pylori infection. *Am J Gastroenterol* 1998 Jul; 93(7):1175-6. *Not on topic*
586. Nayar DM, Vetrivel S, McElroy J, et al. Toxic megacolon complicating Escherichia coli O157 infection. *Journal of Infection* 2006 Apr; 52(4):e103-6. *Not on topic*
587. Neill MA, Rice SK, Ahmad NV, et al. Cryptosporidiosis: an unrecognized cause of diarrhea in elderly hospitalized patients. *Clinic Infect Dis* 1996 Jan; 22(1):168-70. *Not on topic*
588. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.[update of Cochrane Database Syst Rev. 2005;(1):CD004610; PMID: 15674956]. *Cochrane Database Syst Rev* 2007; (3):004610. *Background*
589. Nelson RL, Glenny AM, Song F. Antimicrobial prophylaxis for colorectal surgery. *Cochrane Database Syst Rev* 2009; (1):001181. *Not included publication type*
590. Nemat H, Khan R, Ashraf MS, et al. Diagnostic value of repeated enzyme immunoassays in Clostridium difficile infection. *Am J Gastroenterol* 2009 Aug; 104(8):2035-41. *Not included publication type*
591. Neunlist M, Barouk J, Michel K, et al. Toxin B of Clostridium difficile activates human VIP submucosal neurons, in part via an IL-1beta-dependent pathway. *American Journal of Physiology - Gastrointestinal & Liver Physiology* 2003 Nov; 285(5):G1049-55. *Not on topic*
592. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. *Am J Gastroenterol* 2008 Jun; 103(6):1443-50. *Duplicate listing*
593. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. *Am J Gastroenterol* 2008 Jun; 103(6):1443-50. *Not relevant to key questions*
594. Nguyen NQ, Chapman M, Fraser RJ, et al. Prokinetic therapy for feed intolerance in critical illness: one drug or two? *Critical care medicine* 2007 Nov; 35(11):2561-7. *Not on topic*
595. Nguyen NQ, Ching K, Fraser RJ, et al. Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance. *Intensive care medicine* 2008 Jan; 34(1):169-73. *Not on topic*

596. Niemczyk M, Leszczynski P, Wyzgal J, et al. Infections caused by clostridium difficile in kidney or liver graft recipients. *Annals of Transplantation* 2005; 10(2):70-4. *Not on topic*
597. Nilsson-Ehle I, Nord CE, Ursing B. Ceftriaxone: pharmacokinetics and effect on the intestinal microflora in patients with acute bacterial infections. *Scand J Infect Dis* 1985; 17(1):77-82. *Not on topic*
598. Nomura K, Fujimoto Y, Yamashita M, et al. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. *Scandinavian journal of gastroenterology* 2009; 44(1):74-8. *Not on topic*
599. Nonhoff C, Struelens MJ, Serruys E. Evaluation of gas-liquid chromatography (GLC) for rapid detection of Clostridium difficile in fecal specimens. *Acta Clinica Belgica* 1995; 50(2):76-80. *Not relevant to key questions*
600. Nord CE, Brismar B, Kasholm-Tengve B, et al. Effect of piperacillin/tazobactam therapy on intestinal microflora. *Scand J Infect Dis* 1992; 24(2):209-13. *Not relevant to key questions*
601. Nord CE, Kager L, Philipson A, et al. Effect of imipenem/cilastatin on the colonic microflora. *Reviews of infectious diseases* 1985 Jul-Aug; 7(Suppl 3):S432-4. *Not on topic*
602. Norman FF, Perez-Molina J, Perez de Ayala A, et al. Clostridium difficile-associated diarrhea after antibiotic treatment for traveler's diarrhea. *Clinic Infect Dis* 2008 Apr 1; 46(7):1060-3. *Not on topic*
603. Norrby SR, Dotevall L, Eriksson M, et al. Efficacy and safety of cefpirome (HR810). *J Antimicrob Chemother* 1988 Oct; 22(4):541-7. *Not on topic*
604. Novak E, Paxton LM, Bye A, et al. Human safety and pharmacokinetics of a single intramuscular dose of a novel spectinomycin analog, trospectomycin (U-63,366F). *Antimicrob Agents Chemother* 1990 Dec; 34(12):2342-7. *Not on topic*
605. Novak-Weekley SM, Hollingsworth MH. Comparison of the premier toxin A and B assay and the TOX A/B II assay for diagnosis of Clostridium difficile infection. *Clinical & Vaccine Immunology: CVI* 2008 Mar; 15(3):575-8. *Not relevant to key questions*
606. Novelli A, Mazzei T, Fallani S, et al. Betalactam therapy and intestinal flora. *Journal of Chemotherapy* 1995 May; 7(Suppl 1):25-31. *Duplicate listing*
607. Novelli A, Mazzei T, Fallani S, et al. Betalactam therapy and intestinal flora. *Journal of Chemotherapy* 1995 May; 7(Suppl 1):25-31. *Not relevant to key questions*
608. O'Brien JA, Lahue BJ, Caro JJ, et al. The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. *Infect Control Hosp Epidemiol* 2007 Nov; 28(11):1219-27. *Not relevant to key questions*
609. O'Horo J, Safdar N. The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review. *International Journal of Infectious Diseases* 2009 Nov; 13(6):663-7. *Not relevant to key questions*
610. Oldfield EC, 3rd, Wallace MR. The role of antibiotics in the treatment of infectious diarrhea. *Gastroenterology clinics of North America* 2001 Sep; 30(3):817-36. *Not on topic*
611. Orrhage K, Sjostedt S, Nord CE. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. *J Antimicrob Chemother* 2000 Oct; 46(4):603-12. *Not relevant to key questions*
612. Oshima Y, Nishida K, Kawazoye S, et al. Successful treatment of cytomegalovirus colitis with ganciclovir in a patient with adult T cell leukemia lymphoma: case report. *Journal of Chemotherapy* 1999 Jun; 11(3):215-9. *Not on topic*
613. Oshima Y, Nishida K, Kawazoye S, et al. Successful treatment of cytomegalovirus colitis with ganciclovir in a patient with adult T cell leukemia lymphoma: case report. *Journal of Chemotherapy* 1999 Jun; 11(3):215-9. *Duplicate listing*

614. Owens RC, Jr., Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for *Clostridium difficile* infection. *Clinic Infect Dis* 2008 Jan 15; 46(Suppl 1):S19-31. *Background*
615. Oyoyo BA, Subekti D, Tjaniadi P, et al. Enteropathogens associated with acute diarrhea in community and hospital patients in Jakarta, Indonesia. *FEMS Immunology & Medical Microbiology* 2002 Oct 11; 34(2):139-46. *Not relevant to key questions*
616. Ozaki E, Kato H, Kita H, et al. *Clostridium difficile* colonization in healthy adults: transient colonization and correlation with enterococcal colonization. *Journal of medical microbiology* 2004 Feb; 53(Pt 2):167-72. *Not relevant to key questions*
617. Ozawa TT, Valadez T. *Clostridium difficile* infection associated with levofloxacin treatment. *Tennessee Medicine* 2002 Mar; 95(3):113-5. *Not relevant to key questions*
618. Palmore TN, Sohn S, Malak SF, et al. Risk factors for acquisition of *Clostridium difficile*-associated diarrhea among outpatients at a cancer hospital. *Infect Control Hosp Epidemiol* 2005 Aug; 26(8):680-4. *Not relevant to key questions*
619. Paltansing S, van den Berg RJ, Guseinova RA, et al. Characteristics and incidence of *Clostridium difficile*-associated disease in The Netherlands, 2005. *Clinical Microbiology & Infection* 2007 Nov; 13(11):1058-64. *Not relevant to key questions*
620. Pandey S, Slawik S, Cross K, et al. Laparoscopic appendectomy: a training model for laparoscopic right hemicolectomy? *Colorectal Disease* 2007 Jul; 9(6):536-9. *Not on topic*
621. Panichi G, Pantosti A, Gentile G, et al. *Clostridium difficile* colitis in leukemia patients. *European journal of cancer & clinical oncology* 1985 Oct; 21(10):1159-63. *Not included study design*
622. Pant C, Madonia PN, Jordan P, et al. Harbingers for *Clostridium difficile*-associated diarrhea. *Journal of Investigative Medicine* 2009 Jan; 57(1):40-2. *Not relevant to key questions*
623. Park BJ, Alexander HR, Libutti SK, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). *Annals of Surgical Oncology* 1999 Sep; 6(6):582-90. *Not on topic*
624. Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin phosphate. *Archives of Dermatology* 1986 May; 122(5):583-4. *Not included study design*
625. Pashby NL, Bolton RP, Sherriff RJ. Oral metronidazole in *Clostridium difficile* colitis. *BMJ* 1979 Jun 16; 1(6178):1605-6. *Not included study design*
626. Patel R, Hughes RW, Jr. An unusual case of myxedema megacolon with features of ischemic and pseudomembranous colitis. *May Clinic Proc* 1992 Apr; 67(4):369-72. *Not included study design*
627. Paterson DL. *Clostridium difficile* diarrhoea associated with chemotherapy for ovarian cancer. *Australian & New Zealand Journal of Obstetrics & Gynaecology* 1997 Aug; 37(3):348-9. *Not included study design*
628. Peach SL, Gaya H, Borriello SP. Faecal carriage of *Clostridium difficile* in cystic fibrosis patients. *Annali dell'Istituto Superiore di Sanita* 1986; 22(3):953-7. *Not relevant to key questions*
629. Peacock JE, Jr., Pegram PS, Weber SF, et al. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. *Am J Med* 1989 Nov 30; 87(5A):185S-90S. *Not on topic*
630. Pechine S, Gleizes A, Janoir C, et al. Immunological properties of surface proteins of *Clostridium difficile*. *Journal of medical microbiology* 2005 Feb; 54(Pt 2):193-6. *Not relevant to key questions*
631. Pekova L, Shomov G, Mladenova I, et al. *Clostridium difficile*-associated disease with lethal outcome in a 77-year-old woman. A case report. *Minerva gastroenterologica e dietologica* 2007 Dec; 53(4):383-6. *Not included study design*

632. Penders J, Thijs C, Vink C, et al. Factors influencing the composition of the intestinal microbiota in early infancy. *Pediatrics* 2006 Aug; 118(2):511-21. *Not relevant to key questions*
633. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of *Clostridium difficile* colitis in Quebec, Canada. *Clinic Infect Dis* 2005 Jun 1; 40(11):1591-7. *Not relevant to key questions*
634. Pepin J, Routhier S, Gagnon S, et al. Management and outcomes of a first recurrence of *Clostridium difficile*-associated disease in Quebec, Canada. *Clinic Infect Dis* 2006 Mar 15; 42(6):758-64. *Not relevant to key questions*
635. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for *Clostridium difficile*-associated diarrhea: a cohort study during an epidemic in Quebec. *Clinic Infect Dis* 2005 Nov 1; 41(9):1254-60. *Not relevant to key questions*
636. Pepin J, Valiquette L, Alary ME, et al. *Clostridium difficile*-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. *CMAJ* 2004 Aug 31; 171(5):466-72. *Not relevant to key questions*
637. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial *Clostridium difficile*-associated disease during an epidemic caused by a hypervirulent strain in Quebec. *CMAJ* 2005 Oct 25; 173(9):1037-42. *Not relevant to key questions*
638. Pepin J, Valiquette L, Gagnon S, et al. Outcomes of *Clostridium difficile*-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. *Am J Gastroenterol* 2007 Dec; 102(12):2781-8. *Not relevant to key questions*
639. Pepin J, Vo TT, Boutros M, et al. Risk factors for mortality following emergency colectomy for fulminant *Clostridium difficile* infection. *Dis Colon Rectum* 2009 Mar; 52(3):400-5. *Not on topic*
640. Peppe J, Porzio A, Davidson DM. A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial. *British journal of clinical pharmacology* 2008 Jul; 66(1):102-9. *Duplicate listing*
641. Philbrick AM, Ernst ME. Amoxicillin-associated hemorrhagic colitis in the presence of *Klebsiella oxytoca*. *Pharmacotherapy* 2007 Nov; 27(11):1603-7. *Not included study design*
642. Phillips C. Serum antibody responses to *Clostridium difficile* toxin A: predictive and protective? *Gut* 2001 Aug; 49(2):167-8. *Not included study design*
643. Pidala MJ, Slezak FA, Porter JA. Island flap anoplasty for anal canal stenosis and mucosal ectropion. *American Surgeon* 1994 Mar; 60(3):194-6. *Not included study design*
644. Pochapin M. The effect of probiotics on *Clostridium difficile* diarrhea. *Am J Gastroenterol* 2000 Jan; 95(1 Suppl):S11-3. *Not relevant to key questions*
645. Poduval RD, Kamath RP, Corpuz M, et al. *Clostridium difficile* and vancomycin-resistant enterococcus: the new nosocomial alliance. *Am J Gastroenterol* 2000 Dec; 95(12):3513-5. *Not relevant to key questions*
646. Pogue JM, DePestel DD, Kaul DR, et al. Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract. *Transplant Infectious Disease* 2009 Oct; 11(5):467-70. *Not relevant to key questions*
647. Pokorney BH, Nichols TW, Jr. Pseudomembranous colitis. A complication of sulfasalazine therapy in a patient with Crohn's colitis. *Am J Gastroenterol* 1981 Oct; 76(4):374-6. *Not relevant to key questions*
648. Pokorny CS, Bye PT, MacLeod C, et al. Antibiotic-associated colitis and cystic fibrosis. *Dig Dis Sci* 1992 Sep; 37(9):1464-8. *Not included study design*
649. Porco FV, Visconte EB. *Pseudomonas aeruginosa* as a cause of infectious diarrhea successfully treated with oral ciprofloxacin. *Ann Pharmacother* 1995 Nov; 29(11):1122-3. *Not included study design*

650. Prendergast TM, Marini CP, D'Angelo AJ, et al. Surgical patients with pseudomembranous colitis: factors affecting prognosis. *Surgery 1994 discussion 774-5; Oct; 116(4):768-74. Not relevant to key questions*
651. Price MF, Dao-Tran T, Garey KW, et al. Epidemiology and incidence of *Clostridium difficile*-associated diarrhoea diagnosed upon admission to a university hospital. *J Hosp Infect 2007 Jan; 65(1):42-6. Not relevant to key questions*
652. Privitera G, Scarpellini P, Ortisi G, et al. Prospective study of *Clostridium difficile* intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. *Antimicrob Agents Chemother 1991 Jan; 35(1):208-10. Not relevant to key questions*
653. Pryor WM, Bye WA, Curran DH, et al. Acute diarrhoea in adults: a prospective study. *Medical Journal of Australia 1987 Nov 16; 147(10):490-3. Not relevant to key questions*
654. Pulvirenti JJ, Mehra T, Hafiz I, et al. Epidemiology and outcome of *Clostridium difficile* infection and diarrhea in HIV infected inpatients. *Diagnostic Microbiology & Infectious Disease 2002 Dec; 44(4):325-30. Not relevant to key questions*
655. Pupaibool J, Khantipong M, Suankratay C. A study of *Clostridium difficile*-associated disease at King Chulalongkorn Memorial Hospital, Thailand. *Journal of the Medical Association of Thailand 2008 Jan; 91(1):37-43. Not included study design*
656. Quinn TC, Stamm WE, Goodell SE, et al. The polymicrobial origin of intestinal infections in homosexual men. *New England Journal of Medicine 1983 Sep 8; 309(10):576-82. Not relevant to key questions*
657. Rafferty ME, Baltch AL, Smith RP, et al. Comparison of restriction enzyme analysis, arbitrarily primed PCR, and protein profile analysis typing for epidemiologic investigation of an ongoing *Clostridium difficile* outbreak. *J Clin Microbiol 1998 Oct; 36(10):2957-63. Not relevant to key questions*
658. Raibaud P, Ducluzeau R, Dubos F, et al. Implantation of bacteria from the digestive tract of man and various animals into gnotobiotic mice. *American Journal of Clinical Nutrition 1980 Nov; 33(11 Suppl):2440-7. Not relevant to key questions*
659. Ramaswamy R, Grover H, Corpuz M, et al. Prognostic criteria in *Clostridium difficile* colitis. *Am J Gastroenterol 1996 Mar; 91(3):460-4. Not relevant to key questions*
660. Ramirez-Ronda CH, Balleste CR, Melendez B, et al. Management of urinary tract infections, decubitus ulcer and pneumonia in the aging person. *Boletin - Asociacion Medica de Puerto Rico 2003 Nov-Dec; 95(6):42-50. Not included study design*
661. Rammer M, Kirchgatterer A, Hobling W, et al. Lansoprazole-associated collagenous colitis: a case report. *Zeitschrift fur Gastroenterologie 2005 Jul; 43(7):657-60. Not on topic*
662. Ramos A, Martinez-Taboada VM, Fito C, et al. *Clostridium difficile*-associated diarrhea in rheumatoid arthritis patients who are receiving therapy with low-dose chlorambucil. *Arthritis & Rheumatism 1997 Nov; 40(11):2090-1. Not relevant to key questions*
663. Raveh D, Rabinowitz B, Breuer GS, et al. Risk factors for *Clostridium difficile* toxin-positive nosocomial diarrhoea. *International journal of antimicrobial agents 2006 Sep; 28(3):231-7. Not relevant to key questions*
664. Razavi B. Reactive arthritis after *Helicobacter pylori* eradication. *Lancet 2000 Feb 26; 355(9205):720. Not included study design*
665. Razzaq R, Sukumar SA. Ultrasound diagnosis of clinically undetected *Clostridium difficile* toxin colitis. *Clinical radiology 2006 May; 61(5):446-52. Not included study design*
666. Redelings MD, Sorvillo F, Mascola L. Increase in *Clostridium difficile*-related mortality rates, United States, 1999-2004. *Emerging Infectious Diseases 2007 Sep; 13(9):1417-9. Not relevant to key questions*

667. Ricciardi R, Rothenberger DA, Madoff RD, et al. Increasing prevalence and severity of *Clostridium difficile* colitis in hospitalized patients in the United States. *Archives of Surgery* 2007 discussion 631; Jul; 142(7):624-31. *Not relevant to key questions*
668. Riley TV, Cooper M, Bell B, et al. Community-acquired *Clostridium difficile*-associated diarrhea. *Clinic Infect Dis* 1995 Jun; 20(Suppl 2):S263-5. *Not relevant to key questions*
669. Riley TV, Karthigasu KT. Chronic osteomyelitis due to *Clostridium difficile*. *BMJ Clinical Research Ed* 1982 Apr 24; 284(6324):1217-8. *Not on topic*
670. Riley TV, Wetherall F, Bowman J, et al. Diarrheal disease due to *Clostridium difficile* in general practice. *Pathology* 1991 Oct; 23(4):346-9. *Not relevant to key questions*
671. Riva G, Luppi M, Potenza L, et al. Cytomegalovirus and *Clostridium Difficile* co-infection in severe ulcero-hemorrhagic colitis during induction chemotherapy for acute lymphoblastic leukemia. *Haematologica* 2005 Jan; 90(1):ER01. *Not included study design*
672. Roda PI. *Clostridium difficile* colitis induced by cytarabine. *American Journal of Clinical Oncology* 1987 Oct; 10(5):451-2. *Not included study design*
673. Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of *Clostridium difficile* infection in inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2007 Mar; 5(3):339-44. *Not relevant to key questions*
674. Rogers MA, Blumberg N, Saint S, et al. Hospital variation in transfusion and infection after cardiac surgery: a cohort study. *BMC Medicine* 2009; 7:37. *Not relevant to key questions*
675. Rogers MA, Fries BE, Kaufman SR, et al. Mobility and other predictors of hospitalization for urinary tract infection: a retrospective cohort study. *BMC Geriatrics* 2008; 8:31. *Not relevant to key questions*
676. Roghmann MC, McCarter RJ, Jr., Brewrink J, et al. *Clostridium difficile* infection is a risk factor for bacteremia due to vancomycin-resistant enterococci (VRE) in VRE-colonized patients with acute leukemia. *Clinic Infect Dis* 1997 Nov; 25(5):1056-9. *Not relevant to key questions*
677. Rolny P, Jarnerot G, Mollby R. Occurrence of *Clostridium difficile* toxin in inflammatory bowel disease. *Scandinavian journal of gastroenterology* 1983 Jan; 18(1):61-4. *Not relevant to key questions*
678. Rossel P, Sortsoe Jensen H, Qvist P, et al. Prognosis of adult-onset idiopathic bile acid malabsorption. *Scandinavian journal of gastroenterology* 1999 Jun; 34(6):587-90. *Not on topic*
679. Rotimi VO, Mokaddas EM, Jamal WY, et al. Hospital-acquired *Clostridium difficile* infection amongst ICU and burn patients in Kuwait. *Medical Principles & Practice* 2002 Jan-Mar; 11(1):23-8. *Not relevant to key questions*
680. Roupael NG, O'Donnell JA, Bhatnagar J, et al. *Clostridium difficile*-associated diarrhea: an emerging threat to pregnant women. *American Journal of Obstetrics & Gynecology* 2008 Jun; 198(6):635.e1-e6. *Not relevant to key questions*
681. Rubin MS, Bodenstein LE, Kent KC. Severe *Clostridium difficile* colitis. *Dis Colon Rectum* 1995 Apr; 38(4):350-4. *Not relevant to key questions*
682. Rudensky B, Rosner S, Sonnenblick M, et al. The prevalence and nosocomial acquisition of *Clostridium difficile* in elderly hospitalized patients. *Postgrad Med J* 1993 Jan; 69(807):45-7. *Duplicate listing*
683. Rudensky B, Rosner S, Sonnenblick M, et al. The prevalence and nosocomial acquisition of *Clostridium difficile* in elderly hospitalized patients. *Postgrad Med J* 1993 Jan; 69(807):45-7. *Not relevant to key questions*
684. Safdar N, Barigala R, Said A, et al. Feasibility and tolerability of probiotics for prevention of antibiotic-associated diarrhoea in hospitalized US military veterans. *Journal of Clinical Pharmacy & Therapeutics* 2008 Dec; 33(6):663-8. *Not relevant to key questions*

685. Saginur R, Hawley CR, Bartlett JG. Colitis associated with metronidazole therapy. *J Infect Dis* 1980 Jun; 141(6):772-4. *Not included study design*
686. Sailhamer EA, Carson K, Chang Y, et al. Fulminant *Clostridium difficile* colitis: patterns of care and predictors of mortality. *Archives of Surgery* 2009 discussion 439-40; May; 144(5):433-9. *Not relevant to key questions*
687. Salazar M, Baskin L, Garey KW, et al. *Clostridium difficile*-related death rates in Texas 1999-2005. *Journal of Infection* 2009 Nov; 59(5):303-7. *Not relevant to key questions*
688. Salgado CD, Giannetta ET, Farr BM. Failure to develop vancomycin-resistant *Enterococcus* with oral vancomycin treatment of *Clostridium difficile*. *Infect Control Hosp Epidemiol* 2004 May; 25(5):413-7. *Not relevant to key questions*
689. Sambol SP, Merrigan MM, Lyerly D, et al. Toxin gene analysis of a variant strain of *Clostridium difficile* that causes human clinical disease. *Infect Immun* 2000 Oct; 68(10):5480-7. *Not relevant to key questions*
690. Samore MH, DeGirolami PC, Tlucko A, et al. *Clostridium difficile* colonization and diarrhea at a tertiary care hospital. *Clinic Infect Dis* 1994 Feb; 18(2):181-7. *Background*
691. Samuel SC, Hancock P, Leigh DA. An investigation into *Clostridium perfringens* enterotoxin-associated diarrhoea. *J Hosp Infect* 1991 Jul; 18(3):219-30. *Not on topic*
692. Sanchez TH, Brooks JT, Sullivan PS, et al. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. *Clinic Infect Dis* 2005 Dec 1; 41(11):1621-7. *Not relevant to key questions*
693. Sanchez-Hurtado K, Corretge M, Mutlu E, et al. Systemic antibody response to *Clostridium difficile* in colonized patients with and without symptoms and matched controls. *Journal of medical microbiology* 2008 Jun; 57(Pt 6):717-24. *Not relevant to key questions*
694. Satin AJ, Harrison CR, Hancock KC, et al. Relapsing *Clostridium difficile* toxin-associated colitis in ovarian cancer patients treated with chemotherapy. *Obstetrics & Gynecology* 1989 Sep; 74(3 Pt 2):487-9. *Not included study design*
695. Satin AJ, Harrison CR, Hancock KC, et al. Relapsing *Clostridium difficile* toxin-associated colitis in ovarian cancer patients treated with chemotherapy. *Obstetrics & Gynecology* 1989 Sep; 74(3 Pt 2):487-9. *Duplicate listing*
696. Saunders MD, Kimmey MB. Colonic pseudo-obstruction: the dilated colon in the ICU. *Seminars in gastrointestinal disease* 2003 Jan; 14(1):20-7. *Not on topic*
697. Savage AM, Alford RH. Nosocomial spread of *Clostridium difficile*. *Infection Control* 1983 Jan-Feb; 4(1):31-3. *Not included study design*
698. Scalera NM, File TM, Jr. How long should we treat community-acquired pneumonia? Current opinion in infectious diseases 2007 Apr; 20(2):177-81. *Not on topic*
699. Scanvic-Hameg A, Chachaty E, Rey J, et al. Impact of quinupristin/dalfopristin (RP59500) on the faecal microflora in healthy volunteers. *J Antimicrob Chemother* 2002 Jan; 49(1):135-9. *Not on topic*
700. Scheurer D. Diagnostic and treatment delays in recurrent *Clostridium difficile*-associated disease. *J Hosp Med (Online)* 2008 Mar; 3(2):156-9. *Not on topic*
701. Scheurer DB, Hicks LS, Cook EF, et al. Accuracy of ICD-9 coding for *Clostridium difficile* infections: a retrospective cohort. *Epidemiology & Infection* 2007 Aug; 135(6):1010-3. *Not relevant to key questions*

702. Schmiedeskamp M, Harpe S, Polk R, et al. Use of International Classification of Diseases, Ninth Revision, Clinical Modification codes and medication use data to identify nosocomial *Clostridium difficile* infection. *Infect Control Hosp Epidemiol* 2009 Nov; 30(11):1070-6. *Not relevant to key questions*
703. Schmitt-Grohe S, Wiggert E, Steffan J, et al. Severe antibiotic-associated colitis in a patient with cystic fibrosis and colonic wall thickening. *Journal of Pediatric Gastroenterology & Nutrition* 2002 Feb; 34(2):224-6. *Not included study design*
704. Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. *Aliment Pharmacol Ther* 2009 Aug; 30(3):253-64. *Not relevant to key questions*
705. Schuler A. Risks versus benefits of long-term proton pump inhibitor therapy in the elderly. *Geriatric nursing* 2007 Jul-Aug; 28(4):225-9. *Not included study design*
706. Schwaber MJ, Simhon A, Block C, et al. Factors associated with nosocomial diarrhea and *Clostridium difficile*-associated disease on the adult wards of an urban tertiary care hospital. *Eur J Clin Microbiol Infect Dis* 2000 Jan; 19(1):9-15. *Duplicate listing*
707. Schweitzer MA, Sweiss I, Silver DL, et al. The clinical spectrum of *Clostridium difficile* colitis in immunocompromised patients. *American Surgeon* 1996 discussion 607-8; Jul; 62(7):603-7. *Not relevant to key questions*
708. Sciscione AC, Villeneuve JB, Pitt HA, et al. Surgery for pancreatic tumors during pregnancy: a case report and review of the literature. *American Journal of Perinatology* 1996 Jan; 13(1):21-5. *Not included study design*
709. Scully BE, Henry SA. Clinical experience with aztreonam in the treatment of gram-negative bacteremia. *Reviews of infectious diseases* 1985 Nov-Dec; 7(Suppl 4):S789-93. *Not on topic*
710. Seder CW, Villalba MR, Jr., Robbins J, et al. Early colectomy may be associated with improved survival in fulminant *Clostridium difficile* colitis: an 8-year experience. *American Journal of Surgery* 2009 Mar; 197(3):302-7. *Duplicate listing*
711. Seder CW, Villalba MR, Jr., Robbins J, et al. Early colectomy may be associated with improved survival in fulminant *Clostridium difficile* colitis: an 8-year experience. *American Journal of Surgery* 2009 Mar; 197(3):302-7. *Not relevant to key questions*
712. Sensini A, Marroni M, Bassotti G, et al. *Clostridium difficile*-associated reactive arthritis in an HLA-B27 negative male. *J Clin Gastroenterol* 1993 Jun; 16(4):354-5. *Not included study design*
713. Sethi AK, Al-Nassir WN, Nerandzic MM, et al. Persistence of skin contamination and environmental shedding of *Clostridium difficile* during and after treatment of *C. difficile* infection. *Infect Control Hosp Epidemiol* 2010 Jan; 31(1):21-7. *Not relevant to key questions*
714. Sethi AK, Al-Nassir WN, Nerandzic MM, et al. Skin and environmental contamination with vancomycin-resistant Enterococci in patients receiving oral metronidazole or oral vancomycin treatment for *Clostridium difficile*-associated disease. *Infect Control Hosp Epidemiol* 2009 Jan; 30(1):13-7. *Not relevant to key questions*
715. Settle CD, Wilcox MH, Fawley WN, et al. Prospective study of the risk of *Clostridium difficile* diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. *Aliment Pharmacol Ther* 1998 Dec; 12(12):1217-23. *Not relevant to key questions*
716. Seyler L, Lalvani A, Collins L, et al. Safety and cost savings of an improved three-day rule for stool culture in hospitalised children and adults. *J Hosp Infect* 2007 Oct; 67(2):121-6. *Not on topic*

717. Shadel BN, Puzniak LA, Gillespie KN, et al. Surveillance for vancomycin-resistant enterococci: type, rates, costs, and implications. *Infect Control Hosp Epidemiol* 2006 Oct; 27(10):1068-75. *Not relevant to key questions*
718. Shah S, Lewis A, Leopold D, et al. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. *QJM* 2000 Mar; 93(3):175-81. *Not relevant to key questions*
719. Shah V, Marino C, Altice FL. Albendazole-induced pseudomembranous colitis. *Am J Gastroenterol* 1996 Jul; 91(7):1453-4. *Not included study design*
720. Sharma P, Bomireddy R, Phillips S. Clostridium difficile-associated diarrhoea after internal fixation of intertrochanteric femoral fractures. *Eur J Clin Microbiol Infect Dis* 2003 Oct; 22(10):615-8. *Not relevant to key questions*
721. Shastri YM, Bergis D, Povse N, et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. *Am J Med* 2008 Dec; 121(12):1099-106. *Not on topic*
722. Shedda S, Campbell I, Skinner I. Clostridium difficile splenic abscess. *Australian & New Zealand Journal of Surgery* 2000 Feb; 70(2):147-8. *Not relevant to key questions*
723. Shehabi AA, Abu-Ragheb HA, Allaham NA. Prevalence of Clostridium difficile-associated diarrhoea among hospitalized Jordanian patients. *Eastern Mediterranean Health Journal* 2001 Jul-Sep; 7(4-5):750-5. *Not relevant to key questions*
724. Sheikh RA, Yasmeen S, Pauly MP, et al. Pseudomembranous colitis without diarrhea presenting clinically as acute intestinal pseudo-obstruction. *Journal of gastroenterology* 2001 Sep; 36(9):629-32. *Not included study design*
725. Shen B, Goldblum JR, Hull TL, et al. Clostridium difficile-associated pouchitis. *Dig Dis Sci* 2006 Dec; 51(12):2361-4. *Not relevant to key questions*
726. Shen BO, Jiang ZD, Fazio VW, et al. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. *Clin Gastroenterol Hepatol* 2008 Jul; 6(7):782-8. *Not relevant to key questions*
727. Sheth H, Bernardini J, Burr R, et al. Clostridium difficile infections in outpatient dialysis cohort. *Infect Control Hosp Epidemiol* 2010 Jan; 31(1):89-91. *Not relevant to key questions*
728. Shetler K, Nieuwenhuis R, Wren SM, et al. Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitis. *Surgical endoscopy* 2001 Jul; 15(7):653-9. *Not relevant to key questions*
729. Shim JK, Johnson S, Samore MH, et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. *Lancet* 1998 Feb 28; 351(9103):633-6. *Background*
730. Shimoni Z, Averbuch Y, Shir E, et al. The addition of fiber and the use of continuous infusion decrease the incidence of diarrhea in elderly tube-fed patients in medical wards of a general regional hospital: a controlled clinical trial. *J Clin Gastroenterol* 2007 Nov-Dec; 41(10):901-5. *Not on topic*
731. Shin B-M, Lee E-J, Kuak E-Y, et al. Comparison of VIDAS CDAB and CDA immunoassay for the detection of Clostridium difficile in a tcdA- tcdB+ C. difficile prevalent area. *Anaerobe* 2009 Dec; 15(6):266-9. *Not relevant to key questions*
732. Shin JW, Yong D, Kim MS, et al. Sudden increase of vancomycin-resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin. *Journal of Infection & Chemotherapy* 2003 discussion 104-5; Mar; 9(1):62-7. *Not relevant to key questions*
733. Shinagawa N, Tachi Y, Ishikawa S, et al. Prophylactic antibiotics for patients undergoing elective biliary tract surgery: a prospective randomized study of cefotiam and cefoperazone. *Japanese Journal of Surgery* 1987 Jan; 17(1):1-8. *Not on topic*

734. Shuttleworth R, Taylor M, Jones DM. Antimicrobial susceptibilities of *Clostridium difficile*. *Journal of clinical pathology* 1980 Oct; 33(10):1002-5. *Not relevant to key questions*
735. Si JM, Yu YC, Fan YJ, et al. Intestinal microecology and quality of life in irritable bowel syndrome patients. *World Journal of Gastroenterology* 2004 Jun 15; 10(12):1802-5. *Not on topic*
736. Siegal D, Syed F, Hamid N, et al. *Campylobacter jejuni* pancolitis mimicking idiopathic ulcerative colitis. *Heart & Lung* 2005 Jul-Aug; 34(4):288-90. *Not on topic*
737. Siegle RJ, Fekety R, Sarbone PD, et al. Effects of topical clindamycin on intestinal microflora in patients with acne. *Journal of the American Academy of Dermatology* 1986 Aug; 15(2 Pt 1):180-5. *Not relevant to key questions*
738. Silva J, Jr., Batts DH, Fekety R, et al. Treatment of *Clostridium difficile* colitis and diarrhea with vancomycin. *Am J Med* 1981 Nov; 71(5):815-22. *Not relevant to key questions*
739. Simor AE, Bradley SF, Strausbaugh LJ, et al. *Clostridium difficile* in long-term-care facilities for the elderly. *Infect Control Hosp Epidemiol* 2002 Nov; 23(11):696-703. *Not relevant to key questions*
740. Simor AE, Yake SL, Tsimidis K. Infection due to *Clostridium difficile* among elderly residents of a long-term-care facility. *Clinic Infect Dis* 1993 Oct; 17(4):672-8. *Not relevant to key questions*
741. Sims RV, Hauser RJ, Adewale AO, et al. Acute gastroenteritis in three community-based nursing homes. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences* 1995 Sep; 50(5):M252-6. *Not relevant to key questions*
742. Slotwiner-Nie PK, Brandt LJ. Infectious diarrhea in the elderly. *Gastroenterology clinics of North America* 2001 Sep; 30(3):625-35. *Not relevant to key questions*
743. Soderlin MK, Alasaarela E, Hakala M. Reactive arthritis induced by *Clostridium difficile* enteritis as a complication of *Helicobacter pylori* eradication. *Clinical rheumatology* 1999; 18(4):337-8. *Not included study design*
744. Soes L, Molbak K, Strobaek S, et al. The emergence of *Clostridium difficile* PCR ribotype 027 in Denmark--a possible link with the increased consumption of fluoroquinolones and cephalosporins? *Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2009 2009; 14(15). *Not relevant to key questions*
745. Solaymani-Mohammadi S, Coyle CM, Factor SM, et al. Amebic colitis in an antigenically and serologically negative patient: usefulness of a small-subunit ribosomal RNA gene-based polymerase chain reaction in diagnosis. *Diagnostic Microbiology & Infectious Disease* 2008 Nov; 62(3):333-5. *Not on topic*
746. Soler P, Nogareda F, Cano R. Rates of *Clostridium difficile* infection in patients discharged from Spanish hospitals, 1997-2005. *Infect Control Hosp Epidemiol* 2008 Sep; 29(9):887-9. *Not relevant to key questions*
747. Song HJ, Shim KN, Jung SA, et al. Antibiotic-associated diarrhea: candidate organisms other than *Clostridium difficile*. *Korean Journal of Internal Medicine* 2008 Mar; 23(1):9-15. *Not included study design*
748. Song HJ, Shim KN, Jung SA, et al. Antibiotic-associated diarrhea: candidate organisms other than *Clostridium difficile*. *Korean Journal of Internal Medicine* 2008 Mar; 23(1):9-15. *Duplicate listing*
749. Song X, Bartlett JG, Speck K, et al. Rising economic impact of *clostridium difficile*-associated disease in adult hospitalized patient population. *Infect Control Hosp Epidemiol* 2008 Sep; 29(9):823-8. *Not relevant to key questions*
750. Soyletir G, Eskiturk A, Kilic G, et al. *Clostridium difficile* acquisition rate and its role in nosocomial diarrhoea at a university hospital in Turkey. *European journal of epidemiology* 1996 Aug; 12(4):391-4. *Not relevant to key questions*
751. Spigaglia P, Mastrantonio P. Comparative analysis of *Clostridium difficile* clinical isolates belonging to different genetic lineages and time periods. *Journal of medical microbiology* 2004 Nov; 53(Pt 11):1129-36. *Not relevant to key questions*

752. Stalam M, Kaye D. Antibiotic agents in the elderly. *Infectious disease clinics of North America* 2004 viii; Sep; 18(3):533-49. *Not on topic*
753. Stamper PD, Alcabasa R, Aird D, et al. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing *Clostridium difficile* in clinical samples. *J Clin Microbiol* 2009 Feb; 47(2):373-8. *Duplicate listing*
754. Stamper PD, Alcabasa R, Aird D, et al. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing *Clostridium difficile* in clinical samples. *J Clin Microbiol* 2009 Feb; 47(2):373-8. *Not relevant to key questions*
755. Starks I, Ayub G, Walley G, et al. Single-dose cefuroxime with gentamicin reduces *Clostridium difficile*-associated disease in hip-fracture patients. *J Hosp Infect* 2008 Sep; 70(1):21-6. *Not relevant to key questions*
756. Starr JM, Impallomeni M. Risk of diarrhoea, *Clostridium difficile* and cefotaxime in the elderly. *Biomedicine & Pharmacotherapy* 1997; 51(2):63-7. *Not relevant to key questions*
757. Stein BL, Lamoureux E, Miller M, et al. Glutaraldehyde-induced colitis. *Canadian Journal of Surgery* 2001 Apr; 44(2):113-6. *Not on topic*
758. Stein GE, Christensen S, Mummaw N. Treatment of acute uncomplicated urinary tract infection with ceftibuten. *Infection* 1991 Mar-Apr; 19(2):124-6. *Not relevant to key questions*
759. Stella PA. Evaluation of a commercial latex agglutination assay for screening for *Clostridium difficile*-associated disease. *Clinical Laboratory Science* 1994 Sep-Oct; 7(5):311-3. *Not relevant to key questions*
760. Stelzmueller I, Goegele H, Biebl M, et al. *Clostridium difficile* colitis in solid organ transplantation--a single-center experience. *Dig Dis Sci* 2007 Nov; 52(11):3231-6. *Not relevant to key questions*
761. Sultana Q, Chaudhry NA, Munir M, et al. Diagnosis of *Clostridium difficile* antibiotic associated diarrhoea culture versus toxin assay. *JPMA - Journal of the Pakistan Medical Association* 2000 Aug; 50(8):246-9. *Not relevant to key questions*
762. Sundar S, Chan SY. Cholestatic jaundice and pseudomembranous colitis following combination therapy with doxorubicin and docetaxel. *Anti-Cancer Drugs* 2003 Apr; 14(4):327-9. *Not included study design*
763. Surawicz CM. Update on gastrointestinal infections: *Clostridium difficile* and other bugs. *Current gastroenterology reports* 1999 Oct; 1(5):363-4. *Not relevant to key questions*
764. Surawicz CM. Treatment of recurrent *Clostridium difficile*-associated disease. *Nature Clinical Practice Gastroenterology & Hepatology* 2004 Nov; 1(1):32-8. *Not relevant to key questions*
765. Surawicz CM, McFarland LV, Elmer G, et al. Treatment of recurrent *Clostridium difficile* colitis with vancomycin and *Saccharomyces boulardii*. *Am J Gastroenterol* 1989 Oct; 84(10):1285-7. *Not included study design*
766. Svanteson B, Thoren A, Castor B, et al. Acute diarrhoea in adults: aetiology, clinical appearance and therapeutic aspects. *Scand J Infect Dis* 1988; 20(3):303-14. *Not on topic*
767. Svenungsson B, Burman LG, Jalakas-Pornull K, et al. Epidemiology and molecular characterization of *Clostridium difficile* strains from patients with diarrhea: low disease incidence and evidence of limited cross-infection in a Swedish teaching hospital. *J Clin Microbiol* 2003 Sep; 41(9):4031-7. *Not relevant to key questions*
768. Svenungsson B, Lagergren A, Ekwall E, et al. Enteropathogens in adult patients with diarrhea and healthy control subjects: a 1-year prospective study in a Swedish clinic for infectious diseases. *Clinic Infect Dis* 2000 May; 30(5):770-8. *Not on topic*

769. Svenungsson B, Lagergren A, Lundberg A. Clostridium difficile cytotoxin B in adults with diarrhea: a comparison of patients treated or not treated with antibiotics prior to infection. *Clinical Microbiology & Infection* 2001 Aug; 7(8):447-50. *Not relevant to key questions*
770. Synnott K, Mealy K, Merry C, et al. Timing of surgery for fulminating pseudomembranous colitis. *Br J Surg* 1998 Feb; 85(2):229-31. *Not included study design*
771. Szajewska H, Setty M, Mrukowicz J, et al. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. *Journal of Pediatric Gastroenterology & Nutrition* 2006 May; 42(5):454-75. *Not relevant to key questions*
772. Tabaqchali S, Holland D, O'Farrell S, et al. Typing scheme for Clostridium difficile: its application in clinical and epidemiological studies. *Lancet* 1984 Apr 28; 1(8383):935-8. *Not on topic*
773. Tabaqchali S, O'Farrell S, Holland D, et al. Method for the typing of Clostridium difficile based on polyacrylamide gel electrophoresis of [35S]methionine-labeled proteins. *J Clin Microbiol* 1986 Jan; 23(1):197-8. *Not relevant to key questions*
774. Tae CH, Jung SA, Song HJ, et al. The first case of antibiotic-associated colitis by Clostridium difficile PCR ribotype 027 in Korea. *Journal of Korean medical science* 2009 Jun; 24(3):520-4. *Not included study design*
775. Tal S, Gurevich A, Guller V, et al. Risk factors for recurrence of Clostridium difficile-associated diarrhea in the elderly. *Scand J Infect Dis* 2002; 34(8):594-7. *Not relevant to key questions*
776. Talbot GH, Cassileth PA, Paradiso L, et al. Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group. *Antimicrob Agents Chemother* 1993 Mar; 37(3):474-82. *Not on topic*
777. Talbot RW, Walker RC, Beart RW, Jr. Changing epidemiology, diagnosis, and treatment of Clostridium difficile toxin-associated colitis. *Br J Surg* 1986 Jun; 73(6):457-60. *Not relevant to key questions*
778. Tay JK, Bodle EE, Fisher DA, et al. Screening for vancomycin-resistant enterococci using stools sent for Clostridium difficile cytotoxin assay is effective: results of a survey of 300 Patients in a large Singapore Teaching Hospital. *Ann Acad Med Singapore* 2007 Nov; 36(11):926-9. *Not on topic*
779. Tayek JA, Bistrrian BR, Blackburn GL. The effects of acute clostridium difficile diarrhea on fecal nitrogen content in adult hospitalized patients. *Journal of the American College of Nutrition* 1987 Jun; 6(3):255-9. *Not relevant to key questions*
780. Taylor CP, Tummala S, Molrine D, et al. Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. *Vaccine* 2008 Jun 25; 26(27-28):3404-9. *Duplicate listing*
781. Taylor ME, Oppenheim BA. Hospital-acquired infection in elderly patients. *J Hosp Infect* 1998 Apr; 38(4):245-60. *Not on topic*
782. Taylor ME, Oppenheim BA, Chadwick PR, et al. Detection of glycopeptide-resistant enterococci in routine diagnostic faeces specimens. *J Hosp Infect* 1999 Sep; 43(1):25-32. *Not included study design*
783. Teare JP, Booth JC, Brown JL, et al. Pseudomembranous colitis following clarithromycin therapy. *European journal of gastroenterology & hepatology* 1995 Mar; 7(3):275-7. *Not included study design*
784. Teare JP, Booth JC, Brown JL, et al. Pseudomembranous colitis following clarithromycin therapy. *European journal of gastroenterology & hepatology* 1995 Mar; 7(3):275-7. *Duplicate listing*
785. Tedesco FJ. Bacitracin therapy in antibiotic-associated pseudomembranous colitis. *Dig Dis Sci* 1980 Oct; 25(10):783-4. *Not relevant to key questions*
786. Tedesco FJ, Hardin RD, Harper RN, et al. Infectious colitis endoscopically simulating inflammatory bowel disease: a prospective evaluation. *Gastrointestinal endoscopy* 1983 Aug; 29(3):195-7. *Not on topic*

787. Thamlikitkul V, Danpakdi K, Chokloikaew S. Incidence of diarrhea and Clostridium difficile toxin in stools from hospitalized patients receiving clindamycin, beta-lactams, or nonantibiotic medications. *J Clin Gastroenterol* 1996 Mar; 22(2):161-3. *Not relevant to key questions*
788. Theunissen C, Knoop C, Nonhoff C, et al. Clostridium difficile colitis in cystic fibrosis patients with and without lung transplantation. *Transplant Infectious Disease* 2008 Jul; 10(4):240-4. *Not on topic*
789. Thibault A, Miller MA, Gaese C. Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. *Infect Control Hosp Epidemiol* 1991 Jun; 12(6):345-8. *Not relevant to key questions*
790. Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. *Neurology* 1997 May; 48(5):1253-60. *Not on topic*
791. Thomas DR, Bennett RG, Laughon BE, et al. Postantibiotic colonization with Clostridium difficile in nursing home patients. *Journal of the American Geriatrics Society* 1990 Apr; 38(4):415-20. *Not relevant to key questions*
792. Thompson I. Clostridium difficile-associated disease: update and focus on non-antibiotic strategies. *Age Ageing* 2008 Jan; 37(1):14-8. *Not relevant to key questions*
793. Thorson MA, Bliss DZ, Savik K. Re-examination of risk factors for non-Clostridium difficile-associated diarrhoea in hospitalized patients. *Journal of advanced nursing* 2008 May; 62(3):354-64. *Not relevant to key questions*
794. Titov L, Lebedkova N, Shabanov A, et al. Isolation and molecular characterization of Clostridium difficile strains from patients and the hospital environment in Belarus. *J Clin Microbiol* 2000 Mar; 38(3):1200-2. *Not relevant to key questions*
795. Titu LV, Zafar N, Phillips SM, et al. Emergency laparoscopic surgery for complicated diverticular disease. *Colorectal Disease* 2009 May; 11(4):401-4. *Not on topic*
796. Tomblyn M, Gordon L, Singhal S, et al. Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. *Bone marrow transplantation* 2002 Oct; 30(8):517-9. *Not relevant to key questions*
797. Toor AA, van Burik JA, Weisdorf DJ. Infections during mobilizing chemotherapy and following autologous stem cell transplantation. *Bone marrow transplantation* 2001 Dec; 28(12):1129-34. *Not on topic*
798. Tresallet C, Nguyen-Thanh Q, Aubriot-Lorton MH, et al. Small-bowel infarction from disseminated aspergillosis. *Dis Colon Rectum* 2004 Sep; 47(9):1515-8. *Not included study design*
799. Trevisani F, Simoncini M, Alampi G, et al. Colitis associated to chemotherapy with 5-fluorouracil. *Hepato-gastroenterology* 1997 May-Jun; 44(15):710-2. *Not included study design*
800. Triadafilopoulos G, Hallstone AE. Acute abdomen as the first presentation of pseudomembranous colitis. *Gastroenterol* 1991 Sep; 101(3):685-91. *Not included study design*
801. Triadafilopoulos G, Shah MH, Pothoulakis C. The chemotactic response of human granulocytes to Clostridium difficile toxin A is age dependent. *Am J Gastroenterol* 1991 Oct; 86(10):1461-5. *Not relevant to key questions*
802. Trnka YM, Lamont JT. Clostridium difficile colitis. *Advances in Internal Medicine* 1984; 29:85-107. *Not relevant to key questions*
803. Trowbridge S. Hospital-acquired infections and infection control practices: what are the consequences to the elderly patient? *Perspectives* 2009; 33(1):16-22. *Not on topic*
804. Trudel JL, Deschenes M, Mayrand S, et al. Toxic megacolon complicating pseudomembranous enterocolitis. *Dis Colon Rectum* 1995 Oct; 38(10):1033-8. *Not relevant to key questions*
805. Tsironi E, Irving PM, Feakins RM, et al. "Diversion" colitis caused by Clostridium difficile infection: report of a case. *Dis Colon Rectum* 2006 Jul; 49(7):1074-7. *Not included study design*

806. Tsujimura H, Sakai C, Ishii A, et al. Fatal fulminant *Clostridium difficile* colitis during CHOP therapy for lymphoma: an autopsy case. *Internal Medicine* 2007; 46(7):401-4. *Not included study design*
807. Tumbarello M, Tacconelli E, Leone F, et al. *Clostridium difficile*-associated diarrhoea in patients with human immunodeficiency virus infection: a case-control study. *European journal of gastroenterology & hepatology* 1995 Mar; 7(3):259-63. *Duplicate listing*
808. Tumbarello M, Tacconelli E, Leone F, et al. *Clostridium difficile*-associated diarrhoea in patients with human immunodeficiency virus infection: a case-control study. *European journal of gastroenterology & hepatology* 1995 Mar; 7(3):259-63. *Not relevant to key questions*
809. Turner RJ. Pseudomembranous enterocolitis after gynecologic endoscopy. *Journal of the American Association of Gynecologic Laparoscopists* 1994 Feb; 1(2):168-70. *Not included study design*
810. Uhnoo I, Wadell G, Svensson L, et al. Aetiology and epidemiology of acute gastroenteritis in Swedish children. *Journal of Infection* 1986 Jul; 13(1):73-89. *Not on topic*
811. Urban E, Tusnadi A, Terhes G, et al. Prevalence of gastrointestinal disease caused by *Clostridium difficile* in a university hospital in Hungary. *J Hosp Infect* 2002 Jul; 51(3):175-8. *Not relevant to key questions*
812. Vaishnavi C, Kaur S. *Clostridium perfringens* enterotoxin in antibiotic-associated diarrhea. *Indian journal of pathology & microbiology* 2008 Apr-Jun; 51(2):198-9. *Not on topic*
813. Valentine RJ, Hagino RT, Jackson MR, et al. Gastrointestinal complications after aortic surgery. *Journal of Vascular Surgery* 1998 discussion 411-2; Sep; 28(3):404-11. *Not on topic*
814. Valiquette L, Pepin J, Do XV, et al. Prediction of complicated *Clostridium difficile* infection by pleural effusion and increased wall thickness on computed tomography. *Clinic Infect Dis* 2009 Aug 15; 49(4):554-60. *Not relevant to key questions*
815. van den Berg RJ, Kuijper EJ, van Coppenraet LE, et al. Rapid diagnosis of toxinogenic *Clostridium difficile* in faecal samples with internally controlled real-time PCR. *Clinical Microbiology & Infection* 2006 Feb; 12(2):184-6. *Not relevant to key questions*
816. van Kraaij MG, Dekker AW, Verdonck LF, et al. Infectious gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. *Bone marrow transplantation* 2000 Aug; 26(3):299-303. *Not on topic*
817. van Nispen CH, Hoepelman AI, Rozenberg-Arska M, et al. A double-blind, placebo-controlled, parallel group study of oral trovafloxacin on bowel microflora in healthy male volunteers. *American Journal of Surgery* 1998 Dec; 176(6A Suppl):27S-31S. *Not on topic*
818. Vanjak D, Girault G, Branger C, et al. Risk factors for *Clostridium difficile* infection in a hepatology ward. *Infect Control Hosp Epidemiol* 2007 Feb; 28(2):202-4. *Not included study design*
819. Vasaly FW, Reines D. A quality committee's evaluation of surgical intervention for *Clostridium difficile* infection. *AORN Journal* 2009 quiz 201-4; Aug; 90(2):192-200. *Not relevant to key questions*
820. Veillard E, Guggenbuhl P, Bello S, et al. Reactive oligoarthritis in a patient with *Clostridium difficile* pseudomembranous colitis. Review of the literature. *Revue du Rhumatisme (English Edition)* 1998 Dec; 65(12):795-8. *Not included study design*
821. Verdoorn BP, Orenstein R, Rosenblatt JE, et al. High prevalence of tcdC deletion-carrying *Clostridium difficile* and lack of association with disease severity. *Diagnostic Microbiology & Infectious Disease* 2010 Jan; 66(1):24-8. *Not relevant to key questions*
822. Vermaat JH, Rosebrugh E, Ford-Jones EL, et al. An epidemiologic study of nosocomial infections in a pediatric long-term care facility. *Am J Infect Control* 1993 Aug; 21(4):183-8. *Not on topic*

823. Vermaat JH, Rosebrugh E, Ford-Jones EL, et al. An epidemiologic study of nosocomial infections in a pediatric long-term care facility. *Am J Infect Control* 1993 Aug; 21(4):183-8. *Duplicate listing*
824. Veroux M, Puzzo L, Corona D, et al. Cytomegalovirus and Clostridium difficile ischemic colitis in a renal transplant recipient: a lethal complication of anti-rejection therapy? *Urologia internationalis* 2007 discussion 180; 79(2):177-9. *Not included study design*
825. Vesoulis Z, Lozanski G, Lojudice T. Synchronous occurrence of collagenous colitis and pseudomembranous colitis. *Can J Gastroenterol* 2000 Apr; 14(4):353-8. *Not included study design*
826. Vesoulis Z, Williams G, Matthews B. Pseudomembranous enteritis after proctocolectomy: report of a case. *Dis Colon Rectum* 2000 Apr; 43(4):551-4. *Not included study design*
827. Vesta KS, Wells PG, Gentry CA, et al. Specific risk factors for Clostridium difficile-associated diarrhea: a prospective, multicenter, case control evaluation. *Am J Infect Control* 2005 Oct; 33(8):469-72. *Duplicate listing*
828. Viscidi R, Laughon BE, Yolken R, et al. Serum antibody response to toxins A and B of Clostridium difficile. *J Infect Dis* 1983 Jul; 148(1):93-100. *Not relevant to key questions*
829. Viswanath YK, Griffiths CD. The role of surgery in pseudomembranous enterocolitis. *Postgrad Med J* 1998 Apr; 74(870):216-9. *Not included study design*
830. Viswanath YK, Griffiths CD. The role of surgery in pseudomembranous enterocolitis. *Postgrad Med J* 1998 Apr; 74(870):216-9. *Duplicate listing*
831. von Konow L, Kondell PA, Nord CE, et al. Clindamycin versus phenoxymethylpenicillin in the treatment of acute orofacial infections. *Eur J Clin Microbiol Infect Dis* 1992 Dec; 11(12):1129-35. *Not relevant to key questions*
832. Vonberg RP, Reichardt C, Behnke M, et al. Costs of nosocomial Clostridium difficile-associated diarrhoea. *J Hosp Infect* 2008 Sep; 70(1):15-20. *Not relevant to key questions*
833. Walker KJ, Gilliland SS, Vance-Bryan K, et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. *Journal of the American Geriatrics Society* 1993 Sep; 41(9):940-6. *Not relevant to key questions*
834. Walker RC, Ruane PJ, Rosenblatt JE, et al. Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of Clostridium difficile-related enteric disease. *Diagnostic Microbiology & Infectious Disease* 1986 May; 5(1):61-9. *Not relevant to key questions*
835. Wall R, Klenerman L, McCullough C, et al. A comparison of teicoplanin and cefuroxime as prophylaxis for orthopaedic implant surgery: a preliminary report. *J Antimicrob Chemother* 1988 Jan; 21(Suppl A):141-6. *Not on topic*
836. Walters BA, Roberts R, Stafford R, et al. Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy. *Gut* 1983 Mar; 24(3):206-12. *Not relevant to key questions*
837. Wanahita A, Goldsmith EA, Marino BJ, et al. Clostridium difficile infection in patients with unexplained leukocytosis. *Am J Med* 2003 Nov; 115(7):543-6. *Not relevant to key questions*
838. Wanahita A, Goldsmith EA, Musher DM. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by clostridium difficile. *Clinic Infect Dis* 2002 Jun 15; 34(12):1585-92. *Not relevant to key questions*
839. Wang A, Takeshima F, Ikeda M, et al. Ulcerative colitis complicating pseudomembranous colitis of the right colon. *Journal of gastroenterology* 2002; 37(4):309-12. *Not included study design*

840. Warny M, Vaerman JP, Avesani V, et al. Human antibody response to *Clostridium difficile* toxin A in relation to clinical course of infection. *Infect Immun* 1994 Feb; 62(2):384-9. *Not relevant to key questions*
841. Wasserman E, Hidalgo M, Hornedo J, et al. Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: dose finding study and evaluation of efficacy. *Bone marrow transplantation* 1997 Nov; 20(9):711-4. *Not on topic*
842. Watanakunakorn PW, Watanakunakorn C, Hazy J. Risk factors associated with *Clostridium difficile* diarrhea in hospitalized adult patients: a case-control study--sucralfate ingestion is not a negative risk factor. *Infect Control Hosp Epidemiol* 1996 Apr; 17(4):232-5. *Not relevant to key questions*
843. Watson B, Ellis M, Mandal B, et al. A comparison of the clinico-pathological features with stool pathogens in patients hospitalised with the symptom of diarrhoea. *Scand J Infect Dis* 1986; 18(6):553-9. *Not on topic*
844. Waywa D, Kongkriengdaj S, Chaidatch S, et al. Protozoan enteric infection in AIDS related diarrhea in Thailand. *Southeast Asian Journal of Tropical Medicine & Public Health* 2001; 32(Suppl 2):151-5. *Not on topic*
845. Weber P, Koch M, Heizmann WR, et al. Microbic superinfection in relapse of inflammatory bowel disease. *J Clin Gastroenterol* 1992 Jun; 14(4):302-8. *Not on topic*
846. Wei SC, Wong JM, Hsueh PR, et al. Diagnostic role of endoscopy, stool culture, and toxin A in *Clostridium difficile*-associated disease. *Journal of the Formosan Medical Association* 1997 Nov; 96(11):879-83. *Not relevant to key questions*
847. Weiss B, Kleinkauf N, Eckmanns T, et al. Risk factors related to a hospital-associated cluster of *Clostridium difficile* PCR ribotype 027 infections in Germany During 2007. *Infect Control Hosp Epidemiol* 2009 Mar; 30(3):282-4. *Duplicate listing*
848. Weiss B, Kleinkauf N, Eckmanns T, et al. Risk factors related to a hospital-associated cluster of *Clostridium difficile* PCR ribotype 027 infections in Germany During 2007. *Infect Control Hosp Epidemiol* 2009 Mar; 30(3):282-4. *Not relevant to key questions*
849. Welkon CJ, Long SS, Thompson CM, Jr., et al. *Clostridium difficile* in patients with cystic fibrosis. *American Journal of Diseases of Children* 1985 Aug; 139(8):805-8. *Not included study design*
850. West M, Pirenne J, Chavers B, et al. *Clostridium difficile* colitis after kidney and kidney-pancreas transplantation. *Clinical transplantation* 1999 Aug; 13(4):318-23. *Not relevant to key questions*
851. Whittier S, Shapiro DS, Kelly WF, et al. Evaluation of four commercially available enzyme immunoassays for laboratory diagnosis of *Clostridium difficile*-associated diseases. *J Clin Microbiol* 1993 Nov; 31(11):2861-5. *Not relevant to key questions*
852. Wilcox CM, Gryboski D, Fernandez M, et al. Computed tomographic findings in pseudomembranous colitis: an important clue to the diagnosis. *Southern medical journal* 1995 Sep; 88(9):929-33. *Not relevant to key questions*
853. Wilcox CM, Martin T, Phadnis M, et al. Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole. *BMC Gastroenterology* 2008; 8:18. *Not relevant to key questions*
854. Wilcox MH, Cunniffe JG, Trundle C, et al. Financial burden of hospital-acquired *Clostridium difficile* infection. *J Hosp Infect* 1996 Sep; 34(1):23-30. *Not relevant to key questions*
855. Wilcox MH, Fawley WN, Settle CD, et al. Recurrence of symptoms in *Clostridium difficile* infection--relapse or reinfection?[see comment]. *J Hosp Infect* 1998 Feb; 38(2):93-100. *Not relevant to key questions*

856. Wilcox MH, Fawley WN, Wigglesworth N, et al. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of *Clostridium difficile* infection. *J Hosp Infect* 2003 Jun; 54(2):109-14. *Not relevant to key questions*
857. Wilcox MH, Howe R. Diarrhoea caused by *Clostridium difficile*: response time for treatment with metronidazole and vancomycin. *J Antimicrob Chemother* 1995 Oct; 36(4):673-9. *Not relevant to key questions*
858. Wilcox MH, Mooney L, Bendall R, et al. A case-control study of community-associated *Clostridium difficile* infection. *J Antimicrob Chemother* 2008 Aug; 62(2):388-96. *Not relevant to key questions*
859. Wilcox MH, Smyth ET. Incidence and impact of *Clostridium difficile* infection in the UK, 1993-1996. *J Hosp Infect* 1998 Jul; 39(3):181-7. *Not relevant to key questions*
860. Wilkinson IJ, Rich G, Moore B, et al. Relapse of antibiotic-associated colitis after vancomycin therapy. *Medical Journal of Australia* 1980 Apr 5; 1(7):321-3. *Not relevant to key questions*
861. Williams RN, Hemingway D, Miller AS. Enteric *Clostridium difficile*, an emerging cause for high-output ileostomy. *Journal of Clinical Pathology* 2009 Oct; 62(10):951-3. *Not relevant to key questions*
862. Willingham FF, Ticona Chavez E, Taylor DN, et al. Diarrhea and *Clostridium difficile* infection in Latin American patients with AIDS. Working Group on AIDS in Peru. *Clinic Infect Dis* 1998 Sep; 27(3):487-93. *Not relevant to key questions*
863. Wistrom J, Norrby SR, Myhre EB, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. *J Antimicrob Chemother* 2001 Jan; 47(1):43-50. *Not relevant to key questions*
864. Wolf PL, Kasyan A. Images in clinical medicine. Pseudomembranous colitis associated with *Clostridium difficile*. *New England Journal of Medicine* 2005 Dec 8; 353(23):2491. *Not included study design*
865. Wong AS, Lam CS, Tambyah PA. Fatal chemotherapy associated *Clostridium difficile* infection--a case report. *Singapore medical journal* 2001 May; 42(5):214-6. *Not included study design*
866. Wong NA, Bathgate AJ, Bellamy CO. Colorectal disease in liver allograft recipients -- a clinicopathological study with follow-up. *European journal of gastroenterology & hepatology* 2002 Mar; 14(3):231-6. *Not on topic*
867. Wong NA, Bathgate AJ, Bellamy CO. Colorectal disease in liver allograft recipients -- a clinicopathological study with follow-up. *European journal of gastroenterology & hepatology* 2002 Mar; 14(3):231-6. *Duplicate listing*
868. Wongwanich S, Rugdeekha S, Pongpech P, et al. Detection of *Clostridium difficile* toxin A and B genes from stool samples of Thai diarrheal patients by polymerase chain reaction technique. *Journal of the Medical Association of Thailand* 2003 Oct; 86(10):970-5. *Not relevant to key questions*
869. Woodford HJ, George J. Diagnosis and management of urinary tract infection in hospitalized older people. *Journal of the American Geriatrics Society* 2009 Jan; 57(1):107-14. *Not relevant to key questions*
870. Woodhead M, Macfarlane J, Bts Cap Guidelines C. Local antibiotic guidelines for adult community-acquired pneumonia (CAP): a survey of UK hospital practice in 1999. *J Antimicrob Chemother* 2000 Jul; 46(1):141-3. *Not relevant to key questions*
871. Wren SM, Ahmed N, Jamal A, et al. Preoperative oral antibiotics in colorectal surgery increase the rate of *Clostridium difficile* colitis. *Archives of Surgery* 2005 Aug; 140(8):752-6. *Not relevant to key questions*
872. Wright JM, Adams SP, Gribble MJ, et al. *Clostridium difficile* in Crohn's disease. *Canadian Journal of Surgery* 1984 Sep; 27(5):435-7. *Not on topic*

873. Wright TW, Linscheid RL, O'Duffy JD. Acute flexor tenosynovitis in association with *Clostridium difficile* infection: a case report. *Journal of Hand Surgery - American* Volume 1996 Mar; 21(2):304-6. *Not included study design*
874. Wright TW, Linscheid RL, O'Duffy JD. Acute flexor tenosynovitis in association with *Clostridium difficile* infection: a case report. *Journal of Hand Surgery - American* Volume 1996 Mar; 21(2):304-6. *Duplicate listing*
875. Wu A. Spontaneous persistent pseudomembranous colitis related to *Clostridium difficile* in ischaemic bowel disease. *BMJ Clinical Research* Ed 1982 May 29; 284(6329):1606-7. *Not included study design*
876. Wullt M, Laurell MH. Low prevalence of nosocomial *Clostridium difficile* transmission, as determined by comparison of arbitrarily primed PCR and epidemiological data. *J Hosp Infect* 1999 Dec; 43(4):265-73. *Not relevant to key questions*
877. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of *Clostridium difficile*-associated diarrhoea. *J Antimicrob Chemother* 2004 Jul; 54(1):211-6. *Not included treatment type*
878. Yablon SA, Krotenberg R, Fruhmann K. Diarrhea in hospitalized patients. *American Journal of Physical Medicine & Rehabilitation* 1992 Apr; 71(2):102-7. *Not relevant to key questions*
879. Yadav Y, Garey KW, Dao-Tran TK, et al. Automated system to identify *Clostridium difficile* infection among hospitalised patients. *J Hosp Infect* 2009 Aug; 72(4):337-41. *Background*
880. Yahav J, Samra Z, Blau H, et al. *Helicobacter pylori* and *Clostridium difficile* in cystic fibrosis patients. *Dig Dis Sci* 2006 Dec; 51(12):2274-9. *Not included study design*
881. Yamashita M, Nomura K, Fujimoto Y, et al. Length of vancomycin administration for treatment of *clostridium difficile*-associated diarrhea may depend on presentation of colonic ulcer. *Hepato-gastroenterology* 2009 Mar-Apr; 56(90):313-6. *Not relevant to key questions*
882. Yamazawa K, Kanno H, Seki K, et al. Life-threatening *Clostridium difficile*-associated diarrhea induced by paclitaxel-carboplatin combination chemotherapy. *Acta Obstetrica et Gynecologica Scandinavica* 2001 Aug; 80(8):768-9. *Not included study design*
883. Yangco BG, Sher G, Bardin MC. Nitazoxanide and probiotics for the treatment of recurrent *Clostridium difficile* infection in a peritoneal dialysis patient. *Southern medical journal* 2009 Jul; 102(7):746-7. *Not included study design*
884. Yapar N, Sener A, Karaca B, et al. Antibiotic-associated diarrhea in a Turkish outpatient population: investigation of 288 cases. *Journal of Chemotherapy* 2005 Feb; 17(1):77-81. *Not on topic*
885. Yapar N, Sener A, Karaca B, et al. Antibiotic-associated diarrhea in a Turkish outpatient population: investigation of 288 cases. *Journal of Chemotherapy* 2005 Feb; 17(1):77-81. *Duplicate listing*
886. Yarinsky S, Wheeler WE. Inappropriate antibiotic use and the development of *Clostridium difficile* colitis. *West Virginia Medical Journal* 1990 Jun; 86(6):239-42. *Not relevant to key questions*
887. Yip C, Loeb M, Salama S, et al. Quinolone use as a risk factor for nosocomial *Clostridium difficile*-associated diarrhea. *Infect Control Hosp Epidemiol* 2001 Sep; 22(9):572-5. *Not relevant to key questions*
888. Yokohama S, Aoshima M, Asama T, et al. *Clostridium difficile*-associated enteric disease after percutaneous endoscopic gastrostomy. *Journal of gastroenterology* 2009; 44(2):121-5. *Not relevant to key questions*
889. Yokohama S, Aoshima M, Nakade Y, et al. Investigation and prediction of enteral nutrition problems after percutaneous endoscopic gastrostomy. *World Journal of Gastroenterology* 2009 Mar 21; 15(11):1367-72. *Not on topic*

890. Yolken RH, Bishop CA, Townsend TR, et al. Infectious gastroenteritis in bone-marrow-transplant recipients. *New England Journal of Medicine* 1982 Apr 29; 306(17):1010-2. *Not on topic*
891. Young GP, Bayley N, Ward P, et al. Antibiotic-associated colitis caused by *Clostridium difficile*: relapse and risk factors. *Medical Journal of Australia* 1986 Mar 17; 144(6):303-6. *Not relevant to key questions*
892. Young KW, Munro IC, Taylor SL, et al. The safety of whey protein concentrate derived from the milk of cows immunized against *Clostridium difficile*. *Regulatory Toxicology & Pharmacology* 2007 Apr; 47(3):317-26. *Not on topic*
893. Yousuf K, Saklayen MG, Markert RJ, et al. *Clostridium difficile*-associated diarrhea and chronic renal insufficiency. *Southern medical journal* 2002 Jul; 95(7):681-3. *Not relevant to key questions*
894. Yuen KY, Woo PC, Liang RH, et al. Clinical significance of alimentary tract microbes in bone marrow transplant recipients. *Diagnostic Microbiology & Infectious Disease* 1998 Feb; 30(2):75-81. *Not on topic*
895. Zabolotny B, Meterissian SH. Pseudomembranous colitis. *Journal of the American College of Surgeons* 2005 Jul; 201(1):142. *Not included study design*
896. Zajac BA, Fisher MA, Gibson GA, et al. Safety and efficacy of high-dose treatment with imipenem-cilastatin in seriously ill patients. *Antimicrob Agents Chemother* 1985 May; 27(5):745-8. *Not on topic*
897. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clinic Infect Dis* 2007 Aug 1; 45(3):302-7. *Duplicate listing*
898. Zerey M, Paton BL, Lincourt AE, et al. The burden of *Clostridium difficile* in surgical patients in the United States. *Surgical Infections* 2007 Dec; 8(6):557-66. *Not relevant to key questions*
899. Zetola-Burneo N, Brown C. Cases from the Osler Medical Service at Johns Hopkins University. *Am J Med* 2004 Feb 1; 116(3):198-200. *Not included study design*
900. Zilberberg MD, Nathanson BH, Sadigov S, et al. Epidemiology and outcomes of *clostridium difficile*-associated disease among patients on prolonged acute mechanical ventilation. *Chest* 2009 Sep; 136(3):752-8. *Not relevant to key questions*
901. Zilberberg MD, Shorr AF, Micek ST, et al. *Clostridium difficile*-associated disease and mortality among the elderly critically ill. *Critical care medicine* 2009 Sep; 37(9):2583-9. *Not relevant to key questions*
902. Zimmerman RK. Risk factors for *Clostridium difficile* cytotoxin-positive diarrhea after control for horizontal transmission. *Infect Control Hosp Epidemiol* 1991 Feb; 12(2):96-100. *Not relevant to key questions*
903. Zirakzadeh A, Gastineau DA, Mandrekar JN, et al. Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. *Bone marrow transplantation* 2008 Feb; 41(4):385-92. *Not relevant to key questions*
904. Ziring D, Tran R, Edelstein S, et al. Infectious enteritis after intestinal transplantation: incidence, timing, and outcome. *Transplantation* 2005 Mar 27; 79(6):702-9. *Not on topic*
905. Zollner-Schwetz I, Hogenauer C, Joainig M, et al. Role of *Klebsiella oxytoca* in antibiotic-associated diarrhea. *Clinic Infect Dis* 2008 Nov 1; 47(9):e74-8. *Not on topic*

Excluded References – C Difficile (Diagnostics Search)

1. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003 Mar 1; 36(5):580-5. *Not relevant to key question*
2. Abrahao C, Carman RJ, Hahn H, et al. Similar frequency of detection of Clostridium perfringens enterotoxin and Clostridium difficile toxins in patients with antibiotic-associated diarrhea. Eur J Clin Microbiol Infect Dis 2001 Sep; 20(9):676-7. *Not relevant to key question*
3. Aichinger E, Schleck CD, Harmsen WS, et al. Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay. J Clin Microbiol 2008 Nov; 46(11):3795-7. *Not relevant to key question*
4. Aichinger E, Schleck CD, Harmsen WS, et al. Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay. J Clin Microbiol 2008 Nov; 46(11):3795-7. *Not relevant to key question*
5. Akerlund T, Persson I, Unemo M, et al. Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1. J Clin Microbiol 2008 Apr; 46(4):1530-3. *Not relevant to key question*
6. Akerlund T, Svenungsson B, Lagergren A, et al. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol 2006 Feb; 44(2):353-8. *Not relevant to key question*
7. Albright JB, Bonatti H, Mendez J, et al. Early and late onset Clostridium difficile-associated colitis following liver transplantation. Transplant International 2007 Oct; 20(10):856-66. *Not relevant to key question*
8. Alestig K, Carlberg H, Nord CE, et al. Effect of cefoperazone on faecal flora. J Antimicrob Chemother 1983 Aug; 12(2):163-7. *Not relevant to key question*
9. Alfa MJ, Kabani A, Lysterly D, et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000 Jul; 38(7):2706-14. *Not relevant to key question*
10. Al-Nassir WN, Sethi AK, Nerandzic MM, et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008 Jul 1; 47(1):56-62. *Not relevant to key question*
11. Altaie SS, Meyer P, Dryja D. Comparison of two commercially available enzyme immunoassays for detection of Clostridium difficile in stool specimens. J Clin Microbiol 1994 Jan; 32(1):51-3. *Not relevant to key question*
12. Andrews CN, Raboud J, Kassen BO, et al. Clostridium difficile-associated diarrhea: predictors of severity in patients presenting to the emergency department. Can J Gastroenterol 2003 Jun; 17(6):369-73. *Not relevant to key question*
13. Ang P, Cheong WK, Khoo KS. Pseudomembranous colitis in a patient treated with paclitaxel for carcinoma of the breast: a case report. Ann Acad Med Singapore 2000 Jan; 29(1):132-4. *Not relevant to key question*
14. Aronsson B, Barany P, Nord CE, et al. Clostridium difficile-associated diarrhoea in uremic patients. European J Clin Microbiol 1987 Jun; 6(3):352-6. *Not relevant to key question*
15. Aronsson B, Granstrom M, Mollby R, et al. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 1985 May-Jun; 13(3):97-101. *Not relevant to key question*

16. Aronsson B, Mollby R, Nord CE. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. *J Infect Dis* 1985 Mar; 151(3):476-81. *Not relevant to key question*
17. Arslan H, Inci EK, Azap OK, et al. Etiologic agents of diarrhea in solid organ recipients. *Transplant Infectious Disease* 2007 Dec; 9(4):270-5. *Not relevant to key question*
18. Arsura EL, Fazio RA, Wickremesinghe PC. Pseudomembranous colitis following prophylactic antibiotic use in primary cesarean section. *American Journal of Obstetrics & Gynecology* 1985 Jan 1; 151(1):87-9. *Not relevant to key question*
19. Asha NJ, Tompkins D, Wilcox MH. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. *J Clin Microbiol* 2006 Aug; 44(8):2785-91. *Not relevant to key question*
20. Ayyagari A, Sharma P, Venkateswarlu, et al. Prevalence of Clostridium difficile in pseudomembranous and antibiotic-associated colitis in north India. *Journal of diarrhoeal diseases research* 1986 Sep; 4(3):157-60. *Not relevant to key question*
21. Bacon AE, 3rd, Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea. *Diagnostic Microbiology & Infectious Disease* 1994 Apr; 18(4):205-9. *Not relevant to key question*
22. Balamurugan R, Balaji V, Ramakrishna BS. Estimation of faecal carriage of Clostridium difficile in patients with ulcerative colitis using real time polymerase chain reaction. *Indian Journal of Medical Research* 2008 May; 127(5):472-7. *Not relevant to key question*
23. Balassiano IT, Miranda KR, Boente RF, et al. Characterization of Clostridium difficile strains isolated from immunosuppressed inpatients in a hospital in Rio de Janeiro, Brazil. *Anaerobe* 2009 Jun; 15(3):61-4. *Not relevant to key question*
24. Barany P, Stenvinkel P, Nord CE, et al. Clostridium difficile infection--a poor prognostic sign in uremic patients? *Clinical nephrology* 1992 Jul; 38(1):53-7. *Not relevant to key question*
25. Barbut F, Beaugerie L, Delas N, et al. Comparative value of colonic biopsy and intraluminal fluid culture for diagnosis of bacterial acute colitis in immunocompetent patients. *Infectious Colitis Study Group. Clinic Infect Dis* 1999 Aug; 29(2):356-60. *Not relevant to key question*
26. Barbut F, Corthier G, Charpak Y, et al. Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study. *Arch Intern Med* 1996 Jul 8; 156(13):1449-54. *Not relevant to key question*
27. Barbut F, Decre D, Lalande V, et al. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. *Journal of medical microbiology* 2005 Feb; 54(Pt 2):181-5. *Not relevant to key question*
28. Barbut F, Gariazzo B, Bonne L, et al. Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004. *Infect Control Hosp Epidemiol* 2007 Feb; 28(2):131-9. *Not relevant to key question*
29. Barbut F, Lalande V, Burghoffer B, et al. Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France. *J Clin Microbiol* 2002 Jun; 40(6):2079-83. *Not relevant to key question*
30. Barbut F, Leluan P, Antoniotti G, et al. Value of routine stool cultures in hospitalized patients with diarrhea. *Eur J Clin Microbiol Infect Dis* 1995 Apr; 14(4):346-9. *Not relevant to key question*
31. Barbut F, Meynard JL, Guiguet M, et al. Clostridium difficile-associated diarrhea in HIV-infected patients: epidemiology and risk factors. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology* 1997 Nov 1; 16(3):176-81. *Not relevant to key question*

32. Barbut F, Richard A, Hamadi K, et al. Epidemiology of recurrences or reinfections of *Clostridium difficile*-associated diarrhea. *J Clin Microbiol* 2000 Jun; 38(6):2386-8. *Not relevant to key question*
33. Barbut F, Mastrantonio P, Delmée M, et al. Prospective study of *Clostridium difficile* infections in Europe with phenotypic and genotypic characterisation of the isolates. *Clinical Microbiology & Infection* 2007 Nov; 13(11):1048-57. *Not relevant to key question*
34. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of *Clostridium difficile* infection. *Clinic Infect Dis* 2008 Jan 15; 46(Suppl 1):S12-8. *Not relevant to key question*
35. Bate G. Comparison of Minitek Anaerobe II, API An-Ident, and RapID ANA systems for identification of *Clostridium difficile*. *American Journal of Clinical Pathology* 1986 Jun; 85(6):716-8. *Not relevant to key question*
36. Bauer TM, Lalvani A, Fehrenbach J, et al. Derivation and validation of guidelines for stool cultures for enteropathogenic bacteria other than *Clostridium difficile* in hospitalized adults. *JAMA* 2001 Jan 17; 285(3):313-9. *Not relevant to key question*
37. Bender BS, Bennett R, Laughon BE, et al. Is *Clostridium difficile* endemic in chronic-care facilities? *Lancet* 1986 Jul 5; 2(8497):11-3. *Not relevant to key question*
38. Bennett GC, Allen E, Millard PH. *Clostridium difficile* diarrhoea: a highly infectious organism. *Age Ageing* 1984 Nov; 13(6):363-6. *Not relevant to key question*
39. Bennett RG, Greenough WB, 3rd. *C difficile* diarrhea: a common--and overlooked--nursing home infection. *Geriatrics* 1990 83-7; Sep; 45(9):77-8. *Not relevant to key question*
40. Bennett RG, Laughon BE, Mundy LM, et al. Evaluation of a latex agglutination test for *Clostridium difficile* in two nursing home outbreaks. *J Clin Microbiol* 1989 May; 27(5):889-93. *Not relevant to key question*
41. Benno Y, Shiragami N, Uchida K, et al. Effect of moxalactam on human fecal microflora. *Antimicrob Agents Chemother* 1986 Jan; 29(1):175-8. *Not relevant to key question*
42. Bergan T, Delin C, Johansen S, et al. Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. *Antimicrob Agents Chemother* 1986 Feb; 29(2):298-302. *Not relevant to key question*
43. Berman L, Carling T, Fitzgerald TN, et al. Defining surgical therapy for pseudomembranous colitis with toxic megacolon. *J Clin Gastroenterol* 2008 May-Jun; 42(5):476-80. *Not relevant to key question*
44. Binkovitz LA, Allen E, Bloom D, et al. Atypical presentation of *Clostridium difficile* colitis in patients with cystic fibrosis. *AJR.American Journal of Roentgenology* 1999 Feb; 172(2):517-21. *Not relevant to key question*
45. Bishara J, Bloch Y, Garty M, et al. Antimicrobial resistance of *Clostridium difficile* isolates in a tertiary medical center, Israel. *Diagnostic Microbiology & Infectious Disease* 2006 Feb; 54(2):141-4. *Not relevant to key question*
46. Bishara J, Peled N, Pitlik S, et al. Mortality of patients with antibiotic-associated diarrhoea: the impact of *Clostridium difficile*. *J Hosp Infect* 2008 Apr; 68(4):308-14. *Not relevant to key question*
47. Bishara J, Peled N, Pitlik S, et al. Mortality of patients with antibiotic-associated diarrhoea: the impact of *Clostridium difficile*. *J Hosp Infect* 2008 Apr; 68(4):308-14. *Not relevant to key question*
48. Bliss DZ, Johnson S, Savik K, et al. Fecal incontinence in hospitalized patients who are acutely ill. *Nursing research* 2000 Mar-Apr; 49(2):101-8. *Not relevant to key question*
49. Bloedt K, Riecker M, Poppert S, et al. Evaluation of new selective culture media and a rapid fluorescence in situ hybridization assay for identification of *Clostridium difficile* from stool samples. *Journal of medical microbiology* 2009 Jul; 58(Pt 7):874-7. *Not relevant to key question*

50. Blot E, Escande MC, Besson D, et al. Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. *J Hosp Infect* 2003 Mar; 53(3):187-92. *Not relevant to key question*
51. Blum RN, Berry CD, Phillips MG, et al. Clinical illnesses associated with isolation of dysgonic fermenter 3 from stool samples. *J Clin Microbiol* 1992 Feb; 30(2):396-400. *Not relevant to key question*
52. Bobulsky GS, Al-Nassir WN, Riggs MM, et al. Clostridium difficile skin contamination in patients with C. difficile-associated disease. *Clin Infect Dis* 2008 Feb 1; 46(3):447-50. *Not relevant to key question*
53. Boland GW, Lee MJ, Cats AM, et al. Antibiotic-induced diarrhea: specificity of abdominal CT for the diagnosis of Clostridium difficile disease. *Radiology* 1994 Apr; 191(1):103-6. *Not relevant to key question*
54. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. *Gut* 1986 Oct; 27(10):1169-72. *Not relevant to key question*
55. Bolton RP, Thomas DF. Pseudomembranous colitis in children and adults. *British J Hosp Med* 1986 Jan; 35(1):37-42. *Not relevant to key question*
56. Bond F, Payne G, Borriello SP, et al. Usefulness of culture in the diagnosis of Clostridium difficile infection. *Eur J Clin Microbiol Infect Dis* 1995 Mar; 14(3):223-6. *Not relevant to key question*
57. Borody TJ, Warren EF, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. *J Clin Gastroenterol* 2003 Jul; 37(1):42-7. *Not relevant to key question*
58. Borriello SP, Barclay FE. Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains. *Journal of medical microbiology* 1985 Jun; 19(3):339-50. *Not relevant to key question*
59. Borriello SP, Barclay FE. An in-vitro model of colonisation resistance to Clostridium difficile infection. *Journal of medical microbiology* 1986 Jun; 21(4):299-309. *Not relevant to key question*
60. Borriello SP, Honour P. Concomitance of cytotoxigenic and non-cytotoxigenic Clostridium difficile in stool specimens. *J Clin Microbiol* 1983 Oct; 18(4):1006-7. *Not relevant to key question*
61. Bouza E, Burillo A, Munoz P. Antimicrobial therapy of Clostridium difficile-associated diarrhea. *Medical Clinics of North America* 2006 Nov; 90(6):1141-63. *Not relevant to key question*
62. Bowen KE, McFarland LV, Greenberg RN, et al. Isolation of Clostridium difficile at a university hospital: a two-year study. *Clin Infect Dis* 1995 Jun; 20(Suppl 2):S261-2. *Not relevant to key question*
63. Brazier JS, Borriello SP. Microbiology, epidemiology and diagnosis of Clostridium difficile infection. *Current Topics in Microbiology & Immunology* 2000; 250:1-33. *Not relevant to key question*
64. Brettle RP, Poxton IR, Murdoch JM, et al. Clostridium difficile in association with sporadic diarrhoea. *BMJ Clinical Research Ed* 1982 Jan 23; 284(6311):230-3. *Not relevant to key question*
65. Brettle RP, Wallace E. Clostridium difficile-associated diarrhoea. *Journal of Infection* 1984 Mar; 8(2):123-8. *Not relevant to key question*
66. Bricker E, Garg R, Nelson R, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.[update in Cochrane Database Syst Rev. 2007;(3):CD004610; PMID: 17636768]. *Cochrane Database Syst Rev* 2005; (1):004610. *Not relevant to key question*
67. Briggs S, Upton A, Bilkey M, et al. Vancomycin-resistant enterococcal colonisation of hospitalised patients in Auckland. *New Zealand Medical Journal* 2002 Aug 23; 115(1160):U145. *Not relevant to key question*

68. Brinson RR, Curtis WD, Singh M. Diarrhea in the intensive care unit: the role of hypoalbuminemia and the response to a chemically defined diet (case reports and review of the literature). *Journal of the American College of Nutrition* 1987 Dec; 6(6):517-23. *Not relevant to key question*
69. Brismar B, Edlund C, Nord CE. Effect of ceftibuten on the normal intestinal microflora. *Infection* 1993 Nov-Dec; 21(6):373-5. *Not relevant to key question*
70. Brismar B, Edlund C, Nord CE. Impact of cefpodoxime proxetil and amoxicillin on the normal oral and intestinal microflora. *Eur J Clin Microbiol Infect Dis* 1993 Sep; 12(9):714-9. *Not relevant to key question*
71. Brooks JB, Nunez-Montiel OL, Basta MT, et al. Studies of stools from pseudomembranous colitis, rotaviral, and other diarrheal syndromes by frequency-pulsed electron capture gas-liquid chromatography. *J Clin Microbiol* 1984 Sep; 20(3):549-60. *Not relevant to key question*
72. Bruce D, Ritchie C, Jennings LC, et al. Clostridium difficile-associated colitis: cross infection in predisposed patients with renal failure. *New Zealand Medical Journal* 1982 Apr 28; 95(706):265-7. *Not relevant to key question*
73. Burke DA, Axon AT. Clostridium difficile, sulphasalazine, and ulcerative colitis. *Postgrad Med J* 1987 Nov; 63(745):955-7. *Not relevant to key question*
74. Burke DA, Axon AT. Clostridium difficile, sulphasalazine, and ulcerative colitis. *Postgrad Med J* 1987 Nov; 63(745):955-7. *Not relevant to key question*
75. Byrn JC, Maun DC, Gingold DS, et al. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. *Archives of Surgery* 2008 discussion 155; Feb; 143(2):150-4. *Not relevant to key question*
76. Calame W, Weseler AR, Viebke C, et al. Gum arabic establishes prebiotic functionality in healthy human volunteers in a dose-dependent manner. *British Journal of Nutrition* 2008 Dec; 100(6):1269-75. *Not relevant to key question*
77. Calame W, Weseler AR, Viebke C, et al. Gum arabic establishes prebiotic functionality in healthy human volunteers in a dose-dependent manner. *British Journal of Nutrition* 2008 Dec; 100(6):1269-75. *Not relevant to key question*
78. Campbell RR, Beere D, Wilcock GK, et al. Clostridium difficile in acute and long-stay elderly patients. *Age Ageing* 1988 Sep; 17(5):333-6. *Not relevant to key question*
79. Can M, Besirbellioglu BA, Avci IY, et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. *Medical Science Monitor* 2006 Apr; 12(4):P19-22. *Not relevant to key question*
80. Carmeli Y, Venkataraman L, DeGirolami PC, et al. Stool colonization of healthcare workers with selected resistant bacteria. *Infect Control Hosp Epidemiol* 1998 Jan; 19(1):38-40. *Not relevant to key question*
81. Cartmill TD, Shrimpton SB, Panigrahi H, et al. Nosocomial diarrhoea due to a single strain of Clostridium difficile: a prolonged outbreak in elderly patients. *Age Ageing* 1992 Jul; 21(4):245-9. *Not relevant to key question*
82. Cascinu S, Catalano G. Have enteric infections a role in 5-fluorouracil-associated diarrhea? *Supportive Care in Cancer* 1995 Sep; 3(5):322-3. *Not relevant to key question*
83. Cefai C, Elliott TS, Woodhouse KW. Gastrointestinal carriage rate of Clostridium difficile in elderly, chronic care hospital patients. *J Hosp Infect* 1988 May; 11(4):335-9. *Not relevant to key question*
84. Chachaty E, Bourneix C, Renard S, et al. Shedding of Clostridium difficile, fecal beta-lactamase activity, and gastrointestinal symptoms in 51 volunteers treated with oral cefixime. *Antimicrob Agents Chemother* 1993 Jul; 37(7):1432-5. *Not relevant to key question*
85. Chachaty E, Depitre C, Mario N, et al. Presence of Clostridium difficile and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo. *Antimicrob Agents Chemother* 1992 Sep; 36(9):2009-13. *Not relevant to key question*

86. Chancellor AM, Ellis-Pegler RB. A clinical and aetiological study of adult patients hospitalised for acute diarrhoeal disease. *New Zealand Medical Journal* 1982 Mar 10; 95(703):154-6. *Not relevant to key question*
87. Chang TW, Gorbach SL, Bartlett JG, et al. Bacitracin treatment of antibiotic-associated colitis and diarrhea caused by *Clostridium difficile* toxin. *Gastroenterol* 1980 Jun; 78(6):1584-6. *Not relevant to key question*
88. Chaudhry R, Joshy L, Kumar L, et al. Changing pattern of *Clostridium difficile* associated diarrhoea in a tertiary care hospital: a 5 year retrospective study. *Indian Journal of Medical Research* 2008 Apr; 127(4):377-82. *Not relevant to key question*
89. Cheng SH, Lu JJ, Young TG, et al. *Clostridium difficile*--associated diseases: comparison of symptomatic infection versus carriage on the basis of risk factors, toxin production, and genotyping results. *Clinic Infect Dis* 1997 Jul; 25(1):157-8. *Not relevant to key question*
90. Cherifi S, Delmee M, Van Broeck J, et al. Management of an outbreak of *Clostridium difficile*-associated disease among geriatric patients. *Infect Control Hosp Epidemiol* 2006 Nov; 27(11):1200-5. *Not relevant to key question*
91. Chezmar JL, Nelson RC, Bernardino ME. Portal venous gas after hepatic transplantation: sonographic detection and clinical significance. *AJR.American Journal of Roentgenology* 1989 Dec; 153(6):1203-5. *Not relevant to key question*
92. Church JM, Fazio VW. The significance of quantitative results of *C. difficile* cultures and toxin assays in patients with diarrhea. *Dis Colon Rectum* 1985 Nov; 28(11):765-9. *Not relevant to key question*
93. Church JM, Fazio VW. A role for colonic stasis in the pathogenesis of disease related to *Clostridium difficile*. *Dis Colon Rectum* 1986 Dec; 29(12):804-9. *Not relevant to key question*
94. Churchill DR, Lucas SB, Williams I, et al. Recurrent pseudomembranous colitis due to *Clostridium difficile* in AIDS. *Genitourinary medicine* 1994 Feb; 70(1):51-5. *Not relevant to key question*
95. Clarke HJ, Jinnah RH, Byank RP, et al. *Clostridium difficile* infection in orthopaedic patients. *Journal of Bone & Joint Surgery - American Volume* 1990 Aug; 72(7):1056-9. *Not relevant to key question*
96. Cloud J, Noddin L, Pressman A, et al. *Clostridium difficile* strain NAP-1 is not associated with severe disease in a nonepidemic setting. *Clin Gastroenterol Hepatol* 2009 Aug; 7(8):868-73.e2. *Not relevant to key question*
97. Cohen SH, Tang YJ, Hansen B, et al. Isolation of a toxin B-deficient mutant strain of *Clostridium difficile* in a case of recurrent *C. difficile*-associated diarrhea. *Clinic Infect Dis* 1998 Feb; 26(2):410-2. *Not relevant to key question*
98. Coignard B, Barbut F, Blanckaert K, et al. Emergence of *Clostridium difficile* toxinotype III, PCR-ribotype 027-associated disease, France, 2006. *Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2006; 11(9):E060914.1. *Not relevant to key question*
99. Cooper GS, Lederman MM, Salata RA. A predictive model to identify *Clostridium difficile* toxin in hospitalized patients with diarrhea. *Am J Gastroenterol* 1996 Jan; 91(1):80-4. *Background*
100. Corrado OJ, Mascie-Taylor BH, Hall MJ, et al. Prevalence of *Clostridium difficile* on a mixed-function ward for the elderly. *Journal of Infection* 1990 Nov; 21(3):287-92. *Not relevant to key question*
101. Corthier G, Dubos F, Raibaud P. Modulation of cytotoxin production by *Clostridium difficile* in the intestinal tracts of gnotobiotic mice inoculated with various human intestinal bacteria. *Applied & Environmental Microbiology* 1985 Jan; 49(1):250-2. *Not relevant to key question*
102. Crogan NL, Evans BC. *Clostridium difficile*: an emerging epidemic in nursing homes. *Geriatric nursing* 2007 May-Jun; 28(3):161-4. *Not relevant to key question*

103. Cunney RJ, Magee C, McNamara E, et al. Clostridium difficile colitis associated with chronic renal failure. Nephrology Dialysis Transplantation 1998 Nov; 13(11):2842-6. *Not relevant to key question*
104. Cuzzolin L, Zambrieri D, Donini M, et al. Influence of radiotherapy on intestinal microflora in cancer patients. Journal of Chemotherapy 1992 Jun; 4(3):176-9. *Not relevant to key question*
105. Cuzzolin L, Zambrieri D, Donini M, et al. Influence of radiotherapy on intestinal microflora in cancer patients. Journal of Chemotherapy 1992 Jun; 4(3):176-9. *Not relevant to key question*
106. Danna PL, Urban C, Bellin E, et al. Role of candida in pathogenesis of antibiotic-associated diarrhoea in elderly inpatients. Lancet 1991 Mar 2; 337(8740):511-4. *Not relevant to key question*
107. Dansinger ML, Johnson S, Jansen PC, et al. Protein-losing enteropathy is associated with Clostridium difficile diarrhea but not with asymptomatic colonization: a prospective, case-control study. Clinic Infect Dis 1996 Jun; 22(6):932-7. *Not relevant to key question*
108. Daw NC, Santana VM, Iacono LC, et al. Phase I and pharmacokinetic study of toptecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. Journal of Clinical Oncology 2004 Mar 1; 22(5):829-37. *Not relevant to key question*
109. De La Cochetiere MF, Durand T, Lalande V, et al. Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile. Microbial ecology 2008 Oct; 56(3):395-402. *Not relevant to key question*
110. de Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992 Oct; 36(10):2192-6. *Not relevant to key question*
111. Debast SB, Vaessen N, Choudry A, et al. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clinical Microbiology & Infection 2009 May; 15(5):427-34. *Not relevant to key question*
112. Delmee M, Ramboer I, Van Broeck J, et al. Epidemiology of Clostridium difficile toxinotype III, PCR-ribotype 027 associated disease in Belgium, 2006. Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin 2006; 11(9):E060914.2. *Not relevant to key question*
113. Depitre C, Avesani V, Delmee M, et al. Detection of Clostridium difficile toxins in stools. Comparison between a new enzyme immunoassay for toxin A and other routine tests. Gastroenterologie clinique et biologique 1993; 17(4):283-6. *Not relevant to key question*
114. Dhawan B, Chaudhry R, Sharma N. Incidence of Clostridium difficile infection: a prospective study in an Indian hospital. J Hosp Infect 1999 Dec; 43(4):275-80. *Not relevant to key question*
115. Dickinson RJ, Rampling A, Wight DG. Spontaneous pseudomembranous colitis not associated with Clostridium difficile. Journal of Infection 1985 May; 10(3):252-5. *Not relevant to key question*
116. Djuretic T, Wall PG, Brazier JS. Clostridium difficile: an update on its epidemiology and role in hospital outbreaks in England and Wales. J Hosp Infect 1999 Mar; 41(3):213-8. *Not relevant to key question*
117. Dorman SA, Liggoria E, Winn WC, Jr., et al. Isolation of Clostridium difficile from patients with inactive Crohn's disease. Gastroenterol 1982 Jun; 82(6):1348-51. *Not relevant to key question*
118. Drees M, Snyderman DR, O'Sullivan CE. Repeated enzyme immunoassays have limited utility in diagnosing Clostridium difficile. Eur J Clin Microbiol Infect Dis 2008 May; 27(5):397-9. *Not relevant to key question*

119. Drudy D, Harnedy N, Fanning S, et al. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive *Clostridium difficile*. *Infect Control Hosp Epidemiol* 2007 Aug; 28(8):932-40. *Not relevant to key question*
120. Dubberke ER, Reske KA, McDonald LC, et al. ICD-9 codes and surveillance for *Clostridium difficile*-associated disease. *Emerging Infectious Diseases* 2006 Oct; 12(10):1576-9. *Not relevant to key question*
121. Dudley MN, McLaughlin JC, Carrington G, et al. Oral bacitracin vs vancomycin therapy for *Clostridium difficile*-induced diarrhea. A randomized double-blind trial. *Arch Intern Med* 1986 Jun; 146(6):1101-4. *Not relevant to key question*
122. Edlund C, Alvan G, Barkholt L, et al. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. *J Antimicrob Chemother* 2000 Nov; 46(5):741-9. *Not relevant to key question*
123. Edlund C, Stark C, Nord CE. The relationship between an increase in beta-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances. *J Antimicrob Chemother* 1994 Jul; 34(1):127-38. *Not relevant to key question*
124. Eidhin DN, Ryan AW, Doyle RM, et al. Sequence and phylogenetic analysis of the gene for surface layer protein, slpA, from 14 PCR ribotypes of *Clostridium difficile*. *Journal of medical microbiology* 2006 Jan; 55(Pt 1):69-83. *Not relevant to key question*
125. Elinav E, Planer D, Gatt ME. Prolonged ileus as a sole manifestation of pseudomembranous enterocolitis. *International journal of colorectal disease* 2004 May; 19(3):273-6. *Not relevant to key question*
126. Elvy J, Riordan T, Sarsfield P, et al. A diarrhoeal illness with a difference? *BMJ* 2009; 339:b2648. *Not relevant to key question*
127. Enocksson A, Lundberg J, Weitzberg E, et al. Rectal nitric oxide gas and stool cytokine levels during the course of infectious gastroenteritis. *Clinical & Diagnostic Laboratory Immunology* 2004 Mar; 11(2):250-4. *Not relevant to key question*
128. Enzensberger R, Shah PM, Knothe H. Impact of oral ciprofloxacin on the faecal flora of healthy volunteers. *Infection* 1985 Nov-Dec; 13(6):273-5. *Not relevant to key question*
129. Ergen EK, Akalin H, Yilmaz E, et al. Nosocomial diarrhea and *Clostridium Difficile* associated diarrhea in a Turkish University Hospital. *Medecine et Maladies Infectieuses* 2009 Jun; 39(6):382-7. *Not relevant to key question*
130. Falsen E, Kaijser B, Nehls L, et al. *Clostridium difficile* in relation to enteric bacterial pathogens. *J Clin Microbiol* 1980 Sep; 12(3):297-300. *Not relevant to key question*
131. Fan YJ, Chen SJ, Yu YC, et al. A probiotic treatment containing *Lactobacillus*, *Bifidobacterium* and *Enterococcus* improves IBS symptoms in an open label trial. *Journal of Zhejiang University. Science. B* 2006 Dec; 7(12):987-91. *Not relevant to key question*
132. Fawley WN, Parnell P, Verity P, et al. Molecular epidemiology of endemic *Clostridium difficile* infection and the significance of subtypes of the United Kingdom epidemic strain (PCR ribotype 1). *J Clin Microbiol* 2005 Jun; 43(6):2685-96. *Not relevant to key question*
133. Fawley WN, Wilcox MH. Molecular epidemiology of endemic *Clostridium difficile* infection. *Epidemiology & Infection* 2001 Jun; 126(3):343-50. *Not relevant to key question*
134. Fekety R, McFarland LV, Surawicz CM, et al. Recurrent *Clostridium difficile* diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. *Clinic Infect Dis* 1997 Mar; 24(3):324-33. *Not relevant to key question*

135. Feldman RJ, Kallich M, Weinstein MP. Bacteremia due to *Clostridium difficile*: case report and review of extraintestinal *C. difficile* infections. *Clinic Infect Dis* 1995 Jun; 20(6):1560-2. *Not relevant to key question*
136. Fenner L, Frei R, Gregory M, et al. Epidemiology of *Clostridium difficile*-associated disease at University Hospital Basel including molecular characterisation of the isolates 2006-2007. *Eur J Clin Microbiol Infect Dis* 2008 Dec; 27(12):1201-7. *Not relevant to key question*
137. Fenner L, Widmer AF, Goy G, et al. Rapid and reliable diagnostic algorithm for detection of *Clostridium difficile*. *J Clin Microbiol* 2008 Jan; 46(1):328-30. *Background*
138. Ferroni A, Merckx J, Ancelle T, et al. Nosocomial outbreak of *Clostridium difficile* diarrhea in a pediatric service. *Eur J Clin Microbiol Infect Dis* 1997 Dec; 16(12):928-33. *Not relevant to key question*
139. Fille M, Larcher C, Dierich MP, et al. Evaluation of four methods for detection of *Clostridium difficile* or *C. difficile* toxin: cytotoxin assay, culture, latex agglutination, and a new rapid immunoassay (*C. difficile* toxin A test). *Zeitschrift fur Gastroenterologie* 1998 Feb; 36(2):143-9. *Not relevant to key question*
140. Finegold SM. Clinical considerations in the diagnosis of antimicrobial agent-associated gastroenteritis. *Diagnostic Microbiology & Infectious Disease* 1986 Mar; 4(3 Suppl):87S-91S. *Not relevant to key question*
141. Forward LJ, Tompkins DS, Brett MM. Detection of *Clostridium difficile* cytotoxin and *Clostridium perfringens* enterotoxin in cases of diarrhoea in the community. *Journal of medical microbiology* 2003 Sep; 52(Pt 9):753-7. *Not relevant to key question*
142. Foulke GE, Silva J, Jr. *Clostridium difficile* in the intensive care unit: management problems and prevention issues. *Critical care medicine* 1989 Aug; 17(8):822-6. *Not relevant to key question*
143. Freeman J, Baines SD, Saxton K, et al. Effect of metronidazole on growth and toxin production by epidemic *Clostridium difficile* PCR ribotypes 001 and 027 in a human gut model. *J Antimicrob Chemother* 2007 Jul; 60(1):83-91. *Not relevant to key question*
144. Freeman J, Wilcox MH. The effects of storage conditions on viability of *Clostridium difficile* vegetative cells and spores and toxin activity in human faeces. *Journal of clinical pathology* 2003 Feb; 56(2):126-8. *Not relevant to key question*
145. Frenz MB, McIntyre AS. Reducing delays in the diagnosis and treatment of *Clostridium difficile* diarrhoea. *QJM* 2003 Aug; 96(8):579-82. *Not relevant to key question*
146. Garbutt JM, Littenberg B, Evanoff BA, et al. Enteric carriage of vancomycin-resistant *Enterococcus faecium* in patients tested for *Clostridium difficile*. *Infect Control Hosp Epidemiol* 1999 Oct; 20(10):664-70. *Not relevant to key question*
147. Garcia C, Samalvides F, Vidal M, et al. Epidemiology of *Clostridium difficile*-associated diarrhea in a Peruvian tertiary care hospital. *American Journal of Tropical Medicine & Hygiene* 2007 Nov; 77(5):802-5. *Not relevant to key question*
148. Garner CE, Smith S, de Lacy Costello B, et al. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. *FASEB Journal* 2007 Jun; 21(8):1675-88. *Not relevant to key question*
149. Gebhard RL, Gerding DN, Olson MM, et al. Clinical and endoscopic findings in patients early in the course of *clostridium difficile*-associated pseudomembranous colitis. *Am J Med* 1985 Jan; 78(1):45-8. *Not relevant to key question*
150. George WL, Rolfe RD, Harding GK, et al. *Clostridium difficile* and cytotoxin in feces of patients with antimicrobial agent-associated pseudomembranous colitis. *Infection* 1982; 10(4):205-8. *Not relevant to key question*
151. George WL, Sutter VL, Goldstein EJ, et al. Aetiology of antimicrobial-agent-associated colitis. *Lancet* 1978 Apr 15; 1(8068):802-3. *Not relevant to key question*

152. Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 1986 Jan; 146(1):95-100. *Not relevant to key question*
153. Germani Y, Morillon M, Begaud E, et al. Two-year study of endemic enteric pathogens associated with acute diarrhea in New Caledonia. J Clin Microbiol 1994 Jun; 32(6):1532-6. *Not relevant to key question*
154. Gilbride SJ, Lee BE, Taylor GD, et al. Successful containment of a norovirus outbreak in an acute adult psychiatric area. Infect Control Hosp Epidemiol 2009 Mar; 30(3):289-91. *Not relevant to key question*
155. Gill VJ, Travis LB, Williams DY. Clinical and microbiological observations on CDC group DF-3, a gram-negative coccobacillus. J Clin Microbiol 1991 Aug; 29(8):1589-92. *Not relevant to key question*
156. Gilligan PH, McCarthy LR, Genta VM. Relative frequency of Clostridium difficile in patients with diarrheal disease. J Clin Microbiol 1981 Jul; 14(1):26-31. *Not relevant to key question*
157. Goodman JL, Jurkovich P, Kramber JM, et al. Molecular detection of persistent Borrelia burgdorferi in the urine of patients with active Lyme disease. Infect Immun 1991 Jan; 59(1):269-78. *Not relevant to key question*
158. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008 Nov 1; 47(9):1162-70. *Not relevant to key question*
159. Goorhuis A, Van der Kooi T, Vaessen N, et al. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 2007 Sep 15; 45(6):695-703. *Not relevant to key question*
160. Gorbach SL, Cornick NA, Silva M. Effect of bismuth subsalicylate on fecal microflora. Reviews of infectious diseases 1990 Jan-Feb; 12(Suppl 1):S21-3. *Not relevant to key question*
161. Gorenek L, Dizer U, Besirbellioglu B, et al. The diagnosis and treatment of Clostridium difficile in antibiotic-associated diarrhea. Hepato-gastroenterology 1999 Jan-Feb; 46(25):343-8. *Not relevant to key question*
162. Gravet A, Rondeau M, Harf-Monteil C, et al. Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-lukD. J Clin Microbiol 1999 Dec; 37(12):4012-9. *Not relevant to key question*
163. Greenfield C, Burroughs A, Szawathowski M, et al. Is pseudomembranous colitis infectious? Lancet 1981 Feb 14; 1(8216):371-2. *Not relevant to key question*
164. Grundfest-Broniatowski S, Quader M, Alexander F, et al. Clostridium difficile colitis in the critically ill. Dis Colon Rectum 1996 Jun; 39(6):619-23. *Not relevant to key question*
165. Guenter PA, Settle RG, Perlmutter S, et al. Tube feeding-related diarrhea in acutely ill patients. Jpen: Journal of Parenteral & Enteral Nutrition 1991 May-Jun; 15(3):277-80. *Not relevant to key question*
166. Gujja D, Friedenber FK. Predictors of serious complications due to Clostridium difficile infection. Aliment Pharmacol Ther 2009 Mar 15; 29(6):635-42. *Not relevant to key question*
167. Gurian L, Klein K, Ward TT. Role of Clostridium difficile and Campylobacter jejuni in relapses of inflammatory bowel disease. Western Journal of Medicine 1983 Mar; 138(3):359-60. *Not relevant to key question*
168. Haberberger RL, Jr., Mikhail IA, Burans JP, et al. Travelers' diarrhea among United States military personnel during joint American-Egyptian armed forces exercises in Cairo, Egypt. Military medicine 1991 Jan; 156(1):27-30. *Not relevant to key question*
169. Hall SM, Calver GP, Williams M. A hospital outbreak of Clostridium difficile? J Hosp Infect 1985 Sep; 6(3):312-22. *Not relevant to key question*

170. Harris JP, Edmunds WJ, Pebody R, et al. Deaths from norovirus among the elderly, England and Wales. *Emerging Infectious Diseases* 2008 Oct; 14(10):1546-52. *Not relevant to key question*
171. Harris JP, Edmunds WJ, Pebody R, et al. Deaths from norovirus among the elderly, England and Wales. *Emerging Infectious Diseases* 2008 Oct; 14(10):1546-52. *Not relevant to key question*
172. Harter C, Schulze B, Goldschmidt H, et al. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. *Bone marrow transplantation* 2006 Feb; 37(4):373-9. *Not relevant to key question*
173. Hassoun A, Ibrahim F. Use of intravenous immunoglobulin for the treatment of severe *Clostridium difficile* colitis. *Am J Geriatr Pharmacother* 2007 Mar; 5(1):48-51. *Not relevant to key question*
174. Hayakawa T, Imaeda H, Nakamura M, et al. Association of pseudomembranous colitis with Henoch-Schonlein purpura. *Journal of gastroenterology* 2005 Jun; 40(6):641-5. *Not relevant to key question*
175. Heard SR, Wren B, Barnett MJ, et al. *Clostridium difficile* infection in patients with haematological malignant disease. Risk factors, faecal toxins and pathogenic strains. *Epidemiology & Infection* 1988 Feb; 100(1):63-72. *Not relevant to key question*
176. Heimdahl A, Nord CE. Effect of phenoxymethylpenicillin and clindamycin on the oral, throat and faecal microflora of man. *Scand J Infect Dis* 1979; 11(3):233-42. *Not relevant to key question*
177. Heizmann W, Ehninger G, Vallbracht A, et al. Surveillance cultures and benefit of laminar airflow units in patients undergoing bone marrow transplantation. *Infection* 1987; 15(5):337-43. *Not relevant to key question*
178. Helgason KO, Raby SJ, Kamel HM, et al. Cytomegalovirus colitis in a critically ill patient following elective repair of an abdominal aortic aneurysm. *Anaesthesia & Intensive Care* 2008 Jan; 36(1):107-9. *Not relevant to key question*
179. Henrich TJ, Krakower D, Bitton A, et al. Clinical risk factors for severe *Clostridium difficile*-associated disease. *Emerging Infectious Diseases* 2009 Mar; 15(3):415-22. *Not relevant to key question*
180. Hogenauer C, Langner C, Beubler E, et al. *Klebsiella oxytoca* as a causative organism of antibiotic-associated hemorrhagic colitis. *New England Journal of Medicine* 2006 Dec 7; 355(23):2418-26. *Not relevant to key question*
181. Holt HA, Lewis DA, White LO, et al. Effect of oral ciprofloxacin on the faecal flora of healthy volunteers. *European J Clin Microbiol* 1986 Apr; 5(2):201-5. *Not relevant to key question*
182. Hooker M. *Clostridium difficile*. *Clinical journal of oncology nursing* 2007 Dec; 11(6):801-4. *Not relevant to key question*
183. Hopkins MJ, Macfarlane GT. Changes in predominant bacterial populations in human faeces with age and with *Clostridium difficile* infection. *Journal of medical microbiology* 2002 May; 51(5):448-54. *Not relevant to key question*
184. Hopkins MJ, Sharp R, Macfarlane GT. Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. *Gut* 2001 Feb; 48(2):198-205. *Not relevant to key question*
185. Hopkins MJ, Sharp R, Macfarlane GT. Variation in human intestinal microbiota with age. *Digestive & Liver Disease* 2002 Sep; 34(Suppl 2):S12-8. *Not relevant to key question*
186. Hossain M, Crook TJ, Keoghane SR. *Clostridium difficile* in urology. *Annals of the Royal College of Surgeons of England* 2008 Jan; 90(1):36-9. *Not relevant to key question*
187. Hossain M, Crook TJ, Keoghane SR. *Clostridium difficile* in urology. *Annals of the Royal College of Surgeons of England* 2008 Jan; 90(1):36-9. *Not relevant to key question*

188. Howitt JR, Grace JW, Schaefer MG, et al. Clostridium difficile-positive stools: a retrospective identification of risk factors. *Am J Infect Control* 2008 Sep; 36(7):488-91. *Not relevant to key question*
189. Howitt JR, Grace JW, Schaefer MG, et al. Clostridium difficile-positive stools: a retrospective identification of risk factors. *Am J Infect Control* 2008 Sep; 36(7):488-91. *Not relevant to key question*
190. Hsu MS, Wang JT, Huang WK, et al. Prevalence and clinical features of Clostridium difficile-associated diarrhea in a tertiary hospital in northern Taiwan. *Journal of Microbiology, Immunology & Infection* 2006 Jun; 39(3):242-8. *Not relevant to key question*
191. Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. *Gastroenterol* 2009 Apr; 136(4):1206-14. *Not relevant to key question*
192. Huhulescu S, Kiss R, Brettlecker M, et al. Etiology of acute gastroenteritis in three sentinel general practices, Austria 2007. *Infection* 2009 Apr; 37(2):103-8. *Not relevant to key question*
193. Hutin Y, Casin I, Lesprit P, et al. Prevalence of and risk factors for Clostridium difficile colonization at admission to an infectious diseases ward. *Clinic Infect Dis* 1997 May; 24(5):920-4. *Not relevant to key question*
194. Hutin Y, Molina JM, Casin I, et al. Risk factors for Clostridium difficile-associated diarrhoea in HIV-infected patients. *AIDS* 1993 Nov; 7(11):1441-7. *Not relevant to key question*
195. Iizuka M, Itou H, Konno S, et al. Elemental diet modulates the growth of Clostridium difficile in the gut flora. *Aliment Pharmacol Ther* 2004 Jul; 20(Suppl 1):151-7. *Not relevant to key question*
196. Iizuka M, Konno S, Itou H, et al. Novel evidence suggesting Clostridium difficile is present in human gut microbiota more frequently than previously suspected. *Microbiology & Immunology* 2004; 48(11):889-92. *Not relevant to key question*
197. Imase K, Takahashi M, Tanaka A, et al. Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota. *Microbiology & Immunology* 2008 Mar; 52(3):156-61. *Not relevant to key question*
198. Inagaki Y, Nakaya R, Chida T, et al. The effect of levofloxacin, an optically-active isomer of ofloxacin, on fecal microflora in human volunteers. *Japanese Journal of Antibiotics* 1992 Mar; 45(3):241-52. *Not relevant to key question*
199. Inagaki Y, Yamamoto N, Chida T, et al. The effect of DU-6859a, a new potent fluoroquinolone, on fecal microflora in human volunteers. *Japanese Journal of Antibiotics* 1995 Mar; 48(3):368-79. *Not relevant to key question*
200. Indra A, Huhulescu S, Hasenberger P, et al. First isolation of Clostridium difficile PCR ribotype 027 in Austria. *Euro Surveillance: Bulletin European sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2006; 11(9):E060914.3. *Not relevant to key question*
201. Indra A, Huhulescu S, Kernbichler S, et al. First cases of Clostridium difficile PCR ribotype 027 acquired in Austria. *Euro Surveillance: Bulletin European sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2008 May 15; 13(20). *Not relevant to key question*
202. Indra A, Schmid D, Huhulescu S, et al. Characterization of clinical Clostridium difficile isolates by PCR ribotyping and detection of toxin genes in Austria, 2006-2007. *Journal of medical microbiology* 2008 Jun; 57(Pt 6):702-8. *Not relevant to key question*
203. Ingebretsen A, Hansen G, Harmanus C, et al. First confirmed cases of Clostridium difficile PCR ribotype 027 in Norway. *Euro Surveillance: Bulletin European sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2008 Jan 10; 13(2). *Not relevant to key question*
204. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2007 Mar; 5(3):345-51. *Not relevant to key question*

205. Ito Y, Moriwaki H, Muto Y, et al. Effect of lactulose on short-chain fatty acids and lactate production and on the growth of faecal flora, with special reference to *Clostridium difficile*. *Journal of medical microbiology* 1997 Jan; 46(1):80-4. *Not relevant to key question*
206. Jarvis W, Nunez-Montiel O, Thompson F, et al. Comparison of bacterial isolation, cytotoxicity assay, and counterimmunoelectrophoresis for the detection of *Clostridium difficile* and its toxin. *J Infect Dis* 1983 Apr; 147(4):778. *Not relevant to key question*
207. Jawa P, Conlin F. Pseudomembranes on colostomy. *May Clinic Proc* 2009 Mar; 84(3):214. *Not relevant to key question*
208. Jawa P, Conlin F. Pseudomembranes on colostomy. *May Clinic Proc* 2009 Mar; 84(3):214. *Not relevant to key question*
209. Jensen GL, Bross JE, Bourbeau PP, et al. Risk factors for *Clostridium difficile* stool cytotoxin b among critically ill patients: role of sucralfate. *J Infect Dis* 1994 Jul; 170(1):227-30. *Not relevant to key question*
210. Jiang ZD, DuPont HL, Garey K, et al. A common polymorphism in the interleukin 8 gene promoter is associated with *Clostridium difficile* diarrhea. *Am J Gastroenterol* 2006 May; 101(5):1112-6. *Not relevant to key question*
211. Jiang ZD, Garey KW, Price M, et al. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with *Clostridium difficile*-associated diarrhea. *Clin Gastroenterol Hepatol* 2007 Aug; 5(8):964-8. *Not relevant to key question*
212. Johal SS, Hammond J, Solomon K, et al. *Clostridium difficile* associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. *Gut* 2004 May; 53(5):673-7. *Not relevant to key question*
213. Johnson LL, McFarland LV, Dearing P, et al. Identification of *Clostridium difficile* in stool specimens by culture-enhanced gas-liquid chromatography. *J Clin Microbiol* 1989 Oct; 27(10):2218-21. *Not relevant to key question*
214. Johnson S, Gerding DN, Janoff EN. Systemic and mucosal antibody responses to toxin A in patients infected with *Clostridium difficile*. *J Infect Dis* 1992 Dec; 166(6):1287-94. *Not relevant to key question*
215. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic *Clostridium difficile* carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. *Annals of Internal Medicine* 1992 Aug 15; 117(4):297-302. *Not relevant to key question*
216. Johnson S, Sambol SP, Brazier JS, et al. International typing study of toxin A-negative, toxin B-positive *Clostridium difficile* variants. *J Clin Microbiol* 2003 Apr; 41(4):1543-7. *Not relevant to key question*
217. Joseph R, Demeyer D, Vanrenterghem D, et al. First isolation of *Clostridium difficile* PCR ribotype 027, toxinotype III in Belgium. *Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2005 Oct; 10(10):E051020.4. *Not relevant to key question*
218. Jung K, Aronsson B. Rapid diagnosis of *Clostridium difficile*-associated diarrhoea using a latex agglutination test. *APMIS* 1990 Jul; 98(7):652-4. *Not relevant to key question*
219. Kaatz GW, Gitlin SD, Schaberg DR, et al. Acquisition of *Clostridium difficile* from the hospital environment. *American Journal of Epidemiology* 1988 Jun; 127(6):1289-94. *Not relevant to key question*
220. Kamboj M, Mihu CN, Sepkowitz K, et al. Work-up for infectious diarrhea after allogeneic hematopoietic stem cell transplantation: single specimen testing results in cost savings without compromising diagnostic yield. *Transplant Infectious Disease* 2007 Dec; 9(4):265-9. *Not relevant to key question*
221. Kamthan AG, Bruckner HW, Hirschman SZ, et al. *Clostridium difficile* diarrhea induced by cancer chemotherapy. *Arch Intern Med* 1992 Aug; 152(8):1715-7. *Not relevant to key question*

222. Karasawa T, Nojiri T, Hayashi Y, et al. Laboratory diagnosis of toxigenic *Clostridium difficile* by polymerase chain reaction: presence of toxin genes and their stable expression in toxigenic isolates from Japanese individuals. *Journal of gastroenterology* 1999 Feb; 34(1):41-5. *Not relevant to key question*
223. Katchar K, Taylor CP, Tummala S, et al. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent *Clostridium difficile*-associated disease. *Clin Gastroenterol Hepatol* 2007 Jun; 5(6):707-13. *Not relevant to key question*
224. Kato H, Kato H, Nakamura M, et al. Rapid analysis of *Clostridium difficile* strains recovered from hospitalized patients by using the *slpA* sequence typing system. *Journal of Infection & Chemotherapy* 2009 Jun; 15(3):199-202. *Not relevant to key question*
225. Kato H, Kato N, Katow S, et al. Deletions in the repeating sequences of the toxin A gene of toxin A-negative, toxin B-positive *Clostridium difficile* strains. *FEMS microbiology letters* 1999 Jun 15; 175(2):197-203. *Not relevant to key question*
226. Kato H, Kato N, Watanabe K, et al. Identification of toxin A-negative, toxin B-positive *Clostridium difficile* by PCR. *J Clin Microbiol* 1998 Aug; 36(8):2178-82. *Not relevant to key question*
227. Kato H, Kita H, Karasawa T, et al. Colonisation and transmission of *Clostridium difficile* in healthy individuals examined by PCR ribotyping and pulsed-field gel electrophoresis. *Journal of medical microbiology* 2001 Aug; 50(8):720-7. *Not relevant to key question*
228. Katz DA, Bates DW, Rittenberg E, et al. Predicting *Clostridium difficile* stool cytotoxin results in hospitalized patients with diarrhea. *J Gen Intern Med* 1997 Jan; 12(1):57-62. *Not relevant to key question*
229. Katz DA, Bates DW, Rittenberg E, et al. Predicting *Clostridium difficile* stool cytotoxin results in hospitalized patients with diarrhea. *J Gen Intern Med* 1997 Jan; 12(1):57-62. *Not relevant to key question*
230. Katz DA, Lynch ME, Littenberg B. Clinical prediction rules to optimize cytotoxin testing for *Clostridium difficile* in hospitalized patients with diarrhea. *Am J Med* 1996 May; 100(5):487-95. *Not relevant to key question*
231. Kaukoranta-Tolvanen SS, Renkonen OV, Gordin A, et al. Effect of erythromycin acistrate and erythromycin stearate on human colonic microflora. *Scand J Infect Dis* 1989; 21(6):717-20. *Not relevant to key question*
232. Kawecki D, Chmura A, Pacholczyk M, et al. Detection of *Clostridium difficile* in stool samples from patients in the early period after liver transplantation. *Transplantation proceedings* 2007 Nov; 39(9):2812-5. *Not relevant to key question*
233. Keighley MR, Youngs D, Johnson M, et al. *Clostridium difficile* toxin in acute diarrhoea complicating inflammatory bowel disease. *Gut* 1982 May; 23(5):410-4. *Not relevant to key question*
234. Kelly CP, Chetham S, Keates S, et al. Survival of anti-*Clostridium difficile* bovine immunoglobulin concentrate in the human gastrointestinal tract. *Antimicrob Agents Chemother* 1997 Feb; 41(2):236-41. *Not relevant to key question*
235. Kelly CP, Pothoulakis C, Orellana J, et al. Human colonic aspirates containing immunoglobulin A antibody to *Clostridium difficile* toxin A inhibit toxin A-receptor binding. *Gastroenterol* 1992 Jan; 102(1):35-40. *Not relevant to key question*
236. Kelly MT, Champagne SG, Sherlock CH, et al. Commercial latex agglutination test for detection of *Clostridium difficile*-associated diarrhea. *J Clin Microbiol* 1987 Jul; 25(7):1244-7. *Not relevant to key question*
237. Kenneally C, Rosini JM, Skrupky LP, et al. Analysis of 30-day mortality for *clostridium difficile*-associated disease in the ICU setting. *Chest* 2007 Aug; 132(2):418-24. *Not relevant to key question*
238. Kim SW, Peck KR, Jung SI, et al. *Pseudomonas aeruginosa* as a potential cause of antibiotic-associated diarrhea. *Journal of Korean medical science* 2001 Dec; 16(6):742-4. *Not relevant to key question*

239. Kirkpatrick ID, Greenberg HM. Evaluating the CT diagnosis of *Clostridium difficile* colitis: should CT guide therapy? *AJR.American Journal of Roentgenology* 2001 Mar; 176(3):635-9. *Not relevant to key question*
240. Klarin B, Wullt M, Palmquist I, et al. *Lactobacillus plantarum* 299v reduces colonisation of *Clostridium difficile* in critically ill patients treated with antibiotics. *Acta Anaesthesiologica Scandinavica* 2008 Sep; 52(8):1096-102. *Not relevant to key question*
241. Kleinkauf N, Weiss B, Jansen A, et al. Confirmed cases and report of clusters of severe infections due to *Clostridium difficile* PCR ribotype 027 in Germany. *Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2007 Nov; 12(11):E071115.2. *Not relevant to key question*
242. Knothe H, Schafer V, Sammann A, et al. Influence of cefpirome on pharyngeal and faecal flora after single and multiple intravenous administrations of cefpirome to healthy volunteers. *J Antimicrob Chemother* 1992 Apr; 29(Suppl A):81-6. *Not relevant to key question*
243. Knothe H, Schafer V, Sammann A, et al. Influence of fosfomycin on the intestinal and pharyngeal flora of man. *Infection* 1991 Jan-Feb; 19(1):18-20. *Not relevant to key question*
244. Knudsen JD, Tvede M. Demonstration of toxin A and B by polymerase chain reaction and McCoy cell assay in clinical isolates of *Clostridium difficile* from Denmark. *APMIS* 1993 Jan; 101(1):18-22. *Not relevant to key question*
245. Kocar IH, Caliskaner Z, Pay S, et al. *Clostridium difficile* infection in patients with reactive arthritis of undetermined etiology. *Scandinavian journal of rheumatology* 1998; 27(5):357-62. *Not relevant to key question*
246. Koh TH, Tan AL, Tan ML, et al. Epidemiology of *Clostridium difficile* infection in a large teaching hospital in Singapore. *Pathology* 2007 Aug; 39(4):438-42. *Not relevant to key question*
247. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a *Clostridium difficile* toxoid vaccine administered to healthy adults. *Infect Immun* 2001 Feb; 69(2):988-95. *Not relevant to key question*
248. Kuhl SJ, Tang YJ, Navarro L, et al. Diagnosis and monitoring of *Clostridium difficile* infections with the polymerase chain reaction. *Clinic Infect Dis* 1993 Jun; 16(Suppl 4):S234-8. *Not relevant to key question*
249. Kuijper EJ, de Weerd J, Kato H, et al. Nosocomial outbreak of *Clostridium difficile*-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain. *Eur J Clin Microbiol Infect Dis* 2001 Aug; 20(8):528-34. *Not relevant to key question*
250. Kumar B, Vaishnavi C, Sandhu K, et al. *Clostridium difficile* toxin assay in psoriatic patients. *Tropical Gastroenterology* 2004 Oct-Dec; 25(4):164-7. *Not relevant to key question*
251. Kurzynski TA, Cembrowski GS, Kimball JL. The use of CIE for the detection of *Clostridium difficile* toxin in stool filtrates: laboratory and clinical correlation. *American Journal of Clinical Pathology* 1983 Mar; 79(3):370-4. *Not relevant to key question*
252. Kyne L, Sougioultzis S, McFarland LV, et al. Underlying disease severity as a major risk factor for nosocomial *Clostridium difficile* diarrhea. *Infect Control Hosp Epidemiol* 2002 Nov; 23(11):653-9. *Not relevant to key question*
253. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of *Clostridium difficile* and serum levels of IgG antibody against toxin A. *New England Journal of Medicine* 2000 Feb 10; 342(6):390-7. *Not relevant to key question*
254. Laffan AM, Bellantoni MF, Greenough WB, 3rd, et al. Burden of *Clostridium difficile*-associated diarrhea in a long-term care facility. *Journal of the American Geriatrics Society* 2006 Jul; 54(7):1068-73. *Not relevant to key question*

255. Lahn M, Tyler G, Daubener W, et al. Improvement of *Clostridium difficile* isolation by heat-shock and typing of the isolated strains by SDS-PAGE. *European journal of epidemiology* 1993 May; 9(3):327-34. *Not relevant to key question*
256. Lam S, Singer C, Tucci V, et al. The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study. *Am J Infect Control* 1995 Jun; 23(3):170-80. *Not relevant to key question*
257. Lam S, Singer C, Tucci V, et al. The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study. *Am J Infect Control* 1995 Jun; 23(3):170-80. *Not relevant to key question*
258. LaMont JT, Trnka YM. Therapeutic implications of *Clostridium difficile* toxin during relapse of chronic inflammatory bowel disease. *Lancet* 1980 Feb 23; 1(8165):381-3. *Not relevant to key question*
259. Lau SK, Woo PC, Chan BY, et al. *Haemophilus segnis* polymicrobial and monomicrobial bacteraemia identified by 16S ribosomal RNA gene sequencing. *Journal of medical microbiology* 2002 Aug; 51(8):635-40. *Not relevant to key question*
260. Lau SK, Woo PC, Leung KW, et al. Emergence of cotrimoxazole- and quinolone-resistant *Campylobacter* infections in bone marrow transplant recipients. *Eur J Clin Microbiol Infect Dis* 2002 Feb; 21(2):127-9. *Not relevant to key question*
261. Lee SD, Turgeon DK, Ko CW, et al. Clinical correlation of toxin and common antigen enzyme immunoassay testing in patients with *Clostridium difficile* disease. *Am J Gastroenterol* 2003 Jul; 98(7):1569-72. *Not relevant to key question*
262. Lejko-Zupanc T, Zakelj J, Strle F, et al. Influence of ceftriaxone on emergence of *Clostridium difficile*. *Antimicrob Agents Chemother* 1992 Dec; 36(12):2850-1. *Not relevant to key question*
263. Lemann F, Chambon C, Barbut F, et al. Arbitrary primed PCR rules out *Clostridium difficile* cross-infection among patients in a haematology unit. *J Hosp Infect* 1997 Feb; 35(2):107-15. *Not relevant to key question*
264. Levett PN. *Clostridium difficile* in habitats other than the human gastro-intestinal tract. *Journal of Infection* 1986 May; 12(3):253-63. *Not relevant to key question*
265. Lewis R. Investigation of *Clostridium difficile* diarrhoea in a district general hospital: room for improvement? *J Hosp Infect* 1987 Nov; 10(3):243-7. *Not relevant to key question*
266. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of *Clostridium difficile*-associated diarrhea: a randomized, controlled study. *Clin Gastroenterol Hepatol* 2005 May; 3(5):442-8. *Not relevant to key question*
267. Lewis S, Burmeister S, Cohen S, et al. Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea. *Aliment Pharmacol Ther* 2005 Feb 15; 21(4):469-77. *Not relevant to key question*
268. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of *Saccharomyces boulardii* in the prevention of antibiotic-related diarrhoea in elderly patients. *Journal of Infection* 1998 Mar; 36(2):171-4. *Not relevant to key question*
269. Lishman AH, Al-Jumaili IJ, Record CO. Antitoxin production in antibiotic-associated colitis? *Journal of clinical pathology* 1981 Apr; 34(4):414-5. *Not relevant to key question*
270. Lode H, Von der Hoh N, Ziege S, et al. Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. *Scand J Infect Dis* 2001; 33(12):899-903. *Not relevant to key question*
271. Long S, Fenelon L, Fitzgerald S, et al. First isolation and report of clusters of *Clostridium difficile* PCR 027 cases in Ireland. *Euro Surveillanc: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2007 Apr; 12(4):E070426.3. *Not relevant to key question*
272. Loosli J, Gyr K, Stalder H, et al. Etiology of acute infectious diarrhea in a highly industrialized area of Switzerland. *Gastroenterol* 1985 Jan; 88(1 Pt 1):75-9. *Not relevant to key question*

273. Louie T, Miller M, Donskey C, et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with *Clostridium difficile* infection. *Antimicrob Agents Chemother* 2009 Jan; 53(1):223-8. *Not relevant to key question*
274. Louie T, Miller M, Donskey C, et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with *Clostridium difficile* infection. *Antimicrob Agents Chemother* 2009 Jan; 53(1):223-8. *Not relevant to key question*
275. Louthier J. Enteric precautions for *Clostridium difficile*. *American Journal of Nursing* 1996 Apr; 96(4):19. *Not relevant to key question*
276. Lyytikäinen O, Mentula S, Kononen E, et al. First isolation of *Clostridium difficile* PCR ribotype 027 in Finland. *Euro Surveillanc: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2007 Nov; 12(11):E071108.2. *Not relevant to key question*
277. MacCannell DR, Louie TJ, Gregson DB, et al. Molecular analysis of *Clostridium difficile* PCR ribotype 027 isolates from Eastern and Western Canada. *J Clin Microbiol* 2006 Jun; 44(6):2147-52. *Not relevant to key question*
278. Magee JT, Brazier JS, Hosein IK, et al. An investigation of a nosocomial outbreak of *Clostridium difficile* by pyrolysis mass spectrometry. *Journal of medical microbiology* 1993 Nov; 39(5):345-51. *Not relevant to key question*
279. Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. *Am J Gastroenterol* 2005 Feb; 100(2):373-82. *Not relevant to key question*
280. Manabe YC, Vinetz JM, Moore RD, et al. *Clostridium difficile* colitis: an efficient clinical approach to diagnosis. *Annals of Internal Medicine* 1995 Dec 1; 123(11):835-40. *Not relevant to key question*
281. Marcon AP, Gamba MA, Vianna LA. Nosocomial diarrhea in the intensive care unit. *Brazilian Journal of Infectious Diseases* 2006 Dec; 10(6):384-9. *Not relevant to key question*
282. Marinella MA, Burdette SD, Bedimo R, et al. Leukemoid reactions complicating colitis due to *Clostridium difficile*. *Southern medical journal* 2004 Oct; 97(10):959-63. *Not relevant to key question*
283. Marrie TJ, Faulkner RS, Badley BW, et al. Pseudomembranous colitis: isolation of two species of cytotoxic clostridia and successful treatment with vancomycin. *CMAJ* 1978 Nov 4; 119(9):1058-60. *Not relevant to key question*
284. Marrie TJ, Furlong M, Faulkner RS, et al. *Clostridium difficile*: epidemiology and clinical features. *Canadian Journal of Surgery* 1982 Jul; 25(4):438-42. *Not relevant to key question*
285. Martin H, Willey B, Low DE, et al. Characterization of *Clostridium difficile* strains isolated from patients in Ontario, Canada, from 2004 to 2006. *J Clin Microbiol* 2008 Sep; 46(9):2999-3004. *Not relevant to key question*
286. Martirosian G, Bulanda M, Wojcik-Stojek B, et al. Acute appendicitis: the role of enterotoxigenic strains of *Bacteroides fragilis* and *Clostridium difficile*. *Medical Science Monitor* 2001 May-Jun; 7(3):382-6. *Not relevant to key question*
287. Martirosian G, Polanski JA, Szubert A, et al. *Clostridium difficile* in a department of surgery. *Materia Medica Polona* 1993 Jul-Dec; 25(3-4):145-7. *Not relevant to key question*
288. Marts BC, Longo WE, Vernava AM, 3rd, et al. Patterns and prognosis of *Clostridium difficile* colitis. *Dis Colon Rectum* 1994 Aug; 37(8):837-45. *Not relevant to key question*
289. Marx CE, Morris A, Wilson ML, et al. Fecal leukocytes in stool specimens submitted for *Clostridium difficile* toxin assay. *Diagnostic Microbiology & Infectious Disease* 1993 May-Jun; 16(4):313-5. *Not relevant to key question*

290. Mathai MG, Shanthaveerapa HN, Byrd RP, Jr., et al. Fatal pseudomembranous colitis in a continent urinary neobladder. *Journal of the Kentucky Medical Association* 2002 Jun; 100(6):234-7. *Not relevant to key question*
291. Matute AJ, Schurink CA, Krijnen RM, et al. Double-blind, placebo-controlled study comparing the effect of azithromycin with clarithromycin on oropharyngeal and bowel microflora in volunteers. *Eur J Clin Microbiol Infect Dis* 2002 Jun; 21(6):427-31. *Not relevant to key question*
292. Mayumi T, Takezawa J, Takahashi H, et al. IL-15 is elevated in the patients of postoperative enterocolitis. *Cytokine* 1999 Nov; 11(11):888-93. *Not relevant to key question*
293. Mbonu CC, Davison DL, El-Jazzar KM, et al. Clostridium difficile colitis associated with hemolytic-uremic syndrome. *American Journal of Kidney Diseases* 2003 May; 41(5):E14. *Not relevant to key question*
294. McCluskey J, Riley TV, Owen ET, et al. Reactive arthritis associated with Clostridium difficile. *Australian & New Zealand Journal of Medicine* 1982 Oct; 12(5):535-7. *Not relevant to key question*
295. McDonald M, Ward P, Harvey K. Antibiotic-associated diarrhoea and methicillin-resistant Staphylococcus aureus. *Medical Journal of Australia* 1982 May 29; 1(11):462-4. *Not relevant to key question*
296. McFarland LV, Surawicz CM, Greenberg RN, et al. Possible role of cross-transmission between neonates and mothers with recurrent Clostridium difficile infections. *Am J Infect Control* 1999 Jun; 27(3):301-3. *Not relevant to key question*
297. McFarland LV, Surawicz CM, Greenberg RN, et al. Possible role of cross-transmission between neonates and mothers with recurrent Clostridium difficile infections. *Am J Infect Control* 1999 Jun; 27(3):301-3. *Not relevant to key question*
298. Meijer-Severs GJ, van Santen E. Variations in the anaerobic faecal flora of ten healthy human volunteers with special reference to the Bacteroides fragilis-group and Clostridium difficile. *Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene - Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology* 1986 Feb; 261(1):43-52. *Not relevant to key question*
299. Meijer-Severs GJ, van Santen E. Variations in the anaerobic faecal flora of ten healthy human volunteers with special reference to the Bacteroides fragilis-group and Clostridium difficile. *Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene - Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology* 1986 Feb; 261(1):43-52. *Not relevant to key question*
300. Meijer-Severs GJ, Van Santen E, Meijer BC. Short-chain fatty acid and organic acid concentrations in feces of healthy human volunteers and their correlations with anaerobe cultural counts during systemic ceftriaxone administration. *Scandinavian journal of gastroenterology* 1990 Jul; 25(7):698-704. *Not relevant to key question*
301. Meijer-Severs GJ, van Santen E, Puister SM, et al. The effect of FCE 22891, a new oral penem, on faecal flora anaerobes and their fermentation end products in patients with chronic obstructive pulmonary disease. *Infection* 1993 Sep-Oct; 21(5):311-7. *Not relevant to key question*
302. Methe H, Kim JO, Kofler S, et al. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. *Arteriosclerosis, Thrombosis & Vascular Biology* 2005 Jul; 25(7):1439-45. *Not relevant to key question*
303. Meyer AM, Ramzan NN, Loftus EV, Jr., et al. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. *J Clin Gastroenterol* 2004 Oct; 38(9):772-5. *Not relevant to key question*
304. Mody LR, Smith SM, Dever LL. Clostridium difficile-associated diarrhea in a VA medical center: clustering of cases, association with antibiotic usage, and impact on HIV-infected patients. *Infect Control Hosp Epidemiol* 2001 Jan; 22(1):42-5. *Not relevant to key question*

305. Mogg GA, Keighley MR, Burdon DW, et al. Antibiotic-associated colitis--a review of 66 cases. *Br J Surg* 1979 Oct; 66(10):738-42. *Not relevant to key question*
306. Mollby R, Aronsson B, Nord CE. Pathogenesis and diagnosis of clostridium difficile enterocolitis. *Scand J Infect Dis Supplement* 1985; 46:47-56. *Not relevant to key question*
307. Mollby R, Nord CE, Aronsson B. Diagnosis of Clostridium difficile-associated enterocolitis in Sweden. Laboratory and epidemiological aspects. *Scand J Infect Dis Supplement* 1980; (Suppl 22):30-6. *Not relevant to key question*
308. Morelli MS, Rouster SD, Giannella RA, et al. Clinical application of polymerase chain reaction to diagnose Clostridium difficile in hospitalized patients with diarrhea. *Clin Gastroenterol Hepatol* 2004 Aug; 2(8):669-74. *Not relevant to key question*
309. Morgan OW, Rodrigues B, Elston T, et al. Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study. *PLoS ONE [Electronic Resource]* 2008; 3(3):e1812. *Not relevant to key question*
310. Morgan OW, Rodrigues B, Elston T, et al. Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study. *PLoS ONE [Electronic Resource]* 2008; 3(3):e1812. *Not relevant to key question*
311. Morgan RJ, Gemmell CG, Lee FD, et al. Clostridium difficile isolated from the stool of a patient with pseudomembranous colitis following ampicillin plus flucloxacillin (Magnapen) therapy. *Postgrad Med J* 1980 Jan; 56(651):65-6. *Not relevant to key question*
312. Morgan RJ, Gemmell CG, Lee FD, et al. Clostridium difficile isolated from the stool of a patient with pseudomembranous colitis following ampicillin plus flucloxacillin (Magnapen) therapy. *Postgrad Med J* 1980 Jan; 56(651):65-6. *Not relevant to key question*
313. Morris JG, Jr., Jarvis WR, Nunez-Montiel OL, et al. Clostridium difficile. Colonization and toxin production in a cohort of patients with malignant hematologic disorders. *Arch Intern Med* 1984 May; 144(5):967-9. *Not relevant to key question*
314. Moskovitz M, Bartlett JG. Recurrent pseudomembranous colitis unassociated with prior antibiotic therapy. *Arch Intern Med* 1981 Apr; 141(5):663-4. *Not relevant to key question*
315. Mulligan ME, Citron D, Gabay E, et al. Alterations in human fecal flora, including ingrowth of Clostridium difficile, related to cefoxitin therapy. *Antimicrob Agents Chemother* 1984 Sep; 26(3):343-6. *Not relevant to key question*
316. Munoz P, Palomo J, Yanez J, et al. Clinical microbiological case: a heart transplant recipient with diarrhea and abdominal pain. Recurring C. difficile infection. *Clinical Microbiology & Infection* 2001 458-9; Aug; 7(8):451-2. *Not relevant to key question*
317. Munro R, Foldes M, Morris G. An evaluation of a rapid latex test for the diagnosis of Clostridium difficile-associated diarrhea. *Pathology* 1988 Oct; 20(4):349-52. *Not relevant to key question*
318. Mwachari C, Batchelor BI, Paul J, et al. Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya. *Journal of Infection* 1998 Jul; 37(1):48-53. *Not relevant to key question*
319. Mwachari C, Batchelor BI, Paul J, et al. Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya. *Journal of Infection* 1998 Jul; 37(1):48-53. *Not relevant to key question*
320. Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. *European journal of gastroenterology & hepatology* 2004 Aug; 16(8):775-8. *Not relevant to key question*
321. Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. *European journal of gastroenterology & hepatology* 2004 Aug; 16(8):775-8. *Not relevant to key question*
322. Nakamura S, Mikawa M, Nakashio S, et al. Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults. *Microbiology & Immunology* 1981; 25(4):345-51. *Not relevant to key question*

323. Nakamura S, Nakashio S, Inamatsu T, et al. Toxigenicity of *Clostridium difficile* isolates from patients and healthy adults. *Microbiology & Immunology* 1980; 24(10):995-7. *Not relevant to key question*
324. Nash JQ, Chattopadhyay B, Honeycombe J, et al. *Clostridium difficile* and cytotoxin in routine faecal specimens. *Journal of clinical pathology* 1982 May; 35(5):561-5. *Not relevant to key question*
325. Nathan MA, Seabold JE, Brown BP, et al. Colonic localization of labeled leukocytes in critically ill patients. Scintigraphic detection of pseudomembranous colitis. *Clinical nuclear medicine* 1995 Feb; 20(2):99-106. *Not relevant to key question*
326. Nelson R. Antibiotic treatment for *Clostridium difficile*-associated diarrhea in adults. [update of Cochrane Database Syst Rev. 2005;(1):CD004610; PMID: 15674956]. *Cochrane Database Syst Rev* 2007; (3):004610. *Not relevant to key question*
327. Nemat H, Khan R, Ashraf MS, et al. Diagnostic value of repeated enzyme immunoassays in *Clostridium difficile* infection. *Am J Gastroenterol* 2009 Aug; 104(8):2035-41. *Not relevant to key question*
328. Nomura K, Fujimoto Y, Yamashita M, et al. Absence of pseudomembranes in *Clostridium difficile*-associated diarrhea in patients using immunosuppression agents. *Scandinavian journal of gastroenterology* 2009; 44(1):74-8. *Not relevant to key question*
329. Nonhoff C, Struelens MJ, Serruys E. Evaluation of gas-liquid chromatography (GLC) for rapid detection of *Clostridium difficile* in fecal specimens. *Acta Clinica Belgica* 1995; 50(2):76-80. *Not relevant to key question*
330. Nord CE, Brismar B, Kasholm-Tengve B, et al. Effect of piperacillin/tazobactam therapy on intestinal microflora. *Scand J Infect Dis* 1992; 24(2):209-13. *Not relevant to key question*
331. Nord CE, Kager L, Philipson A, et al. Impact of imipenem/cilastatin therapy on faecal flora. *European J Clin Microbiol* 1984 Oct; 3(5):475-7. *Not relevant to key question*
332. Nord CE, Kager L, Philipson A, et al. Effect of imipenem/cilastatin on the colonic microflora. *Reviews of infectious diseases* 1985 Jul-Aug; 7(Suppl 3):S432-4. *Not relevant to key question*
333. Nord CE, Movin G, Stalberg D. Impact of cefixime on the normal intestinal microflora. *Scand J Infect Dis* 1988; 20(5):547-52. *Not relevant to key question*
334. Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. *J Antimicrob Chemother* 2006 Sep; 58(3):627-31. *Not relevant to key question*
335. Nord CE, Sillerstrom E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. *Antimicrob Agents Chemother* 2006 Oct; 50(10):3375-80. *Not relevant to key question*
336. Noren T, Tang-Feldman YJ, Cohen SH, et al. Clindamycin resistant strains of *Clostridium difficile* isolated from cases of *C. difficile* associated diarrhea (CDAD) in a hospital in Sweden. *Diagnostic Microbiology & Infectious Disease* 2002 Feb; 42(2):149-51. *Not relevant to key question*
337. Novak E, Paxton LM, Bye A, et al. Human safety and pharmacokinetics of a single intramuscular dose of a novel spectinomycin analog, trospetomycin (U-63,366F). *Antimicrob Agents Chemother* 1990 Dec; 34(12):2342-7. *Not relevant to key question*
338. Novak-Weekley SM, Hollingsworth MH. Comparison of the premier toxin A and B assay and the TOX A/B II assay for diagnosis of *Clostridium difficile* infection. *Clinical & Vaccine Immunology: CVI* 2008 Mar; 15(3):575-8. *Not relevant to key question*
339. Novelli A, Mazzei T, Fallani S, et al. Betalactam therapy and intestinal flora. *Journal of Chemotherapy* 1995 May; 7(Suppl 1):25-31. *Not relevant to key question*
340. Novelli A, Mazzei T, Fallani S, et al. Betalactam therapy and intestinal flora. *Journal of Chemotherapy* 1995 May; 7(Suppl 1):25-31. *Not relevant to key question*

341. Orrhage K, Sjostedt S, Nord CE. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxitil. *J Antimicrob Chemother* 2000 Oct; 46(4):603-12. *Not relevant to key question*
342. Ozaki E, Kato H, Kita H, et al. Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. *Journal of medical microbiology* 2004 Feb; 53(Pt 2):167-72. *Not relevant to key question*
343. Ozawa TT, Valadez T. Clostridium difficile infection associated with levofloxacin treatment. *Tennessee Medicine* 2002 Mar; 95(3):113-5. *Not relevant to key question*
344. Paltansing S, van den Berg RJ, Guseinova RA, et al. Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005. *Clinical Microbiology & Infection* 2007 Nov; 13(11):1058-64. *Not relevant to key question*
345. Panichi G, Pantosti A, Gentile G, et al. Clostridium difficile colitis in leukemia patients. *European journal of cancer & clinical oncology* 1985 Oct; 21(10):1159-63. *Not relevant to key question*
346. Peach SL, Borriello SP, Gaya H, et al. Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis. *Journal of clinical pathology* 1986 Sep; 39(9):1013-8. *Not relevant to key question*
347. Peach SL, Gaya H, Borriello SP. Faecal carriage of Clostridium difficile in cystic fibrosis patients. *Annali dell'Istituto Superiore di Sanita* 1986; 22(3):953-7. *Not relevant to key question*
348. Pechine S, Gleizes A, Janoir C, et al. Immunological properties of surface proteins of Clostridium difficile. *Journal of medical microbiology* 2005 Feb; 54(Pt 2):193-6. *Not relevant to key question*
349. Pecquet S, Ravoire S, Andremont A. Faecal excretion of ciprofloxacin after a single oral dose and its effect on faecal bacteria in healthy volunteers. *J Antimicrob Chemother* 1990 Jul; 26(1):125-9. *Not relevant to key question*
350. Peikin SR, Galdibini J, Bartlett JG. Role of Clostridium difficile in a case of nonantibiotic-associated pseudomembranous colitis. *Gastroenterol* 1980 Nov; 79(5 Pt 1):948-51. *Not relevant to key question*
351. Peled N, Pitlik S, Samra Z, et al. Predicting Clostridium difficile toxin in hospitalized patients with antibiotic-associated diarrhea. *Infect Control Hosp Epidemiol* 2007 Apr; 28(4):377-81. *Not relevant to key question*
352. Penders J, Thijs C, Vink C, et al. Factors influencing the composition of the intestinal microbiota in early infancy. *Pediatrics* 2006 Aug; 118(2):511-21. *Not relevant to key question*
353. Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. *Am J Gastroenterol* 2000 Nov; 95(11):3283-5. *Not relevant to key question*
354. Phillips C. Serum antibody responses to Clostridium difficile toxin A: predictive and protective? *Gut* 2001 Aug; 49(2):167-8. *Not relevant to key question*
355. Phillips KD, Rogers PA. Rapid detection and presumptive identification of Clostridium difficile by p-cresol production on a selective medium. *Journal of clinical pathology* 1981 Jun; 34(6):642-4. *Not relevant to key question*
356. Piche T, Vanbiervliet G, Pipau FG, et al. Low risk of irritable bowel syndrome after Clostridium difficile infection. *Can J Gastroenterol* 2007 Nov; 21(11):727-31. *Not relevant to key question*
357. Piche T, Vanbiervliet G, Pipau FG, et al. Low risk of irritable bowel syndrome after Clostridium difficile infection. *Can J Gastroenterol* 2007 Nov; 21(11):727-31. *Not relevant to key question*
358. Pituch H, Bakker D, Kuijper E, et al. First isolation of Clostridium difficile PCR-ribotype 027/toxinotype III in Poland. *Polish Journal of Microbiology/Polskie Towarzystwo Mikrobiologow/The Polish Society of Microbiologists* 2008; 57(3):267-8. *Not relevant to key question*

359. Pituch H, Kreft D, Obuch-Woszczatynski P, et al. Clonal spread of a *Clostridium difficile* strain with a complete set of toxin A, toxin B, and binary toxin genes among Polish patients with *Clostridium difficile*-associated diarrhea. *J Clin Microbiol* 2005 Jan; 43(1):472-5. *Not relevant to key question*
360. Pituch H, Rupnik M, Obuch-Woszczatynski P, et al. Detection of binary-toxin genes (cdtA and cdtB) among *Clostridium difficile* strains isolated from patients with *C. difficile*-associated diarrhoea (CDAD) in Poland. *Journal of medical microbiology* 2005 Feb; 54(Pt 2):143-7. *Not relevant to key question*
361. Pituch H, van Leeuwen W, Maquelin K, et al. Toxin profiles and resistances to macrolides and newer fluoroquinolones as epidemicity determinants of clinical isolates of *Clostridium difficile* from Warsaw, Poland. *J Clin Microbiol* 2007 May; 45(5):1607-10. *Not relevant to key question*
362. Pokorny CS, Bye PT, MacLeod C, et al. Antibiotic-associated colitis and cystic fibrosis. *Dig Dis Sci* 1992 Sep; 37(9):1464-8. *Not relevant to key question*
363. Porco FV, Visconte EB. *Pseudomonas aeruginosa* as a cause of infectious diarrhea successfully treated with oral ciprofloxacin. *Ann Pharmacother* 1995 Nov; 29(11):1122-3. *Not relevant to key question*
364. Probert CS, Jones PR, Ratcliffe NM. A novel method for rapidly diagnosing the causes of diarrhoea. *Gut* 2004 Jan; 53(1):58-61. *Not relevant to key question*
365. Pryor WM, Bye WA, Curran DH, et al. Acute diarrhoea in adults: a prospective study. *Medical Journal of Australia* 1987 Nov 16; 147(10):490-3. *Not relevant to key question*
366. Rafferty ME, Baltch AL, Smith RP, et al. Comparison of restriction enzyme analysis, arbitrarily primed PCR, and protein profile analysis typing for epidemiologic investigation of an ongoing *Clostridium difficile* outbreak. *J Clin Microbiol* 1998 Oct; 36(10):2957-63. *Not relevant to key question*
367. Raibaud P, Ducluzeau R, Dubos F, et al. Implantation of bacteria from the digestive tract of man and various animals into gnotobiotic mice. *American Journal of Clinical Nutrition* 1980 Nov; 33(11 Suppl):2440-7. *Not relevant to key question*
368. Rampling A, Warren RE, Bevan PC, et al. *Clostridium difficile* in haematological malignancy. *Journal of clinical pathology* 1985 Apr; 38(4):445-51. *Not relevant to key question*
369. Raveh D, Rabinowitz B, Breuer GS, et al. Risk factors for *Clostridium difficile* toxin-positive nosocomial diarrhoea. *International journal of antimicrobial agents* 2006 Sep; 28(3):231-7. *Not relevant to key question*
370. Razzaq R, Sukumar SA. Ultrasound diagnosis of clinically undetected *Clostridium difficile* toxin colitis. *Clinical radiology* 2006 May; 61(5):446-52. *Not relevant to key question*
371. Rea MC, Clayton E, O'Connor PM, et al. Antimicrobial activity of lacticin 3,147 against clinical *Clostridium difficile* strains. *Journal of medical microbiology* 2007 Jul; 56(Pt 7):940-6. *Not relevant to key question*
372. Riggs MM, Sethi AK, Zabarsky TF, et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic *Clostridium difficile* strains among long-term care facility residents. *Clinic Infect Dis* 2007 Oct 15; 45(8):992-8. *Not relevant to key question*
373. Riley TV, Cooper M, Bell B, et al. Community-acquired *Clostridium difficile*-associated diarrhea. *Clinic Infect Dis* 1995 Jun; 20(Suppl 2):S263-5. *Not relevant to key question*
374. Riley TV, O'Neill GL, Bowman RA, et al. *Clostridium difficile*-associated diarrhoea: epidemiological data from Western Australia. *Epidemiology & Infection* 1994 Aug; 113(1):13-20. *Not relevant to key question*
375. Riley TV, Thean S, Hool G, et al. First Australian isolation of epidemic *Clostridium difficile* PCR ribotype 027. *Medical Journal of Australia* 2009 Jun 15; 190(12):706-8. *Not relevant to key question*

376. Riley TV, Wetherall F, Bowman J, et al. Diarrheal disease due to *Clostridium difficile* in general practice. *Pathology* 1991 Oct; 23(4):346-9. *Not relevant to key question*
377. Rinttila T, Kassinen A, Malinen E, et al. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. *Journal of applied microbiology* 2004; 97(6):1166-77. *Not relevant to key question*
378. Roberts K, Smith CF, Snelling AM, et al. Aerial dissemination of *Clostridium difficile* spores. *BMC Infectious Diseases* 2008; 8:7. *Background*
379. Rohner P, Pittet D, Pepey B, et al. Etiological agents of infectious diarrhea: implications for requests for microbial culture. *J Clin Microbiol* 1997 Jun; 35(6):1427-32. *Not relevant to key question*
380. Rolny P, Jarnerot G, Mollby R. Occurrence of *Clostridium difficile* toxin in inflammatory bowel disease. *Scandinavian journal of gastroenterology* 1983 Jan; 18(1):61-4. *Not relevant to key question*
381. Rossel P, Sortsoe Jensen H, Qvist P, et al. Prognosis of adult-onset idiopathic bile acid malabsorption. *Scandinavian journal of gastroenterology* 1999 Jun; 34(6):587-90. *Not relevant to key question*
382. Rotimi VO, Akindutire D. *Clostridium difficile* in the normal adult faecal flora. *African Journal of Medicine & Medical Sciences* 1986 Sep-Oct; 15(3-4):73-7. *Not relevant to key question*
383. Rotimi VO, Akindutire D. Faecal carriage of cytotoxigenic strains of *Clostridium difficile* by adult Nigerians. *East African medical journal* 1989 May; 66(5):319-23. *Not relevant to key question*
384. Rotimi VO, Mokaddas EM, Jamal WY, et al. Hospital-acquired *Clostridium difficile* infection amongst ICU and burn patients in Kuwait. *Medical Principles & Practice* 2002 Jan-Mar; 11(1):23-8. *Not relevant to key question*
385. Rutgeerts L, Ghillebert G, Drognee W, et al. Ischemic colitis in a patient with Crohn's disease taking an oral contraceptive and an ergotamine alkaloid. *Acta Clinica Belgica* 1993; 48(1):48-51. *Not relevant to key question*
386. Rybolt AH, Bennett RG, Laughon BE, et al. Protein-losing enteropathy associated with *Clostridium difficile* infection. *Lancet* 1989 Jun 17; 1(8651):1353-5. *Not relevant to key question*
387. Sailhamer EA, Carson K, Chang Y, et al. Fulminant *Clostridium difficile* colitis: patterns of care and predictors of mortality. *Archives of Surgery* 2009 discussion 439-40; May; 144(5):433-9. *Not relevant to key question*
388. Salcedo J, Keates S, Pothoulakis C, et al. Intravenous immunoglobulin therapy for severe *Clostridium difficile* colitis. *Gut* 1997 Sep; 41(3):366-70. *Not relevant to key question*
389. Sambol SP, Merrigan MM, Lyerly D, et al. Toxin gene analysis of a variant strain of *Clostridium difficile* that causes human clinical disease. *Infect Immun* 2000 Oct; 68(10):5480-7. *Not relevant to key question*
390. Samore MH, Bettin KM, DeGirolami PC, et al. Wide diversity of *Clostridium difficile* types at a tertiary referral hospital. *J Infect Dis* 1994 Sep; 170(3):615-21. *Not relevant to key question*
391. Samore MH, DeGirolami PC, Tlucko A, et al. *Clostridium difficile* colonization and diarrhea at a tertiary care hospital. *Clinic Infect Dis* 1994 Feb; 18(2):181-7. *Not relevant to key question*
392. Samuel SC, Hancock P, Leigh DA. An investigation into *Clostridium perfringens* enterotoxin-associated diarrhoea. *J Hosp Infect* 1991 Jul; 18(3):219-30. *Not relevant to key question*
393. Sanchez-Hurtado K, Corretge M, Mutlu E, et al. Systemic antibody response to *Clostridium difficile* in colonized patients with and without symptoms and matched controls. *Journal of medical microbiology* 2008 Jun; 57(Pt 6):717-24. *Not relevant to key question*

394. Savage AM, Alford RH. Nosocomial spread of *Clostridium difficile*. *Infection Control* 1983 Jan-Feb; 4(1):31-3. *Not relevant to key question*
395. Savariau-Lacomme MP, Lebarbier C, Karjalainen T, et al. Transcription and analysis of polymorphism in a cluster of genes encoding surface-associated proteins of *Clostridium difficile*. *Journal of Bacteriology* 2003 Aug; 185(15):4461-70. *Not relevant to key question*
396. Scanvic-Hameg A, Chachaty E, Rey J, et al. Impact of quinupristin/dalfopristin (RP59500) on the faecal microflora in healthy volunteers. *J Antimicrob Chemother* 2002 Jan; 49(1):135-9. *Not relevant to key question*
397. Scheurer DB, Hicks LS, Cook EF, et al. Accuracy of ICD-9 coding for *Clostridium difficile* infections: a retrospective cohort. *Epidemiology & Infection* 2007 Aug; 135(6):1010-3. *Not relevant to key question*
398. Schmidt NJ, Ho HH, Dondero ME. *Clostridium difficile* toxin as a confounding factor in enterovirus isolation. *J Clin Microbiol* 1980 Dec; 12(6):796-8. *Not relevant to key question*
399. Schmitt-Grohe S, Wiggert E, Steffan J, et al. Severe antibiotic-associated colitis in a patient with cystic fibrosis and colonic wall thickening. *Journal of Pediatric Gastroenterology & Nutrition* 2002 Feb; 34(2):224-6. *Not relevant to key question*
400. Schroeder MS. *Clostridium difficile*--associated diarrhea. *American Family Physician* 2005 Mar 1; 71(5):921-8. *Not relevant to key question*
401. Schwaber MJ, Simhon A, Block C, et al. Factors associated with nosocomial diarrhea and *Clostridium difficile*-associated disease on the adult wards of an urban tertiary care hospital. *Eur J Clin Microbiol Infect Dis* 2000 Jan; 19(1):9-15. *Not relevant to key question*
402. Schwaber MJ, Simhon A, Block C, et al. Factors associated with nosocomial diarrhea and *Clostridium difficile*-associated disease on the adult wards of an urban tertiary care hospital. *Eur J Clin Microbiol Infect Dis* 2000 Jan; 19(1):9-15. *Not relevant to key question*
403. Schwan A, Sjolín S, Trottestam U, et al. Relapsing *Clostridium difficile* enterocolitis cured by rectal infusion of normal faeces. *Scand J Infect Dis* 1984; 16(2):211-5. *Not relevant to key question*
404. Schweitzer MA, Sweiss I, Silver DL, et al. The clinical spectrum of *Clostridium difficile* colitis in immunocompromised patients. *American Surgeon* 1996 discussion 607-8; Jul; 62(7):603-7. *Not relevant to key question*
405. Sethi AK, Al-Nassir WN, Nerandzic MM, et al. Skin and environmental contamination with vancomycin-resistant Enterococci in patients receiving oral metronidazole or oral vancomycin treatment for *Clostridium difficile*-associated disease. *Infect Control Hosp Epidemiol* 2009 Jan; 30(1):13-7. *Not relevant to key question*
406. Seyler L, Lalvani A, Collins L, et al. Safety and cost savings of an improved three-day rule for stool culture in hospitalised children and adults. *J Hosp Infect* 2007 Oct; 67(2):121-6. *Not relevant to key question*
407. Shadel BN, Puzniak LA, Gillespie KN, et al. Surveillance for vancomycin-resistant enterococci: type, rates, costs, and implications. *Infect Control Hosp Epidemiol* 2006 Oct; 27(10):1068-75. *Not relevant to key question*
408. Shastri S, Doane AM, Gonzales J, et al. Prevalence of astroviruses in a children's hospital. *J Clin Microbiol* 1998 Sep; 36(9):2571-4. *Not relevant to key question*
409. Shastri YM, Bergis D, Povse N, et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. *Am J Med* 2008 Dec; 121(12):1099-106. *Not relevant to key question*
410. Shehabi AA, Abu-Ragheb HA, Allaham NA. Prevalence of *Clostridium difficile*-associated diarrhoea among hospitalized Jordanian patients. *Eastern Mediterranean Health Journal* 2001 Jul-Sep; 7(4-5):750-5. *Not relevant to key question*
411. Shen B, Remzi FH, Fazio VW. Fulminant *Clostridium difficile*-associated pouchitis with a fatal outcome. *Nature Reviews Gastroenterology & Hepatology* 2009 Aug; 6(8):492-5. *Not relevant to key question*

412. Shen BO, Jiang ZD, Fazio VW, et al. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2008 Jul; 6(7):782-8. *Not relevant to key question*
413. Shim JK, Johnson S, Samore MH, et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998 Feb 28; 351(9103):633-6. *Not relevant to key question*
414. Shin JW, Yong D, Kim MS, et al. Sudden increase of vancomycin-resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin. Journal of Infection & Chemotherapy 2003 discussion 104-5; Mar; 9(1):62-7. *Not relevant to key question*
415. Shuttleworth R, Taylor M, Jones DM. Antimicrobial susceptibilities of Clostridium difficile. Journal of clinical pathology 1980 Oct; 33(10):1002-5. *Not relevant to key question*
416. Si JM, Yu YC, Fan YJ, et al. Intestinal microecology and quality of life in irritable bowel syndrome patients. World Journal of Gastroenterology 2004 Jun 15; 10(12):1802-5. *Not relevant to key question*
417. Siegel DL, Edelstein PH, Nachamkin I. Inappropriate testing for diarrheal diseases in the hospital. JAMA 1990 Feb 16; 263(7):979-82. *Not relevant to key question*
418. Siegle RJ, Fekety R, Sarbone PD, et al. Effects of topical clindamycin on intestinal microflora in patients with acne. Journal of the American Academy of Dermatology 1986 Aug; 15(2 Pt 1):180-5. *Not relevant to key question*
419. Siemann M, Koch-Dorfler M, Rabenhorst G. Clostridium difficile-associated diseases. The clinical courses of 18 fatal cases. Intensive care medicine 2000 Apr; 26(4):416-21. *Not relevant to key question*
420. Silva J, Jr., Batts DH, Fekety R, et al. Treatment of Clostridium difficile colitis and diarrhea with vancomycin. Am J Med 1981 Nov; 71(5):815-22. *Not relevant to key question*
421. Simmonds SD, Noble MA, Freeman HJ. Gastrointestinal features of culture-positive Yersinia enterocolitica infection. Gastroenterol 1987 Jan; 92(1):112-7. *Not relevant to key question*
422. Simor AE, Yake SL, Tsimidis K. Infection due to Clostridium difficile among elderly residents of a long-term-care facility. Clin Infect Dis 1993 Oct; 17(4):672-8. *Not relevant to key question*
423. Sims RV, Hauser RJ, Adewale AO, et al. Acute gastroenteritis in three community-based nursing homes. Journals of Gerontology Series A-Biological Sciences & Medical Sciences 1995 Sep; 50(5):M252-6. *Not relevant to key question*
424. Sobko T, Reinders CI, Jansson E, et al. Gastrointestinal bacteria generate nitric oxide from nitrate and nitrite. Nitric Oxide 2005 Dec; 13(4):272-8. *Not relevant to key question*
425. Solaymani-Mohammadi S, Coyle CM, Factor SM, et al. Amebic colitis in an antigenically and serologically negative patient: usefulness of a small-subunit ribosomal RNA gene-based polymerase chain reaction in diagnosis. Diagnostic Microbiology & Infectious Disease 2008 Nov; 62(3):333-5. *Not relevant to key question*
426. Song HJ, Shim KN, Jung SA, et al. Antibiotic-associated diarrhea: candidate organisms other than Clostridium difficile. Korean Journal of Internal Medicine 2008 Mar; 23(1):9-15. *Not relevant to key question*
427. Song HJ, Shim KN, Jung SA, et al. Antibiotic-associated diarrhea: candidate organisms other than Clostridium difficile. Korean Journal of Internal Medicine 2008 Mar; 23(1):9-15. *Not relevant to key question*
428. Soyletir G, Eskitürk A, Kilic G, et al. Clostridium difficile acquisition rate and its role in nosocomial diarrhoea at a university hospital in Turkey. European journal of epidemiology 1996 Aug; 12(4):391-4. *Not relevant to key question*

429. Sriuranpong V, Voravud N. Antineoplastic-associated colitis in Chulalongkorn University Hospital. *Journal of the Medical Association of Thailand* 1995 Aug; 78(8):424-30. *Not relevant to key question*
430. Stamper PD, Alcabasa R, Aird D, et al. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing *Clostridium difficile* in clinical samples. *J Clin Microbiol* 2009 Feb; 47(2):373-8. *Not relevant to key question*
431. Stamper PD, Alcabasa R, Aird D, et al. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing *Clostridium difficile* in clinical samples. *J Clin Microbiol* 2009 Feb; 47(2):373-8. *Not relevant to key question*
432. Starr JM, Martin H, McCoubrey J, et al. Risk factors for *Clostridium difficile* colonisation and toxin production. *Age Ageing* 2003 Nov; 32(6):657-60. *Not relevant to key question*
433. Steiner TS, Flores CA, Pizarro TT, et al. Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe *Clostridium difficile* colitis. *Clinical & Diagnostic Laboratory Immunology* 1997 Nov; 4(6):719-22. *Not relevant to key question*
434. Stella PA. Evaluation of a commercial latex agglutination assay for screening for *Clostridium difficile*-associated disease. *Clinical Laboratory Science* 1994 Sep-Oct; 7(5):311-3. *Not relevant to key question*
435. Stelzmueller I, Goegele H, Biebl M, et al. *Clostridium difficile* colitis in solid organ transplantation--a single-center experience. *Dig Dis Sci* 2007 Nov; 52(11):3231-6. *Not relevant to key question*
436. Stelzmueller I, Wiesmayr S, Eller M, et al. Enterocolitis due to simultaneous infection with rotavirus and *Clostridium difficile* in adult and pediatric solid organ transplantation. *Journal of Gastrointestinal Surgery* 2007 Jul; 11(7):911-7. *Not relevant to key question*
437. Strada M, Meregaglia D, Donzelli R. Double-contrast enema in antibiotic-related pseudomembranous colitis. *Gastrointestinal radiology* 1983; 8(1):67-9. *Not relevant to key question*
438. Sultana Q, Chaudhry NA, Munir M, et al. Diagnosis of *Clostridium difficile* antibiotic associated diarrhoea culture versus toxin assay. *JPMA - Journal of the Pakistan Medical Association* 2000 Aug; 50(8):246-9. *Not relevant to key question*
439. Sundram F, Guyot A, Carboo I, et al. *Clostridium difficile* ribotypes 027 and 106: clinical outcomes and risk factors. *J Hosp Infect* 2009 Jun; 72(2):111-8. *Not relevant to key question*
440. Surawicz CM. Treatment of recurrent *Clostridium difficile*-associated disease. *Nature Clinical Practice Gastroenterology & Hepatology* 2004 Nov; 1(1):32-8. *Not relevant to key question*
441. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by *Saccharomyces boulardii*: a prospective study. *Gastroenterol* 1989 Apr; 96(4):981-8. *Not relevant to key question*
442. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent *Clostridium difficile* disease: use of high-dose vancomycin combined with *Saccharomyces boulardii*. *Clinic Infect Dis* 2000 Oct; 31(4):1012-7. *Not relevant to key question*
443. Svanteson B, Thoren A, Castor B, et al. Acute diarrhoea in adults: aetiology, clinical appearance and therapeutic aspects. *Scand J Infect Dis* 1988; 20(3):303-14. *Not relevant to key question*
444. Svenungsson B, Burman LG, Jalakas-Pornull K, et al. Epidemiology and molecular characterization of *Clostridium difficile* strains from patients with diarrhea: low disease incidence and evidence of limited cross-infection in a Swedish teaching hospital. *J Clin Microbiol* 2003 Sep; 41(9):4031-7. *Not relevant to key question*

445. Svenungsson B, Lagergren A, Ekwall E, et al. Enteropathogens in adult patients with diarrhea and healthy control subjects: a 1-year prospective study in a Swedish clinic for infectious diseases. *Clinic Infect Dis* 2000 May; 30(5):770-8. *Not relevant to key question*
446. Svenungsson B, Lagergren A, Lundberg A. Clostridium difficile cytotoxin B in adults with diarrhea: a comparison of patients treated or not treated with antibiotics prior to infection. *Clinical Microbiology & Infection* 2001 Aug; 7(8):447-50. *Not relevant to key question*
447. Tabaqchali S, O'Farrell S, Holland D, et al. Method for the typing of Clostridium difficile based on polyacrylamide gel electrophoresis of [35S]methionine-labeled proteins. *J Clin Microbiol* 1986 Jan; 23(1):197-8. *Not relevant to key question*
448. Tachon M, Cattoen C, Blanckaert K, et al. First cluster of C. difficile toxinotype III, PCR-ribotype 027 associated disease in France: preliminary report. *Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2006; 11(5):E060504.1. *Not relevant to key question*
449. Tae CH, Jung SA, Song HJ, et al. The first case of antibiotic-associated colitis by Clostridium difficile PCR ribotype 027 in Korea. *Journal of Korean medical science* 2009 Jun; 24(3):520-4. *Not relevant to key question*
450. Tal S, Gurevich A, Guller V, et al. Risk factors for recurrence of Clostridium difficile-associated diarrhea in the elderly. *Scand J Infect Dis* 2002; 34(8):594-7. *Not relevant to key question*
451. Tay JK, Bodle EE, Fisher DA, et al. Screening for vancomycin-resistant enterococci using stools sent for Clostridium difficile cytotoxin assay is effective: results of a survey of 300 Patients in a large Singapore Teaching Hospital. *Ann Acad Med Singapore* 2007 Nov; 36(11):926-9. *Not relevant to key question*
452. Tayek JA, Bistran BR, Blackburn GL. The effects of acute clostridium difficile diarrhea on fecal nitrogen content in adult hospitalized patients. *Journal of the American College of Nutrition* 1987 Jun; 6(3):255-9. *Not relevant to key question*
453. Taylor CP, Tummala S, Molrine D, et al. Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. *Vaccine* 2008 Jun 25; 26(27-28):3404-9. *Not relevant to key question*
454. Taylor CP, Tummala S, Molrine D, et al. Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. *Vaccine* 2008 Jun 25; 26(27-28):3404-9. *Not relevant to key question*
455. Taylor ME, Oppenheim BA, Chadwick PR, et al. Detection of glycopeptide-resistant enterococci in routine diagnostic faeces specimens. *J Hosp Infect* 1999 Sep; 43(1):25-32. *Not relevant to key question*
456. Terhes G, Brazier JS, Urban E, et al. Distribution of Clostridium difficile PCR ribotypes in regions of Hungary. *Journal of medical microbiology* 2006 Mar; 55(Pt 3):279-82. *Not relevant to key question*
457. Testore GP, Pantosti A, Cerquetti M, et al. Evidence for cross-infection in an outbreak of Clostridium difficile-associated diarrhoea in a surgical unit. *Journal of medical microbiology* 1988 Jun; 26(2):125-8. *Not relevant to key question*
458. Thamlikitkul V, Danpakdi K, Chokloikaew S. Incidence of diarrhea and Clostridium difficile toxin in stools from hospitalized patients receiving clindamycin, beta-lactams, or nonantibiotic medications. *J Clin Gastroenterol* 1996 Mar; 22(2):161-3. *Not relevant to key question*
459. Thibault A, Miller MA, Gaese C. Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. *Infect Control Hosp Epidemiol* 1991 Jun; 12(6):345-8. *Not relevant to key question*

460. Thomas DR, Bennett RG, Laughon BE, et al. Postantibiotic colonization with *Clostridium difficile* in nursing home patients. *Journal of the American Geriatrics Society* 1990 Apr; 38(4):415-20. *Not relevant to key question*
461. Titov L, Lebedkova N, Shabanov A, et al. Isolation and molecular characterization of *Clostridium difficile* strains from patients and the hospital environment in Belarus. *J Clin Microbiol* 2000 Mar; 38(3):1200-2. *Not relevant to key question*
462. Toyokawa M, Ueda A, Tsukamoto H, et al. Pseudomembranous colitis caused by toxin A-negative/toxin B-positive variant strain of *Clostridium difficile*. *Journal of Infection & Chemotherapy* 2003 Dec; 9(4):351-4. *Not relevant to key question*
463. Trnka YM, Lamont JT. *Clostridium difficile* colitis. *Advances in Internal Medicine* 1984; 29:85-107. *Not relevant to key question*
464. Turner RJ. Pseudomembranous enterocolitis after gynecologic endoscopy. *Journal of the American Association of Gynecologic Laparoscopists* 1994 Feb; 1(2):168-70. *Not relevant to key question*
465. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing *Clostridium difficile* diarrhoea in six patients. *Lancet* 1989 May 27; 1(8648):1156-60. *Not relevant to key question*
466. Uhnoo I, Wadell G, Svensson L, et al. Aetiology and epidemiology of acute gastroenteritis in Swedish children. *Journal of Infection* 1986 Jul; 13(1):73-89. *Not relevant to key question*
467. Urban E, Tusnadi A, Terhes G, et al. Prevalence of gastrointestinal disease caused by *Clostridium difficile* in a university hospital in Hungary. *J Hosp Infect* 2002 Jul; 51(3):175-8. *Not relevant to key question*
468. Vaishnavi C, Bhasin D, Kochhar R, et al. *Clostridium difficile* toxin and faecal lactoferrin assays in adult patients. *Microbes & Infection* 2000 Dec; 2(15):1827-30. *Not relevant to key question*
469. Vaishnavi C, Kaur S. *Clostridium perfringens* enterotoxin in antibiotic-associated diarrhea. *Indian journal of pathology & microbiology* 2008 Apr-Jun; 51(2):198-9. *Not relevant to key question*
470. Vaishnavi C, Kaur S, Prakash S. Speciation of fecal *Candida* isolates in antibiotic-associated diarrhea in non-HIV patients. *Japanese journal of infectious diseases* 2008 Jan; 61(1):1-4. *Not relevant to key question*
471. Vaishnavi C, Kaur S, Prakash S. Speciation of fecal *Candida* isolates in antibiotic-associated diarrhea in non-HIV patients. *Japanese journal of infectious diseases* 2008 Jan; 61(1):1-4. *Not relevant to key question*
472. Vaishnavi C, Kaur S, Singh K. *Clostridium perfringens* type A & antibiotic associated diarrhoea. *Indian Journal of Medical Research* 2005 Jul; 122(1):52-6. *Not relevant to key question*
473. Vaishnavi C, Kochhar R, Bhasin D, et al. Simultaneous assays for *Clostridium difficile* and faecal lactoferrin in ulcerative colitis. *Tropical Gastroenterology* 2003 Jan-Mar; 24(1):13-6. *Not relevant to key question*
474. Valiquette L, Pepin J, Do XV, et al. Prediction of complicated *Clostridium difficile* infection by pleural effusion and increased wall thickness on computed tomography. *Clinic Infect Dis* 2009 Aug 15; 49(4):554-60. *Not relevant to key question*
475. van den Berg RJ, Kuijper EJ, van Coppenraet LE, et al. Rapid diagnosis of toxinogenic *Clostridium difficile* in faecal samples with internally controlled real-time PCR. *Clinical Microbiology & Infection* 2006 Feb; 12(2):184-6. *Not relevant to key question*
476. van Kraaij MG, Dekker AW, Verdonck LF, et al. Infectious gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. *Bone marrow transplantation* 2000 Aug; 26(3):299-303. *Not relevant to key question*
477. van Nispen CH, Hoepelman AI, Rozenberg-Arska M, et al. A double-blind, placebo-controlled, parallel group study of oral trovafloxacin on bowel microflora in healthy male volunteers. *American Journal of Surgery* 1998 Dec; 176(6A Suppl):27S-31S. *Not relevant to key question*

478. Varki NM, Aquino TI. Isolation of *Clostridium difficile* from hospitalized patients without antibiotic-associated diarrhea or colitis. *J Clin Microbiol* 1982 Oct; 16(4):659-62. *Not relevant to key question*
479. Verity P, Wilcox MH, Fawley W, et al. Prospective evaluation of environmental contamination by *Clostridium difficile* in isolation side rooms. *J Hosp Infect* 2001 Nov; 49(3):204-9. *Not relevant to key question*
480. Vesoulis Z, Williams G, Matthews B. Pseudomembranous enteritis after proctocolectomy: report of a case. *Dis Colon Rectum* 2000 Apr; 43(4):551-4. *Not relevant to key question*
481. Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of *Clostridium difficile* isolates from various patient populations. *Gastroenterol* 1981 Jul; 81(1):5-9. *Not relevant to key question*
482. Walker KJ, Gilliland SS, Vance-Bryan K, et al. *Clostridium difficile* colonization in residents of long-term care facilities: prevalence and risk factors. *Journal of the American Geriatrics Society* 1993 Sep; 41(9):940-6. *Not relevant to key question*
483. Walker RC, Ruane PJ, Rosenblatt JE, et al. Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of *Clostridium difficile*-related enteric disease. *Diagnostic Microbiology & Infectious Disease* 1986 May; 5(1):61-9. *Not relevant to key question*
484. Walters BA, Roberts R, Stafford R, et al. Relapse of antibiotic associated colitis: endogenous persistence of *Clostridium difficile* during vancomycin therapy. *Gut* 1983 Mar; 24(3):206-12. *Not relevant to key question*
485. Walters BA, Stafford R, Roberts RK, et al. Contamination and crossinfection with *Clostridium difficile* in an intensive care unit. *Australian & New Zealand Journal of Medicine* 1982 Jun; 12(3):255-8. *Not relevant to key question*
486. Wanahita A, Goldsmith EA, Marino BJ, et al. *Clostridium difficile* infection in patients with unexplained leukocytosis. *Am J Med* 2003 Nov; 115(7):543-6. *Not relevant to key question*
487. Warny M, Vaerman JP, Avesani V, et al. Human antibody response to *Clostridium difficile* toxin A in relation to clinical course of infection. *Infect Immun* 1994 Feb; 62(2):384-9. *Not relevant to key question*
488. Wasserman E, Hidalgo M, Hornedo J, et al. Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: dose finding study and evaluation of efficacy. *Bone marrow transplantation* 1997 Nov; 20(9):711-4. *Not relevant to key question*
489. Watanakunakorn PW, Watanakunakorn C, Hazy J. Risk factors associated with *Clostridium difficile* diarrhea in hospitalized adult patients: a case-control study--sucralfate ingestion is not a negative risk factor. *Infect Control Hosp Epidemiol* 1996 Apr; 17(4):232-5. *Not relevant to key question*
490. Watson B, Ellis M, Mandal B, et al. A comparison of the clinico-pathological features with stool pathogens in patients hospitalised with the symptom of diarrhoea. *Scand J Infect Dis* 1986; 18(6):553-9. *Not relevant to key question*
491. Waywa D, Kongkriengdaj S, Chaidatch S, et al. Protozoan enteric infection in AIDS related diarrhea in Thailand. *Southeast Asian Journal of Tropical Medicine & Public Health* 2001; 32(Suppl 2):151-5. *Not relevant to key question*
492. Wei SC, Wong JM, Hsueh PR, et al. Diagnostic role of endoscopy, stool culture, and toxin A in *Clostridium difficile*-associated disease. *Journal of the Formosan Medical Association* 1997 Nov; 96(11):879-83. *Not relevant to key question*
493. Weiss B, Kleinkauf N, Eckmanns T, et al. Risk factors related to a hospital-associated cluster of *Clostridium difficile* PCR ribotype 027 infections in Germany During 2007. *Infect Control Hosp Epidemiol* 2009 Mar; 30(3):282-4. *Not relevant to key question*

494. Weiss B, Kleinkauf N, Eckmanns T, et al. Risk factors related to a hospital-associated cluster of *Clostridium difficile* PCR ribotype 027 infections in Germany During 2007. *Infect Control Hosp Epidemiol* 2009 Mar; 30(3):282-4. *Not relevant to key question*
495. Welkon CJ, Long SS, Thompson CM, Jr., et al. *Clostridium difficile* in patients with cystic fibrosis. *American Journal of Diseases of Children* 1985 Aug; 139(8):805-8. *Not relevant to key question*
496. Whelan K, Judd PA, Preedy VR, et al. Covert assessment of concurrent and construct validity of a chart to characterize fecal output and diarrhea in patients receiving enteral nutrition. *Jpen: Journal of Parenteral & Enteral Nutrition* 2008 Mar-Apr; 32(2):160-8. *Not relevant to key question*
497. Whittier S, Shapiro DS, Kelly WF, et al. Evaluation of four commercially available enzyme immunoassays for laboratory diagnosis of *Clostridium difficile*-associated diseases. *J Clin Microbiol* 1993 Nov; 31(11):2861-5. *Not relevant to key question*
498. Wilcox MH, Mooney L, Bendall R, et al. A case-control study of community-associated *Clostridium difficile* infection. *J Antimicrob Chemother* 2008 Aug; 62(2):388-96. *Not relevant to key question*
499. Wongwanich S, Pongpech P, Dhiraputra C, et al. Characteristics of *Clostridium difficile* strains isolated from asymptomatic individuals and from diarrheal patients. *Clinical Microbiology & Infection* 2001 Aug; 7(8):438-41. *Not relevant to key question*
500. Wongwanich S, Ramsiri S, Vanasin B, et al. *Clostridium difficile* associated disease in Thailand. *Southeast Asian Journal of Tropical Medicine & Public Health* 1990 Sep; 21(3):367-72. *Not relevant to key question*
501. Wongwanich S, Rugdeekha S, Pongpech P, et al. Detection of *Clostridium difficile* toxin A and B genes from stool samples of Thai diarrheal patients by polymerase chain reaction technique. *Journal of the Medical Association of Thailand* 2003 Oct; 86(10):970-5. *Not relevant to key question*
502. Wright JM, Adams SP, Gribble MJ, et al. *Clostridium difficile* in Crohn's disease. *Canadian Journal of Surgery* 1984 Sep; 27(5):435-7. *Not relevant to key question*
503. Wullt M, Laurell MH. Low prevalence of nosocomial *Clostridium difficile* transmission, as determined by comparison of arbitrarily primed PCR and epidemiological data. *J Hosp Infect* 1999 Dec; 43(4):265-73. *Not relevant to key question*
504. Yablon SA, Krotenberg R, Fruhmann K. Diarrhea in hospitalized patients. *American Journal of Physical Medicine & Rehabilitation* 1992 Apr; 71(2):102-7. *Not relevant to key question*
505. Yadav Y, Garey KW, Dao-Tran TK, et al. Automated system to identify *Clostridium difficile* infection among hospitalised patients. *J Hosp Infect* 2009 Aug; 72(4):337-41. *Not relevant to key question*
506. Yapar N, Sener A, Karaca B, et al. Antibiotic-associated diarrhea in a Turkish outpatient population: investigation of 288 cases. *Journal of Chemotherapy* 2005 Feb; 17(1):77-81. *Not relevant to key question*
507. Yapar N, Sener A, Karaca B, et al. Antibiotic-associated diarrhea in a Turkish outpatient population: investigation of 288 cases. *Journal of Chemotherapy* 2005 Feb; 17(1):77-81. *Not relevant to key question*
508. Yokohama S, Aoshima M, Nakade Y, et al. Investigation and prediction of enteral nutrition problems after percutaneous endoscopic gastrostomy. *World Journal of Gastroenterology* 2009 Mar 21; 15(11):1367-72. *Not relevant to key question*
509. Yolken RH, Bishop CA, Townsend TR, et al. Infectious gastroenteritis in bone-marrow-transplant recipients. *New England Journal of Medicine* 1982 Apr 29; 306(17):1010-2. *Not relevant to key question*
510. Young GP, Bayley N, Ward P, et al. Antibiotic-associated colitis caused by *Clostridium difficile*: relapse and risk factors. *Medical Journal of Australia* 1986 Mar 17; 144(6):303-6. *Not relevant to key question*

511. Young GP, Ward PB, Bayley N, et al. Antibiotic-associated colitis due to *Clostridium difficile*: double-blind comparison of vancomycin with bacitracin. *Gastroenterol* 1985 Nov; 89(5):1038-45. *Not relevant to key question*
512. Younus F, Steigbigel RT. Images in clinical medicine. Nodular *Clostridium difficile* colitis. *New England Journal of Medicine* 2004 Mar 4; 350(10):e9. *Not relevant to key question*
513. Zaiss NH, Weile J, Ackermann G, et al. A case of *Clostridium difficile*-associated disease due to the highly virulent clone of *Clostridium difficile* PCR ribotype 027, March 2007 in Germany. *Euro Surveillace: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin* 2007 Nov; 12(11):E071115.1. *Not relevant to key question*
514. Zedd AJ, Sell TL, Schaberg DR, et al. Nosocomial *Clostridium difficile* reservoir in a neonatal intensive care unit. *Pediatric infectious disease* 1984 Sep-Oct; 3(5):429-32. *Not relevant to key question*
515. Zilberberg MD, Nathanson BH, Sadigov S, et al. Epidemiology and outcomes of *clostridium difficile*-associated disease among patients on prolonged acute mechanical ventilation. *Chest* 2009 Sep; 136(3):752-8. *Not relevant to key question*
516. Zumbado-Salas R, Gamboa-Coronado Mdel M, Rodriguez-Cavallini E, et al. *Clostridium difficile* in adult patients with nosocomial diarrhea in a Costa Rican hospital. *American Journal of Tropical Medicine & Hygiene* 2008 Aug; 79(2):164-5. *Not relevant to key question*